

A&A Ref: 149901

PUBLICATION PARTICULARS AND ABSTRACT
(Section 32(3)(a) - Regulations 22(1)(g) and 31)

21	01	PATENT APPLICATION NO	22	LODGING DATE	43	ACCEPTANCE DATE
----	----	-----------------------	----	--------------	----	-----------------

2004/2513

30 March 2004

12-09-05

51	INTERNATIONAL CLASSIFICATION	NOT FOR PUBLICATION
----	------------------------------	---------------------

C12N

CLASSIFIED BY: ISA

71	FULL NAME(S) OF APPLICANT(S)
----	------------------------------

Chiron Corporation

NOVARTIS VACCINES & DIAGNOSTICS INC.

72	FULL NAME(S) OF INVENTOR(S)
----	-----------------------------

ZUR MEGEDE, Jan
LIAN, Ying

BARNETT, Susan W.

NAME & NUMBER
CHANGED
12-09-05

EARLIEST PRIORITY CLAIMED	COUNTRY	NUMBER	DATE
	33 US	31 60/316,860	32 31 August 2001

NOTE: The country must be indicated by its International Abbreviation - see schedule 4 of the Regulations

54	TITLE OF INVENTION
----	--------------------

Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

57	ABSTRACT (NOT MORE THAN 150 WORDS)
----	------------------------------------

NUMBER OF SHEETS	22
------------------	----

The sheet(s) containing the abstract is/are attached.

If no classification is furnished, Form P.9 should accompany this form.
The figure of the drawing to which the abstract refers is attached.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 2003/020876 A3

(51) International Patent Classification⁷:

C12N 15/00

(74) Agents: DOLLARD, Anne, S. et al.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(21) International Application Number:

PCT/US2002/021342

(22) International Filing Date:

5 July 2002 (05.07.2002)

(81) Designated States (national): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/316,860

31 August 2001 (31.08.2001) US

60/349,728

16 January 2002 (16.01.2002) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).

Published:

with international search report

(72) Inventors; and

(75) Inventors/Applicants (for US only): ZUR MEGEDE, Jan [DE/US]; Chiron Corporation, 4560 Horton Street - R440, Emeryville, CA 94608 (US). BARNETT, Susan, W. [US/US]; Chiron Corporation, 4560 Horton Street - R440, Emeryville, CA 94608 (US). LIAN, Ying [CN/US]; Chiron Corporation, 4560 Horton Street - R440, Emeryville, CA 94608 (US).

(88) Date of publication of the international search report: 8 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/020876 A3

(54) Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

(57) Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

TECHNICAL FIELD

5 Polynucleotides encoding antigenic HIV polypeptides (e.g., those shown in Table C) are described, as are uses of these polynucleotides and polypeptide products including formulations of immunogenic compositions and uses thereof.

BACKGROUND OF THE INVENTION

10 Acquired immune deficiency syndrome (AIDS) is recognized as one of the greatest health threats facing modern medicine. There is, as yet, no cure for this disease.

In 1983-1984, three groups independently identified the suspected etiological agent of AIDS. See, e.g., Barre-Sinoussi et al. (1983) *Science* 220:868-871; 15 Montagnier et al., in *Human T-Cell Leukemia Viruses* (Gallo, Essex & Gross, eds., 1984); Vilmer et al. (1984) *The Lancet* 1:753; Popovic et al. (1984) *Science* 224:497-500; Levy et al. (1984) *Science* 225:840-842. These isolates were variously called lymphadenopathy-associated virus (LAV), human T-cell lymphotropic virus type III (HTLV-III), or AIDS-associated retrovirus (ARV). All of these isolates are 20 strains of the same virus, and were later collectively named Human Immunodeficiency Virus (HIV). With the isolation of a related AIDS-causing virus, the strains originally called HIV are now termed HIV-1 and the related virus is called HIV-2 See, e.g., Guyader et al. (1987) *Nature* 326:662-669; Brun-Vezinet et al. (1986) *Science* 233:343-346; Clavel et al. (1986) *Nature* 324:691-695.

25 A great deal of information has been gathered about the HIV virus, however, to date an effective vaccine has not been identified. Several targets for vaccine development have been examined including the *env* and *Gag* gene products encoded by HIV. *Gag* gene products include, but are not limited to, *Gag*-polymerase and *Gag*-protease. *Env* gene products include, but are not limited to, monomeric gp120 30 polypeptides, oligomeric gp140 polypeptides and gp160 polypeptides.

Haas, et al., (*Current Biology* 6(3):315-324, 1996) suggested that selective codon usage by HIV-1 appeared to account for a substantial fraction of the inefficiency of viral protein synthesis. Andre, et al., (*J. Virol.* 72(2):1497-1503, 1998) described an increased immune response elicited by DNA vaccination employing a synthetic 5 gp120 sequence with modified codon usage. Schneider, et al., (*J Virol.* 71(7):4892-4903, 1997) discuss inactivation of inhibitory (or instability) elements (INS) located within the coding sequences of the Gag and Gag-protease coding sequences.

The *Gag* proteins of HIV-1 are necessary for the assembly of virus-like particles. HIV-1 *Gag* proteins are involved in many stages of the life cycle of the virus 10 including, assembly, virion maturation after particle release, and early post-entry steps in virus replication. The roles of HIV-1 *Gag* proteins are numerous and complex (Freed, E.O., *Virology* 251:1-15, 1998).

Wolf, et al., (PCT International Application, WO 96/30523, published 3 October 1996; European Patent Application, Publication No. 0 449 116 A1, published 15 2 October 1991) have described the use of altered pr55 *Gag* of HIV-1 to act as a non-infectious retroviral-like particulate carrier, in particular, for the presentation of immunologically important epitopes. Wang, et al., (*Virology* 200:524-534, 1994) describe a system to study assembly of HIV *Gag*- β -galactosidase fusion proteins into virions. They describe the construction of sequences encoding HIV *Gag*- β -galactosidase fusion proteins, the expression of such sequences in the presence of HIV 20 *Gag* proteins, and assembly of these proteins into virus particles.

Shiver, et al., (PCT International Application, WO 98/34640, published 13 August 1998) described altering HIV-1 (CAM1) *Gag* coding sequences to produce synthetic DNA molecules encoding HIV *Gag* and modifications of HIV *Gag*. The 25 codons of the synthetic molecules were codons preferred by a projected host cell.

Recently, use of HIV Env polypeptides in immunogenic compositions has been described. (see, U.S. Patent No. 5,846,546 to Hurwitz et al., issued December 8, 1998, describing immunogenic compositions comprising a mixture of at least four different recombinant virus that each express a different HIV env variant; and U.S. 30 Patent No. 5,840,313 to Vahlne et al., issued November 24, 1998, describing peptides which correspond to epitopes of the HIV-1 gp120 protein). In addition, U.S. Patent

No. 5,876,731 to Sia et al, issued March 2, 1999 describes candidate vaccines against HIV comprising an amino acid sequence of a T-cell epitope of Gag linked directly to an amino acid sequence of a B-cell epitope of the V3 loop protein of an HIV-1 isolate containing the sequence GPGR.

5

SUMMARY OF THE INVENTION

Described herein are novel HIV sequences, polypeptides encoded by these novel sequences, and synthetic expression cassettes generated from these and other HIV sequences. In one aspect, the present invention relates to improved HIV 10 expression cassettes. In a second aspect, the present invention relates to generating an immune response in a subject using the expression cassettes of the present invention. In a further aspect, the present invention relates to generating an immune response in a subject using the expression cassettes of the present invention, as well as, polypeptides encoded by the expression cassettes of the present invention. In another aspect, the 15 present invention relates to enhanced vaccine technologies for the induction of potent neutralizing antibodies and/or cellular immune responses against HIV in a subject.

In certain embodiments, the present invention relates to synthetic polynucleotides and/or expression cassettes encoding HIV polypeptides, including, but not limited to, Env, Gag, Pol, RT, Int, Prot, Vpr, Vpu, Vif, Nef, Tat, Rev and/or 20 fragments or combinations thereof. In addition, the present invention also relates to improved expression of HIV polypeptides and production of virus-like particles. Synthetic expression cassettes encoding the HIV polypeptides (e.g., Gag-, pol-, 25 protease (prot)-, reverse transcriptase, integrase, RNaseH, Tat, Rev, Nef, Vpr, Vpu, Vif and/or Env- containing polypeptides) are described, as are uses of the expression cassettes. Mutations in some of the genes are described that reduce or eliminate the activity of the gene product without adversely affecting the ability of the gene product to generate an immune response. Exemplary synthetic polynucleotides include, but are not limited to, GagComplPolmut.SF2 (SEQ ID NO:9), GagComplPolmutAtt.SF2 (SEQ ID NO:10), GagComplPolmutIna.SF2 (SEQ ID NO:11), 30 gagCpolInaTatRevNef.opt_B (SEQ ID NO:12), GagPolmutAtt.SF2 (SEQ ID NO:13), GagPolmutIna.SF2 (SEQ ID NO:14), GagProtInaRTmut.SF2 (SEQ ID NO:15),

GagProtInaRTmutTatRevNef.opt_B (SEQ ID NO:16), GagRTmut.SF2 (SEQ ID NO:17), GagTatRevNef.opt_B (SEQ ID NO:18), gp140.modSF162.CwtLmod (SEQ ID NO:19), gp140.modSF162.CwtLnat (SEQ ID NO:20),
5 gp160.modSF162.delV2.mut7 (SEQ ID NO:21), gp160.modSF162.delV2.mut8 (SEQ ID NO:22), int.opt.mut.SF2 (SEQ ID NO:23), int.opt.SF2 (SEQ ID NO:24), nef.D125G.-myr.opt.SF162 (SEQ ID NO:25), nef.D107G.-myr18.opt.SF162 (SEQ ID NO:26), nef.opt.D125G.SF162 (SEQ ID NO:27), nef.opt.SF162 (SEQ ID NO:28), p15RnaseH.opt.SF2 (SEQ ID NO:29), p2Pol.opt.YMWM.SF2 (SEQ ID NO:30), p2PolInaopt.YM.SF2 (SEQ ID NO:31), p2Polopt.SF2 (SEQ ID NO:32),
10 p2PolTatRevNef.opt.native_B (SEQ ID NO:33), p2PolTatRevNef.opt_B (SEQ ID NO:34), pol.opt.SF2 (SEQ ID NO:35), prot.opt.SF2 (SEQ ID NO:36), protIna.opt.SF2 (SEQ ID NO:37), protInaRT.YM.opt.SF2 (SEQ ID NO:38), protInaRT.YMWM.opt.SF2 (SEQ ID NO:39), ProtInaRTmut.SF2 (SEQ ID NO:40), protRT.opt.SF2 (SEQ ID NO:41), ProtRT.TatRevNef.opt_B (SEQ ID NO:42),
15 ProtRTTatRevNef.opt_B (SEQ ID NO:43), rev.exon1_2.M5-10.opt.SF162 (SEQ ID NO:44), rev.exon1_2.opt.SF162 (SEQ ID NO:45), RT.opt.SF2 (mutant) (SEQ ID NO:46), RT.opt.SF2 (native) (SEQ ID NO:47), RTmut.SF2 (SEQ ID NO:48), tat.exon1_2.opt.C22-37.SF2 (SEQ ID NO:49), tat.exon1_2.opt.C37.SF2 (SEQ ID NO:50), TatRevNef.opt.native.SF162 (SEQ ID NO:51), TatRevNef.opt.SF162 (SEQ ID NO:52), TatRevNefGag B (SEQ ID NO:53), TatRevNefgagCpolIna B (SEQ ID NO:54), TatRevNefGagProtInaRTmut B (SEQ ID NO:55), TatRevNefp2Pol.opt_B, (SEQ ID NO:56) TatRevNefprotRTopt B (SEQ ID NO:57), vif.opt.SF2 (SEQ ID NO:58), vpr.opt.SF2 (SEQ ID NO:59), and vpu.opt.SF162 (SEQ ID NO:60).

Thus, one aspect of the present invention relates to expression cassettes and 25 polynucleotides contained therein. The expression cassettes typically include an HIV-polypeptide encoding sequence inserted into an expression vector backbone. In one embodiment, an expression cassette comprises a polynucleotide sequence encoding one or more polypeptides, wherein the polynucleotide sequence comprises a sequence having between about 85% to 100% and any integer values therebetween, for example, 30 at least about 85%, preferably about 90%, more preferably about 95%, and more

preferably about 98% sequence identity to the sequences taught in the present specification.

The polynucleotides encoding the HIV polypeptides of the present invention may also include sequences encoding additional polypeptides. Such additional 5 polynucleotides encoding polypeptides may include, for example, coding sequences for other viral proteins (e.g., hepatitis B or C or other HIV proteins, such as, polynucleotide sequences encoding an HIV *Gag* polypeptide, polynucleotide sequences encoding an HIV *Env* polypeptide and/or polynucleotides encoding one or more of *vif*, *vpr*, *tat*, *rev*, *vpu* and *nef*); cytokines or other transgenes.

10 In one embodiment, the sequence encoding the HIV *Pol* polypeptide(s) can be modified by deletions of coding regions corresponding to reverse transcriptase and integrase. Such deletions in the polymerase polypeptide can also be made such that the polynucleotide sequence preserves T-helper cell and CTL epitopes. Other antigens of interest may be inserted into the polymerase as well.

15 In another embodiment, an expression cassette comprises a polynucleotide sequence encoding a polypeptide, for example, *GagComplPolmut.SF2* (SEQ ID NO:9), *GagComplPolmutAtt.SF2* (SEQ ID NO:10), *GagComplPolmutIna.SF2* (SEQ ID NO:11), *gagCpolInaTatRevNef.opt_B* (SEQ ID NO:12), *GagPolmutAtt.SF2* (SEQ ID NO:13), *GagPolmutIna.SF2* (SEQ ID NO:14), *GagProtInaRTmut.SF2* (SEQ ID NO:15), *GagProtInaRTmutTatRevNef.opt_B* (SEQ ID NO:16), *GagRTmut.SF2*, (SEQ ID NO:17) *GagTatRevNef.opt_B* (SEQ ID NO:18),
gp140.modSF162.CwtLmod (SEQ ID NO:19), gp140.modSF162.CwtLnat (SEQ ID NO:20), gp160.modSF162.delV2.mut7 (SEQ ID NO:21),
gp160.modSF162.delV2.mut8 (SEQ ID NO:22), *int.opt.mut.SF2* (SEQ ID NO:23),
25 *int.opt.SF2* (SEQ ID NO:24), *nef.D125G.-myr.opt.SF162* (SEQ ID NO:25),
nef.D107G.-myr18.opt.SF162 (SEQ ID NO:26), *nef.opt.D125G.SF162* (SEQ ID NO:27), *nef.opt.SF162* (SEQ ID NO:28), *p15RnaseH.opt.SF2* (SEQ ID NO:29),
p2Pol.opt.YMWM.SF2 (SEQ ID NO:30), *p2PolInaopt.YM.SF2*, (SEQ ID NO:31)
p2Polopt.SF2 (SEQ ID NO:32), *p2PoITatRevNef.opt.native_B* (SEQ ID NO:33),
30 *p2PoITatRevNef.opt_B* (SEQ ID NO:34), *pol.opt.SF2* (SEQ ID NO:35), *prot.opt.SF2* (SEQ ID NO:36), *protIna.opt.SF2* (SEQ ID NO:37), *protInaRT.YM.opt.SF2* (SEQ

ID NO:38), protInaRT.YMWM.opt.SF2 (SEQ ID NO:39), ProtInaRTmut.SF2 (SEQ ID NO:40), protRT.opt.SF2 (SEQ ID NO:41), ProtRT.TatRevNef.opt_B (SEQ ID NO:42), ProtRTTatRevNef.opt_B (SEQ ID NO:43), rev.exon1_2.M5-10.opt.SF162 (SEQ ID NO:44), rev.exon1_2.opt.SF162 (SEQ ID NO:45), RT.opt.SF2 (mutant) 5 (SEQ ID NO:46), RT.opt.SF2 (native) (SEQ ID NO:47), RTmut.SF2 (SEQ ID NO:48), tat.exon1_2.opt.C22-37.SF2 (SEQ ID NO:49), tat.exon1_2.opt.C37.SF2 (SEQ ID NO:50), TatRevNef.opt.native.SF162 (SEQ ID NO:51), TatRevNef.opt.SF162 (SEQ ID NO:52), TatRevNefGag B (SEQ ID NO:53), TatRevNefgagCpolIna B (SEQ ID NO:54), TatRevNefGagProtInaRTmut B (SEQ ID 10 NO:55), TatRevNefp2Pol.opt_B (SEQ ID NO:56), TatRevNefprotRTopt B (SEQ ID NO:57), vif.opt.SF2 (SEQ ID NO:58), vpr.opt.SF2 (SEQ ID NO:59), and vpu.opt.SF162 (SEQ ID NO:60), wherein the polynucleotide sequence encoding the polypeptide comprises a sequence having between about 85% to 100% and any integer values therebetween, for example, at least about 85%, preferably about 90%, more 15 preferably about 95%, and most preferably about 98% sequence identity to the sequences taught in the present specification.

The native and synthetic polynucleotide sequences encoding the HIV polypeptides of the present invention typically have between about 85% to 100% and any integer values therebetween, for example, at least about 85%, preferably about 20 90%, more preferably about 95%, and more preferably about 98% sequence identity to the sequences taught herein. Further, in certain embodiments, the polynucleotide sequences encoding the HIV polypeptides of the invention will exhibit 100% sequence identity to the sequences taught herein.

The polynucleotides of the present invention can be produced by recombinant 25 techniques, synthetic techniques, or combinations thereof.

The present invention further includes recombinant expression systems for use in selected host cells, wherein the recombinant expression systems employ one or more of the polynucleotides and expression cassettes of the present invention. In such systems, the polynucleotide sequences are operably linked to control elements 30 compatible with expression in the selected host cell. Numerous expression control elements are known to those in the art, including, but not limited to, the following:

transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences. Exemplary transcription promoters include, but are not limited to those derived from CMV, CMV+intron A, SV40, RSV,
5 HIV-Ltr, MMLV-ltr, and metallothionein.

In another aspect the invention includes cells comprising one or more of the expression cassettes of the present invention where the polynucleotide sequences are operably linked to control elements compatible with expression in the selected cell. In one embodiment such cells are mammalian cells. Exemplary mammalian cells include,
10 but are not limited to, BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells. Other cells, cell types, tissue types, etc., that may be useful in the practice of the present invention include, but are not limited to, those obtained from the following: insects (e.g., *Trichoplusia ni* (Tn5) and Sf9), bacteria, yeast, plants, antigen presenting cells (e.g., macrophage, monocytes, dendritic cells, B-cells, T-cells, stem cells, and
15 progenitor cells thereof), primary cells, immortalized cells, tumor-derived cells.

In a further aspect, the present invention includes compositions for generating an immunological response, where the composition typically comprises at least one of the expression cassettes of the present invention and may, for example, contain combinations of expression cassettes such as one or more expression cassettes carrying
20 a Pol-derived-polypeptide-encoding polynucleotide, one or more expression cassettes carrying a Gag-derived-polypeptide-encoding polynucleotide, one or more expression cassettes carrying accessory polypeptide-encoding polynucleotides (e.g., native or synthetic vpu, vpr, nef, vif, tat, rev), and/or one or more expression cassettes carrying an Env-derived-polypeptide-encoding polynucleotide. Such compositions may further
25 contain an adjuvant or adjuvants. The compositions may also contain one or more HIV polypeptides. The HIV polypeptides may correspond to the polypeptides encoded by the expression cassette(s) in the composition, or may be different from those encoded by the expression cassettes. In compositions containing both expression cassettes (or polynucleotides of the present invention) and polypeptides,
30 various expression cassettes of the present invention can be mixed and/or matched with various HIV polypeptides described herein.

In another aspect the present invention includes methods of immunization of a subject. In the method any of the above described compositions are into the subject under conditions that are compatible with expression of the expression cassette(s) in the subject. In one embodiment, the expression cassettes (or polynucleotides of the present invention) can be introduced using a gene delivery vector. The gene delivery vector can, for example, be a non-viral vector or a viral vector. Exemplary viral vectors include, but are not limited to eucaryotic layered vector initiation systems, Sindbis-virus (or other alphavirus) derived vectors, retroviral vectors, and lentiviral vectors. Other exemplary vectors include, but are not limited to, pCMVKm2, pCMV6a, pCMV-link, and pCMVPLEdhfr. Compositions useful for generating an immunological response can also be delivered using a particulate carrier (e.g., PLG or CTAB-PLG microparticles). Further, such compositions can be coated on, for example, gold or tungsten particles and the coated particles delivered to the subject using, for example, a gene gun. The compositions can also be formulated as liposomes. In one embodiment of this method, the subject is a mammal and can, for example, be a human.

In a further aspect, the invention includes methods of generating an immune response in a subject. Any of the expression cassettes described herein can be expressed in a suitable cell to provide for the expression of the HIV polypeptides encoded by the polynucleotides of the present invention. The polypeptide(s) are then isolated (e.g., substantially purified) and administered to the subject in an amount sufficient to elicit an immune response. In certain embodiments, the methods comprise administration of one or more of the expression cassettes or polynucleotides of the present invention, using any of the gene delivery techniques described herein. In other embodiments, the methods comprise co-administration of one or more of the expression cassettes or polynucleotides of the present invention and one or more polypeptides, wherein the polypeptides can be expressed from these polynucleotides or can be other HIV polypeptides. In other embodiments, the methods comprise co-administration of multiple expression cassettes or polynucleotides of the present invention. In still further embodiments, the methods comprise co-administration of

multiple polypeptides, for example polypeptides expressed from the polynucleotides of the present invention and/or other HIV polypeptides.

The invention further includes methods of generating an immune response in a subject, where cells of a subject are transfected with any of the above-described 5 expression cassettes or polynucleotides of the present invention, under conditions that permit the expression of a selected polynucleotide and production of a polypeptide of interest (e.g., encoded by any expression cassette of the present invention). By this method an immunological response to the polypeptide is elicited in the subject. Transfection of the cells may be performed *ex vivo* and the transfected cells are 10 reintroduced into the subject. Alternately, or in addition, the cells may be transfected *in vivo* in the subject. The immune response may be humoral and/or cell-mediated (cellular). In a further embodiment, this method may also include administration of an HIV polypeptides before, concurrently with, and/or after introduction of the expression cassette into the subject.

15 The polynucleotides of the present invention may be employed singly or in combination. The polynucleotides of the present invention, encoding HIV-derived polypeptides, may be expressed in a variety of ways, including, but not limited to the following: a polynucleotide encoding a single gene product (or portion thereof) expressed from a promoter; multiple polynucleotides encoding a more than one gene 20 product (or portion thereof) (e.g., polycistronic coding sequences); multiple polynucleotides in-frame to produce a single polyprotein; and, multiple polynucleotides in-frame to produce a single polyprotein wherein the polyprotein has protein cleavage sites between one or more of the polypeptides comprising the polyprotein.

25 These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A to 1D depict the nucleotide sequence of HIV Type C 8_5_TV1_C.ZA (SEQ ID NO:1; referred to herein as TV1). Various regions are 30 shown in Table A.

Figures 2A-C depicts an alignment of Env polypeptides from various HIV isolates (SF162, SEQ ID NO:2; TV1.8_2, SEQ ID NO:3; TV1.8_5, SEQ ID NO:4; TV2.12-5/1, SEQ ID NO:5; Consensus Sequence, SEQ ID NO:6). The regions between the arrows indicate regions (of TV1 and TV2 clones, both HIV Type C isolates) in the beta and/or bridging sheet region(s) that can be deleted and/or truncated. The “*” denotes N-linked glycosylation sites (of TV1 and TV2 clones), one or more of which can be modified (e.g., deleted and/or mutated).

Figure 3 presents a schematic diagram showing the relationships between the following forms of the HIV Env polypeptide: gp160, gp140, gp120, and gp41.

10 Figure 4 presents exemplary data concerning transactivation activity of Tat mutants on LTR-CAT plasmid expression in 293 cells.

Figure 5 presents exemplary data concerning export activity of Rev mutants monitored by CAT expression.

15 Figure 6, sheets 1 and 2, presents the sequence of GagComplPolmut.SF2 (SEQ ID NO:9).

Figure 7, sheets 1 and 2, presents the sequence of GagComplPolmutAtt.SF2 (SEQ ID NO:10).

Figure 8, sheets 1 and 2, presents the sequence of GagComplPolmutIna.SF2 (SEQ ID NO:11).

20 Figure 9, sheets 1 and 2, presents the sequence of gagCpolInaTatRevNef.opt_B (SEQ ID NO:12).

Figure 10, sheets 1 and 2, presents the sequence of GagPolmutAtt.SF2 (SEQ ID NO:13).

25 Figure 11, sheets 1 and 2, presents the sequence of GagPolmutIna.SF2 (SEQ ID NO:14).

Figure 12, sheets 1 and 2, presents the sequence of GagProtInaRTmut.SF2 (SEQ ID NO:15).

Figure 13, sheets 1 and 2, presents the sequence of GagProtInaRTmutTatRevNef.opt_B (SEQ ID NO:16).

30 Figure 14, sheets 1 and 2, presents the sequence of GagRTmut.SF2 (SEQ ID NO:17).

Figure 15, presents the sequence of GagTatRevNef.opt_B (SEQ ID NO:18).

Figure 16, presents the sequence of gp140.modSF162.CwtLmod (SEQ ID NO:19).

5 Figure 17, presents the sequence of gp140.modSF162.CwtLnat (SEQ ID NO:20).

Figure 18, presents the sequence of gp160.modSF162.delV2.mut7 (SEQ ID NO:21).

Figure 19, presents the sequence of gp160.modSF162.delV2.mut8 (SEQ ID NO:22).

10 Figure 20, presents the sequence of int.opt.mut.SF2 (SEQ ID NO:23).

Figure 21, presents the sequence of int.opt.SF2 (SEQ ID NO:24).

Figure 22, presents the sequence of nef.D125G.-myr.opt.SF162 (SEQ ID NO:25).

15 Figure 23, presents the sequence of nef.D107G.-myr18.opt.SF162 (SEQ ID NO:26).

Figure 24, presents the sequence of nef.opt.D125G.SF162 (SEQ ID NO:27).

Figure 25, presents the sequence of nef.opt.SF162 (SEQ ID NO:28).

Figure 26, presents the sequence of p15RnaseH.opt.SF2 (SEQ ID NO:29).

Figure 27, presents the sequence of p2Pol.opt.YMWM.SF2 (SEQ ID NO:30).

20 Figure 28, presents the sequence of p2PolInaopt.YM.SF2 (SEQ ID NO:31).

Figure 29, presents the sequence of p2Polopt.SF2 (SEQ ID NO:32).

Figure 30, presents the sequence of p2PolTatRevNef.opt.native_B (SEQ ID NO:33).

25 Figure 31, sheets 1 and 2, presents the sequence of p2PolTatRevNef.opt_B (SEQ ID NO:34).

Figure 32, presents the sequence of pol.opt.SF2 (SEQ ID NO:35).

Figure 33, presents the sequence of prot.opt.SF2 (SEQ ID NO:36).

Figure 34, presents the sequence of protIna.opt.SF2 (SEQ ID NO:37).

Figure 35, presents the sequence of protInaRT.YM.opt.SF2 (SEQ ID NO:38).

30 Figure 36, presents the sequence of protInaRT.YMWM.opt.SF2 (SEQ ID NO:39).

Figure 37, presents the sequence of ProtInaRTmut.SF2 (SEQ ID NO:40).

Figure 38, presents the sequence of protRT.opt.SF2 (SEQ ID NO:41).

Figure 39, presents the sequence of ProtRT.TatRevNef.opt_B (SEQ ID NO:42).

5 Figure 40, presents the sequence of ProtRTTatRevNef.opt_B (SEQ ID NO:43).

Figure 41, presents the sequence of rev.exon1_2.M5-10.opt.SF162 (SEQ ID NO:44).

Figure 42, presents the sequence of rev.exon1_2.opt.SF162 (SEQ ID NO:45).

10 Figure 43, presents the sequence of RT.opt.SF2 (mutant) (SEQ ID NO:46).

Figure 44, presents the sequence of RT.opt.SF2 (native) (SEQ ID NO:47).

Figure 45, presents the sequence of RTmut.SF2 (SEQ ID NO:48).

Figure 46, presents the sequence of tat.exon1_2.opt.C22-37.SF2 (SEQ ID NO:49).

15 Figure 47, presents the sequence of tat.exon1_2.opt.C37.SF2 (SEQ ID NO:50).

Figure 48, presents the sequence of TatRevNef.opt.native.SF162 (SEQ ID NO:51).

Figure 49, presents the sequence of TatRevNef.opt.SF162 (SEQ ID NO:52).

20 Figure 50, presents the sequence of TatRevNefGag B (SEQ ID NO:53).

Figure 51, sheets 1 and 2, presents the sequence of TatRevNefgagCpolIna B (SEQ ID NO:54).

Figure 52, sheets 1 and 2, presents the sequence of TatRevNefGagProtInaRTmut B (SEQ ID NO:55).

25 Figure 53, presents the sequence of TatRevNefp2Pol.opt_B (SEQ ID NO:56).

Figure 54, presents the sequence of TatRevNefprotRTopt B (SEQ ID NO:57).

Figure 55, presents the sequence of vif.opt.SF2 (SEQ ID NO:58).

Figure 56, presents the sequence of vpr.opt.SF2 (SEQ ID NO:59).

Figure 57, presents the sequence of vpu.opt.SF162 (SEQ ID NO:60).

30 Figure 58, presents the sequence of gp140modSF162.GM135-154-186-195 (SEQ ID NO:61).

Figure 59, presents the sequence of gp140modSF162.GM154 (SEQ ID NO:62).

Figure 60, presents the sequence of gp140modSF162.GM154-186-195 (SEQ ID NO:63).

5 Figure 61, presents the sequence of gp140mut7.modSF162.GM154 (SEQ ID NO:64).

Figure 62 depicts alignment of amino acid sequences of various Env glycosylation mutants (GM), including amino acid translation of gp140modSF162 (SEQ ID NO:65); translation of gp140.modSF162.GM154 (SEQ ID NO:66);
10 translation of gp140.modSF162.GM154-186-195 (SEQ ID NO:67); and gp140.modSF162.GM135-154-186-195 (SEQ ID NO:68).

Figure 63 presents an overview of genome organization of HIV-1 and useful subgenomic fragments.

15 Figure 64 presents antibody titer data from immunized rabbits following immunization with HIV Envelope DNA constructs and protein.

Figure 65 presents a comparison of ELISA titers against subtype B and C Envelope proteins in rabbit sera collected after three DNA immunizations and a single protein boost.

20 Figure 66 presents data of neutralizing antibody responses against subtype B SF162 EnvDV2 strain in rabbits immunized with subtype C TV1 Env in a DNA prime protein boost regimen.

Figure 67 presents data of neutralizing antibody responses against subtype C primary strains, TV1 and TV2 in 5.25 reporter cell assay after a single protein boost.

25 Figure 68 presents data of neutralizing antibody responses against subtype C, TV1 and Du174, and subtype B, SF162 after a single protein boost (as measured by Duke PBMC assay).

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwise indicated, 30 conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the

literature. See, e.g., *Remington's Pharmaceutical Sciences*, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); *Methods In Enzymology* (S. Colowick and N. Kaplan, eds., Academic Press, Inc.); and *Handbook of Experimental Immunology*, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds., 1986, Blackwell Scientific Publications); Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *Short Protocols in Molecular Biology*, 4th ed. (Ausubel et al. eds., 1999, John Wiley & Sons); *Molecular Biology Techniques: An Intensive Laboratory Course*, (Ream et al., eds., 1998, Academic Press); *PCR (Introduction to Biotechniques Series)*, 2nd ed. (Newton & Graham eds., 1997, Springer Verlag).

5 As used in this specification, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a mixture of two or more such agents.

10

1. DEFINITIONS

15 In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

"Synthetic" sequences, as used herein, refers to HIV polypeptide-encoding polynucleotides whose expression has been modified as described herein, for example, by codon substitution, altered activities, and/or inactivation of inhibitory sequences.

20 "Wild-type" or "native" sequences, as used herein, refers to polypeptide encoding sequences that are essentially as they are found in nature, e.g., Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, Env and/or Nef encoding sequences as found in HIV isolates, e.g., SF162, SF2, AF110965, AF110967, AF110968, AF110975, 8_5_TV1_C.ZA, 8_2_TV1_C.ZA or 12-5_1_TV2_C.ZA. The various regions of the HIV genome are shown in Table A, with numbering relative to 8_5_TV1_C.ZA (Figures 1A-1D).

25 Thus, the term "Pol" refers to one or more of the following polypeptides: polymerase (p6Pol); protease (prot); reverse transcriptase (p66RT or RT); RNaseH (p15RNaseH); and/or integrase (p31Int or Int). Identification of gene regions for any selected HIV isolate can be performed by one of ordinary skill in the art based on the teachings presented herein and the information known in the art, for example, by performing alignments relative to 8_5_TV1_C.ZA (Figures 1A-1D) or alignment to

30

other known HIV isolates, for example, Subtype B isolates with gene regions (e.g., SF2, GenBank Accession number K02007; SF162, GenBank Accession Number M38428) and Subtype C isolates with gene regions (e.g., GenBank Accession Number AF110965 and GenBank Accession Number AF110975).

5 As used herein, the term "virus-like particle" or "VLP" refers to a nonreplicating, viral shell, derived from any of several viruses discussed further below. VLPs are generally composed of one or more viral proteins, such as, but not limited to those proteins referred to as capsid, coat, shell, surface and/or envelope proteins, or particle-forming polypeptides derived from these proteins. VLPs can form
10 spontaneously upon recombinant expression of the protein in an appropriate expression system. Methods for producing particular VLPs are known in the art and discussed more fully below. The presence of VLPs following recombinant expression of viral proteins can be detected using conventional techniques known in the art, such as by electron microscopy, X-ray crystallography, and the like. See, e.g., Baker et al.,
15 *Biophys. J.* (1991) 60:1445-1456; Hagensee et al., *J. Virol.* (1994) 68:4503-4505. For example, VLPs can be isolated by density gradient centrifugation and/or identified by characteristic density banding. Alternatively, cryoelectron microscopy can be performed on vitrified aqueous samples of the VLP preparation in question, and images recorded under appropriate exposure conditions.
20 By "particle-forming polypeptide" derived from a particular viral protein is meant a full-length or near full-length viral protein, as well as a fragment thereof, or a viral protein with internal deletions, which has the ability to form VLPs under conditions that favor VLP formation. Accordingly, the polypeptide may comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs
25 and precursor forms of the reference molecule. The term therefore intends deletions, additions and substitutions to the sequence, so long as the polypeptide retains the ability to form a VLP. Thus, the term includes natural variations of the specified polypeptide since variations in coat proteins often occur between viral isolates. The term also includes deletions, additions and substitutions that do not naturally occur in the reference protein, so long as the protein retains the ability to form a VLP.
30 Preferred substitutions are those which are conservative in nature, i.e., those

substitutions that take place within a family of amino acids that are related in their side chains. Specifically, amino acids are generally divided into four families: (1) acidic -- aspartate and glutamate; (2) basic -- lysine, arginine, histidine; (3) non-polar -- alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar -- glycine, asparagine, glutamine, cystine, serine threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids.

The term "HIV polypeptide" refers to any amino acid sequence that exhibits sequence homology to native HIV polypeptides (e.g., Gag, Env, Prot, Pol, RT, Int, vif, 10 vpr, vpu, tat, rev, nef and/or combinations thereof) and/or which is functional. Non-limiting examples of functions that may be exhibited by HIV polypeptides include, use as immunogens (e.g., to generate a humoral and/or cellular immune response), use in diagnostics (e.g., bound by suitable antibodies for use in ELISAs or other immunoassays) and/or polypeptides which exhibit one or more biological activities 15 associated with the wild type or synthetic HIV polypeptide. For example, as used herein, the term "Gag polypeptide" may refer to a polypeptide that is bound by one or more anti-Gag antibodies; elicits a humoral and/or cellular immune response; and/or exhibits the ability to form particles.

An “antigen” refers to a molecule containing one or more epitopes (either linear, conformational or both) that will stimulate a host’s immune system to make a humoral and/or cellular antigen-specific response. The term is used interchangeably with the term “immunogen.” Normally, a B-cell epitope will include at least about 5 amino acids but can be as small as 3-4 amino acids. A T-cell epitope, such as a CTL epitope, will include at least about 7-9 amino acids, and a helper T-cell epitope at least about 12-20 amino acids. Normally, an epitope will include between about 7 and 15 amino acids, such as, 9, 10, 12 or 15 amino acids. The term “antigen” denotes both subunit antigens, (i.e., antigens which are separate and discrete from a whole organism with which the antigen is associated in nature), as well as, killed, attenuated or inactivated bacteria, viruses, fungi, parasites or other microbes. Antibodies such as anti-idiotype antibodies, or fragments thereof, and synthetic peptide mimotopes, which can mimic an antigen or antigenic determinant, are also captured under the definition

of antigen as used herein. Similarly, an oligonucleotide or polynucleotide which expresses an antigen or antigenic determinant *in vivo*, such as in gene therapy and DNA immunization applications, is also included in the definition of antigen herein.

For purposes of the present invention, antigens can be derived from any of 5 several known viruses, bacteria, parasites and fungi, as described more fully below. The term also intends any of the various tumor antigens. Furthermore, for purposes of the present invention, an "antigen" refers to a protein which includes modifications, such as deletions, additions and substitutions (generally conservative in nature), to the native sequence, so long as the protein maintains the ability to elicit an immunological 10 response, as defined herein. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the antigens.

An "immunological response" to an antigen or composition is the development 15 in a subject of a humoral and/or a cellular immune response to an antigen present in the composition of interest. For purposes of the present invention, a "humoral immune response" refers to an immune response mediated by antibody molecules, while a "cellular immune response" is one mediated by T-lymphocytes and/or other white blood cells. One important aspect of cellular immunity involves an antigen-specific 20 response by cytolytic T-cells ("CTL"s). CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the surfaces of cells. CTLs help induce and promote the destruction of intracellular microbes, or the lysis of cells infected with such microbes. Another aspect of cellular immunity involves an antigen-specific 25 response by helper T-cells. Helper T-cells act to help stimulate the function, and focus the activity of, nonspecific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface. A "cellular immune response" also refers to the production of cytokines, chemokines and other such molecules produced by activated T-cells and/or other white blood cells, including those derived from CD4+ and CD8+ T-cells.

30 A composition or vaccine that elicits a cellular immune response may serve to sensitize a vertebrate subject by the presentation of antigen in association with MHC

molecules at the cell surface. The cell-mediated immune response is directed at, or near, cells presenting antigen at their surface. In addition, antigen-specific T-lymphocytes can be generated to allow for the future protection of an immunized host.

The ability of a particular antigen to stimulate a cell-mediated immunological response may be determined by a number of assays, such as by lymphoproliferation (lymphocyte activation) assays, CTL cytotoxic cell assays, or by assaying for T-lymphocytes specific for the antigen in a sensitized subject. Such assays are well known in the art. See, e.g., Erickson et al., *J. Immunol.* (1993) 151:4189-4199; Doe et al., *Eur. J. Immunol.* (1994) 24:2369-2376. Recent methods of measuring cell-mediated immune response include measurement of intracellular cytokines or cytokine secretion by T-cell populations, or by measurement of epitope specific T-cells (e.g., by the tetramer technique)(reviewed by McMichael, A.J., and O'Callaghan, C.A., *J. Exp. Med.* 187(9):1367-1371, 1998; Mcheyzer-Williams, M.G., et al, *Immunol. Rev.* 150:5-21, 1996; Lalvani, A., et al, *J. Exp. Med.* 186:859-865, 1997).

Thus, an immunological response as used herein may be one which stimulates the production of CTLs, and/or the production or activation of helper T- cells. The antigen of interest may also elicit an antibody-mediated immune response. Hence, an immunological response may include one or more of the following effects: the production of antibodies by B-cells; and/or the activation of suppressor T-cells and/or $\gamma\delta$ T-cells directed specifically to an antigen or antigens present in the composition or vaccine of interest. These responses may serve to neutralize infectivity, and/or mediate antibody-complement, or antibody dependent cell cytotoxicity (ADCC) to provide protection to an immunized host. Such responses can be determined using standard immunoassays and neutralization assays, well known in the art.

An "immunogenic composition" is a composition that comprises an antigenic molecule where administration of the composition to a subject results in the development in the subject of a humoral and/or a cellular immune response to the antigenic molecule of interest. The immunogenic composition can be introduced directly into a recipient subject, such as by injection, inhalation, oral, intranasal and mucosal (e.g., intra-rectally or intra-vaginally) administration.

By "subunit vaccine" is meant a vaccine composition which includes one or more selected antigens but not all antigens, derived from or homologous to, an antigen from a pathogen of interest such as from a virus, bacterium, parasite or fungus. Such a composition is substantially free of intact pathogen cells or pathogenic particles, or the lysate of such cells or particles. Thus, a "subunit vaccine" can be prepared from at least partially purified (preferably substantially purified) immunogenic polypeptides from the pathogen, or analogs thereof. The method of obtaining an antigen included in the subunit vaccine can thus include standard purification techniques, recombinant production, or synthetic production.

"Substantially purified" general refers to isolation of a substance (compound, polynucleotide, protein, polypeptide, polypeptide composition) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample. Techniques for purifying polynucleotides and polypeptides of interest are well-known in the art and include, for example, ion-exchange chromatography, affinity chromatography and sedimentation according to density.

A "coding sequence" or a sequence which "encodes" a selected polypeptide, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences (or "control elements"). The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from viral, prokaryotic or eucaryotic mRNA, genomic DNA sequences from viral or prokaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence such as a stop codon may be located 3' to the coding sequence.

Typical "control elements", include, but are not limited to, transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5' to the coding sequence), and

translation termination sequences. For example, the sequences and/or vectors described herein may also include one or more additional sequences that may optimize translation and/or termination including, but not limited to, a Kozak sequence (e.g., GCCACC placed in front (5') of the ATG of the codon-optimized wild-type leader or 5 any other suitable leader sequence (e.g., tpa1, tpa2, wtLnat (native wild-type leader)) or a termination sequence (e.g., TAA or, preferably, TAAA placed after (3') the coding sequence.

A "polynucleotide coding sequence" or a sequence which "encodes" a selected polypeptide, is a nucleic acid molecule which is transcribed (in the case of DNA) and 10 translated (in the case of mRNA) into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences (or "control elements"). The boundaries of the coding sequence are determined by a start codon, for example, at or near the 5' terminus and a translation stop codon, for example, at or near the 3' terminus. Exemplary coding sequences are the modified viral polypeptide-coding sequences of 15 the present invention. The coding regions of the polynucleotide sequences of the present invention are identifiable by one of skill in the art and may, for example, be easily identified by performing translations of all three frames of the polynucleotide and identifying the frame corresponding to the encoded polypeptide, for example, a synthetic nef polynucleotide of the present invention encodes a nef-derived 20 polypeptide. A transcription termination sequence may be located 3' to the coding sequence. Typical "control elements", include, but are not limited to, transcription regulators, such as promoters, transcription enhancer elements, transcription 25 termination signals, and polyadenylation sequences; and translation regulators, such as sequences for optimization of initiation of translation, e.g., Shine-Dalgarno (ribosome binding site) sequences, Kozak sequences (i.e., sequences for the optimization of translation, located, for example, 5' to the coding sequence), leader sequences, translation initiation codon (e.g., ATG), and translation termination sequences. In certain embodiments, one or more translation regulation or initiation sequences (e.g., the leader sequence) are derived from wild-type translation initiation sequences, *i.e.*, 30 sequences that regulate translation of the coding region in their native state. Wild-type leader sequences that have been modified, using the methods described herein, also

find use in the present invention. Promoters can include inducible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, 5 cofactor, regulatory protein, etc.), and constitutive promoters.

A "nucleic acid" molecule can include, but is not limited to, prokaryotic sequences, eucaryotic mRNA, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. The term also captures sequences that include any of the known base 10 analogs of DNA and RNA.

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence when the proper enzymes are present. The 15 promoter need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

20 "Recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of the polynucleotide with which it is associated in nature; and/or (2) is linked to a polynucleotide other than that to which it is linked in nature. The term "recombinant" 25 as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. "Recombinant host cells," "host cells," "cells," "cell lines," "cell cultures," and other such terms denoting prokaryotic microorganisms or eucaryotic cell lines cultured as unicellular entities, are used interchangeably, and refer to cells which can be, or have been, used as recipients for 30 recombinant vectors or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental

cell may not necessarily be completely identical in morphology or in genomic or total DNA complement to the original parent, due to accidental or deliberate mutation. Progeny of the parental cell which are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence 5 encoding a desired peptide, are included in the progeny intended by this definition, and are covered by the above terms.

Techniques for determining amino acid sequence "similarity" are well known in the art. In general, "similarity" means the exact amino acid to amino acid comparison of two or more polypeptides at the appropriate place, where amino acids are identical or possess similar chemical and/or physical properties such as charge or 10 hydrophobicity. A so-termed "percent similarity" then can be determined between the compared polypeptide sequences. Techniques for determining nucleic acid and amino acid sequence identity also are well known in the art and include determining the nucleotide sequence of the mRNA for that gene (usually via a cDNA intermediate) and 15 determining the amino acid sequence encoded thereby, and comparing this to a second amino acid sequence. In general, "identity" refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two polynucleotides or polypeptide sequences, respectively.

Two or more polynucleotide sequences can be compared by determining their "percent identity." Two or more amino acid sequences likewise can be compared by determining their "percent identity." The percent identity of two sequences, whether nucleic acid or peptide sequences, is generally described as the number of exact matches between two aligned sequences divided by the length of the shorter sequence and multiplied by 100. An approximate alignment for nucleic acid sequences is 20 provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be extended to use with peptide sequences using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M.O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, Nucl. 25 Acids Res. 14(6):6745-6763 (1986). An implementation of this algorithm for nucleic acid and peptide sequences is provided by the Genetics Computer Group (Madison, 30

WT) in their BestFit utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, WI). Other equally suitable programs for calculating the percent identity or similarity between sequences

5 are generally known in the art.

For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions. Another method of establishing percent identity in the context of the present invention is to use 10 the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages, the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). 15 From the data generated, the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, such as the alignment program BLAST, which can also be used with default parameters. For example, BLASTN and BLASTP can be used with the following default parameters: genetic code = standard; filter = none; strand = 20 both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs can be found at the following internet address: <http://www.ncbi.nlm.gov/cgi-bin/BLAST>.

25 One of skill in the art can readily determine the proper search parameters to use for a given sequence, exemplary preferred Smith Waterman based parameters are presented above. For example, the search parameters may vary based on the size of the sequence in question. Thus, for the polynucleotide sequences of the present invention the length of the polynucleotide sequence disclosed herein is searched against 30 a selected database and compared to sequences of essentially the same length to determine percent identity. For example, a representative embodiment of the present

invention would include an isolated polynucleotide comprising X contiguous nucleotides, wherein (i) the X contiguous nucleotides have at least about a selected level of percent identity relative to Y contiguous nucleotides of one or more of the sequences described herein (e.g., in Table C) or fragment thereof, and (ii) for search purposes X equals Y, wherein Y is a selected reference polynucleotide of defined length (for example, a length of from 15 nucleotides up to the number of nucleotides present in a selected full-length sequence).

The sequences of the present invention can include fragments of the sequences, for example, from about 15 nucleotides up to the number of nucleotides present in the full-length sequences described herein (e.g., see the Figures), including all integer values falling within the above-described range. For example, fragments of the polynucleotide sequences of the present invention may be 30-60 nucleotides, 60-120 nucleotides, 120-240 nucleotides, 240-480 nucleotides, 480-1000 nucleotides, and all integer values therebetween.

The synthetic expression cassettes (and purified polynucleotides) of the present invention include related polynucleotide sequences having about 80% to 100%, greater than 80-85%, preferably greater than 90-92%, more preferably greater than 95%, and most preferably greater than 98% up to 100% (including all integer values falling within these described ranges) sequence identity to the synthetic expression cassette and/or polynucleotide sequences disclosed herein (for example, to the sequences of the present invention) when the sequences of the present invention are used as the query sequence against, for example, a database of sequences.

Two nucleic acid fragments are considered to "selectively hybridize" as described herein. The degree of sequence identity between two nucleic acid molecules affects the efficiency and strength of hybridization events between such molecules. A partially identical nucleic acid sequence will at least partially inhibit a completely identical sequence from hybridizing to a target molecule. Inhibition of hybridization of the completely identical sequence can be assessed using hybridization assays that are well known in the art (e.g., Southern blot, Northern blot, solution hybridization, or the like, see Sambrook, et al., *supra* or Ausubel et al., *supra*). Such assays can be conducted using varying degrees of selectivity, for example, using conditions varying

from low to high stringency. If conditions of low stringency are employed, the absence of non-specific binding can be assessed using a secondary probe that lacks even a partial degree of sequence identity (for example, a probe having less than about 30% sequence identity with the target molecule), such that, in the absence of non-specific binding events, the secondary probe will not hybridize to the target.

When utilizing a hybridization-based detection system, a nucleic acid probe is chosen that is complementary to a target nucleic acid sequence, and then by selection of appropriate conditions the probe and the target sequence "selectively hybridize," or bind, to each other to form a hybrid molecule. A nucleic acid molecule that is capable of hybridizing selectively to a target sequence under "moderately stringent" typically hybridizes under conditions that allow detection of a target nucleic acid sequence of at least about 10-14 nucleotides in length having at least approximately 70% sequence identity with the sequence of the selected nucleic acid probe. Stringent hybridization conditions typically allow detection of target nucleic acid sequences of at least about 10-14 nucleotides in length having a sequence identity of greater than about 90-95% with the sequence of the selected nucleic acid probe. Hybridization conditions useful for probe/target hybridization where the probe and target have a specific degree of sequence identity, can be determined as is known in the art (see, for example, Nucleic Acid Hybridization: A Practical Approach, editors B.D. Hames and S.J. Higgins, (1985) Oxford; Washington, DC; IRL Press).

With respect to stringency conditions for hybridization, it is well known in the art that numerous equivalent conditions can be employed to establish a particular stringency by varying, for example, the following factors: the length and nature of probe and target sequences, base composition of the various sequences, concentrations of salts and other hybridization solution components, the presence or absence of blocking agents in the hybridization solutions (e.g., formamide, dextran sulfate, and polyethylene glycol), hybridization reaction temperature and time parameters, as well as, varying wash conditions. The selection of a particular set of hybridization conditions is selected following standard methods in the art (see, for example, Sambrook, et al., *supra* or Ausubel et al., *supra*).

A first polynucleotide is "derived from" second polynucleotide if it has the same or substantially the same basepair sequence as a region of the second polynucleotide, its cDNA, complements thereof, or if it displays sequence identity as described above.

5 A first polypeptide is "derived from" a second polypeptide if it is (i) encoded by a first polynucleotide derived from a second polynucleotide, or (ii) displays sequence identity to the second polypeptides as described above.

10 Generally, a viral polypeptide is "derived from" a particular polypeptide of a virus (viral polypeptide) if it is (i) encoded by an open reading frame of a polynucleotide of that virus (viral polynucleotide), or (ii) displays sequence identity to polypeptides of that virus as described above.

15 "Encoded by" refers to a nucleic acid sequence which codes for a polypeptide sequence, wherein the polypeptide sequence or a portion thereof contains an amino acid sequence of at least 3 to 5 amino acids, more preferably at least 8 to 10 amino acids, and even more preferably at least 15 to 20 amino acids from a polypeptide encoded by the nucleic acid sequence. Also encompassed are polypeptide sequences which are immunologically identifiable with a polypeptide encoded by the sequence. Further, polyproteins can be constructed by fusing in-frame two or more polynucleotide sequences encoding polypeptide or peptide products. Further, 20 polycistronic coding sequences may be produced by placing two or more polynucleotide sequences encoding polypeptide products adjacent each other, typically under the control of one promoter, wherein each polypeptide coding sequence may be modified to include sequences for internal ribosome binding sites.

25 "Purified polynucleotide" refers to a polynucleotide of interest or fragment thereof which is essentially free, e.g., contains less than about 50%, preferably less than about 70%, and more preferably less than about 90%, of the protein with which the polynucleotide is naturally associated. Techniques for purifying polynucleotides of interest are well-known in the art and include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the 30 polynucleotide(s) and proteins by ion-exchange chromatography, affinity chromatography and sedimentation according to density.

By "nucleic acid immunization" is meant the introduction of a nucleic acid molecule encoding one or more selected antigens into a host cell, for the *in vivo* expression of an antigen, antigens, an epitope, or epitopes. The nucleic acid molecule can be introduced directly into a recipient subject, such as by injection, inhalation, oral, 5 intranasal and mucosal administration, or the like, or can be introduced *ex vivo*, into cells which have been removed from the host. In the latter case, the transformed cells are reintroduced into the subject where an immune response can be mounted against the antigen encoded by the nucleic acid molecule.

"Gene transfer" or "gene delivery" refers to methods or systems for reliably 10 inserting DNA of interest into a host cell. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., episomes), or integration of transferred genetic material into the genomic DNA of host cells. Gene delivery expression vectors include, but are not limited to, vectors derived from alphaviruses, pox viruses and 15 vaccinia viruses. When used for immunization, such gene delivery expression vectors may be referred to as vaccines or vaccine vectors.

"T lymphocytes" or "T cells" are non-antibody producing lymphocytes that 20 constitute a part of the cell-mediated arm of the immune system. T cells arise from immature lymphocytes that migrate from the bone marrow to the thymus, where they undergo a maturation process under the direction of thymic hormones. Here, the mature lymphocytes rapidly divide increasing to very large numbers. The maturing T cells become immunocompetent based on their ability to recognize and bind a specific antigen. Activation of immunocompetent T cells is triggered when an antigen binds to the lymphocyte's surface receptors.

25 The term "transfection" is used to refer to the uptake of foreign DNA by a cell. A cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, Davis et 30 al. (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu et al. (1981) *Gene* 13:197. Such techniques can be used to introduce one or more exogenous DNA

moieties into suitable host cells. The term refers to both stable and transient uptake of the genetic material, and includes uptake of peptide- or antibody-linked DNAs.

5 A "vector" is capable of transferring gene sequences to target cells (e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes). Typically, "vector construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors.

Transfer of a "suicide gene" (e.g., a drug-susceptibility gene) to a target cell 10 renders the cell sensitive to compounds or compositions that are relatively nontoxic to normal cells. Moolten, F.L. (1994) *Cancer Gene Ther.* 1:279-287. Examples of suicide genes are thymidine kinase of herpes simplex virus (HSV-tk), cytochrome P450 (Manome et al. (1996) *Gene Therapy* 3:513-520), human deoxycytidine kinase 15 (Manome et al. (1996) *Nature Medicine* 2(5):567-573) and the bacterial enzyme cytosine deaminase (Dong et al. (1996) *Human Gene Therapy* 7:713-720). Cells which express these genes are rendered sensitive to the effects of the relatively 20 nontoxic prodrugs ganciclovir (HSV-tk), cyclophosphamide (cytochrome P450 2B1), cytosine arabinoside (human deoxycytidine kinase) or 5-fluorocytosine (bacterial cytosine deaminase). Culver et al. (1992) *Science* 256:1550-1552, Huber et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:8302-8306.

A "selectable marker" or "reporter marker" refers to a nucleotide sequence included in a gene transfer vector that has no therapeutic activity, but rather is included to allow for simpler preparation, manufacturing, characterization or testing of the gene transfer vector.

25 A "specific binding agent" refers to a member of a specific binding pair of molecules wherein one of the molecules specifically binds to the second molecule through chemical and/or physical means. One example of a specific binding agent is an antibody directed against a selected antigen.

30 By "subject" is meant any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as rhesus macaque, chimpanzees and other apes and monkey species; farm animals such

as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular 5 age. Thus, both adult and newborn individuals are intended to be covered. The system described above is intended for use in any of the above vertebrate species, since the immune systems of all of these vertebrates operate similarly.

By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be 10 administered to an individual in a formulation or composition without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

By "physiological pH" or a "pH in the physiological range" is meant a pH in the range of approximately 7.0 to 8.0 inclusive, more typically in the range of 15 approximately 7.2 to 7.6 inclusive.

As used herein, "treatment" refers to any of (i) the prevention of infection or reinfection, as in a traditional vaccine, (ii) the reduction or elimination of symptoms, and (iii) the substantial or complete elimination of the pathogen in question. Treatment may be effected prophylactically (prior to infection) or therapeutically (following 20 infection).

By "co-administration" is meant administration of more than one composition or molecule. Thus, co-administration includes concurrent administration or sequentially administration (in any order), via the same or different routes of administration. Non-limiting examples of co-administration regimes include, co- 25 administration of nucleic acid and polypeptide; co-administration of different nucleic acids (e.g., different expression cassettes as described herein and/or different gene delivery vectors); and co-administration of different polypeptides (e.g., different HIV polypeptides and/or different adjuvants). The term also encompasses multiple administrations of one of the co-administered molecules or compositions (e.g., multiple 30 administrations of one or more of the expression cassettes described herein followed by one or more administrations of a polypeptide-containing composition). In cases

where the molecules or compositions are delivered sequentially, the time between each administration can be readily determined by one of skill in the art in view of the teachings herein.

“Lentiviral vector”, and “recombinant lentiviral vector” refer to a nucleic acid construct which carries, and within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest. The lentiviral vector include at least one transcriptional promoter/enhancer or locus defining element(s), or other elements which control gene expression by other means such as alternate splicing, nuclear RNA export, post-translational modification of messenger, or post-transcriptional modification of protein. Such vector constructs must also include a packaging signal, long terminal repeats (LTRS) or portion thereof, and positive and negative strand primer binding sites appropriate to the retrovirus used (if these are not already present in the retroviral vector). Optionally, the recombinant lentiviral vector may also include a signal which directs polyadenylation, selectable markers such as Neo, TK, hygromycin, phleomycin, histidinol, or DHFR, as well as one or more restriction sites and a translation termination sequence. By way of example, such vectors typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3'LTR or a portion thereof

“Lentiviral vector particle” as utilized within the present invention refers to a lentivirus which carries at least one gene of interest. The retrovirus may also contain a selectable marker. The recombinant lentivirus is capable of reverse transcribing its genetic material (RNA) into DNA and incorporating this genetic material into a host cell's DNA upon infection. Lentiviral vector particles may have a lentiviral envelope, a non-lentiviral envelope (e.g., an amphi or VSV-G envelope), or a chimeric envelope.

“Nucleic acid expression vector” or “Expression cassette” refers to an assembly which is capable of directing the expression of a sequence or gene of interest. The nucleic acid expression vector includes a promoter which is operably linked to the sequences or gene(s) of interest. Other control elements may be present as well. Expression cassettes described herein may be contained within a plasmid construct. In addition to the components of the expression cassette, the plasmid construct may also include a bacterial origin of replication, one or more selectable markers, a signal which

allows the plasmid construct to exist as single-stranded DNA (e.g., a M13 origin of replication), a multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).

5 "Packaging cell" refers to a cell which contains those elements necessary for production of infectious recombinant retrovirus which are lacking in a recombinant retroviral vector. Typically, such packaging cells contain one or more expression cassettes which are capable of expressing proteins which encode *Gag*, *pol* and *env* proteins.

10 "Producer cell" or "vector producing cell" refers to a cell which contains all elements necessary for production of recombinant retroviral vector particles.

2. MODES OF CARRYING OUT THE INVENTION

Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, 15 of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

20 Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.

2.1. THE HIV GENOME

The HIV genome and various polypeptide-encoding regions are shown in Table A. The nucleotide positions are given relative to 8_5_TV1_C.ZA (Figure 1; an HIV 25 Type C isolate). However, it will be readily apparent to one of ordinary skill in the art in view of the teachings of the present disclosure how to determine corresponding regions in other HIV strains or variants (e.g., isolates HIV_{MB}, HIV_{SF2}, HIV-1_{SF162}, HIV-1_{SF170}, HIV_{LAV}, HIV_{LAI}, HIV_{MN}, HIV-1_{CM235}, HIV-1_{US4}, other HIV-1 strains from diverse subtypes (e.g., subtypes, A through G, and O), HIV-2 strains and diverse 30 subtypes (e.g., HIV-2_{UC1} and HIV-2_{UC2}), and simian immunodeficiency virus (SIV). (See, e.g., Virology, 3rd Edition (W.K. Joklik ed. 1988); *Fundamental Virology*, 2nd

Edition (B.N. Fields and D.M. Knipe, eds. 1991); *Virology*, 3rd Edition (Fields, BN, DM Knipe, PM Howley, Editors, 1996, Lippincott-Raven, Philadelphia, PA; for a description of these and other related viruses), using for example, sequence comparison programs (*e.g.*, BLAST and others described herein) or identification and alignment of structural features (*e.g.*, a program such as the “ALB” program described herein that can identify the various regions).

Table A: Regions of the HIV Genome relative to 8_5_TV1_C.ZA

	Region	Position in nucleotide sequence
10	5'LTR	1-636
	U3	1-457
	R	458-553
	U5	554-636
	NFkB II	340-348
15	NFkB I	354-362
	Sp1 III	379-388
	Sp1 II	390-398
	Sp1 I	400-410
	TATA Box	429-433
20	TAR	474-499
	Poly A signal	529-534
	PBS	638-655
25	p7 binding region, packaging signal	685-791
	Gag:	792-2285
	p17	792-1178
	p24	1179-1871
30	Cyclophilin A bdg.	1395-1505
	MHR	1632-1694
	p2	1872-1907
	p7	1908-2072
	Frameshift slip	2072-2078
35	p1	2073-2120
	p6Gag	2121-2285
	Zn-motif I	1950-1991

	Zn-motif II	2013-2054
	Pol:	2072-5086
	p6Pol	2072-2245
5	Prot	2246-2542
	p66RT	2543-4210
	p15RNaseH	3857-4210
	p31Int	4211-5086
10	Vif:	5034-5612
	Hydrophilic region	5292-5315
	Vpr:	5552-5839
	Oligomerization	5552-5677
15	Amphipathic a-helix	5597-5653
	Tat:	5823-6038 and 8417-8509
	Tat-1 exon	5823-6038
	Tat-2 exon	8417-8509
20	N-terminal domain	5823-5885
	Trans-activation domain	5886-5933
	Transduction domain	5961-5993
	Rev:	5962-6037 and 8416-8663
25	Rev-1 exon	5962-6037
	Rev-2 exon	8416-8663
	High-affinity bdg. site	8439-8486
	Leu-rich effector domain	8562-8588
30	Vpu:	6060-6326
	Transmembrane domain	6060-6161
	Cytoplasmic domain	6162-6326

	Env (gp160):	6244-8853
	Signal peptide	6244-6324
	gp120	6325-7794
	V1	6628-6729
5	V2	6727-6852
	V3	7150-7254
	V4	7411-7506
	V5	7663-7674
	C1	6325-6627
10	C2	6853-7149
	C3	7255-7410
	C4	7507-7662
	C5	7675-7794
	CD4 binding	7540-7566
15	gp41	7795-8853
	Fusion peptide	7789-7842
	Oligomerization domain	7924-7959
	N-terminal heptad repeat	7921-8028
	C-terminal heptad repeat	8173-8280
20	Immunodominant region	8023-8076
	Nef:	8855-9478
	Myristylation	8858-8875
	SH3 binding	9062-9091
25	Polypurine tract	9128-9154
	SH3 binding	9296-9307

It will be readily apparent that one of skill in the art can readily align any sequence to that shown in Table A to determine relative locations of any particular HIV gene. For example, using one of the alignment programs described herein (e.g., BLAST), other HIV genomic sequences can be aligned with 8_5_TV1_C.ZA (Table A) and locations of genes determined. Polypeptide sequences can be similarly aligned. For example, Figures 2A-2C shows the alignment of Env polypeptide sequences from various strains, relative to SF-162. As described in detail in co-owned WO/39303, Env polypeptides (e.g., gp120, gp140 and gp160) include a "bridging sheet" comprised of 4 anti-parallel b-strands (b-2, b-3, b-20 and b-21) that form a b-sheet. Extruding from one pair of the b-strands (b-2 and b-3) are two loops, V1 and V2. The

b-2 sheet occurs at approximately amino acid residue 113 (Cys) to amino acid residue 117 (Thr) while b-3 occurs at approximately amino acid residue 192 (Ser) to amino acid residue 194 (Ile), relative to SF-162. The "V1/V2 region" occurs at approximately amino acid positions 120 (Cys) to residue 189 (Cys), relative to SF-162.

5 Extruding from the second pair of b-strands (b-20 and b-21) is a "small-loop" structure, also referred to herein as "the bridging sheet small loop." The locations of both the small loop and bridging sheet small loop can be determined relative to HXB-2 following the teachings herein and in WO/39303. Also shown by arrows in Figure 2A-C are approximate sites for deletions sequence from the beta sheet region. The

10 denotes N-glycosylation sites that can be mutated following the teachings of the present specification.

2.2.0 SYNTHETIC EXPRESSION CASSETTES

One aspect of the present invention is the generation of HIV-1 coding sequences, and related sequences, for example having improved expression relative to the corresponding wild-type sequences.

2.2.1 MODIFICATION OF HIV-1 NUCLEIC ACID CODING SEQUENCES

First, the HIV-1 codon usage pattern was modified so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes. The HIV codon usage reflects a high content of the nucleotides A or T of the codon-triplet. The effect of the HIV-1 codon usage is a high AT content in the DNA sequence that results in a decreased translation ability and instability of the mRNA. In comparison, highly expressed human codons prefer the nucleotides G or C.

20 The HIV coding sequences were modified to be comparable to codon usage found in highly expressed human genes.

Second, there are inhibitory (or instability) elements (INS) located within the coding sequences of, for example, the Gag coding sequences. The RRE is a secondary RNA structure that interacts with the HIV encoded Rev-protein to overcome the expression down-regulating effects of the INS. To overcome the post-transcriptional activating mechanisms of RRE and Rev, the instability elements can be inactivated by

introducing multiple point mutations that do not alter the reading frame of the encoded proteins.

Third, for some genes the coding sequence has been altered such that the polynucleotide coding sequence encodes a gene product that is inactive or non-functional (e.g., inactivated polymerase, protease, tat, rev, nef, vif, vpr, and/or vpu gene products). Example 1 describes some exemplary mutations. Example 8 presents information concerning functional analysis of mutated Tat, Rev and Nef antigens.

The synthetic coding sequences are assembled by methods known in the art, for example by companies such as the Midland Certified Reagent Company (Midland, 10 Texas).

Modification of the Gag polypeptide coding sequences results in improved expression relative to the wild-type coding sequences in a number of mammalian cell lines (as well as other types of cell lines, including, but not limited to, insect cells).

Some exemplary polynucleotide sequences encoding Gag-containing 15 polypeptides are GagComplPolmut.SF2, GagComplPolmutAtt.SF2, GagComplPolmutIna.SF2, gagCpolInaTatRevNef.opt_B, GagPolmutAtt.SF2, GagPolmutIna.SF2, GagProtInaRTmut.SF2, GagProtInaRTmutTatRevNef.opt_B, GagRTmut.SF2, and GagTatRevNef.opt_B.

Similarly, the present invention also includes synthetic Env-encoding 20 polynucleotides and modified Env proteins, for example, gp140.modSF162.CwtLmod, gp140.modSF162.CwtLnat, gp160.modSF162.delV2.mut7, and gp160.modSF162.delV2.mut8.

The codon usage pattern for Env was modified as described above for Gag so 25 that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes. Experiments performed in support of the present invention show that the synthetic Env sequences were capable of higher level of protein production relative to the native Env sequences.

Modification of the Env polypeptide coding sequences results in improved 30 expression relative to the wild-type coding sequences in a number of mammalian cell lines (as well as other types of cell lines, including, but not limited to, insect cells). Similar Env polypeptide coding sequences can be obtained, modified and tested for

improved expression from a variety of isolates, including those described above for Gag.

Further modifications of Env include, but are not limited to, generating polynucleotides that encode Env polypeptides having mutations and/or deletions 5 therein. For instance, the hypervariable regions, V1 and/or V2, can be deleted as described herein. Additionally, other modifications, for example to the bridging sheet region and/or to N-glycosylation sites within Env can also be performed following the teachings of the present specification. (see, Figure2A-C, as well as WO 00/39303, WO 00/39302, WO 00/39304, WO 02/04493). Various combinations of these 10 modifications can be employed to generate synthetic expression cassettes as described herein.

The present invention also includes expression cassettes which include synthetic Pol sequences. As noted above, "Pol" includes, but is not limited to, the protein-encoding regions comprising polymerase, protease, reverse transcriptase 15 and/or integrase-containing sequences (Wan et al (1996) *Biochem. J.* 316:569-573; Kohl et al. (1988) *PNAS USA* 85:4686-4690; Krausslich et al. (1988) *J. Virol.* 62:4393-4397; Coffin, "Retroviridae and their Replication" in *Virology*, pp1437-1500 (Raven, New York, 1990); Patel et. al. (1995) *Biochemistry* 34:5351-5363). Thus, the synthetic expression cassettes exemplified herein include one or more of these regions 20 and one or more changes to the resulting amino acid sequences. Some exemplary polynucleotide sequences encoding Pol-derived polypeptides are presented in Table C.

The codon usage pattern for Pol was modified as described above for Gag and Env so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes.

25 Constructs may be modified in various ways. For example, the expression constructs may include a sequence that encodes the first 6 amino acids of the integrase polypeptide. This 6 amino acid region is believed to provide a cleavage recognition site recognized by HIV protease (see, e.g., McCornack et al. (1997) *FEBS Letts* 414:84-88). Constructs may include a multiple cloning site (MCS) for insertion of 30 one or more transgenes, typically at the 3' end of the construct. In addition, a cassette encoding a catalytic center epitope derived from the catalytic center in RT is typically

included 3' of the sequence encoding 6 amino acids of integrase. This cassette encodes Ile178 through Serine 191 of RT and may be added to keep this well conserved region as a possible CTL epitope. Further, the constructs contain an insertion mutations to preserve the reading frame. (see, e.g., Park et al. (1991) *J. Virol.* 65:5111).

5 In certain embodiments, the catalytic center and/or primer grip region of RT are modified. The catalytic center and primer grip regions of RT are described, for example, in Patel et al. (1995) *Biochem.* 34:5351 and Palaniappan et al. (1997) *J. Biol. Chem.* 272(17):11157. For example, wild type sequence encoding the amino acids YMDD at positions 183-185 of p66 RT, numbered relative to AF110975, may be 10 replaced with sequence encoding the amino acids "AP". Further, the primer grip region (amino acids WMGY, residues 229-232 of p66RT, numbered relative to AF110975) may be replaced with sequence encoding the amino acids "PI."

15 For the Pol sequence, the changes in codon usage are typically restricted to the regions up to the -1 frameshift and starting again at the end of the Gag reading frame; however, regions within the frameshift translation region can be modified as well. Finally, inhibitory (or instability) elements (INS) located within the coding sequences 20 of the protease polypeptide coding sequence can be altered as well.

Experiments can be performed in support of the present invention to show that the synthetic Pol sequences were capable of higher level of protein production relative 25 to the native Pol sequences. Modification of the Pol polypeptide coding sequences results in improved expression relative to the wild-type coding sequences in a number of mammalian cell lines (as well as other types of cell lines, including, but not limited to, insect cells). Similar Pol polypeptide coding sequences can be obtained, modified and tested for improved expression from a variety of isolates, including those described above for Gag and Env.

The present invention also includes expression cassettes which include synthetic sequences derived HIV genes other than Gag, Env and Pol, including but not limited to, regions within Gag, Env, Pol, as well as, GagComplPolmut.SF2, GagComplPolmutAtt.SF2, GagComplPolmutIna.SF2, gagCpolInaTatRevNef.opt_B, 30 GagPolmutAtt.SF2, GagPolmutIna.SF2, GagProtInaRTmut.SF2, GagProtInaRTmutTatRevNef.opt_B, GagRTmut.SF2, GagTatRevNef.opt_B,

gp140.modSF162.CwtLmod, gp140.modSF162.CwtLnat,
gp160.modSF162.delV2.mut7, gp160.modSF162.delV2.mut8, int.opt.mut.SF2,
int.opt.SF2, nef.D125G.-myr.opt.SF162, nef.D107G.-myr18.opt.SF162,
nef.opt.D125G.SF162, nef.opt.SF162, p15RnaseH.opt.SF2, p2Pol.opt.YMWM.SF2,
5 p2PolInaopt.YM.SF2, p2Polopt.SF2, p2PolTatRevNef.opt.native_B,
p2PolTatRevNef.opt_B, pol.opt.SF2, prot.opt.SF2, protIna.opt.SF2,
protInaRT.YM.opt.SF2, protInaRT.YMWM.opt.SF2, ProtInaRTmut.SF2,
protRT.opt.SF2, ProtRT.TatRevNef.opt_B, ProtRTTatRevNef.opt_B,
rev.exon1_2.M5-10.opt.SF162, rev.exon1_2.opt.SF162, RT.opt.SF2 (mutant),
10 RT.opt.SF2 (native), RTmut.SF2, tat.exon1_2.opt.C22-37.SF2,
tat.exon1_2.opt.C37.SF2, TatRevNef.opt.native.SF162, TatRevNef.opt.SF162,
TatRevNefGag B, TatRevNefgagCpolIna B, TatRevNefGagProtInaRTmut B,
TatRevNefp2Pol.opt_B, TatRevNefprotRTopt B, vif.opt.SF2, vpr.opt.SF2, and
vpu.opt.SF162. Sequences obtained from other strains can be manipulated in similar
15 fashion following the teachings of the present specification. As noted above, the
codon usage pattern is modified as described above for Gag, Env and Pol so that the
resulting nucleic acid coding sequence is comparable to codon usage found in highly
expressed human genes. Typically these synthetic sequences are capable of higher
level of protein production relative to the native sequences and that modification of the
20 wild-type polypeptide coding sequences results in improved expression relative to the
wild-type coding sequences in a number of mammalian cell lines (as well as other types
of cell lines, including, but not limited to, insect cells). Furthermore, the nucleic acid
sequence can also be modified to introduce mutations into one or more regions of the
gene, for instance to alter the function of the gene product (e.g., render the gene
25 product non-functional) and/or to eliminate site modifications (e.g., the myristylation
site in Nef).

Synthetic expression cassettes, derived from HIV Type B coding sequences,
exemplified herein include, but are not limited to, those comprising one or more of the
following synthetic polynucleotides: GagComplPolmut.SF2,
30 GagComplPolmutAtt.SF2, GagComplPolmutIna.SF2, gagCpolInaTatRevNef.opt_B,
GagPolmutAtt.SF2, GagPolmutIna.SF2, GagProtInaRTmut.SF2,

GagProtInaRTmutTatRevNef.opt_B, GagRTmut.SF2, GagTatRevNef.opt_B,
gp140.modSF162.CwtLmod, gp140.modSF162.CwtLnat,
gp160.modSF162.delV2.mut7, gp160.modSF162.delV2.mut8, int.opt.mut.SF2,
int.opt.SF2, nef.D125G.-myr.opt.SF162, nef.D107G.-myr18.opt.SF162,
5 nef.opt.D125G.SF162, nef.opt.SF162, p15RnaseH.opt.SF2, p2Pol.opt.YMWM.SF2,
p2PolInaopt.YM.SF2, p2Polopt.SF2, p2PolTatRevNef.opt.native_B,
p2PolTatRevNef.opt_B, pol.opt.SF2, prot.opt.SF2, protIna.opt.SF2,
protInaRT.YM.opt.SF2, protInaRT.YMWM.opt.SF2, ProtInaRTmut.SF2,
protRT.opt.SF2, ProtRT.TatRevNef.opt_B, ProtRTTatRevNef.opt_B,
10 rev.exon1_2.M5-10.opt.SF162, rev.exon1_2.opt.SF162, RT.opt.SF2 (mutant),
RT.opt.SF2 (native), RTmut.SF2, tat.exon1_2.opt.C22-37.SF2,
tat.exon1_2.opt.C37.SF2, TatRevNef.opt.native.SF162, TatRevNef.opt.SF162,
TatRevNefGag B, TatRevNefgagCpolIna B, TatRevNefGagProtInaRTmut B,
TatRevNefp2Pol.opt_B, TatRevNefprotRTopt B, vif.opt.SF2, vpr.opt.SF2, and
15 vpu.opt.SF162.

Gag-complete refers to in-frame polyproteins comprising, e.g., Gag and pol,
wherein the p6 portion of Gag is present.

Additional sequences that may be employed in some aspects of the present
invention have been described in WO 00/39302, WO 00/39303, WO 00/39304, and
20 WO 02/04493.

2.2.2 FURTHER MODIFICATION OF SEQUENCES INCLUDING HIV NUCLEIC ACID CODING SEQUENCES

The HIV polypeptide-encoding expression cassettes described herein may also
25 contain one or more further sequences encoding, for example, one or more transgenes.
Further sequences (e.g., transgenes) useful in the practice of the present invention
include, but are not limited to, further sequences are those encoding further viral
epitopes/antigens {including but not limited to, HCV antigens (e.g., E1, E2;
Houghton, M., et al., U.S. Patent No. 5,714,596, issued February 3, 1998; Houghton,
30 M., et al., U.S. Patent No. 5,712,088, issued January 27, 1998; Houghton, M., et al.,
U.S. Patent No. 5,683,864, issued November 4, 1997; Weiner, A.J., et al., U.S. Patent

No. 5,728,520, issued March 17, 1998; Weiner, A.J., et al., U.S. Patent No. 5,766,845, issued June 16, 1998; Weiner, A.J., et al., U.S. Patent No. 5,670,152, issued September 23, 1997), HIV antigens (e.g., derived from one or more HIV isolate); and sequences encoding tumor antigens/epitopes. Further sequences may also 5 be derived from non-viral sources, for instance, sequences encoding cytokines such interleukin-2 (IL-2), stem cell factor (SCF), interleukin 3 (IL-3), interleukin 6 (IL-6), interleukin 12 (IL-12), G-CSF, granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 alpha (IL-1 α), interleukin-11 (IL-11), MIP-1 α , tumor necrosis factor (TNF), leukemia inhibitory factor (LIF), c-kit ligand, thrombopoietin (TPO) and 10 flt3 ligand, commercially available from several vendors such as, for example, Genzyme (Framingham, MA), Genentech (South San Francisco, CA), Amgen (Thousand Oaks, CA), R&D Systems and Immunex (Seattle, WA). Additional sequences are described below. Also, variations on the orientation of the Gag and other coding sequences, relative to each other, are described below.

15 HIV polypeptide coding sequences can be obtained from other HIV isolates, see, e.g., Myers et al. Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico (1992); Myers et al., *Human Retroviruses and Aids, 1997*, Los Alamos, New Mexico: Los Alamos National Laboratory. Synthetic expression cassettes can be generated using such coding sequences as starting material by 20 following the teachings of the present specification.

25 Further, the synthetic expression cassettes of the present invention include related polypeptide sequences having greater than 85%, preferably greater than 90%, more preferably greater than 95%, and most preferably greater than 98% sequence identity to the polypeptides encoded by the synthetic expression cassette sequences disclosed herein.

Exemplary expression cassettes and modifications are set forth in Example 1.

2.2.3 EXPRESSION OF SYNTHETIC SEQUENCES ENCODING HIV-1 POLYPEPTIDES AND RELATED POLYPEPTIDES

30 Synthetic HIV-encoding sequences (expression cassettes) of the present invention can be cloned into a number of different expression vectors to evaluate levels

of expression and, in the case of Gag-containing constructs, production of VLPs. The synthetic DNA fragments for HIV polypeptides can be cloned into eucaryotic expression vectors, including, a transient expression vector, CMV-promoter-based mammalian vectors, and a shuttle vector for use in baculovirus expression systems.

5 Corresponding wild-type sequences can also be cloned into the same vectors.

These vectors can then be transfected into a several different cell types, including a variety of mammalian cell lines (293, RD, COS-7, and CHO, cell lines available, for example, from the A.T.C.C.). The cell lines are then cultured under appropriate conditions and the levels of any appropriate polypeptide product can be evaluated in supernatants. (see, Table A). For example, p24 can be used to evaluate Gag expression; gp160, gp140 or gp120 can be used to evaluate Env expression; p6pol can be used to evaluate Pol expression; prot can be used to evaluate protease; p15 for RNaseH; p31 for Integrase; and other appropriate polypeptides for Vif, Vpr, Tat, Rev, Vpu and Nef. Further, modified polypeptides can also be used, for example, other Env polypeptides include, but are not limited to, for example, native gp160, oligomeric gp140, monomeric gp120 as well as modified and/or synthetic sequences of these polypeptides. The results of these assays demonstrate that expression of synthetic HIV polypeptide-encoding sequences are significantly higher than corresponding wild-type sequences.

20 Further, Western Blot analysis can be used to show that cells containing the synthetic expression cassette produce the expected protein at higher per-cell concentrations than cells containing the native expression cassette. The HIV proteins can be seen in both cell lysates and supernatants. The levels of production are significantly higher in cell supernatants for cells transfected with the synthetic expression cassettes of the present invention.

25 Fractionation of the supernatants from mammalian cells transfected with the synthetic expression cassette can be used to show that the cassettes provide superior production of HIV proteins and, in the case of Gag, VLPs, relative to the wild-type sequences.

30 Efficient expression of these HIV-containing polypeptides in mammalian cell lines provides the following benefits: the polypeptides are free of baculovirus

contaminants; production by established methods approved by the FDA; increased purity; greater yields (relative to native coding sequences); and a novel method of producing the Sub HIV-containing polypeptides in CHO cells which is not feasible in the absence of the increased expression obtained using the constructs of the present invention. Exemplary Mammalian cell lines include, but are not limited to, BHK, VERO, HT1080, 293, 293T, RD, COS-7, CHO, Jurkat, HUT, SUPT, C8166, MOLT4/clone8, MT-2, MT-4, H9, PM1, CEM, and CEMX174 (such cell lines are available, for example, from the A.T.C.C.).

A synthetic Gag expression cassette of the present invention will also exhibit high levels of expression and VLP production when transfected into insect cells. Synthetic expression cassettes described herein also demonstrate high levels of expression in insect cells. Further, in addition to a higher total protein yield, the final product from the synthetic polypeptides consistently contains lower amounts of contaminating baculovirus proteins than the final product from the native sequences.

Further, synthetic expression cassettes of the present invention can also be introduced into yeast vectors which, in turn, can be transformed into and efficiently expressed by yeast cells (*Saccharomyces cerevisiae*; using vectors as described in Rosenberg, S. and Tekamp-Olson, P., U.S. Patent No. RE35,749, issued, March 17, 1998).

In addition to the mammalian and insect vectors, the synthetic expression cassettes of the present invention can be incorporated into a variety of expression vectors using selected expression control elements. Appropriate vectors and control elements for any given cell can be selected by one having ordinary skill in the art in view of the teachings of the present specification and information known in the art about expression vectors.

For example, a synthetic expression cassette can be inserted into a vector which includes control elements operably linked to the desired coding sequence, which allow for the expression of the gene in a selected cell-type. For example, typical promoters for mammalian cell expression include the SV40 early promoter, a CMV promoter such as the CMV immediate early promoter (a CMV promoter can include intron A), RSV, HIV-Ltr, the mouse mammary tumor virus LTR promoter (MMLV-

ltr), the adenovirus major late promoter (Ad MLP), and the herpes simplex virus promoter, among others. Other nonviral promoters, such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression. Typically, transcription termination and polyadenylation sequences will also be present, 5 located 3' to the translation stop codon. Preferably, a sequence for optimization of initiation of translation, located 5' to the coding sequence, is also present. Examples of transcription terminator/polyadenylation signals include those derived from SV40, as described in Sambrook, et al., *supra*, as well as a bovine growth hormone terminator sequence. Introns, containing splice donor and acceptor sites, may also be 10 designed into the constructs for use with the present invention (Chapman et al., *Nuc. Acids Res.* (1991) 19:3979-3986).

Enhancer elements may also be used herein to increase expression levels of the mammalian constructs. Examples include the SV40 early gene enhancer, as described in Dijkema et al., *EMBO J.* (1985) 4:761, the enhancer/promoter derived from the 15 long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et al., *Proc. Natl. Acad. Sci. USA* (1982b) 79:6777 and elements derived from human CMV, as described in Boshart et al., *Cell* (1985) 41:521, such as elements included in the CMV intron A sequence (Chapman et al., *Nuc. Acids Res.* (1991) 19:3979-3986).

The desired synthetic polypeptide encoding sequences can be cloned into any 20 number of commercially available vectors to generate expression of the polypeptide in an appropriate host system. These systems include, but are not limited to, the following: baculovirus expression {Reilly, P.R., et al., BACULOVIRUS EXPRESSION VECTORS: A LABORATORY MANUAL (1992); Beames, et al., *Biotechniques* 11:378 (1991); Pharmingen; Clontech, Palo Alto, CA)}, vaccinia expression {Earl, P. L., et 25 al., "Expression of proteins in mammalian cells using vaccinia" In *Current Protocols in Molecular Biology* (F. M. Ausubel, et al. Eds.), Greene Publishing Associates & Wiley Interscience, New York (1991); Moss, B., et al., U.S. Patent Number 5,135,855, issued 4 August 1992}, expression in bacteria {Ausubel, F.M., et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Inc., Media 30 PA; Clontech}, expression in yeast {Rosenberg, S. and Tekamp-Olson, P., U.S. Patent No. RE35,749, issued, March 17, 1998; Shuster, J.R., U.S. Patent No. 5,629,203,

issued May 13, 1997; Gellissen, G., *et al.*, *Antonie Van Leeuwenhoek*, 62(1-2):79-93 (1992); Romanos, M.A., *et al.*, *Yeast* 8(6):423-488 (1992); Goeddel, D.V., *Methods in Enzymology* 185 (1990); Guthrie, C., and G.R. Fink, *Methods in Enzymology* 194 (1991)}, expression in mammalian cells {Clontech; Gibco-BRL, Ground Island, NY; 5 e.g., Chinese hamster ovary (CHO) cell lines (Haynes, J., *et al.*, *Nuc. Acid. Res.* 11:687-706 (1983); 1983, Lau, Y.F., *et al.*, *Mol. Cell. Biol.* 4:1469-1475 (1984); Kaufman, R. J., "Selection and coamplification of heterologous genes in mammalian cells," in *Methods in Enzymology*, vol. 185, pp537-566. Academic Press, Inc., San Diego CA (1991)}, and expression in plant cells {plant cloning vectors, Clontech 10 Laboratories, Inc., Palo Alto, CA, and Pharmacia LKB Biotechnology, Inc., Piscataway, NJ; Hood, E., *et al.*, *J. Bacteriol.* 168:1291-1301 (1986); Nagel, R., *et al.*, *FEMS Microbiol. Lett.* 67:325 (1990); An, *et al.*, "Binary Vectors", and others in Plant Molecular Biology Manual A3:1-19 (1988); Miki, B.L.A., *et al.*, pp.249-265, and others in Plant DNA Infectious Agents (Hohn, T., *et al.*, eds.) Springer-Verlag, 15 Wien, Austria, (1987); *Plant Molecular Biology: Essential Techniques*, P.G. Jones and J.M. Sutton, New York, J. Wiley, 1997; Miglani, Gurbachan *Dictionary of Plant Genetics and Molecular Biology*, New York, Food Products Press, 1998; Henry, R. J., *Practical Applications of Plant Molecular Biology*, New York, Chapman & Hall, 1997}.

20 Also included in the invention is an expression vector, containing coding sequences and expression control elements which allow expression of the coding regions in a suitable host. The control elements generally include a promoter, translation initiation codon, and translation and transcription termination sequences, and an insertion site for introducing the insert into the vector. Translational control 25 elements have been reviewed by M. Kozak (e.g., Kozak, M., *Mamm. Genome* 7(8):563-574, 1996; Kozak, M., *Biochimie* 76(9):815-821, 1994; Kozak, M., *J Cell Biol* 108(2):229-241, 1989; Kozak, M., and Shatkin, A.J., *Methods Enzymol* 60:360-375, 1979).

20 Expression in yeast systems has the advantage of commercial production. Recombinant protein production by vaccinia and CHO cell line have the advantage of being mammalian expression systems. Further, vaccinia virus expression has several

advantages including the following: (i) its wide host range; (ii) faithful post-transcriptional modification, processing, folding, transport, secretion, and assembly of recombinant proteins; (iii) high level expression of relatively soluble recombinant proteins; and (iv) a large capacity to accommodate foreign DNA.

5 The recombinantly expressed polypeptides from synthetic HIV polypeptide-encoding expression cassettes are typically isolated from lysed cells or culture media. Purification can be carried out by methods known in the art including salt fractionation, ion exchange chromatography, gel filtration, size-exclusion chromatography, size-fractionation, and affinity chromatography. Immunoaffinity chromatography can be employed using antibodies generated based on, for example, 10 HIV antigens.

15 Advantages of expressing the proteins of the present invention using mammalian cells include, but are not limited to, the following: well-established protocols for scale-up production; the ability to produce VLPs; cell lines are suitable to meet good manufacturing process (GMP) standards; culture conditions for mammalian cells are known in the art.

20 Synthetic HIV 1 polynucleotides are described herein, see, for example, the figures. Various forms of the different embodiments of the invention, described herein, may be combined.

25 Exemplary expression assays are set forth in Example 2. Exemplary conditions for Western Blot analysis are presented in Example 3.

2.3.0 PRODUCTION OF VIRUS-LIKE PARTICLES AND USE OF THE CONSTRUCTS OF THE PRESENT INVENTION TO CREATE PACKAGING CELL LINES.

25 The group-specific antigens (Gag) of human immunodeficiency virus type-1 (HIV-1) self-assemble into noninfectious virus-like particles (VLP) that are released from various eucaryotic cells by budding (reviewed by Freed, E.O., *Virology* 251:1-15, 1998). The Gag-containing synthetic expression cassettes of the present invention 30 provide for the production of HIV-Gag virus-like particles (VLPs) using a variety of different cell types, including, but not limited to, mammalian cells.

Viral particles can be used as a matrix for the proper presentation of an antigen entrapped or associated therewith to the immune system of the host.

5 **2.3.1 VLP PRODUCTION USING THE SYNTHETIC EXPRESSION CASSETTES
OF THE PRESENT INVENTION**

The Gag-containing synthetic expression cassettes of the present invention may provide superior production of both Gag proteins and VLPs, relative to native Gag coding sequences. Further, electron microscopic evaluation of VLP production can be used to show that free and budding immature virus particles of the expected size are 10 produced by cells containing the synthetic expression cassettes.

15 Using the synthetic expression cassettes of the present invention, rather than native Gag coding sequences, for the production of virus-like particles provide several advantages. First, VLPs can be produced in enhanced quantity making isolation and purification of the VLPs easier. Second, VLPs can be produced in a variety of cell types using the synthetic expression cassettes, in particular, mammalian cell lines can be used for VLP production, for example, CHO cells. Production using CHO cells provides (i) VLP formation; (ii) correct myristylation and budding; (iii) absence of non-Macmillian cell contaminants (e.g., insect viruses and/or cells); and (iv) ease of purification. The synthetic expression cassettes of the present invention are also useful 20 for enhanced expression in cell-types other than mammalian cell lines. For example, infection of insect cells with baculovirus vectors encoding the synthetic expression cassettes results in higher levels of total Gag protein yield and higher levels of VLP production (relative to wild-coding sequences). Further, the final product from insect 25 cells infected with the baculovirus-Gag synthetic expression cassettes consistently contains lower amounts of contaminating insect proteins than the final product when wild-coding sequences are used.

30 VLPs can spontaneously form when the particle-forming polypeptide of interest is recombinantly expressed in an appropriate host cell. Thus, the VLPs produced using the synthetic expression cassettes of the present invention are conveniently prepared using recombinant techniques. As discussed below, the Gag

polypeptide encoding synthetic expression cassettes of the present invention can include other polypeptide coding sequences of interest (for example, HIV protease, HIV polymerase, Env; synthetic Env). Expression of such synthetic expression cassettes yields VLPs comprising the Gag polypeptide, as well as, the polypeptide of interest.

Once coding sequences for the desired particle-forming polypeptides have been isolated or synthesized, they can be cloned into any suitable vector or replicon for expression. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. See, generally, 10 Sambrook et al, *supra*. The vector is then used to transform an appropriate host cell. Suitable recombinant expression systems include, but are not limited to, bacterial, mammalian, baculovirus/insect, vaccinia, Semliki Forest virus (SFV), Alphaviruses (such as, Sindbis, Venezuelan Equine Encephalitis (VEE)), mammalian, yeast and 15 Xenopus expression systems, well known in the art. Particularly preferred expression systems are mammalian cell lines, vaccinia, Sindbis, eucaryotic layered vector initiation systems (e.g., US Patent No. 6,015,686, US Patent No. 5, 814,482, US Patent No. 6,015,694, US Patent No. 5,789,245, EP 1029068A2, WO 9918226A2/A3, EP 00907746A2, WO 9738087A2), insect and yeast systems.

The synthetic DNA fragments for the expression cassettes of the present 20 invention, e.g., Pol, Gag, Env, Tat, Rev, Nef, Vif, Vpr, and/or Vpu, may be cloned into the following eucaryotic expression vectors: pCMVKm2, for transient expression assays and DNA immunization studies, the pCMVKm2 vector is derived from pCMV6a (Chapman et al., *Nuc. Acids Res.* (1991) 19:3979-3986) and comprises a kanamycin selectable marker, a ColE1 origin of replication, a CMV promoter enhancer 25 and Intron A, followed by an insertion site for the synthetic sequences described below followed by a polyadenylation signal derived from bovine growth hormone -- the pCMVKm2 vector differs from the pCMV-link vector only in that a polylinker site is inserted into pCMVKm2 to generate pCMV-link; pESN2dhfr and pCMVPLEdhfr, for expression in Chinese Hamster Ovary (CHO) cells; and, pAcC13, a shuttle vector for 30 use in the Baculovirus expression system (pAcC13, is derived from pAcC12 which is described by Munemitsu S., et al., *Mol Cell Biol.* **10**(11):5977-5982, 1990).

Briefly, construction of pCMVPLEdhfr was as follows.

To construct a DHFR cassette, the EMCV IRES (internal ribosome entry site) leader was PCR-amplified from pCite-4a+ (Novagen, Inc., Milwaukee, WI) and inserted into pET-23d (Novagen, Inc., Milwaukee, WI) as an *Xba*-*Nco* fragment to give pET-EMCV. The *dhfr* gene was PCR-amplified from pESN2dhfr to give a product with a Gly-Gly-Gly-Ser spacer in place of the translation stop codon and inserted as an *Nco*-*Bam*H1 fragment to give pET-E-DHFR. Next, the attenuated *neo* gene was PCR amplified from a pSV2Neo (Clontech, Palo Alto, CA) derivative and inserted into the unique *Bam*H1 site of pET-E-DHFR to give pET-E-DHFR/*Neo*_(m2).
5 Finally the bovine growth hormone terminator from pCDNA3 (Invitrogen, Inc., Carlsbad, CA) was inserted downstream of the *neo* gene to give pET-E-DHFR/*Neo*_(m2)BGHt. The EMCV-*dhfr/neo* selectable marker cassette fragment was prepared by cleavage of pET-E-DHFR/*Neo*_(m2)BGHt.
10

In one vector construct the CMV enhancer/promoter plus Intron A was transferred from pCMV6a (Chapman et al., *Nuc. Acids Res.* (1991) 19:3979-3986) as a *Hind*III-*Sal*I fragment into pUC19 (New England Biolabs, Inc., Beverly, MA). The vector backbone of pUC19 was deleted from the *Nde*I to the *Sap*I sites. The above described DHFR cassette was added to the construct such that the EMCV IRES followed the CMV promoter. The vector also contained an *amp*^r gene and an SV40 20 origin of replication.

A number of mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (A.T.C.C.), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), as well as others. Similarly, bacterial hosts such as *E. coli*, *Bacillus subtilis*, and *Streptococcus* spp., will find use with the present expression constructs. Yeast hosts useful in the present invention include *inter alia*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis*, *Kluyveromyces lactis*, *Pichia guillermondii*, *Pichia pastoris*, *Schizosaccharomyces pombe* and *Yarrowia lipolytica*. Insect cells for use with baculovirus expression vectors include, *inter alia*, *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Spodoptera frugiperda*, and
25
30

Trichoplusia ni. See, e.g., Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987).

Viral vectors can be used for the production of particles in eucaryotic cells, such as those derived from the pox family of viruses, including vaccinia virus and avian poxvirus. Additionally, a vaccinia based infection/transfection system, as described in Tomei et al., *J. Virol.* (1993) 67:4017-4026 and Selby et al., *J. Gen. Virol.* (1993) 74:1103-1113, will also find use with the present invention. In this system, cells are first infected *in vitro* with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the DNA of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into protein by the host translational machinery. Alternately, T7 can be added as a purified protein or enzyme as in the "Progenitor" system (Studier and Moffatt, *J. Mol. Biol.* (1986) 189:113-130). The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation product(s).

Depending on the expression system and host selected, the VLPS are produced by growing host cells transformed by an expression vector under conditions whereby the particle-forming polypeptide is expressed and VLPs can be formed. The selection of the appropriate growth conditions is within the skill of the art. If the VLPs are formed intracellularly, the cells are then disrupted, using chemical, physical or mechanical means, which lyse the cells yet keep the VLPs substantially intact. Such methods are known to those of skill in the art and are described in, e.g., *Protein Purification Applications: A Practical Approach*, (E.L.V. Harris and S. Angal, Eds., 1990).

The particles are then isolated (or substantially purified) using methods that preserve the integrity thereof, such as, by gradient centrifugation, e.g., cesium chloride (CsCl) sucrose gradients, pelleting and the like (see, e.g., Kirnbauer et al. *J. Virol.* (1993) 67:6929-6936), as well as standard purification techniques including, e.g., ion exchange and gel filtration chromatography.

VLPs produced by cells containing the synthetic expression cassettes of the present invention can be used to elicit an immune response when administered to a subject. One advantage of the present invention is that VLPs can be produced by mammalian cells carrying the synthetic expression cassettes at levels previously not possible. As discussed above, the VLPs can comprise a variety of antigens in addition to the Gag polypeptide (e.g., Gag-protease, Gag-polymerase, Env, synthetic Env, etc.). Purified VLPs, produced using the synthetic expression cassettes of the present invention, can be administered to a vertebrate subject, usually in the form of vaccine compositions. Combination vaccines may also be used, where such vaccines contain, for example, an adjuvant subunit protein (e.g., Env). Administration can take place using the VLPs formulated alone or formulated with other antigens. Further, the VLPs can be administered prior to, concurrent with, or subsequent to, delivery of the synthetic expression cassettes for DNA immunization (see below) and/or delivery of other vaccines. Also, the site of VLP administration may be the same or different as other vaccine compositions that are being administered. Gene delivery can be accomplished by a number of methods including, but are not limited to, immunization with DNA, alphavirus vectors, pox virus vectors, and vaccinia virus vectors.

VLP immune-stimulating (or vaccine) compositions can include various excipients, adjuvants, carriers, auxiliary substances, modulating agents, and the like. The immune stimulating compositions will include an amount of the VLP/antigen sufficient to mount an immunological response. An appropriate effective amount can be determined by one of skill in the art. Such an amount will fall in a relatively broad range that can be determined through routine trials and will generally be an amount on the order of about 0.1 μ g to about 1000 μ g, more preferably about 1 μ g to about 300 μ g, of VLP/antigen.

A carrier is optionally present which is a molecule that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Examples of particulate carriers include those derived from

polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PLG. See, e.g., Jeffery et al., *Pharm. Res.* (1993) **10**:362-368; McGee JP, et al., *J Microencapsul.* **14**(2):197-210, 1997; O'Hagan DT, et al., *Vaccine* **11**(2):149-54, 1993. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen may be conjugated to a bacterial toxoid, such as toxoid from diphtheria, tetanus, cholera, etc., as well as toxins derived from *E. coli*.

Adjuvants may also be used to enhance the effectiveness of the compositions. Such adjuvants include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (International Publication No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DetoxTM); (3) saponin adjuvants, such as StimulonTM (Cambridge Bioscience, Worcester, MA) may be used or particle generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA); (5) cytokines, such as interleukins (IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (6) oligonucleotides or polymeric molecules encoding immunostimulatory CpG motifs (Davis, H.L., et al., *J. Immunology* **160**:870-876, 1998; Sato, Y. et al., *Science* **273**:352-354, 1996) or complexes of

antigens/oligonucleotides {Polymeric molecules include double and single stranded RNA and DNA, and backbone modifications thereof, for example, methylphosphonate linkages; or (7) detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an *E. coli* heat-labile toxin (LT),

5 particularly LT-K63 (where lysine is substituted for the wild-type amino acid at position 63) LT-R72 (where arginine is substituted for the wild-type amino acid at position 72), CT-S109 (where serine is substituted for the wild-type amino acid at position 109), and PT-K9/G129 (where lysine is substituted for the wild-type amino acid at position 9 and glycine substituted at position 129) (see, e.g., International

10 Publication Nos. W093/13202 and W092/19265); and (8) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Further, such polymeric molecules include alternative polymer backbone structures such as, but not limited to, polyvinyl backbones (Pitha, *Biochem Biophys Acta*, 204:39, 1970a; Pitha, *Biopolymers*, 9:965, 1970b), and morpholino backbones (Summerton, J., *et al.*,

15 U.S. Patent No. 5,142,047, issued 08/25/92; Summerton, J., *et al.*, U.S. Patent No. 5,185,444 issued 02/09/93). A variety of other charged and uncharged polynucleotide analogs have been reported. Numerous backbone modifications are known in the art, including, but not limited to, uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, and carbamates) and charged linkages (e.g., phosphorothioates and phosphorodithioates).}; and (7) other substances that act as immunostimulating agents to enhance the effectiveness of the VLP immune-stimulating (or vaccine) composition. Alum, CpG oligonucleotides, and MF59 are preferred.

20

Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

Dosage treatment with the VLP composition may be a single dose schedule or a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at 30 subsequent time intervals, chosen to maintain and/or reinforce the immune response, for example at 1-4 months for a second dose, and if needed, a subsequent dose(s) after

several months. The dosage regimen will also, at least in part, be determined by the need of the subject and be dependent on the judgment of the practitioner.

If prevention of disease is desired, the antigen carrying VLPs are generally administered prior to primary infection with the pathogen of interest. If treatment is 5 desired, e.g., the reduction of symptoms or recurrences, the VLP compositions are generally administered subsequent to primary infection.

2.3.2 USING THE SYNTHETIC EXPRESSION CASSETTES OF THE PRESENT INVENTION TO CREATE PACKAGING CELL LINES

10 A number of viral based systems have been developed for use as gene transfer vectors for mammalian host cells. For example, retroviruses (in particular, lentiviral vectors) provide a convenient platform for gene delivery systems. A coding sequence of interest (for example, a sequence useful for gene therapy applications) can be inserted into a gene delivery vector and packaged in retroviral particles using 15 techniques known in the art. Recombinant virus can then be isolated and delivered to cells of the subject either *in vivo* or *ex vivo*. A number of retroviral systems have been described, including, for example, the following: (U.S. Patent No. 5,219,740; Miller et al. (1989) *BioTechniques* 7:980; Miller, A.D. (1990) *Human Gene Therapy* 1:5; Scarpa et al. (1991) *Virology* 180:849; Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 20 90:8033; Boris-Lawrie et al. (1993) *Cur. Opin. Genet. Develop.* 3:102; GB 2200651; EP 0415731; EP 0345242; WO 89/02468; WO 89/05349; WO 89/09271; WO 90/02806; WO 90/07936; WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; WO 93/11230; WO 93/10218; WO 91/02805; in U.S. 5,219,740; U.S. 4,405,712; U.S. 4,861,719; U.S. 4,980,289 and U.S. 4,777,127; in U.S. Serial No. 25 07/800,921; and in Vile (1993) *Cancer Res* 53:3860-3864; Vile (1993) *Cancer Res* 53:962-967; Ram (1993) *Cancer Res* 53:83-88; Takamiya (1992) *J Neurosci Res* 33:493-503; Baba (1993) *J Neurosurg* 79:729-735; Mann (1983) *Cell* 33:153; Cane (1984) *Proc Natl Acad Sci USA* 81:6349; and Miller (1990) *Human Gene Therapy* 1.

30 In other embodiments, gene transfer vectors can be constructed to encode a cytokine or other immunomodulatory molecule. For example, nucleic acid sequences encoding native IL-2 and gamma-interferon can be obtained as described in US Patent

Nos. 4,738,927 and 5,326,859, respectively, while useful muteins of these proteins can be obtained as described in U.S. Patent No. 4,853,332. Nucleic acid sequences encoding the short and long forms of mCSF can be obtained as described in US Patent Nos. 4,847,201 and 4,879,227, respectively. In particular aspects of the invention, 5 retroviral vectors expressing cytokine or immunomodulatory genes can be produced as described herein (for example, employing the packaging cell lines of the present invention) and in International Application No. PCT US 94/02951, entitled "Compositions and Methods for Cancer Immunotherapy."

Examples of suitable immunomodulatory molecules for use herein include the 10 following: IL-1 and IL-2 (Karupiah et al. (1990) *J. Immunology* 144:290-298, Weber et al. (1987) *J. Exp. Med.* 166:1716-1733, Gansbacher et al. (1990) *J. Exp. Med.* 172:1217-1224, and U.S. Patent No. 4,738,927); IL-3 and IL-4 (Tepper et al. (1989) *Cell* 57:503-512, Golumbek et al. (1991) *Science* 254:713-716, and U.S. Patent No. 5,017,691); IL-5 and IL-6 (Brakenhof et al. (1987) *J. Immunol.* 139:4116-4121, and 15 International Publication No. WO 90/06370); IL-7 (U.S. Patent No. 4,965,195); IL-8, IL-9, IL-10, IL-11, IL-12, and IL-13 (*Cytokine Bulletin*, Summer 1994); IL-14 and IL-15; alpha interferon (Finter et al. (1991) *Drugs* 42:749-765, U.S. Patent Nos. 4,892,743 and 4,966,843, International Publication No. WO 85/02862, Nagata et al. 20 (1980) *Nature* 284:316-320, Familletti et al. (1981) *Methods in Enz.* 78:387-394, Twu et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:2046-2050, and Faktor et al. (1990) *Oncogene* 5:867-872); beta-interferon (Seif et al. (1991) *J. Virol.* 65:664-671); gamma-interferons (Radford et al. (1991) *The American Society of Hepatology* 20082015, Watanabe et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:9456-9460, Gansbacher et al. (1990) *Cancer Research* 50:7820-7825, Maio et al. (1989) *Can. 25 Immunol. Immunother.* 30:34-42, and U.S. Patent Nos. 4,762,791 and 4,727,138); G-CSF (U.S. Patent Nos. 4,999,291 and 4,810,643); GM-CSF (International Publication No. WO 85/04188).

30 Immunomodulatory factors may also be agonists, antagonists, or ligands for these molecules. For example, soluble forms of receptors can often behave as antagonists for these types of factors, as can mutated forms of the factors themselves.

Nucleic acid molecules that encode the above-described substances, as well as other nucleic acid molecules that are advantageous for use within the present invention, may be readily obtained from a variety of sources, including, for example, depositories such as the American Type Culture Collection, or from commercial sources such as British Bio-Technology Limited (Cowley, Oxford England).
5 Representative examples include BBG 12 (containing the GM-CSF gene coding for the mature protein of 127 amino acids), BBG 6 (which contains sequences encoding gamma interferon), A.T.C.C. Deposit No. 39656 (which contains sequences encoding TNF), A.T.C.C. Deposit No. 20663 (which contains sequences encoding alpha-
10 interferon), A.T.C.C. Deposit Nos. 31902, 31902 and 39517 (which contain sequences encoding beta-interferon), A.T.C.C. Deposit No. 67024 (which contains a sequence which encodes Interleukin-1b), A.T.C.C. Deposit Nos. 39405, 39452, 39516, 39626 and 39673 (which contain sequences encoding Interleukin-2), A.T.C.C. Deposit Nos. 59399, 59398, and 67326 (which contain sequences encoding Interleukin-3), A.T.C.C.
15 Deposit No. 57592 (which contains sequences encoding Interleukin-4), A.T.C.C. Deposit Nos. 59394 and 59395 (which contain sequences encoding Interleukin-5), and A.T.C.C. Deposit No. 67153 (which contains sequences encoding Interleukin-6).

Plasmids containing cytokine genes or immunomodulatory genes (International Publication Nos. WO 94/02951 and WO 96/21015) can be digested with appropriate restriction enzymes, and DNA fragments containing the particular gene of interest can be inserted into a gene transfer vector using standard molecular biology techniques.
20 (See, e.g., Sambrook et al., *supra.*, or Ausubel et al. (eds) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience).

Polynucleotide sequences coding for the above-described molecules can be obtained using recombinant methods, such as by screening cDNA and genomic libraries from cells expressing the gene, or by deriving the gene from a vector known to include the same. For example, plasmids which contain sequences that encode altered cellular products may be obtained from a depository such as the A.T.C.C., or from commercial sources. Plasmids containing the nucleotide sequences of interest
25 can be digested with appropriate restriction enzymes, and DNA fragments containing

the nucleotide sequences can be inserted into a gene transfer vector using standard molecular biology techniques.

Alternatively, cDNA sequences for use with the present invention may be obtained from cells which express or contain the sequences, using standard techniques, 5 such as phenol extraction and PCR of cDNA or genomic DNA. See, e.g., Sambrook et al., *supra*, for a description of techniques used to obtain and isolate DNA. Briefly, mRNA from a cell which expresses the gene of interest can be reverse transcribed with reverse transcriptase using oligo-dT or random primers. The single stranded cDNA may then be amplified by PCR (see U.S. Patent Nos. 4,683,202, 4,683,195 and 10 4,800,159, see also *PCR Technology: Principles and Applications for DNA Amplification*, Erlich (ed.), Stockton Press, 1989)) using oligonucleotide primers complementary to sequences on either side of desired sequences.

The nucleotide sequence of interest can also be produced synthetically, rather than cloned, using a DNA synthesizer (e.g., an Applied Biosystems Model 392 DNA 15 Synthesizer, available from ABI, Foster City, California). The nucleotide sequence can be designed with the appropriate codons for the expression product desired. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge (1981) *Nature* 292:756; Nambair et al. (1984) *Science* 223:1299; Jay et al. (1984) *J. 20 Biol. Chem.* 259:6311.

The synthetic expression cassettes of the present invention can be employed in the construction of packaging cell lines for use with retroviral vectors.

One type of retrovirus, the murine leukemia virus, or "MLV", has been widely utilized for gene therapy applications (see generally Mann et al. (*Cell* 33:153, 1993), 25 Cane and Mulligan (*Proc, Nat'l. Acad. Sci. USA* 81:6349, 1984), and Miller et al., *Human Gene Therapy* 1:5-14,1990.

Lentiviral vectors typically, comprise a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to one or more genes of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR, wherein the lentiviral 30 vector contains a nuclear transport element. The nuclear transport element may be located either upstream (5') or downstream (3') of a coding sequence of interest (for

example, a synthetic Gag or Env expression cassette of the present invention). Within certain embodiments, the nuclear transport element is not RRE. Within one embodiment the packaging signal is an extended packaging signal. Within other embodiments the promoter is a tissue specific promoter, or, alternatively, a promoter such as CMV. Within other embodiments, the lentiviral vector further comprises an internal ribosome entry site.

5 A wide variety of lentiviruses may be utilized within the context of the present invention, including for example, lentiviruses selected from the group consisting of HIV, HIV-1, HIV-2, FIV and SIV.

10 Within yet another aspect of the invention, host cells (e.g., packaging cell lines) are provided which contain any of the expression cassettes described herein. For example, within one aspect packaging cell line are provided comprising an expression cassette that comprises a sequence encoding synthetic Gag-polymerase, and a nuclear transport element, wherein the promoter is operably linked to the sequence encoding Gag-polymerase. Packaging cell lines may further comprise a promoter and a sequence encoding tat, rev, or an envelope, wherein the promoter is operably linked to the sequence encoding tat, rev, Env or sequences encoding modified versions of these proteins. The packaging cell line may further comprise a sequence encoding any one or more of other HIV gene encoding sequences.

15 20 In one embodiment, the expression cassette (carrying, for example, the synthetic Gag-polymerase) is stably integrated. The packaging cell line, upon introduction of a lentiviral vector, typically produces particles. The promoter regulating expression of the synthetic expression cassette may be inducible. Typically, the packaging cell line, upon introduction of a lentiviral vector, produces particles that are essentially free of replication competent virus.

25 Packaging cell lines are provided comprising an expression cassette which directs the expression of a synthetic *Gag-polymerase* gene or comprising an expression cassette which directs the expression of a synthetic Env genes described herein. (See, also, Andre, S., et al., *Journal of Virology* 72(2):1497-1503, 1998; Haas, J., et al., 30 *Current Biology* 6(3):315-324, 1996) for a description of other modified Env

sequences). A lentiviral vector is introduced into the packaging cell line to produce a vector producing cell line.

As noted above, lentiviral vectors can be designed to carry or express a selected gene(s) or sequences of interest. Lentiviral vectors may be readily 5 constructed from a wide variety of lentiviruses (*see* RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Representative examples of lentiviruses included HIV, HIV-1, HIV-2, FIV and SIV. Such lentiviruses may either be obtained from patient isolates, or, more preferably, from depositories or collections such as the American Type Culture Collection, or isolated from known sources using 10 available techniques.

Portions of the lentiviral gene delivery vectors (or vehicles) may be derived from different viruses. For example, in a given recombinant lentiviral vector, LTRs may be derived from an HIV, a packaging signal from SIV, and an origin of second strand synthesis from HrV-2. Lentiviral vector constructs may comprise a 5' lentiviral 15 LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein said lentiviral vector contains a nuclear transport element that is not RRE.

Briefly, Long Terminal Repeats ("LTRs") are subdivided into three elements, designated U5, R and U3. These elements contain a variety of signals which are 20 responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements which are located within U3. LTRs may be readily identified in the provirus (integrated DNA form) due to their precise duplication at either end of the genome. As utilized herein, a 5' LTR should be understood to include a 5' promoter element and sufficient LTR sequence to allow reverse transcription and integration of 25 the DNA form of the vector. The 3' LTR should be understood to include a polyadenylation signal, and sufficient LTR sequence to allow reverse transcription and integration of the DNA form of the vector.

The tRNA binding site and origin of second strand DNA synthesis are also 30 important for a retrovirus to be biologically active, and may be readily identified by one of skill in the art. For example, retroviral tRNA binds to a tRNA binding site by Watson-Crick base pairing, and is carried with the retrovirus genome into a viral

particle. The tRNA is then utilized as a primer for DNA synthesis by reverse transcriptase. The tRNA binding site may be readily identified based upon its location just downstream from the 5'LTR. Similarly, the origin of second strand DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus.

5 This region, which is also referred to as the poly-purine tract, is located just upstream of the 3'LTR.

In addition to a 5' and 3'LTR, tRNA binding site, and origin of second strand DNA synthesis, recombinant retroviral vector constructs may also comprise a packaging signal, as well as one or more genes or coding sequences of interest. In

10 addition, the lentiviral vectors have a nuclear transport element which, in preferred embodiments is not RRE. Representative examples of suitable nuclear transport elements include the element in Rous sarcoma virus (Ogert, et al., *J ViroL* 70, 3834-3843, 1996), the element in Rous sarcoma virus (Liu & Mertz, *Genes & Dev.*, 9, 1766-1789, 1995) and the element in the genome of simian retrovirus type I (Zolotukhin, et al., *J Virol.* 68, 7944-7952, 1994). Other potential elements include the elements in the histone gene (Kedes, *Annu. Rev. Biochem.* 48, 837-870, 1970), the α -interferon gene (Nagata et al., *Nature* 287, 401-408, 1980), the β -adrenergic receptor gene (Koikka, et al., *Nature* 329, 75-79, 1987), and the c-Jun gene (Hattorie, et al., *Proc. Natl. Acad. Sci. USA* 85, 9148-9152, 1988).

15

20 Recombinant lentiviral vector constructs typically lack both *Gag-polymerase* and *Env* coding sequences. Recombinant lentiviral vector typically contain less than 20, preferably 15, more preferably 10, and most preferably 8 consecutive nucleotides found in *Gag-polymerase* and *Env* genes. One advantage of the present invention is that the synthetic *Gag-polymerase* expression cassettes, which can be used to

25 construct packaging cell lines for the recombinant retroviral vector constructs, have little homology to wild-type *Gag-polymerase* sequences and thus considerably reduce or eliminate the possibility of homologous recombination between the synthetic and wild-type sequences.

30 Lentiviral vectors may also include tissue-specific promoters to drive expression of one or more genes or sequences of interest.

Lentiviral vector constructs may be generated such that more than one gene of interest is expressed. This may be accomplished through the use of di- or oligo-cistronic cassettes (e.g., where the coding regions are separated by 80 nucleotides or less, *see generally* Levin et al., *Gene* 108:167-174, 1991), or through the use of 5 Internal Ribosome Entry Sites ("IRES").

Packaging cell lines suitable for use with the above described recombinant retroviral vector constructs may be readily prepared given the disclosure provided herein. Briefly, the parent cell line from which the packaging cell line is derived can be selected from a variety of mammalian cell lines, including for example, 293, RD, COS-10 7, CHO, BHK, VERO, HT1080, and myeloma cells.

After selection of a suitable host cell for the generation of a packaging cell line, one or more expression cassettes are introduced into the cell line in order to complement or supply in *trans* components of the vector which have been deleted.

Representative examples of suitable synthetic HIV polynucleotide sequences 15 have been described herein for use in expression cassettes of the present invention. As described above, the native and/or synthetic coding sequences may also be utilized in these expression cassettes.

Utilizing the above-described expression cassettes, a wide variety of packaging cell lines can be generated. For example, within one aspect packaging cell line are 20 provided comprising an expression cassette that comprises a sequence encoding synthetic Gag-polymerase, and a nuclear transport element, wherein the promoter is operably linked to the sequence encoding Gag-polymerase. Within other aspects, packaging cell lines are provided comprising a promoter and a sequence encoding tat, rev, Env, or other HIV antigens or epitopes derived therefrom, wherein the promoter 25 is operably linked to the sequence encoding tat, rev, Env, or the HIV antigen or epitope. Within further embodiments, the packaging cell line may comprise a sequence encoding any one or more of tat, rev, nef, vif, vpu or vpr. For example, the packaging cell line may contain only tat, rev, nef, vif, vpu, or vpr alone, tat rev and nef, nef and vif, nef and vpu, nef and vpr, vif and vpu, vif and vpr, vpu and vpr, nef vif and vpu, nef 30 vif and vpr, nef vpu and vpr, vif vpu and vpr, all four of nef, vif, vpu, and vpr, etc.

In one embodiment, the expression cassette is stably integrated. Within another embodiment, the packaging cell line, upon introduction of a lentiviral vector, produces particles. Within further embodiments the promoter is inducible. Within certain preferred embodiments of the invention, the packaging cell line, upon 5 introduction of a lentiviral vector, produces particles that are free of replication competent virus.

The synthetic cassettes containing modified coding sequences are transfected into a selected cell line. Transfected cells are selected that (i) carry, typically, integrated, stable copies of the HIV coding sequences, and (ii) are expressing 10 acceptable levels of these polypeptides (expression can be evaluated by methods known in the prior art in view of the teachings of the present disclosure). The ability of the cell line to produce VLPs may also be verified.

A sequence of interest is constructed into a suitable viral vector as discussed above. This defective virus is then transfected into the packaging cell line. The 15 packaging cell line provides the viral functions necessary for producing virus-like particles into which the defective viral genome, containing the sequence of interest, are packaged. These VLPs are then isolated and can be used, for example, in gene delivery or gene therapy.

Further, such packaging cell lines can also be used to produce VLPs alone, 20 which can, for example, be used as adjuvants for administration with other antigens or in vaccine compositions. Also, co-expression of a selected sequence of interest encoding a polypeptide (for example, an antigen) in the packaging cell line can also result in the entrapment and/or association of the selected polypeptide in/with the VLPs.

25 Various forms of the different embodiments of the present invention (e.g., synthetic constructs) may be combined.

2.4.0 DNA IMMUNIZATION AND GENE DELIVERY

A variety of HIV polypeptide antigens, particularly HIV antigens, can be used 30 in the practice of the present invention. HIV antigens can be included in DNA immunization constructs containing, for example, a synthetic Env expression cassettes,

a synthetic Gag expression cassette, a synthetic pol-derived polypeptide expression cassette, a synthetic expression cassette comprising sequences encoding one or more accessory or regulatory genes (e.g., tat, rev, nef, vif, vpu, vpr), and/or a synthetic Gag expression cassette fused in-frame to a coding sequence for the polypeptide antigen (synthetic or wild-type), where expression of the construct results in VLPs presenting the antigen of interest.

5 HIV antigens of particular interest to be used in the practice of the present invention include pol, tat, rev, nef, vif, vpu, vpr, and other HIV-1 (also known as HTLV-III, LAV, ARV, etc.) antigens or epitopes derived therefrom, including, but not limited to, antigens such as gp120, gp41, gp160 (both native and modified); Gag; and pol from a variety of isolates including, but not limited to, HIV_{MB}, HIV_{SF2}, HIV-1_{SF162}, HIV-1_{SF170}, HIV_{LAV}, HIV_{LAI}, HIV_{MN}, HIV-1_{CM235}, HIV-1_{US4}, other HIV-1 strains from diverse subtypes (e.g., subtypes, A through G, and O), HIV-2 strains and diverse subtypes (e.g., HIV-2_{UC1} and HIV-2_{UC2}). See, e.g., Myers, et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico; Myers, et al., *Human Retroviruses and Aids*, 1990, Los Alamos, New Mexico: Los Alamos National Laboratory. These antigens may be synthetic (as described herein) or wild-type.

10 To evaluate efficacy, DNA immunization using synthetic expression cassettes of the present invention can be performed, for example, as follows. Mice are immunized with a tat/rev/nef synthetic expression cassette. Other mice are immunized with a tat/rev/nef wild type expression cassette. Mouse immunizations with plasmid-DNAs typically show that the synthetic expression cassettes provide a clear improvement of immunogenicity relative to the native expression cassettes. Also, a second boost immunization will induce a secondary immune response, for example, after approximately two weeks. Further, the results of CTL assays typically show increased potency of synthetic expression cassettes for induction of cytotoxic T-lymphocyte (CTL) responses by DNA immunization.

15 Exemplary primate studies directed at the evaluation of neutralizing antibodies and cellular immune responses against HIV are described below.

It is readily apparent that the subject invention can be used to mount an immune response to a wide variety of antigens and hence to treat or prevent infection, particularly HIV infection.

5

2.4.1 DELIVERY OF THE SYNTHETIC EXPRESSION CASSETTES OF THE PRESENT INVENTION

Polynucleotide sequences coding for the above-described molecules can be obtained using recombinant methods, such as by screening cDNA and genomic libraries from cells expressing the gene, or by deriving the gene from a vector known to include the same. Furthermore, the desired gene can be isolated directly from cells and tissues containing the same, using standard techniques, such as phenol extraction and PCR of cDNA or genomic DNA. See, e.g., Sambrook et al., *supra*, for a description of techniques used to obtain and isolate DNA. The gene of interest can also be produced synthetically, rather than cloned. The nucleotide sequence can be designed with the appropriate codons for the particular amino acid sequence desired. In general, one will select preferred codons for the intended host in which the sequence will be expressed. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, *Nature* (1981) 292:756; Nambair et al., *Science* (1984) 223:1299; Jay et al., *J. Biol. Chem.* (1984) 259:6311; Stemmer, W.P.C., (1995) *Gene* 164:49-53.

Next, the gene sequence encoding the desired antigen can be inserted into a vector containing a synthetic expression cassette of the present invention. In one embodiment, polynucleotides encoding selected antigens are separately cloned into expression vectors (e.g., Env-coding polynucleotide in a first vector, Gag-coding polynucleotide in a second vector, Pol-derived polypeptide-coding polynucleotide in a third vector, tat-, rev-, nef-, vif-, vpu-, vpr-coding polynucleotides in further vectors, etc.). In certain embodiments, the antigen is inserted into or adjacent a synthetic Gag coding sequence such that when the combined sequence is expressed it results in the production of VLPs comprising the Gag polypeptide and the antigen of interest, e.g., Env (native or modified) or other antigen(s) (native or modified) derived from HIV.

Insertions can be made within the coding sequence or at either end of the coding sequence (5', amino terminus of the expressed Gag polypeptide; or 3', carboxy terminus of the expressed Gag polypeptide)(Wagner, R., et al., *Arch Virol.* 127:117-137, 1992; Wagner, R., et al., *Virology* 200:162-175, 1994; Wu, X., et al., *J. Virol.* 69(6):3389-3398, 1995; Wang, C-T., et al., *Virology* 200:524-534, 1994; Chazal, N., et al., *Virology* 68(1):111-122, 1994; Griffiths, J.C., et al., *J. Virol.* 67(6):3191-3198, 1993; Reicin, A.S., et al., *J. Virol.* 69(2):642-650, 1995).

Up to 50% of the coding sequences of p55Gag can be deleted without affecting the assembly to virus-like particles and expression efficiency (Borsetti, A., et al., *J. Virol.* 72(11):9313-9317, 1998; Gamier, L., et al., *J. Virol.* 72(6):4667-4677, 1998; Zhang, Y., et al., *J. Virol.* 72(3):1782-1789, 1998; Wang, C., et al., *J. Virol.* 72(10): 7950-7959, 1998). In one embodiment of the present invention, immunogenicity of the high level expressing synthetic Gag expression cassettes can be increased by the insertion of different structural or non-structural HIV antigens, multi-epitope cassettes, or cytokine sequences into deleted regions of Gag sequence. Such deletions may be generated following the teachings of the present invention and information available to one of ordinary skill in the art. One possible advantage of this approach, relative to using full-length sequences fused to heterologous polypeptides, can be higher expression/secretion efficiency of the expression product.

When sequences are added to the amino terminal end of Gag, the polynucleotide can contain coding sequences at the 5' end that encode a signal for addition of a myristic moiety to the Gag-containing polypeptide (e.g., sequences that encode Met-Gly).

The ability of Gag-containing polypeptide constructs to form VLPs can be empirically determined following the teachings of the present specification.

The synthetic expression cassettes can also include control elements operably linked to the coding sequence, which allow for the expression of the gene *in vivo* in the subject species. For example, typical promoters for mammalian cell expression include the SV40 early promoter, a CMV promoter such as the CMV immediate early promoter, the mouse mammary tumor virus LTR promoter, the adenovirus major late promoter (Ad MLP), and the herpes simplex virus promoter, among others. Other

nonviral promoters, such as a promoter derived from the murine metallothionein gene, will also find use for mammalian expression. Typically, transcription termination and polyadenylation sequences will also be present, located 3' to the translation stop codon. Preferably, a sequence for optimization of initiation of translation, located 5' to the coding sequence, is also present. Examples of transcription 5
terminator/polyadenylation signals include those derived from SV40, as described in 10 Sambrook et al., *supra*, as well as a bovine growth hormone terminator sequence.

Enhancer elements may also be used herein to increase expression levels of the mammalian constructs. Examples include the SV40 early gene enhancer, as described 10 in Dijkema et al., *EMBO J.* (1985) 4:761, the enhancer/promoter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, as described in Gorman et al., *Proc. Natl. Acad. Sci. USA* (1982b) 79:6777 and elements derived from human CMV, as described in Boshart et al., *Cell* (1985) 41:521, such as elements included in the CMV intron A sequence.

15 Furthermore, plasmids can be constructed which include a chimeric antigen-coding gene sequences, encoding, e.g., multiple antigens/epitopes of interest, for example derived from more than one viral isolate.

Typically the antigen coding sequences precede or follow the synthetic coding 20 sequence and the chimeric transcription unit will have a single open reading frame encoding both the antigen of interest and the synthetic coding sequences. Alternatively, multi-cistronic cassettes (e.g., bi-cistronic cassettes) can be constructed allowing expression of multiple antigens from a single mRNA using the EMCV IRES, or the like (Example 7).

In one embodiment of the present invention, a nucleic acid immunizing 25 composition may comprise, for example, the following: a first expression vector comprising a Gag expression cassette, a second vector comprising an Env expression cassette, and a third expression vector comprising a Pol expression cassette, or one or more coding region of Pol (e.g., Prot, RT, RNase, Int), wherein further antigen coding sequences may be associated with the Pol expression, such antigens may be obtained, 30 for example, from accessory genes (e.g., vpr, vpu, vif), regulatory genes (e.g., nef, tat, rev), or portions of the Pol sequences (e.g., Prot, RT, RNase, Int)). In another

embodiment, a nucleic acid immunizing composition may comprise, for example, an expression cassette comprising any of the synthetic polynucleotide sequences of the present invention. In another embodiment, a nucleic acid immunizing composition may comprise, for example, an expression cassette comprising coding sequences for a 5 number of HIV genes (or sequences derived from such genes) wherein the coding sequences are in-frame and under the control of a single promoter, for example, Gag-Env constructs, Tat-Rev-Nef constructs, P2Pol-tat-rev-nef constructs, etc. The synthetic coding sequences of the present invention may be combined in any number of combinations depending on the coding sequence products (i.e., HIV polypeptides) to 10 which, for example, an immunological response is desired to be raised. In yet another embodiment, synthetic coding sequences for multiple HIV-derived polypeptides may be constructed into a polycistronic message under the control of a single promoter wherein IRES are placed adjacent the coding sequence for each encoded polypeptide.

Once complete, the constructs are used for nucleic acid immunization using 15 standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Patent Nos. 5,399,346, 5,580,859, 5,589,466. Genes can be delivered either directly to the vertebrate subject or, alternatively, delivered *ex vivo*, to cells derived from the subject and the cells reimplanted in the subject.

A number of viral based systems have been developed for gene transfer into 20 mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Selected sequences can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either *in vivo* or *ex vivo*. A number of retroviral systems have been described (U.S. Patent No. 5,219,740; Miller and 25 Rosman, *BioTechniques* (1989) 7:980-990; Miller, A.D., *Human Gene Therapy* (1990) 1:5-14; Scarpa et al., *Virology* (1991) 180:849-852; Burns et al., *Proc. Natl. Acad. Sci. USA* (1993) 90:8033-8037; and Boris-Lawrie and Temin, *Cur. Opin. Genet. Develop.* (1993) 3:102-109.

A number of adenovirus vectors have also been described. Unlike retroviruses 30 which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham,

J. Virol. (1986) 57:267-274; Bett et al., *J. Virol.* (1993) 67:5911-5921; Mittereder et al., *Human Gene Therapy* (1994) 5:717-729; Seth et al., *J. Virol.* (1994) 68:933-940; Barr et al., *Gene Therapy* (1994) 1:51-58; Berkner, K.L. *BioTechniques* (1988) 6:616-629; and Rich et al., *Human Gene Therapy* (1993) 4:461-476).

5 Additionally, various adeno-associated virus (AAV) vector systems have been developed for gene delivery. AAV vectors can be readily constructed using techniques well known in the art. See, e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al., *Molec. Cell. Biol.* (1988) 8:3988-3996; Vincent et al., *Vaccines* 90 (1990) (Cold Spring Harbor Laboratory Press); Carter, B.J. *Current Opinion in Biotechnology* (1992) 3:533-539; Muzyczka, N. *Current Topics in Microbiol. and Immunol.* (1992) 158:97-129; Kotin, R.M. *Human Gene Therapy* (1994) 5:793-801; Shelling and Smith, *Gene Therapy* (1994) 1:165-169; and Zhou et al., *J. Exp. Med.* (1994) 179:1867-1875.

15 Another vector system useful for delivering the polynucleotides of the present invention is the enterically administered recombinant poxvirus vaccines described by Small, Jr., P.A., et al. (U.S. Patent No. 5,676,950, issued October 14, 1997).

20 Additional viral vectors which will find use for delivering the nucleic acid molecules encoding the antigens of interest include those derived from the pox family of viruses, including vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the genes can be constructed as follows. The DNA encoding the particular synthetic HIV polypeptide coding sequence is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is 25 then used to transfect cells which are simultaneously infected with vaccinia.

Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the coding sequences of interest into the viral genome. The resulting TK⁻ recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

30 Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the genes. Recombinant avipox viruses, expressing

immunogens from mammalian pathogens, are known to confer protective immunity when administered to non-avian species. The use of an avipox vector is particularly desirable in human and other mammalian species since members of the avipox genus can only productively replicate in susceptible avian species and therefore are not 5 infective in mammalian cells. Methods for producing recombinant avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.

10 Molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al., *J. Biol. Chem.* (1993) 268:6866-6869 and Wagner et al., *Proc. Natl. Acad. Sci. USA* (1992) 89:6099-6103, can also be used for gene delivery.

15 Members of the Alphavirus genus, such as, but not limited to, vectors derived from the Sindbis, Semliki Forest, and Venezuelan Equine Encephalitis viruses, will also find use as viral vectors for delivering the polynucleotides of the present invention (for example, a synthetic Gag-polypeptide encoding expression cassette). For a description of Sindbis-virus derived vectors useful for the practice of the instant methods, see, Dubensky et al., *J. Virol.* (1996) 70:508-519; and International Publication Nos. WO 95/07995 and WO 96/17072; as well as, Dubensky, Jr., T.W., et al., U.S. Patent No. 5,843,723, issued December 1, 1998, and Dubensky, Jr., T.W., U.S. Patent No. 5,789,245, issued August 4, 1998. Preferred expression systems include, but are not 20 limited to, eucaryotic layered vector initiation systems (e.g., US Patent No. 6,015,686, US Patent No. 5,814,482, US Patent No. 6,015,694, US Patent No. 5,789,245, EP 1029068A2, WO 9918226A2/A3, EP 00907746A2, WO 9738087A2).

25 A vaccinia based infection/transfection system can be conveniently used to provide for inducible, transient expression of the coding sequences of interest in a host cell. In this system, cells are first infected *in vitro* with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide of interest, driven by 30 a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into

protein by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy-Stein and Moss, *Proc. Natl. Acad. Sci. USA* (1990) 87:6743-6747; Fuerst et al., *Proc. Natl. Acad. Sci. USA* (1986) 83:8122-8126.

5 As an alternative approach to infection with vaccinia or avipox virus recombinants, or to the delivery of genes using other viral vectors, an amplification system can be used that will lead to high level expression following introduction into host cells. Specifically, a T7 RNA polymerase promoter preceding the coding region for T7 RNA polymerase can be engineered. Translation of RNA derived from this 10 template will generate T7 RNA polymerase which in turn will transcribe more template. Concomitantly, there will be a cDNA whose expression is under the control of the T7 promoter. Thus, some of the T7 RNA polymerase generated from translation of the amplification template RNA will lead to transcription of the desired gene. Because some T7 RNA polymerase is required to initiate the amplification, T7 15 RNA polymerase can be introduced into cells along with the template(s) to prime the transcription reaction. The polymerase can be introduced as a protein or on a plasmid encoding the RNA polymerase. For a further discussion of T7 systems and their use for transforming cells, see, e.g., International Publication No. WO 94/26911; Studier and Moffatt, *J. Mol. Biol.* (1986) 189:113-130; Deng and Wolff, *Gene* (1994) 20 143:245-249; Gao et al., *Biochem. Biophys. Res. Commun.* (1994) 200:1201-1206; Gao and Huang, *Nuc. Acids Res.* (1993) 21:2867-2872; Chen et al., *Nuc. Acids Res.* (1994) 22:2114-2120; and U.S. Patent No. 5,135,855.

25 Delivery of the expression cassettes of the present invention can also be accomplished using eucaryotic expression vectors comprising CMV-derived elements, such vectors include, but are not limited to, the following: pCMVKm2, pCMV-link pCMVPLEdhfr, and pCMV6a (all described above).

30 Synthetic expression cassettes of interest can also be delivered without a viral vector. For example, the synthetic expression cassette can be packaged in liposomes prior to delivery to the subject or to cells derived therefrom. Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed DNA to lipid preparation can vary but will

generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight, *Biochim. Biophys. Acta.* (1991) 1097:1-17; Straubinger et al., in *Methods of Enzymology* (1983), Vol. 101, pp. 512-527.

5 Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations, with cationic liposomes particularly preferred. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., *Proc. Natl. Acad. Sci. USA* (1987) 84:7413-7416); mRNA (Malone et al., *Proc. Natl. Acad. Sci. USA* (1989) 86:6077-6081); and purified transcription factors (Debs et al., *J. Biol. Chem.* (1990) 265:10189-10192), in functional form.

10 Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy]propyl]-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, NY. (See, also, Felgner et al., *Proc. Natl. Acad. Sci. USA* (1987) 84:7413-7416). Other commercially available lipids include (DDAB/DOPE) and DOTAP/DOPE (Boerhinger). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g., Szoka et al., *Proc. Natl. Acad. Sci. USA* (1978) 75:4194-4198; PCT Publication No. WO 90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.

15 Similarly, anionic and neutral liposomes are readily available, such as, from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

20 The liposomes can comprise multilammellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See, e.g., Straubinger et

al., in METHODS OF IMMUNOLOGY (1983), Vol. 101, pp. 512-527; Szoka et al., *Proc. Natl. Acad. Sci. USA* (1978) 75:4194-4198; Papahadjopoulos et al., *Biochim. Biophys. Acta* (1975) 394:483; Wilson et al., *Cell* (1979) 17:77; Deamer and Bangham, *Biochim. Biophys. Acta* (1976) 443:629; Ostro et al., *Biochem. Biophys. Res. Commun.* (1977) 76:836; Fraley et al., *Proc. Natl. Acad. Sci. USA* (1979) 76:3348; Enoch and Strittmatter, *Proc. Natl. Acad. Sci. USA* (1979) 76:145; Fraley et al., *J. Biol. Chem.* (1980) 255:10431; Szoka and Papahadjopoulos, *Proc. Natl. Acad. Sci. USA* (1978) 75:145; and Schaefer-Ridder et al., *Science* (1982) 215:166.

5 The DNA and/or protein antigen(s) can also be delivered in cochleate lipid compositions similar to those described by Papahadjopoulos et al., *Biochim. Biophys. Acta* (1975) 394:483-491. See, also, U.S. Patent Nos. 4,663,161 and 4,871,488.

10 The synthetic expression cassette of interest may also be encapsulated, adsorbed to, or associated with, particulate carriers. Such carriers present multiple copies of a selected antigen to the immune system and promote trapping and retention of antigens in local lymph nodes. The particles can be phagocytosed by macrophages and can enhance antigen presentation through cytokine release. Examples of 15 particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PLG. See, e.g., Jeffery et al., *Pharm. Res.* (1993) 10:362-368; McGee JP, 20 et al., *J Microencapsul.* 14(2):197-210, 1997; O'Hagan DT, et al., *Vaccine* 11(2):149-54, 1993. Suitable microparticles may also be manufactured in the presence of charged detergents, such as anionic or cationic detergents, to yield microparticles with a surface having a net negative or a net positive charge. For example, microparticles manufactured with anionic detergents, such as hexadecyltrimethylammonium bromide 25 (CTAB), i.e. CTAB-PLG microparticles, adsorb negatively charged macromolecules, such as DNA. (see, e.g., Int'l Application Number PCT/US99/17308).

Furthermore, other particulate systems and polymers can be used for the *in vivo* or *ex vivo* delivery of the gene of interest. For example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of 30 these molecules, are useful for transferring a nucleic acid of interest. Similarly, DEAE dextran-mediated transfection, calcium phosphate precipitation or precipitation using

other insoluble inorganic salts, such as strontium phosphate, aluminum silicates including bentonite and kaolin, chromic oxide, magnesium silicate, talc, and the like, will find use with the present methods. See, e.g., Felgner, P.L., *Advanced Drug Delivery Reviews* (1990) 5:163-187, for a review of delivery systems useful for gene transfer. Peptoids (Zuckerman, R.N., et al., U.S. Patent No. 5,831,005, issued November 3, 1998) may also be used for delivery of a construct of the present invention.

5 Additionally, biolistic delivery systems employing particulate carriers such as gold and tungsten, are especially useful for delivering synthetic expression cassettes of the present invention. The particles are coated with the synthetic expression cassette(s) to be delivered and accelerated to high velocity, generally under a reduced atmosphere, using a gun powder discharge from a "gene gun." For a description of such techniques, and apparatuses useful therefore, see, e.g., U.S. Patent Nos. 10 4,945,050; 5,036,006; 5,100,792; 5,179,022; 5,371,015; and 5,478,744. Also, needle-less injection systems can be used (Davis, H.L., et al, *Vaccine* 12:1503-1509, 1994; 15 Bioject, Inc., Portland, OR).

20 Recombinant vectors carrying a synthetic expression cassette of the present invention are formulated into compositions for delivery to the vertebrate subject. These compositions may either be prophylactic (to prevent infection) or therapeutic (to 25 treat disease after infection). The compositions will comprise a "therapeutically effective amount" of the gene of interest such that an amount of the antigen can be produced *in vivo* so that an immune response is generated in the individual to which it is administered. The exact amount necessary will vary depending on the subject being treated; the age and general condition of the subject to be treated; the capacity of the subject's immune system to synthesize antibodies; the degree of protection desired; the severity of the condition being treated; the particular antigen selected and its mode of administration, among other factors. An appropriate effective amount can be readily determined by one of skill in the art. Thus, a "therapeutically effective amount" will fall in a relatively broad range that can be determined through routine trials.

30 The compositions will generally include one or more "pharmaceutically acceptable excipients or vehicles" such as water, saline, glycerol, polyethyleneglycol,

hyaluronic acid, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Certain facilitators of nucleic acid uptake and/or expression can also be included in the compositions or coadministered, such as, but not limited to,

5 bupivacaine, cardiotoxin and sucrose.

Once formulated, the compositions of the invention can be administered directly to the subject (e.g., as described above) or, alternatively, delivered *ex vivo*, to cells derived from the subject, using methods such as those described above. For example, methods for the *ex vivo* delivery and reimplantation of transformed cells into 10 a subject are known in the art and can include, e.g., dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, lipofectamine and LT-1 mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) (with or without the corresponding antigen) in liposomes, and direct microinjection of the DNA into nuclei.

15 Direct delivery of synthetic expression cassette compositions *in vivo* will generally be accomplished with or without viral vectors, as described above, by injection using either a conventional syringe or a gene gun, such as the Accell® gene delivery system (PowderJect Technologies, Inc., Oxford, England). The constructs can be injected either subcutaneously, epidermally, intradermally, intramucosally such 20 as nasally, rectally and vaginally, intraperitoneally, intravenously, orally or intramuscularly. Delivery of DNA into cells of the epidermis is particularly preferred as this mode of administration provides access to skin-associated lymphoid cells and provides for a transient presence of DNA in the recipient. Other modes of administration include oral and pulmonary administration, suppositories, needle-less 25 injection, transcutaneous and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. Administration of nucleic acids may also be combined with administration of peptides or other substances.

Exemplary immunogenicity studies are presented in Examples 4, 5, 6, 9, 10, 11, and 12.

2.4.2 EX VIVO DELIVERY OF THE SYNTHETIC EXPRESSION CASSETTES OF THE PRESENT INVENTION

In one embodiment, T cells, and related cell types (including but not limited to antigen presenting cells, such as, macrophage, monocytes, lymphoid cells, dendritic 5 cells, B-cells, T-cells, stem cells, and progenitor cells thereof), can be used for *ex vivo* delivery of the synthetic expression cassettes of the present invention. T cells can be isolated from peripheral blood lymphocytes (PBLs) by a variety of procedures known to those skilled in the art. For example, T cell populations can be "enriched" from a population of PBLs through the removal of accessory and B cells. In particular, T cell 10 enrichment can be accomplished by the elimination of non-T cells using anti-MHC class II monoclonal antibodies. Similarly, other antibodies can be used to deplete specific populations of non-T cells. For example, anti-Ig antibody molecules can be used to deplete B cells and anti-MacI antibody molecules can be used to deplete macrophages.

15 T cells can be further fractionated into a number of different subpopulations by techniques known to those skilled in the art. Two major subpopulations can be isolated based on their differential expression of the cell surface markers CD4 and CD8. For example, following the enrichment of T cells as described above, CD4⁺ cells can be enriched using antibodies specific for CD4 (see Coligan et al., *supra*). The 20 antibodies may be coupled to a solid support such as magnetic beads. Conversely, CD8⁺ cells can be enriched through the use of antibodies specific for CD4 (to remove CD4⁺ cells), or can be isolated by the use of CD8 antibodies coupled to a solid support. CD4 lymphocytes from HIV-1 infected patients can be expanded *ex vivo*, before or after transduction as described by Wilson et. al. (1995) *J. Infect. Dis.*

25 172:88.

Following purification of T cells, a variety of methods of genetic modification known to those skilled in the art can be performed using non-viral or viral-based gene transfer vectors constructed as described herein. For example, one such approach involves transduction of the purified T cell population with vector-containing 30 supernatant of cultures derived from vector producing cells. A second approach involves co-cultivation of an irradiated monolayer of vector-producing cells with the

purified T cells. A third approach involves a similar co-cultivation approach; however, the purified T cells are pre-stimulated with various cytokines and cultured 48 hours prior to the co-cultivation with the irradiated vector producing cells. Pre-stimulation prior to such transduction increases effective gene transfer (Nolta et al. (1992) *Exp. 5 Hematol.* 20:1065). Stimulation of these cultures to proliferate also provides increased cell populations for re-infusion into the patient. Subsequent to co-cultivation, T cells are collected from the vector producing cell monolayer, expanded, and frozen in liquid nitrogen.

Gene transfer vectors, containing one or more synthetic expression cassette of 10 the present invention (associated with appropriate control elements for delivery to the isolated T cells) can be assembled using known methods and following the guidance of the present specification.

Selectable markers can also be used in the construction of gene transfer vectors. For example, a marker can be used which imparts to a mammalian cell 15 transduced with the gene transfer vector resistance to a cytotoxic agent. The cytotoxic agent can be, but is not limited to, neomycin, aminoglycoside, tetracycline, chloramphenicol, sulfonamide, actinomycin, netropsin, distamycin A, anthracycline, or pyrazinamide. For example, neomycin phosphotransferase II imparts resistance to the neomycin analogue geneticin (G418).

20 The T cells can also be maintained in a medium containing at least one type of growth factor prior to being selected. A variety of growth factors are known in the art which sustain the growth of a particular cell type. Examples of such growth factors are cytokine mitogens such as rIL-2, IL-10, IL-12, and IL-15, which promote growth and activation of lymphocytes. Certain types of cells are stimulated by other growth 25 factors such as hormones, including human chorionic gonadotropin (hCG) and human growth hormone. The selection of an appropriate growth factor for a particular cell population is readily accomplished by one of skill in the art.

For example, white blood cells such as differentiated progenitor and stem cells 30 are stimulated by a variety of growth factors. More particularly, IL-3, IL-4, IL-5, IL-6, IL-9, GM-CSF, M-CSF, and G-CSF, produced by activated T_H and activated macrophages, stimulate myeloid stem cells, which then differentiate into pluripotent

stem cells, granulocyte-monocyte progenitors, eosinophil progenitors, basophil progenitors, megakaryocytes, and erythroid progenitors. Differentiation is modulated by growth factors such as GM-CSF, IL-3, IL-6, IL-11, and EPO.

5 Pluripotent stem cells then differentiate into lymphoid stem cells, bone marrow stromal cells, T cell progenitors, B cell progenitors, thymocytes, T_H Cells, T_C cells, and B cells. This differentiation is modulated by growth factors such as IL-3, IL-4, IL-6, IL-7, GM-CSF, M-CSF, G-CSF, IL-2, and IL-5.

10 Granulocyte-monocyte progenitors differentiate to monocytes, macrophages, and neutrophils. Such differentiation is modulated by the growth factors GM-CSF, M-CSF, and IL-8. Eosinophil progenitors differentiate into eosinophils. This process is modulated by GM-CSF and IL-5.

15 The differentiation of basophil progenitors into mast cells and basophils is modulated by GM-CSF, IL-4, and IL-9. Megakaryocytes produce platelets in response to GM-CSF, EPO, and IL-6. Erythroid progenitor cells differentiate into red blood cells in response to EPO.

20 Thus, during activation by the CD3-binding agent, T cells can also be contacted with a mitogen, for example a cytokine such as IL-2. In particularly preferred embodiments, the IL-2 is added to the population of T cells at a concentration of about 50 to 100 μ g/ml. Activation with the CD3-binding agent can be carried out for 2 to 4 days.

25 Once suitably activated, the T cells are genetically modified by contacting the same with a suitable gene transfer vector under conditions that allow for transfection of the vectors into the T cells. Genetic modification is carried out when the cell density of the T cell population is between about 0.1×10^6 and 5×10^6 , preferably between about 0.5×10^6 and 2×10^6 . A number of suitable viral and nonviral-based gene transfer vectors have been described for use herein.

30 After transduction, transduced cells are selected away from non-transduced cells using known techniques. For example, if the gene transfer vector used in the transduction includes a selectable marker which confers resistance to a cytotoxic agent, the cells can be contacted with the appropriate cytotoxic agent, whereby non-transduced cells can be negatively selected away from the transduced cells. If the

selectable marker is a cell surface marker, the cells can be contacted with a binding agent specific for the particular cell surface marker, whereby the transduced cells can be positively selected away from the population. The selection step can also entail fluorescence-activated cell sorting (FACS) techniques, such as where FACS is used to 5 select cells from the population containing a particular surface marker, or the selection step can entail the use of magnetically responsive particles as retrievable supports for target cell capture and/or background removal.

More particularly, positive selection of the transduced cells can be performed using a FACS cell sorter (e.g. a FACS Vantage™ Cell Sorter, Becton Dickinson 10 Immunocytometry Systems, San Jose, CA) to sort and collect transduced cells expressing a selectable cell surface marker. Following transduction, the cells are stained with fluorescent-labeled antibody molecules directed against the particular cell surface marker. The amount of bound antibody on each cell can be measured by passing droplets containing the cells through the cell sorter. By imparting an 15 electromagnetic charge to droplets containing the stained cells, the transduced cells can be separated from other cells. The positively selected cells are then harvested in sterile collection vessels. These cell sorting procedures are described in detail, for example, in the FACS Vantage™ Training Manual, with particular reference to sections 3-11 to 3-28 and 10-1 to 10-17.

Positive selection of the transduced cells can also be performed using magnetic 20 separation of cells based on expression of a particular cell surface marker. In such separation techniques, cells to be positively selected are first contacted with specific binding agent (e.g., an antibody or reagent that interacts specifically with the cell surface marker). The cells are then contacted with retrievable particles (e.g., 25 magnetically responsive particles) which are coupled with a reagent that binds the specific binding agent (that has bound to the positive cells). The cell-binding agent-particle complex can then be physically separated from non-labeled cells, for example using a magnetic field. When using magnetically responsive particles, the labeled cells can be retained in a container using a magnetic field while the negative cells are 30 removed. These and similar separation procedures are known to those of ordinary skill in the art.

Expression of the vector in the selected transduced cells can be assessed by a number of assays known to those skilled in the art. For example, Western blot or Northern analysis can be employed depending on the nature of the inserted nucleotide sequence of interest. Once expression has been established and the transformed T cells 5 have been tested for the presence of the selected synthetic expression cassette, they are ready for infusion into a patient via the peripheral blood stream.

The invention includes a kit for genetic modification of an *ex vivo* population of primary mammalian cells. The kit typically contains a gene transfer vector coding for at least one selectable marker and at least one synthetic expression cassette contained 10 in one or more containers, ancillary reagents or hardware, and instructions for use of the kit.

2.4.3 FURTHER DELIVERY REGIMES

Any of the polynucleotides (*e.g.*, expression cassettes) or polypeptides 15 described herein (delivered by any of the methods described above) can also be used in combination with other DNA delivery systems and/or protein delivery systems. Non-limiting examples include co-administration of these molecules, for example, in prime-boost methods where one or more molecules are delivered in a “priming” step and, subsequently, one or more molecules are delivered in a “boosting” step. In certain 20 embodiments, the delivery of one or more nucleic acid-containing compositions and is followed by delivery of one or more nucleic acid-containing compositions and/or one or more polypeptide-containing compositions (*e.g.*, polypeptides comprising HIV 25 antigens). In other embodiments, multiple nucleic acid “primes” (of the same or different nucleic acid molecules) can be followed by multiple polypeptide “boosts” (of the same or different polypeptides). Other examples include multiple nucleic acid administrations and multiple polypeptide administrations.

In any method involving co-administration, the various compositions can be delivered in any order. Thus, in embodiments including delivery of multiple different compositions or molecules, the nucleic acids need not be all delivered before the 30 polypeptides. For example, the priming step may include delivery of one or more polypeptides and the boosting comprises delivery of one or more nucleic acids and/or

one more polypeptides. Multiple polypeptide administrations can be followed by multiple nucleic acid administrations or polypeptide and nucleic acid administrations can be performed in any order. In any of the embodiments described herein, the nucleic acid molecules can encode all, some or none of the polypeptides. Thus, one or 5 more or the nucleic acid molecules (e.g., expression cassettes) described herein and/or one or more of the polypeptides described herein can be co-administered in any order and via any administration routes. Therefore, any combination of polynucleotides and/or polypeptides described herein can be used to generate elicit an immune reaction.

10

3.0 IMPROVED HIV-1 GAG AND POL EXPRESSION CASSETTES

While not desiring to be bound by any particular model, theory, or hypothesis, the following information is presented to provide a more complete understanding of the present invention.

15

The world health organization (WHO) estimated the number of people worldwide that are infected with HIV-1 to exceed 36.1 million. The development of a safe and effective HIV vaccine is therefore essential at this time. Recent studies have demonstrated the importance of CTL in controlling the HIV-1 replication in infected patients. Furthermore, CTL reactivity with multiple HIV antigens will be necessary for 20 the effective control of virus replication. Experiments performed in support of the present invention suggest that the inclusion of HIV-1 Gag and Pol, beside Env for the induction of neutralizing antibodies, into the vaccine is useful.

25

To increase the potency of HIV-1 vaccine candidates, codon modified Gag and Pol expression cassettes were designed, either for Gag alone or Gag plus Pol. To evaluate possible differences in expression and potency, the expression of these constructs was analyzed and immunogenicity studies carried out in mice.

30

Several expression cassettes encoding Gag and Pol were designed, including, but not limited to, the following: GagProtease, GagPolΔintegrase with frameshift (gagFSpol), and GagPolΔintegrase in-frame (gagpol). Versions of GagPolΔintegrase in-frame were also designed with attenuated (Att) or non-functional Protease (Ina). The nucleic acid sequences were codon modified to correspond to the codon usage of

highly expressed human genes. Mice were immunized with titrated DNA doses and humoral and cellular immune responses evaluated by ELISA and intracellular cytokine staining (Example 10).

5 The immune responses in mice has been seen to be correlated with relative levels of expression *in vitro*. Vaccine studies in rhesus monkeys will further address immune responses and expression levels *in vivo*.

10

4.0 ENHANCED VACCINE TECHNOLOGIES FOR THE INDUCTION OF POTENT NEUTRALIZING ANTIBODIES AND CELLULAR IMMUNE RESPONSES AGAINST HIV.

While not desiring to be bound by any particular model, theory, or hypothesis, the following information is presented to provide a more complete understanding of the present invention.

15 Protection against HIV infection will likely require potent and broadly reactive pre-existing neutralizing antibodies in vaccinated individuals exposed to a virus challenge. Although cellular immune responses are desirable to control viremia in those who get infected, protection against infection has not been demonstrated for vaccine approaches that rely exclusively on the induction of these responses. For this reason, experiments performed in support of the present invention use prime-boost
20 approaches that employ novel V-deleted envelope antigens from primary HIV isolates (e.g., R5 subtype B (HIV-1_{SF162}) and subtype C (HIV-1_{TVD}) strains). These antigens were delivered by enhanced DNA [polyactide co-glycolide (PLG) microparticle formulations or electroporation] or alphavirus replicon particle-based vaccine approaches, followed by booster immunizations with Env proteins in MF59 adjuvant.
25 Efficient in vivo expression of plasmid encoded genes by electrical permeabilization has been described (see, e.g., Zucchelli et al. (2000) *J. Virol.* 74:11598-11607; Banga et al. (1998) *Trends Biotechnol.* 16:408-412; Heller et al. (1996) *Febs Lett.* 389:225-228; Mathiesen et al. (1999) *Gene Ther.* 4:508-514; Mir et al. (1999) *Proc. Nat'l Acad. Sci. USA* 96:4262-4267; Nishi et al. (1996) *Cancer Res.* 56:1050-1055). Both native
30 and V-deleted monomeric (gp120) and oligomeric (o-gp140) forms of protein from the SF162 strain were tested as boosters. All protein preparations were highly purified

and extensively characterized by biophysical and immunochemical methodologies. Results from rabbit and primate immunogenicity studies indicated that, whereas neutralizing antibody responses could be consistently induced against the parental non-V2-deleted SF162 virus, the induction of responses against heterologous HIV strains 5 improved with deletion of the V2 loop of the immunogens. Moreover, using these prime-boost vaccine regimens, potent HIV antigen-specific CD4 + and CD8+ T-cell responses were also demonstrated.

Based on these findings, V2-deleted envelope DNA and protein vaccines were chosen for advancement toward clinical evaluation. Similar approaches for 10 immunization may be employed using, for example, nucleic acid immunization employing the synthetic HIV polynucleotides of the present invention coupled with corresponding or heterologous HIV-derived polypeptide boosts.

One embodiment of this aspect of the present invention may be described generally as follows. Antigens are selected for the vaccine composition(s). Env 15 polypeptides are typically employed in a first antigenic composition used to induce an immune response. Further, Gag polypeptides are typically employed in a second antigenic composition used to induce an immune response. The second antigenic composition may include further HIV-derived polypeptide sequences, including, but not limited to, Pol, Tat, Rev, Nef, Vif, Vpr, and/or Vpu sequences. A DNA prime vaccination is typically performed with the first and second antigenic compositions. 20 Further DNA vaccinations with one or more of the antigenic compositions may also be included at selected time intervals. The prime is typically followed by at least one boost. The boost may, for example, include adjuvanted HIV-derived polypeptides (e.g., corresponding to those used for the DNA vaccinations), coding sequences for 25 HIV-derived polypeptides (e.g., corresponding to those used for the DNA vaccinations) encoded by a viral vector, further DNA vaccinations, and/or combinations of the foregoing. In one embodiment, a DNA prime is administered with a first antigenic composition (e.g., a DNA construct encoding an Envelope 30 polypeptide) and second antigenic composition (e.g., a DNA construct encoding a Gag polypeptide, a Pol polypeptide, a Tat polypeptide, a Nef polypeptide, and a Rev polypeptide). The DNA construct for use in the prime may, for example, comprise a

CMV promoter operably linked to the polynucleotide encoding the polypeptide sequence. The DNA prime is followed by a boost, for example, an adjuvanted Envelope polypeptide boost and a viral vector boost (where the viral vector encodes, e.g., a Gag polypeptide, a Pol polypeptide, a Tat polypeptide, a Nef polypeptide, and a Rev polypeptide). Alternately (or in addition), the boost may be an adjuvanted Gag polypeptide, Pol polypeptide, Tat polypeptide, Nef polypeptide, and Rev polypeptide boost and a viral vector boost (where the viral vector encodes, e.g., an Envelope polypeptide). The boost may include all polypeptide antigens which were encoded in the DNA prime; however, this is not required. Further, different polypeptide antigens may be used in the boost relative to the initial vaccination and visa versa. Further, the initial vaccination may be a viral vector rather than a DNA construct.

Some factors that may be considered in HIV envelope vaccine design are as follows. Envelope-based vaccines have demonstrated protection against infection in non-human primate models. Passive antibody studies have demonstrated protection against HIV infection in the presence of neutralizing antibodies against the virus challenge stock. Vaccines that exclude Env generally confer less protective efficacy. Experiments performed in support of the present invention have demonstrated that monomeric gp120 protein-derived from the SF2 lab strain provided neutralization of HIV-1 lab strains and protection against virus challenges in primate models. Primary gp120 protein derived from Thai E field strains provided cross-subtype neutralization of lab strains. Primary sub-type B oligomeric o-gp140 protein provided partial neutralization of subtype B primary (field) isolates. Primary sub-type B o-gp140 Δ V2 DNA prime plus protein boost provided potent neutralization of diverse subtype B primary isolates and protection against virus challenge in primate models. Primary sub-type C o-gp140 and o-gp140 Δ V2 likely provide similar results to those just described for sub-type B.

Vaccine strategies for induction of potent, broadly reactive, neutralizing antibodies may be assisted by construction of Envelope polypeptide structures that expose conserved neutralizing epitopes, for example, variable-region deletions and de-glycosylations, envelope protein-receptor complexes, rational design based on crystal structure (e.g., β -sheet deletions), and gp41-fusion domain based immunogens.

Stable CHO cell lines for envelope protein production have been developed using optimized envelope polypeptide coding sequences, including, but not limited to, the following: gp120, o-gp140, gp120ΔV2, o-gp140ΔV2, gp120ΔV1V2, o-gp140ΔV1V2.

5 In addition, following prime-boost regimes (such as those described above) appear to be beneficial to help reduce viral load in infected subjects, as well as possibly slow or prevent progression of HIV-related disease (relative to untreated subjects).

Exemplary antigenic compositions and immunogenicity studies are presented in Examples 9, 10, 11, and 12.

10

EXPERIMENTAL

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

15 Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

Example 1

20 Generation of Synthetic Expression Cassettes

A. Generating Synthetic Polynucleotides

The polynucleotide sequences of the present invention were manipulated to maximize expression of their gene products. The order of the following steps may vary.

25 First, the HIV-1 codon usage pattern was modified so that the resulting nucleic acid coding sequence was comparable to codon usage found in highly expressed human genes. The HIV codon usage reflects a high content of the nucleotides A or T of the codon-triplet. The effect of the HIV-1 codon usage is a high AT content in the DNA sequence that results in a high AU content in the RNA and in a decreased 30 translation ability and instability of the mRNA. In comparison, highly expressed

human codons prefer the nucleotides G or C. The wild-type sequences were modified to be comparable to codon usage found in highly expressed human genes.

Second, for some genes non-functional variants were created. In the following table (Table B) mutations affecting the activity of several HIV genes are disclosed.

5

Table B

Gene	"Region"	Exemplary Mutations
Pol	prot	<p>Att = Reduced activity by attenuation of Protease (Thr26Ser) (e.g., Konvalinka et al., 1995, J Virol 69: 7180-86)</p> <p>Ina = Mutated Protease, nonfunctional enzyme (Asp25Ala)(e.g., Konvalinka et al., 1995, J Virol 69: 7180-86)</p>
	RT	<p>YM = Deletion of catalytic center (YMDD_AP; SEQ ID NO:7) (e.g., Biochemistry, 1995, 34, 5351, Patel et. al.)</p> <p>WM = Deletion of primer grip region (WMGY_PI; SEQ ID NO:8)) (e.g., J Biol Chem, 272, 17, 11157, Palaniappan, et. al., 1997)</p>
	RNase	no direct mutations, RnaseH is affected by "WM" mutation in RT
	Integrase	<p>1) Mutation of HHCC domain, Cys40Ala (e.g., Wiskerchen et. al., 1995, J Virol, 69: 376).</p> <p>2.) Inactivation catalytic center, Asp64Ala, Asp116Ala, Glu152Ala (e.g., Wiskerchen et. al., 1995, J Virol, 69: 376).</p> <p>3) Inactivation of minimal DNA binding domain (MDBD), deletion of Trp235(e.g., Ishikawa et. al., 1999, J Virol, 73: 4475).</p> <p>Constructs int.opt.mut.SF2 and int.opt.mut_C (South Africa TV1) both contain all these mutations (1, 2, and 3)</p>
Env		<p>Mutations in cleavage site (e.g., mut1-4, 7)</p> <p>Mutations in glycosylation site (e.g., GM mutants, for example, change Q residue in V1 and/or V2 to N residue; may also be designated by residue altered in sequence)</p>

Gene	"Region"	Exemplary Mutations
Tat		Mutants of Tat in transactivation domain (e.g., Caputo et al., 1996, <i>Gene Ther.</i> 3:235) cys22 mutant (Cys22Gly) = TatC22 cys37 mutant (Cys37Ser) = TatC37 cys22/37 double mutant = TatC22/37
Rev		Mutations in Rev domains (e.g., Thomas et al., 1998, <i>J Virol.</i> 72:2935-44) Mutation in RNA binding-nuclear localization ArgArg38,39AspLeu = M5 Mutation in activation domain LeuGlu78,79AspLeu = M10
Nef		Mutations of myristoylation signal and in oligomerization domain: 1. Single point mutation myristoylation signal: Gly-to-Ala = -Myr 2. Deletion of N-terminal first 18 (sub-type B, e.g., SF162) or 19 (sub-type C, e.g., South Africa clones) amino acids: -Myr18 or -Myr19 (respectively) (e.g., Peng and Robert-Guroff, 2001, <i>Immunol Letters</i> 78: 195-200) Single point mutation oligomerization: (e.g., Liu et al., 2000, <i>J Virol</i> 74: 5310-19) Asp125Gly (sub B SF162) or Asp124Gly (sub C South Africa clones) Mutations affecting (1) infectivity (replication) of HIV-virions and/or (2) CD4 down regulation. (e.g., Lundquist et al. (2002) <i>J Virol.</i> 76(9):4625-33)
Vif		Mutations of Vif: e.g., Simon et al., 1999, <i>J Virol</i> 73:2675-81
Vpr		Mutations of Vpr: e.g., Singh et al., 2000, <i>J Virol</i> 74: 10650-57
Vpu		Mutations of Vpu: e.g., Tiganos et al., 1998, <i>Virology</i> 251: 96-107

5

Constructs comprising some of these mutations are described herein. Vif, vpr and vpu synthetic constructs are described. Reducing or eliminating the function of

the associated gene products can be accomplished employing the teachings set forth in the above table, in view of the teachings of the present specification.

In one embodiment of the invention, the full length coding region of the Gag-polymerase sequence is included with the synthetic Gag sequences in order to increase the number of epitopes for virus-like particles expressed by the synthetic, optimized Gag expression cassette. Because synthetic HIV-1 Gag-polymerase expresses the potentially deleterious functional enzymes reverse transcriptase (RT) and integrase (INT) (in addition to the structural proteins and protease), it is important to inactivate RT and INT functions. Several in-frame deletions in the RT and INT reading frame can be made to achieve catalytic nonfunctional enzymes with respect to their RT and INT activity. {Jay. A. Levy (Editor) (1995) *The Retroviridae*, Plenum Press, New York. ISBN 0-306-45033X. Pages 215-20; Grimison, B. and Laurence, J. (1995), *Journal Of Acquired Immune Deficiency Syndromes and Human Retrovirology* 9(1):58-68; Wakefield, J. K., et al., (1992) *Journal Of Virology* 66(11):6806-6812; 10 Esnouf, R., et al., (1995) *Nature Structural Biology* 2(4):303-308; Maignan, S., et al., (1998) *Journal Of Molecular Biology* 282(2):359-368; Katz, R. A. and Skalka, A. M. (1994) *Annual Review Of Biochemistry* 73 (1994); Jacobo-Molina, A., et al., (1993) 15 *Proceedings Of the National Academy Of Sciences Of the United States Of America* 90(13):6320-6324; Hickman, A. B., et al., (1994) *Journal Of Biological Chemistry* 269(46):29279-29287; Goldgur, Y., et al., (1998) *Proceedings Of the National 20 Academy Of Sciences Of the United States Of America* 95(16):9150-9154; Goette, M., et al., (1998) *Journal Of Biological Chemistry* 273(17):10139-10146; Gorton, J. L., et al., (1998) *Journal of Virology* 72(6):5046-5055; Engelman, A., et al., (1997) *Journal Of Virology* 71(5):3507-3514; Dyda, F., et al., *Science* 266(5193):1981-1986; 25 Davies, J. F., et al., (1991) *Science* 252(5002):88-95; Bujacz, G., et al., (1996) *Febs Letters* 398(2-3):175-178; Beard, W. A., et al., (1996) *Journal Of Biological Chemistry* 271(21):12213-12220; Kohlstaedt, L. A., et al., (1992) *Science* 256(5065):1783-1790; Krug, M. S. and Berger, S. L. (1991) *Biochemistry* 30(44):10614-10623; Mazumder, A., et al., (1996) *Molecular Pharmacology* 30(4):621-628; Palaniappan, C., et al., (1997) *Journal Of Biological Chemistry* 272(17):11157-11164; Rodgers, D. W., et al., (1995) *Proceedings Of the National 30 Academy Of Sciences Of the United States Of America* 92(17):7755-7760; 35

Academy Of Sciences Of the United States Of America 92(4):1222-1226; Sheng, N. and Dennis, D. (1993) *Biochemistry* 32(18):4938-4942; Spence, R. A., et al., (1995) *Science* 267(5200):988-993.}

Furthermore selected B- and/or T-cell epitopes can be added to the Gag-
5 polymerase constructs within the deletions of the RT- and INT-coding sequence to
replace and augment any epitopes deleted by the functional modifications of RT and
INT. Alternately, selected B- and T-cell epitopes (including CTL epitopes) from RT
and INT can be included in a minimal VLP formed by expression of the synthetic Gag
10 or synthetic GagProt cassette, described above. (For descriptions of known HIV B-
and T-cell epitopes see, HIV Molecular Immunology Database CTL Search Interface;
Los Alamos Sequence Compendia, 1987-1997; Internet address: <http://hiv-web.lanl.gov/immunology/index.html>.)

In another aspect, the present invention comprises *Env* coding sequences that
15 include, but are not limited to, polynucleotide sequences encoding the following HIV-
encoded polypeptides: gp160, gp140, and gp120 (see, e.g., U.S. Patent No. 5,792,459
for a description of the HIV-1_{SF2} ("SF2") Env polypeptide). The relationships between
these polypeptides is shown schematically in Figure 3 (in the figure: the polypeptides
are indicated as lines, the amino and carboxy termini are indicated on the gp160 line;
20 the open circle represents the oligomerization domain; the open square represents a
transmembrane spanning domain (TM); and "c" represents the location of a cleavage
site, in gp140 mut the "X" indicates that the cleavage site has been mutated such that it
no longer functions as a cleavage site). The polypeptide gp160 includes the coding
sequences for gp120 and gp41. The polypeptide gp41 is comprised of several domains
25 including an oligomerization domain (OD) and a transmembrane spanning domain
(TM). In the native envelope, the oligomerization domain is required for the non-
covalent association of three gp41 polypeptides to form a trimeric structure: through
non-covalent interactions with the gp41 trimer (and itself), the gp120 polypeptides are
also organized in a trimeric structure. A cleavage site (or cleavage sites) exists
30 approximately between the polypeptide sequences for gp120 and the polypeptide
sequences corresponding to gp41. This cleavage site(s) can be mutated to prevent
cleavage at the site. The resulting gp140 polypeptide corresponds to a truncated form

of gp160 where the transmembrane spanning domain of gp41 has been deleted. This gp140 polypeptide can exist in both monomeric and oligomeric (*i.e.* trimeric) forms by virtue of the presence of the oligomerization domain in the gp41 moiety. In the situation where the cleavage site has been mutated to prevent cleavage and the 5 transmembrane portion of gp41 has been deleted the resulting polypeptide product is designated "mutated" gp140 (*e.g.*, gp140.mut). As will be apparent to those in the field, the cleavage site can be mutated in a variety of ways. (See, also, WO 00/39302).

Wild-type HIV coding sequences (*e.g.*, Gag, Env, Pol, tat, rev, nef, vpr, vpu, vif, etc.) can be selected from any known HIV isolate and these sequences 10 manipulated to maximize expression of their gene products following the teachings of the present invention. The wild-type coding region maybe modified in one or more of the following ways. In one embodiment, sequences encoding hypervariable regions of Env, particularly V1 and/or V2 were deleted. In other embodiments, mutations were introduced into sequences, for example, encoding the cleavage site in Env to abrogate 15 the enzymatic cleavage of oligomeric gp140 into gp120 monomers. (See, *e.g.*, Earl et al. (1990) *PNAS USA* 87:648-652; Earl et al. (1991) *J. Virol.* 65:31-41). In yet other embodiments, hypervariable region(s) were deleted, N-glycosylation sites were removed and/or cleavage sites mutated. As discussed above, different mutations may be introduced into the coding sequences of different genes (see, *e.g.*, Table B). For 20 example, *Tat* coding sequences were modified according to the teachings of the present specification, for example to affect the transactivation domain of the gene product (*e.g.*, replacing a cystein residue at position 22 with a glycine, Caputo et al. (1996) *Gene Therapy* 3:235).

To create the synthetic coding sequences of the present invention the gene 25 cassettes are designed to comprise the entire coding sequence of interest. Synthetic gene cassettes are constructed by oligonucleotide synthesis and PCR amplification to generate gene fragments. Primers are chosen to provide convenient restriction sites for subcloning. The resulting fragments are then ligated to create the entire desired sequence which is then cloned into an appropriate vector. The final synthetic 30 sequences are (i) screened by restriction endonuclease digestion and analysis, (ii) subjected to DNA sequencing in order to confirm that the desired sequence has been

obtained and (iii) the identity and integrity of the expressed protein confirmed by SDS-PAGE and Western blotting. The synthetic coding sequences are assembled at Chiron Corp. (Emeryville, CA) or by the Midland Certified Reagent Company (Midland, Texas).

5 Percent identity to the synthetic sequences of the present invention can be determined, for example, using the Smith-Waterman search algorithm (Time Logic, Incline Village, NV), with the following exemplary parameters: weight matrix = nuc4x4hb; gap opening penalty = 20, gap extension penalty = 5, reporting threshold = 1; alignment threshold = 20.

10 Various forms of the different embodiments of the present invention (e.g., constructs) may be combined.

Exemplary embodiments of the synthetic polynucleotides of the present invention include, but are not limited to, the sequences presented in Table C.

15

Table C
Type B Synthetic, Codon Optimized Polynucleotides

	Name	Figure Number	Description (encoding)
20	GagComplPolmut.SF2 (SEQ ID NO:9)	6	Gag complete, RT mutated, Protease functional; all in frame
	GagComplPolmutAtt.SF2 (SEQ ID NO:10)	7	Gag complete, RT mutated, Protease attenuated; all in frame
	GagComplPolmutIna.SF2 (SEQ ID NO:11)	8	Gag complete, RT mutated, Protease non-functional; all in frame
25	gagCpolInaTatRevNef.opt_B (SEQ ID NO:12)	9	Gag complete, protease non-functional, RT mutated, tat mutated, rev mutated, nef mutated; all in frame
	GagPolmutAtt.SF2 (SEQ ID NO:13)	10	Gag, RT mutated, Protease attenuated; all in frame

	Name	Figure Number	Description (encoding)
	GagPolmutIna.SF2 (SEQ ID NO:14)	11	Gag, RT mutated, Protease non-functional; all in frame
	GagProtInaRTmut.SF2 (SEQ ID NO:15)	12	Gag, Protease non-functional, RT mutated; all in frame
5	GagProtInaRTmutTatRevNef.opt_B (SEQ ID NO:16)	13	Gag, protease non-functional, RT mutated, tat mutated, rev mutated, nef mutated; all in frame
	GagRTmut.SF2 (SEQ ID NO:17)	14	Gag, RT mutated; all in frame
10	GagTatRevNef.opt_B (SEQ ID NO:18)	15	Gag, tat mutated, rev mutated, nef mutated; all in frame
	gp140.modSF162.CwtLmod (SEQ ID NO:19)	16	gp140 derived from SF162 with a HIV Type C (TV1) optimized leader sequence
	gp140.modSF162.CwtLnat (SEQ ID NO:20)	17	gp140 derived from SF162 with a HIV Type C (TV1) native leader sequence
15	gp160.modSF162.delV2.mut7 (SEQ ID NO:21)	18	gp160 derived from SF162, deletion of V2 loop, mutated cleavage site
	gp160.modSF162.delV2.mut8 (SEQ ID NO:22)	19	gp160 derived from SF162, deletion of V2 loop, mutated cleavage site
20	int.opt.mut.SF2 (SEQ ID NO:23)	20	integrase mutated
	int.opt.SF2 (SEQ ID NO:24)	21	integrase
	nef.D125G.-myr.opt.SF162 (SEQ ID NO:25)	22	nef mutated, myristoylation defective
25	nef.D107G.-myr18.opt.SF162 (SEQ ID NO:26)	23	nef mutated, myristoylation defective
	nef.opt.D125G.SF162 (SEQ ID NO:27)	24	nef mutated

	Name	Figure Number	Description (encoding)
	nef.opt.SF162 (SEQ ID NO:28)	25	nef
5	p15RnaseH.opt.SF2 (SEQ ID NO:29)	26	p15 RNase H; in-frame
	p2Pol.opt.YMWM.SF2 (SEQ ID NO:30)	27	p2.pol-mutated (RT YM, WM)
	p2PolInaopt.YM.SF2 (SEQ ID NO:31)	28	p2 pol, protease non-functional, RT YM; all in frame
10	p2Polopt.SF2 (SEQ ID NO:32)	29	p2 pol; all in frame
	p2PolTatRevNef.opt.native_B (SEQ ID NO:33)	30	p2 pol tat rev nef; all native; all in frame
	p2PolTatRevNef.opt_B (SEQ ID NO:34)	31	p2 pol, protease mutated, RT mutated, tat mutated, rev mutated, nef, mutated; all in frame
15	pol.opt.SF2 (SEQ ID NO:35)	32	pol
	prot.opt.SF2 (SEQ ID NO:36)	33	protease
20	protIna.opt.SF2 (SEQ ID NO:37)	34	protease non-functional
	protInaRT.YM.opt.SF2 (SEQ ID NO:38)	35	protease non-functional, RT YM mutated; all in frame
	protInaRT.YMWM.opt.SF2 (SEQ ID NO:39)	36	protease non-functional, RT YM WM mutated; all in frame
25	ProtInaRTmut.SF2 (SEQ ID NO:40)	37	Protease inactive, RT mutated; all in frame
	protRT.opt.SF2 (SEQ ID NO:41)	38	protease RT; all in frame
30	ProtRT.TatRevNef.opt_B (SEQ ID NO:42)	39	protease mutated, RT mutated, tat mutated, rev mutated, nef, mutated; all in frame

	Name	Figure Number	Description (encoding)
	ProtRTTatRevNef.opt_B (SEQ ID NO:43)	40	protease mutated, RT mutated, tat mutated, rev mutated, nef, mutated; all in frame
	rev.exon1_2.M5-10.opt.SF162 (SEQ ID NO:44)	41	rev exon 1 and 2 in-frame, rev mutated
5	rev.exon1_2.opt.SF162 (SEQ ID NO:45)	42	rev exon 1 and 2 in-frame
10	RT.opt.SF2 (mutant) (SEQ ID NO:46)	43	RT mutant
15	RT.opt.SF2 (native) (SEQ ID NO:47)	44	RT native
20	RTmut.SF2 (SEQ ID NO:48)	45	RT mutated
25	tat.exon1_2.opt.C22-37.SF2 (SEQ ID NO:49)	46	tat exon 1 and 2 in-frame, tat mutated
	tat.exon1_2.opt.C37.SF2 (SEQ ID NO:50)	47	tat exon 1 and 2 in-frame, tat mutated
	TatRevNef.opt.native.SF162 (SEQ ID NO:51)	48	tat native, rev native, nef native; all in frame
	TatRevNef.opt.SF162 (SEQ ID NO:52)	49	tat mutated, rev mutated, nef mutated; all in frame
	TatRevNefGag B (SEQ ID NO:53)	50	tat mutated, rev mutated, nef mutated, gag; all in frame
	TatRevNefgagCpolIna B (SEQ ID NO:54)	51	tat mutated, rev mutated, nef mutated, gag complete, protease non-functional, RT mutated; all in frame
	TatRevNefGagProtInaRTmut B (SEQ ID NO:55)	52	tat mutated, rev mutated, nef mutated, gag, protease non-functional, RT mutant; all in frame
	TatRevNefp2Pol.opt_B (SEQ ID NO:56)	53	tat mutated, rev mutated, nef mutated, p2 pol, protease mutated, RT mutated; all in frame

Name	Figure Number	Description (encoding)
TatRevNefprotRTopt B (SEQ ID NO:57)	54	tat mutated, rev mutated, nef mutated, protease mutated, RT mutated; all in frame
vif.opt.SF2 (SEQ ID NO:58)	55	optimized vif derived from SF2
5 vpr.opt.SF2 (SEQ ID NO:59)	56	optimized vpr derived from SF2
vpu.opt.SF162 (SEQ ID NO:60)	57	optimized vpu derived from SF162

10 {In Table C, **.mut** or **.mut7** or **.mut 8** = envelope mutated in cellular protease cleavage site between gp120/gp41 (i.e., to prevent cleavage; e.g., better for purifying protein)}

15 **B. Creating Expression Cassettes Comprising the Synthetic Polynucleotides of the Present Invention.**

The synthetic DNA fragments of the present invention are cloned into the following expression vectors: pCMVKm2, for transient expression assays and DNA immunization studies, the pCMVKm2 vector was derived from pCMV6a (Chapman et al., *Nuc. Acids Res.* (1991) 19:3979-3986) and comprises a kanamycin selectable marker, a ColE1 origin of replication, a CMV promoter enhancer and Intron A, followed by an insertion site for the synthetic sequences described below followed by a polyadenylation signal derived from bovine growth hormone -- the pCMVKm2 vector differs from the pCMV-link vector only in that a polylinker site was inserted into pCMVKm2 to generate pCMV-link; pESN2dhfr and pCMVPLEdhfr (also known as pCMVIII), for expression in Chinese Hamster Ovary (CHO) cells; and, pAcC13, a shuttle vector for use in the Baculovirus expression system (pAcC13, was derived from pAcC12 which was described by Munemitsu S., et al., *Mol Cell Biol.* 10(11):5977-5982, 1990). See, also co-owned WO 00/39302, WO 00/39303, WO 00/39304, and WO 02/04493, for a description of these vectors.

Briefly, construction of pCMVPLEdhfr (pCMVIII) was as follows. To construct a DHFR cassette, the EMCV IRES (internal ribosome entry site) leader was PCR-amplified from pCite-4a+ (Novagen, Inc., Milwaukee, WI) and inserted into pET-23d (Novagen, Inc., Milwaukee, WI) as an *Xba*-*Nco* fragment to give pET-EMCV. The *dhfr* gene was PCR-amplified from pESN2dhfr to give a product with a Gly-Gly-Gly-Ser spacer in place of the translation stop codon and inserted as an *Nco*-*Bam*H1 fragment to give pET-E-DHFR. Next, the attenuated *neo* gene was PCR amplified from a pSV2Neo (Clontech, Palo Alto, CA) derivative and inserted into the unique *Bam*H1 site of pET-E-DHFR to give pET-E-DHFR/*Neo*_(m2). Then, the bovine growth hormone terminator from pCDNA3 (Invitrogen, Inc., Carlsbad, CA) was inserted downstream of the *neo* gene to give pET-E-DHFR/*Neo*_(m2)BGHt. The EMCV-*dhfr/neo* selectable marker cassette fragment was prepared by cleavage of pET-E-DHFR/*Neo*_(m2)BGHt. The CMV enhancer/promoter plus Intron A was transferred from pCMV6a (Chapman et al., *Nuc. Acids Res.* (1991) 19:3979-3986) as a *Hind*III-*Sall* fragment into pUC19 (New England Biolabs, Inc., Beverly, MA). The vector backbone of pUC19 was deleted from the *Nde*1 to the *Sap*1 sites. The above described DHFR cassette was added to the construct such that the EMCV IRES followed the CMV promoter to produce the final construct. The vector also contained an *amp*^r gene and an SV40 origin of replication.

Expression vectors of the present invention contain one or more of the synthetic coding sequences disclosed herein, e.g., shown in the Figures. When the expression cassette contains more than one coding sequence the coding sequences may all be in-frame to generate one polyprotein; alternately, the more than one polypeptide coding sequences may comprise a polycistronic message where, for example, an IRES is placed 5' to each polypeptide coding sequence.

Example 2

Expression Assays for the Synthetic Coding Sequences

The wild-type sequences are cloned into expression vectors having the same features as the vectors into which the synthetic HIV-derived sequences were cloned.

Expression efficiencies for various vectors carrying the wild-type (any known isolated) and corresponding synthetic sequence(s) are evaluated as follows. Cells from several mammalian cell lines (293, RD, COS-7, and CHO; all obtained from the American Type Culture Collection, 10801 University Boulevard, Manassas, VA

5 20110-2209) are transfected with 2 μ g of DNA in transfection reagent LT1 (PanVera Corporation, 545 Science Dr., Madison, WI). The cells are incubated for 5 hours in reduced serum medium (Opti-MEM, Gibco-BRL, Gaithersburg, MD). The medium is then replaced with normal medium as follows: 293 cells, IMDM, 10% fetal calf serum, 2% glutamine (BioWhittaker, Walkersville, MD); RD and COS-7 cells, D-MEM, 10%
10 fetal calf serum, 2% glutamine (Opti-MEM, Gibco-BRL, Gaithersburg, MD); and CHO cells, Ham's F-12, 10% fetal calf serum, 2% glutamine (Opti-MEM, Gibco-BRL, Gaithersburg, MD). The cells are incubated for either 48 or 60 hours. Supernatants are harvested and filtered through 0.45 μ m syringe filters and, optionally, stored at -20°C.

15 Supernatants are evaluated using the Coulter p24-assay (Coulter Corporation, Hialeah, FL, US), using 96-well plates coated with a suitable monoclonal antibody directed against an HIV antigen (e.g., a murine monoclonal directed against an HIV core antigen). The appropriate HIV antigen binds to the coated wells and biotinylated antibodies against HIV recognize the bound antigen. Conjugated strepavidin-
20 horseradish peroxidase reacts with the biotin. Color develops from the reaction of peroxidase with TMB substrate. The reaction is terminated by addition of 4N H₂SO₄. The intensity of the color is directly proportional to the amount of HIV antigen in a sample.

Chinese hamster ovary (CHO) cells are also transfected with plasmid DNA
25 encoding the synthetic HIV polypeptides described herein (e.g., pESN2dhfr or pCMVIII vector backbone) using Mirus TransIT-LT1 polyamine transfection reagent (Pan Vera) according to the manufacturers instructions and incubated for 96 hours. After 96 hours, media is changed to selective media (F12 special with 250 μ g/ml G418) and cells are split 1:5 and incubated for an additional 48 hours. Media is
30 changed every 5-7 days until colonies start forming at which time the colonies are picked, plated into 96 well plates and screened by Capture ELISA. Positive clones are

expanded in 24 well plates and are screened several times for HIV protein production by Capture ELISA, as described above. After reaching confluence in 24 well plates, positive clones are expanded to T25 flasks (Corning, Corning, NY). These are screened several times after confluence and positive clones are expanded to T75 flasks.

5 Positive T75 clones are frozen in LN2 and the highest expressing clones are amplified with 0-5 μ M methotrexate (MTX) at several concentrations and plated in 100mm culture dishes. Plates are screened for colony formation and all positive clones are again expanded as described above. Clones are expanded and amplified and screened at each step capture ELISA. Positive clones are frozen at each methotrexate 10 level. Highest producing clones are grown in perfusion bioreactors (3L, 100L) for expansion and adaptation to low serum suspension culture conditions for scale-up to larger bioreactors.

15 Data from experiments performed in support of the present invention show that the synthetic HIV expression cassettes provided dramatic increases in production of their protein products, relative to the native (wild-type) sequences, when expressed in a variety of cell lines and that stably transfected CHO cell lines, which express the desired HIV polypeptide(s), may be produced. Production of HIV polypeptides using CHO cells provides (i) correct glycosylation patterns and protein conformation (as determined by binding to panel of MAbs); (ii) correct binding to CD4 receptor 20 molecules; (iii) absence of non-mammalian cell contaminants (e.g., insect viruses and/or cells); and (iv) ease of purification.

Example 3

Western Blot Analysis of Expression

25 Western blot analysis of cells transfected with the HIV expression cassettes described herein are performed essentially as described in co-owned WO 00/39302. Briefly, human 293 cells are transfected as described in Example 2 with pCMV6a-based vectors containing native or synthetic HIV expression cassettes. Cells are cultivated for 60 hours post-transfection. Supernatants are prepared as described. 30 Cell lysates are prepared as follows. The cells are washed once with phosphate-buffered saline, lysed with detergent [1% NP40 (Sigma Chemical Co., St. Louis, MO)

in 0.1 M Tris-HCl, pH 7.5], and the lysate transferred into fresh tubes. SDS-polyacrylamide gels (pre-cast 8-16%; Novex, San Diego, CA) are loaded with 20 μ l of supernatant or 12.5 μ l of cell lysate. A protein standard is also loaded (5 μ l, broad size range standard; BioRad Laboratories, Hercules, CA). Electrophoresis is carried
5 out and the proteins are transferred using a BioRad Transfer Chamber (BioRad Laboratories, Hercules, CA) to Immobilon P membranes (Millipore Corp., Bedford, MA) using the transfer buffer recommended by the manufacturer (Millipore), where the transfer is performed at 100 volts for 90 minutes. The membranes are exposed to HIV-1-positive human patient serum and immunostained using o-phenylenediamine
10 dihydrochloride (OPD; Sigma).

The results of the immunoblotting analysis are used to show that cells containing the synthetic HIV expression cassette produce the expected HIV-polypeptide(s) at higher per-cell concentrations than cells containing the native expression cassette.

15

Example 4

In Vivo Immunogenicity of Synthetic HIV Expression Cassettes

A. Immunization

To evaluate the immunogenicity of the synthetic HIV expression cassettes, a
20 mouse study may be performed. The plasmid DNA, e.g., pCMVKM2 carrying an expression cassette comprising a synthetic sequence of the present invention, is diluted to the following final concentrations in a total injection volume of 100 μ l: 20 μ g, 2 μ g, 0.2 μ g, and 0.02 μ g. To overcome possible negative dilution effects of the diluted DNA, the total DNA concentration in each sample is brought up to 20 μ g using the vector (pCMVKM2) alone. As a control, plasmid DNA comprising an expression
25 cassette encoding the native, corresponding polypeptide is handled in the same manner. Twelve groups of four Balb/c mice (Charles River, Boston, MA) are intramuscularly immunized (50 μ l per leg, intramuscular injection into the *tibialis anterior*) using varying dosages.

30

B. Humoral Immune Response

The humoral immune response is checked with a suitable anti-HIV antibody ELISAs (enzyme-linked immunosorbent assays) of the mice sera 0 and 4 weeks post immunization (groups 5-12) and, in addition, 6 and 8 weeks post immunization, 5 respectively, 2 and 4 weeks post second immunization (groups 1-4).

The antibody titers of the sera are determined by anti-HIV antibody ELISA. Briefly, sera from immunized mice were screened for antibodies directed against an appropriate HIV protein (e.g., HIV p55 for Gag). ELISA microtiter plates are coated with 0.2 µg of HIV protein per well overnight and washed four times; subsequently, 10 blocking is done with PBS-0.2% Tween (Sigma) for 2 hours. After removal of the blocking solution, 100 µl of diluted mouse serum is added. Sera are tested at 1/25 dilutions and by serial 3-fold dilutions, thereafter. Microtiter plates are washed four times and incubated with a secondary, peroxidase-coupled anti-mouse IgG antibody (Pierce, Rockford, IL). ELISA plates are washed and 100 µl of 3, 3', 5, 5'-tetramethyl 15 benzidine (TMB; Pierce) was added per well. The optical density of each well is measured after 15 minutes. The titers reported are the reciprocal of the dilution of serum that gave a half-maximum optical density (O.D.).

The results of the mouse immunizations with plasmid-DNAs are used to show that the synthetic expression cassettes provide improvement of immunogenicity 20 relative to the native expression cassettes. Also, the second boost immunization induces a secondary immune response after two weeks (groups 1-3).

C. Cellular Immune Response

The frequency of specific cytotoxic T-lymphocytes (CTL) is evaluated by a 25 standard chromium release assay of peptide pulsed Balb/c mouse CD4 cells. HIV protein-expressing vaccinia virus infected CD-8 cells are used as a positive control (vv-protein). Briefly, spleen cells (Effector cells, E) are obtained from the BALB/c mice (immunized as described above). The cells are cultured, restimulated, and assayed for 30 CTL activity against, e.g., Gag peptide-pulsed target cells as described (Doe, B., and Walker, C.M., AIDS 10(7):793-794, 1996). Cytotoxic activity is measured in a standard ⁵¹Cr release assay. Target (T) cells are cultured with effector (E) cells at

various E:T ratios for 4 hours and the average cpm from duplicate wells is used to calculate percent specific ^{51}Cr release.

Cytotoxic T-cell (CTL) activity is measured in splenocytes recovered from the mice immunized with HIV DNA constructs described herein. Effector cells from the 5 DNA-immunized animals exhibit specific lysis of HIV peptide-pulsed SV-BALB (MHC matched) targets cells indicative of a CTL response. Target cells that are peptide-pulsed and derived from an MHC-unmatched mouse strain (MCS7) are not lysed. The results of the CTL assays are used to show increased potency of synthetic HIV expression cassettes for induction of cytotoxic T-lymphocyte (CTL) responses by 10 DNA immunization.

Example 5

In Vivo Immunogenicity of Synthetic HIV Expression Cassettes

A. General Immunization Methods

15 To evaluate the immunogenicity of the synthetic HIV expression cassettes, studies using guinea pigs, rabbits, mice, rhesus macaques and baboons are performed. The studies are typically structured as follows: DNA immunization alone (single or multiple); DNA immunization followed by protein immunization (boost); DNA immunization followed by Sindbis particle immunization; immunization by Sindbis 20 particles alone.

B. Guinea Pigs

Experiments may be performed using guinea pigs as follows. Groups comprising six guinea pigs each are immunized intramuscularly or mucosally at 0, 4, 25 and 12 weeks with plasmid DNAs encoding expression cassettes comprising one or more the sequences described herein. The animals are subsequently boosted at approximately 18 weeks with a single dose (intramuscular, intradermally or mucosally) of the HIV protein encoded by the sequence(s) of the plasmid boost and/or other HIV proteins. Antibody titers (geometric mean titers) are measured at two weeks following 30 the third DNA immunization and at two weeks after the protein boost. These results are used to demonstrate the usefulness of the synthetic constructs to generate immune

responses, as well as, the advantage of providing a protein boost to enhance the immune response following DNA immunization.

C. Rabbits

5 Experiments may be performed using rabbits as follows. Rabbits are immunized intramuscularly, mucosally, or intradermally (using a Bioject needless syringe) with plasmid DNAs encoding the HIV proteins described herein. The nucleic acid immunizations are followed by protein boosting after the initial immunization. Typically, constructs comprising the synthetic HIV-polypeptide-encoding 10 polynucleotides of the present invention are highly immunogenic and generate substantial antigen binding antibody responses after only 2 immunizations in rabbits.

D. Humoral Immune Response

In any immunized animal model, the humoral immune response is checked in 15 serum specimens from the immunized animals with an anti-HIV antibody ELISAs (enzyme-linked immunosorbent assays) at various times post-immunization. The antibody titers of the sera are determined by anti-HIV antibody ELISA as described above. Briefly, sera from immunized animals are screened for antibodies directed 20 against the HIV polypeptide/protein(s) encoded by the DNA and/or polypeptide used to immunize the animals. Wells of ELISA microtiter plates are coated overnight with the selected HIV polypeptide/protein and washed four times; subsequently, blocking is done with PBS-0.2% Tween (Sigma) for 2 hours. After removal of the blocking solution, 100 µl of diluted mouse serum is added. Sera are tested at 1/25 dilutions and by serial 3-fold dilutions, thereafter. Microtiter plates are washed four times and 25 incubated with a secondary, peroxidase-coupled anti-mouse IgG antibody (Pierce, Rockford, IL). ELISA plates are washed and 100 µl of 3, 3', 5, 5'-tetramethyl benzidine (TMB; Pierce) was added per well. The optical density of each well is measured after 15 minutes. Titers are typically reported as the reciprocal of the dilution of serum that gave a half-maximum optical density (O.D.).

30 Cellular immune response may also be evaluated.

Example 6DNA-immunization of Baboons and Rhesus Macaques Using Expression CassettesComprising the Synthetic HIV Polynucleotides of the Present InventionA. Baboons

5 Four baboons are immunized 3 times (weeks 0, 4 and 8) bilaterally, intramuscular into the quadriceps or mucosally using the gene delivery vehicles described herein. The animals are bled two weeks after each immunization and an HIV antibody ELISA is performed with isolated plasma. The ELISA is performed essentially as described above except the second antibody-conjugate is an anti-human
10 IgG, g-chain specific, peroxidase conjugate (Sigma Chemical Co., St. Louis, MD 63178) used at a dilution of 1:500. Fifty µg/ml yeast extract may be added to the dilutions of plasma samples and antibody conjugate to reduce non-specific background due to preexisting yeast antibodies in the baboons. Lymphoproliferative responses to are observed in baboons two weeks post-fourth immunization (at week 14), and
15 enhanced substantially post-boosting with HIV-polypeptide (at week 44 and 76). Such proliferation results are indicative of induction of T-helper cell functions.

B. Rhesus Macaques

20 The improved potency of the synthetic, codon-modified *HIV*-polypeptide encoding polynucleotides of the present invention, when constructed into expression plasmids may be confirmed in rhesus macaques. Typically, the macaques have detectable HIV-specific CTL after two or three 1 mg doses of modified *HIV* polynucleotide. In sum, these results demonstrate that the synthetic HIV DNA is immunogenic in non-human primates. Neutralizing antibodies may also detected.

25

Example 7Co-Transfection of Monocistronic and Multicistronic Constructs

30 The present invention includes co-transfection with multiple, monocistronic expression cassettes, as well as, co-transfection with one or more multi-cistronic expression cassettes, or combinations thereof.

Such constructs, in a variety of combinations, may be transfected into 293T cells for transient transfection studies.

For example, a bicistronic construct may be made where the coding sequences for the different HIV polypeptides are under the control of a single CMV promoter and, between the two coding sequences, an IRES (internal ribosome entry site (EMCV IRES); Kozak, M., *Critical Reviews in Biochemistry and Molecular Biology* 27(45):385-402, 1992; Witherell, G.W., et al., *Virology* 214:660-663, 1995) sequence is introduced after the first HIV coding sequence and before the second HIV coding sequence.

10 Supernatants collected from cell culture are tested for the presence of the HIV proteins and indicate that appropriate proteins are expressed in the transfected cells (e.g., if an Env coding sequence was present the corresponding Env protein was detected; if a Gag coding sequence was present the corresponding Gag protein was detected, etc.).

15 The production of chimeric VLPs by these cell lines may be determined using electron microscopic analysis. (See, e.g., co-owned WO 00/39302).

Example 8

Accessory gene components for an HIV-1 vaccine: functional analysis of mutated Tat,

Rev and Nef Type C antigens

The HIV-1 regulatory and accessory genes have received increased attention as components of HIV vaccines due to their role in viral pathogenesis, the high ratio of highly conserved CTL epitopes and their early expression in the viral life cycle. Because of various undesirable properties of these genes, questions regarding their safety and suitability as vaccine components have been raised. Experiments performed in support of the present invention have analyzed candidate HIV-1 subtype C *tat*, *rev*, and *nef* mutants for efficient expression and inactivation of potential deleterious functions. Other HIV subtype accessory genes may be evaluated similarly.

30 Sequence-modified, mutant *tat*, *rev*, and *nef* genes coding for consensus Tat, Rev and Nef proteins of South African HIV-1 subtype C were constructed using overlapping synthetic oligonucleotides and PCR-based site-directed mutagenesis.

Constructs of the wild-type genes of the isolates closely resembling the respective consensus sequences were also made by PCR. *In vitro* expression of the constructs was analyzed by western blotting. The *trans*-activation activity of the Tat mutants and nuclear RNA export activity of the Rev mutants were studied after transfection of 5 various cell lines using reporter-gene-based functionality assays.

In vitro expression of all constructs was demonstrated by western blotting using antigen specific mouse serum generated by DNA vaccination of mice with Tat, Rev, or Nef-expression plasmids. Expression levels of the sequence-modified genes were significantly higher than the wild-type genes.

10 Subtype B and C Tat cDNA was mutated to get TatC22, TatC37, and TatC22/37. Tat activity assays in three cell lines (RD, HeLa and 293). In the background of the subtype C consensus Tat, a single mutation at C22 was insufficient to inactivate LTR-dependent CAT expression. In contrast, this activity was significantly impaired in RD, 293 and HeLa cells using the single mutation, C37, or the 15 double mutation, C22C37 (see Table B). Corresponding results were obtained for Tat mutants derived from subtype B strains.

Exemplary results are presented in Figure 4 for transactivation activity of Tat mutants on LTR-CAT plasmid in 293 cells. Three independent assays were performed for each construct (Figure 4, legend (1), (2), (3)).

20 The subtype C constructs TatC22ProtRTTatRevNef and ProtRTTatC22RevNef showed reduced Tat activity when compared to TatC22 alone, probably due to structural changes caused by the fusion protein.

For Rev constructs, to test for the loss of function, a CAT assay with a 25 reporter plasmid including native or mutated Rev was used. As shown in Figure 5, compared to wild-type Rev, the mRNA export function of the subtype C Rev with a double mutation, M5M10 (see Table B), was significantly lower. The background levels are shown in the "mock" data and the pDM128 reporter plasmid without Rev data. Two independent assays were performed for each construct (Figure 5, legend (1), (2)).

30 Assays to measure Nef-specific functions may also be performed (Nef mutations are described in Table B). For example, FACs analysis is used to look for

the presence of MHC1 and CD4 on cell surfaces. Cells are assayed in the presence and absence of Nef expression (for controls), as well as using the synthetic polynucleotides of the present invention that encode native nef protein and mutated nef protein. Down-regulation of MHC1 and CD4 expression indicates that the nef gene product is not functional, i.e., if nef is non-functional there is no down regulation.

5 These data demonstrate the impaired functionality of *tat* and *rev* DNA immunogens that may form part of a multi-component HIV-1 subtype C vaccine. In contrast to previous published data by other groups, the C22 mutation did not sufficiently inactivate the transactivation function of Tat. The C37 mutation appeared 10 to be required for inactivation of subtype C and subtype B Tat proteins.

Example 9

Evaluation of immunogenicity of various HIV polypeptide encoding plasmids

As noted above, the immunogenicity of any of the polynucleotides or 15 expression cassettes described herein is readily evaluated. In the following table (Table D) are exemplified procedures involving a comparison of the immunogenicity of subtype B and C envelope plasmids, both individually and as a mixed-subtype vaccine, using electroporation, in rabbits. It will be apparent that such methods are equally applicable to any other HIV polypeptide.

20

Table D

Grp	Animal	Imm'n #	Adjuvant	Immunogen	Total Dose	Vol/ Site	Sites/ Animal	Route
25	1-4	1, 2	-	pCMV 160 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		3	-	pCMV 160 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		MF59C	Protein TBD		0.05mg	0.5ml	2	IM/Glut
2	5-8	1, 2	-	pCMV 160 dV2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		3	-	pCMV 160 dV2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)

Grp	Animal	Imm'n #	Adjuvant	Immunogen	Total Dose	Vol/ Site	Sites/ Animal	Route	
30			MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut	
3	9-12	1, 2	-	pCMV 160 dV1/V2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)	
		3	-	pCMV 160 dV1/V2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)	
			MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut	
35	4	13-16	1, 2	-	pCMV 140 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		3	-	pCMV 140 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)	
			MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut	
40	5	17-20	1, 2	-	pCMV140dV2TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		3	-	pCMV140dV2TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)	
			MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut	
45	6	21-24	1, 2	-	pCMV 140 dV1/V2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		3	-	pCMV 140 dV1/V2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)	
			MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut	
50	7	25-28	1, 2	-	pSIN140dV2SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
		3	-	pSIN 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)	
			MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut	

8	29-32	1, 2	-	pCMV 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
				pCMV 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
5	9	1, 2	-	MF59C Protein TBD	0.05mg	0.5ml	2	IM/Glut
				pCMV 140 Q154 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
10	37-40	1, 2	-	pCMV 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
				pCMV 140 dV2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
10		3	-	pCMV 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
				pCMV 140 dV2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
	MF59C	Protein TBD		0.05mg	0.5ml	2	IM/Glut	
				pCMV 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
				pCMV 140 dV2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
11	41-44	1, 2	-	pCMV 140 dV2 SF162 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)
				pCMV 140 dV2 TV1 DNA	1.0mg	0.5ml	2	IM/Quad (Electro)

		3	MF59C	Protein TBD	0.05mg	0.5ml	2	IM/Glut
--	--	---	-------	-------------	--------	-------	---	---------

The MF59C adjuvant is a microfluidized emulsion containing 5% squalene, 0.5% tween 80, 0.5% span 85, in 10mM citrate pH 6, stored in 10mL aliquots at 4°C.

5 Immunogens are prepared as described in the following table (Table E) for administration to animals in the various groups. Concentrations may vary from those described in the table, for example depending on the sequences and/or proteins being used.

10

Table E

Group	Preparation
1-9	<p>Immunization 1-3: pCMV and pSIN based plasmid DNA in Saline + Electroporation</p> <p>Subtype B and C plasmids will be provided frozen at a concentration of 1.0mg/ml in sterile 0.9% saline. Store at -80°C until use. Thaw DNA at room temperature; the material should be clear or slightly opaque, with no particulate matter. Animals will be shaved prior to immunization, under sedation of 1x dose IP (by animal weight) of Ketamine-Xylazine (80mg/ml - 4mg/ml). Immunize each rabbit with 0.5ml DNA mixture per side (IM/Quadriceps), 1.0ml per animal. Follow the DNA injection with Electroporation using a 6-needle circular array with 1cm diameter, 1cm needle length. Electroporation pulses were given at 20V/mm, 50ms pulse length, 1 pulse/s.</p>
15	<p>Immunization 3: Protein Immunization</p> <p>Proteins will be provided at 0.1mg/ml in citrate buffer. Store at -80°C until use. Thaw at room temperature; material should be clear with no particulate matter. Add equal volume of MF59C adjuvant to thawed protein and mix well by inverting the tube. Immunize each rabbit with 0.5ml adjuvanted protein per side, IM/Glut for a total of 1.0ml per animal. Use material within 1 hour of the addition of adjuvant.</p>
20	<p>Immunization 1-3: Combined subtype B and C plasmid DNA in Saline</p> <p>The immunogen will be provided at 2.0mg/ml total DNA (1mg/ml of each plasmid) in sterile 0.9% saline. Store at -80°C until use. Thaw DNA at room temperature; the material should be clear or slightly opaque, with no particulate matter. Animals will be shaved prior to immunization, under sedation of 1x dose IP (by animal weight) of Ketamine-Xylazine (80mg/ml - 4mg/ml). Immunize each rabbit with 0.5ml DNA mixture per side (IM/Quadriceps), 1.0ml per animal. Follow the DNA injection with Electroporation using a 6-needle circular array with 1cm diameter, 1cm needle length. Electroporation pulses were given at 20V/mm, 50ms pulse length, 1 pulse/s.</p>
25	
30	

Group	Preparation
10-11	<p>Immunization 3: Protein Immunization</p> <p>Proteins will be provided at 0.1mg/ml in citrate buffer. Store at -80°C until use. Thaw at room temperature; material should be clear with no particulate matter. Add equal volume of MF59C adjuvant to thawed protein and mix well by inverting the tube. Immunize each rabbit with 0.5ml adjuvanted protein per side, IM/Glut for a total of 1.0ml per animal. Use material within 1 hour of the addition of adjuvant.</p>

The immunization (Table F) and bleeding (Table G) schedules are as follows:

Table F

Imm'n:	Weeks:	1	2	3	4	16	16	16	16
	Group	PCMV 160 TV1 DNA							
5	1	PCMV 160 dV2 TV1 DNA							
	2	PCMV 160 dV1/V2 TV1 DNA							
	3	PCMV 160 dV1/V2 TV1 DNA							
	4	PCMV 140 TV1 DNA	PCMV 140 dV2 TV1 DNA	PCMV 140 dV2 TV1 DNA	PCMV 140 dV2 TV1 DNA	PCMV 140 dV2 TV1 DNA	PCMV 140 dV2 TV1 DNA	PCMV 140 dV2 TV1 DNA	PCMV 140 dV2 TV1 DNA
10	5	PCMV 140 dV2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA	PCMV 140 dV1/V2 TV1 DNA
	6	PCMV 140 dV1/V2 TV1 DNA							
	7	PSIN 140 dV2 SF162 DNA							
	8	PCMV 140 dV2 SF162 DNA							
	9	PCMV 140 Q154 SF162 DNA							
	10	PCMV 140 dV2 SF162 DNA +							
	11	PCMV 140 dV2 SF162 DNA +							
15		PCMV 140 dV1/V2 TV1 DNA							

Table G

Bleed:	0	1	2	3	4	5	6	7	8	9	10
Week:	-3	4	6	8	12	16	18	20	24	28	TBD
Sample:	Clotted Bld.										
	for Serum										
20	Volume:	20cc each									
	Method:	AA/MEV	CP								

Example 10Mice Immunization Studies with Gag and Pol Constructs

Cellular and Humoral immune responses were evaluated in mice (essentially as described in Example 4) for the following constructs: Gag, GagProtease(+FS) (GP1, 5 protease codon optimized and inactivation of INS; GP2, protease only inactivation of INS), GagPolΔintegrase with frameshift (gagFSpol), and GagPolΔintegrase in-frame (GagPol) (see Figure 63). Versions of GagPolΔintegrase in-frame were also designed with attenuated (GagPolAtt) or non-functional Protease (GagPolIna).

In vitro expression data showed comparable expression of p55Gag and p66RT 10 using Gag alone, GagProtease(+FS), GagFSpol and GagPolIna. Constructs with fully functional or attenuated protease (GagPol or GagPolAtt) were less efficient in expression of p55Gag and p66RT, possibly due to cytotoxic effects of protease.

DNA immunization of mice using Gag vs. GP1 and GP2 in pCMV vectors was 15 performed intramuscularly in the tibialis anterior. Mice were immunized at the start of the study (0 week) and 4 weeks later. Bleeds were performed at 0, 4, and 6 weeks. DNA doses used were as follows: 20 µg, 2 µg, 0.2 µg, and 0.02 µg.

DNA immunization of mice using Gag vs. gagFSpol in pCMV vectors was 20 performed intramuscularly in the tibialis anterior. Mice were immunized at the start of the study (0 week) and challenged 4 weeks later with recombinant vaccinia virus encoding Gag (rVVgag). Bleeds were performed at 0 and 4 weeks. DNA doses used were as follows: 20 µg, 2 µg, 0.2 µg, and 0.02 µg.

DNA immunization of mice using Gag vs. gagFSpol and gagpol in pCMV 25 vectors was performed intramuscularly in the tibialis anterior. Mice were immunized at the start of the study (0 week) and challenged 4 weeks later with recombinant vaccinia virus encoding Gag (rVVgag). Bleeds were performed at 0 and 4 weeks. DNA doses used were as follows: 2 µg, 0.2 µg, 0.02 µg, and 0.002 µg.

Cellular immune responses against Gag were comparable for all tested variants, for example, Gag, GagProtease, gagFSpol and GagPolIna all had comparable 30 potencies.

Humoral immune responses to Gag were also comparable with the exception of GP2 and especially GP1. Humoral immune responses were weaker in constructs

comprising functional or attenuated proteases which may be due to less efficient secretion of p55Gag caused by overactive protease.

In vitro and in vivo experiments, performed in support of the present invention, suggest that the expression and immunogenicity of Gag was comparable with all constructs. Exceptions were GagPol in-frame with fully functional or attenuated protease. This may be the result of cytotoxic effects of protease. The immune response in mice correlated with relative levels of expression in vitro.

Example 11

10 Protein Expression, Immunogenicity, and Generation of Neutralizing Antibodies Using Type C Derived Envelope Polypeptides

Envelope (Env) vaccines derived from the subtype C primary isolate, TV1, recovered from a South African individual, were tested in rabbits as follows. Gene cassettes were designed to express the gp120 (surface antigen), gp140 (surface antigen plus ectodomain of transmembrane protein, gp41), and full-length (gp120 plus gp41) gp160 forms of the HIV-1 envelope polyprotein with and without deletions of the variable loop regions, V2 and V1V2. All of the genes were sequence-modified to enhance expression of the encoded Env glycoproteins in a Rev-independent fashion and they were subsequently cloned into pCMV-based plasmid vectors for DNA vaccine and protein production applications as described above. The sequences were codon optimized as described herein. Briefly, all the modified envelope genes were cloned into the Chiron pCMVlink plasmid vector, preferably into EcoRI/XhoI sites.

A. Protein Expression

25 Full-length (gp160), truncated gp140 (Env ectodomain only) and gp120 native versions of the TV1 Env antigen were produced from the expression cassettes described herein. The gp140 encoding sequences were transiently transfected into 293T cells. The expression levels of the gene products were evaluated by an in-house antigen capture ELISA. Envelope genes constructed from the native sequences of 30 TV001c8.2, TV001c8.5 and TV002c12.1 expressed the correct proteins in vitro, with gp140TV001c8.2 exhibiting the highest level of expression. In addition, the Env

protein expressed from the TV1-derived clone 8.2 was found to bind the CD4 receptor protein indicating that this feature of the expressed protein is maintained in a functional conformation. The receptor binding properties/functionality of the expressed TV1 gp160 protein result was also confirmed by a cell-fusion assay.

5 Total expression increased approximately 10-fold for synthetic gp140 constructs compared with the native gp140 gene cassettes. Both the modified gp120 and gp140 variants secreted high amounts of protein in the supernatant. In addition, the V2 and V1V2 deleted forms of gp140 expressed approximately 2-fold more protein than the intact gp140. Overall, the expression levels of synthetic gp140 gene variants increased 10 to 26-fold compared with the gp140 gene with native sequences.

10 In sum, each synthetic construct tested showed more than 10-fold increased levels of expression relative to those using the native coding sequences. Moreover, all expressed proteins were of the expected molecular weights and were shown to bind CD4. Stable CHO cell lines were derived and small-scale protein purification methods 15 were used to produce small quantities of each of the undeleted and V-deleted oligomeric forms (o-gp140) of these proteins for vaccine studies.

B. Neutralization properties of TV001 and TV002 viral isolates

20 The transient expression experiment showed that the envelope genes derived from the TV001 and TV002 virus isolates expressed the desired protein products. Relative neutralization sensitivities of these two viral strains using sera from 18 infected South African individuals (subtypes B and C) were as follows. At a 1:10 serum dilution, the TV2 strain was neutralized by 18 of 18 sera; at 1:50, 16 of 18; at 1:250, 15/18. In comparison, the TV1 isolate was neutralized by 15 of 18 at 1:10; 25 only 6 of 18 at 1:50; and none of the specimens at 1:250. In addition, the TV001 patient serum showed neutralization activity against the TV002 isolate at all dilutions tested. In contrast, the TV002 showed neutralization of TV001 only at the 1:10 serum dilution. These results suggest that TV001 isolate is capable of inducing a broader and more potent neutralizing antibody response in its infected host than TV002.

C. Immunogenicity of the modified TV1 Env DNA and protein antigens in rabbit studies

TV1 Env DNA (comprising the synthetic expression cassettes) and protein vaccines were administrated as shown in the following Table H.

5

Table H

Groups	Plasmid DNA (0, 4, and 20 wks)	Protein boost (20 wks)
1	pCMVgp160.TV1	o-gp140.TV1
2	pCMVgp160dV2.TV1	o-gp140dV2.TV1
3	pCMVgp160dV1V2.TV1	o-gp140dV1V2.TV1
4	pCMVgp140.TV1	o-gp140.TV1
5	pCMVgp140dV2.TV1	o-gp140dV2.TV1
6	pCMVgp140dV1V2.TV1	o-gp140dV1V2.TV1
7	pCMVgp140dV2.SF162	o-gp140dV2.SF162

15

Seven groups of 4 rabbits per group were immunized with the designated plasmid DNA and oligomeric Env protein antigens. Three doses of DNA, 1mg of DNA per animal per immunization, were administrated intramuscularly by needle injection followed by electroporation on weeks 0, 4, and 20 weeks. A single dose of 100 ug of Env protein in MF59 adjuvant also was given intramuscularly in a separate site at 20 weeks.

The DNA immunization used subtype C sequence-modified genes (TV1) -- gp160, gp160dV2, gp160dV1V2, gp140, gp140dV2 and gp140dV1V2 -- as well as a subtype B SF162 sequence modified gp140dV2. DNA immunizations were performed at 0, 4, and 20 weeks by needle injection by the intramuscular route using electroporation to facilitate transfection of the muscle cells and of resident antigen presenting cells.

A single Env protein booster (in MF59 adjuvant) was given at 20 weeks by intramuscular injection at a separate site. Antibody titers were evaluated by ELISA following each successive immunization. Serum specimens were collected at 0, 4, 6, 8, 12, 22, and 24 weeks. Serum antibody titers were measured on ELISA 96-well plates were coated with a protein in a concentration of 1ug/ml. Serum samples were diluted serially 3-fold. Goat anti-rabbit peroxidase conjugate (1:20,000) was used for

detection. TMB was used as the substrate, and the antibody titers were read at 0.6 OD at 450nm.

Neutralizing antibody responses against PBMC-grown R5 HIV-1 strains were monitored in the sera collected from the immunized rabbits using two different assays 5 in two different laboratories, the 5.25 reporter cell-line based assay at Chiron and the PBMC-based assay of David Montefiori at Duke University. Results are shown in Figures 66, 67, and 68. The Chiron assay was conducted essentially as follows. Neutralizing antibody responses against the PBMC-grown subtype C TV001 and 10 TV002 strains were measured using an in-house reporter cell line assay that uses the 5.25 cell line. This cell has CD4, CCR5, CXCR4 and BONZO receptor/co-receptors on its cell membrane. The parental CEM cell line was derived from a 4-year-old Caucasian female with acute lymphoblastic leukemia, which was fused with the human B cell line 721.174, creating CEMx174. LTR-GFP was transfected into the cells after 15 the CCR5 gene (about 1.1 kb) was cloned into the BamH-I (5') and Sal-I (3') of the pBABE puro retroviral vector, and subsequently introduced into the CEMx174. The green fluorescence protein (GFP) of the cells was detected by flow cytometer (FACScan). For the virus neutralization assay, 50 ul of titrated virus and 50 ul of 20 diluted immune or pre-immune serum were incubated at room temperature for one hour. This mixture was added into wells with 10⁴/ml cells plated in a 24 well plate, and incubated at 37°C for 5 to 7 days. The cells were then fixed with 2% of formaldehyde after washing with PBS. Fifteen thousand events (cells) were collected for each sample 25 on a Becton Dickinson FACScan using Cellquest software. The data presented were the mean of the triplicate wells. The percent neutralization was calculated compared to the virus control using the following equation: % virus Inhibition = (virus control-experimental)/(virus control -cell control) x 100. Any virus inhibition observed in the pre-bleed has been subtracted for each individual animal. Values >50% are considered positive and are highlighted in gray.

In Figure 67, the “#” indicates that animals had high levels of virus inhibition in 30 pre-bleed serum (>20% virus inhibition) that impacted the magnitude of the observed inhibition and in some cases, our ability to score the serum as a positive or negative for the presence of significant neutralizing antibody activity (< 50% inhibition).

For the data presented in Figure 68, serum samples were collected after a single protein boost (post-third) were screened in triplicate at a 1:8 dilution with virus (1:24 after addition of cells). Values shown are the % reduction in p24 synthesis relative to that in the corresponding pre-bleed control samples. Zero values indicate 5 no or negative values were measured. NV, not valid due to virus inhibition in pre-immune serum. Neutralization was considered positive when p24 was reduced by at least 80%; these samples are highlighted in dark gray. Sample with lighter gray shading showed at least a 50% reduction in p24 synthesis.

Figure 64 shows the ELISA data when plates were coated with the monomeric 10 gp120.TV1 protein. This protein is homologous to the subtype C genes used for the immunization. All immunization groups produced high antibody titers after the second DNA immunization. The groups immunized with gp140 forms of DNA have relatively higher geometric mean antibody titers as compared to the groups using gp160 forms after both first and second DNA immunizations. Both the gp140.TV1 and 15 gp140dV1V2.TV1 genes produced high antibody titers at about 10^4 at two weeks post second DNA; the gp140dV2.TV1 plasmid yielded the highest titers of antibodies ($>10^4$) at this time point and all others.. The binding antibody titers to the gp120.TV1 protein were higher for the group immunized with the homologous gp140dV2.TV1 genes than that with the heterologous gp140dV2.SF162 gene which showed titers of 20 about 10^3 . All the groups, showed some decline in antibody titers by 8 weeks post the second DNA immunization. Following the DNA plus protein booster at 20 weeks, all groups reached titers above that previously observed after the second DNA immunization (0. 5 –1.0 log increases were observed). After the protein boost, all 25 animals receiving the o-gp140dV2.TV1 protein whether primed by the gp140dV2.TV1 or gp160dV2.TV1 DNA, showed the highest Ab titers.

Binding antibody titers were also measured using ELISA plates coated with either oligomeric subtype C o-gp140dV2.TV1 or subtype B o-gp140dV2.SF162 proteins (Figure 65). For all the TV1 Env immunized groups, the antibody titers measured using the oligomeric protein, o-gp140dV2.TV1 were higher than those 30 measured using the monomeric (non-V2-deleted) protein, gp120.TV1. In fact, for these groups, the titers observed with the heterologous subtype B o-gp140dV2.SF162

protein were comparable to or greater than those measured with the subtype C TV1 gp120. Nevertheless, all groups immunized with subtype C immunogens showed higher titers binding to the subtype C o-gp140dV2.TV1 protein than to the subtype B protein gp140dV2.SF162. Conversely, the group immunized with the 5 gp140dV2.SF162 immunogen showed higher antibody titers with the oligomeric subtype B protein relative its subtype C counterpart. Overall, all three assays demonstrated that high antibody cross-reactive antibodies were generated by the subtype CTV1-based DNA and protein immunogens.

The results indicate that the subtype C TV1-derived Env DNA and protein 10 antigens are immunogenic inducing high titers of antibodies in immunized rabbits and substantial evidence of neutralizing antibodies against both subtype B and subtype C R5 virus strains. In particular, the gp140dV2.TV1 antigens have induced consistent neutralizing responses against the subtype B SF162EnvDV2 and subtype C TV2 strains. Thus, TV1-based Env DNA and protein-based antigens are immunogenic and 15 induce high titer antibody responses reactive with both subtype C and subtype B HIV-1 Env antigens. Neutralizing antibody responses against the neutralization sensitive subtype B R5 HIV-1_{SF162DV2} strain were observed in some groups after only two DNA immunizations. Following a single booster immunization with Env protein, the majority of rabbits in groups that received V2-deleted forms of the TV1 Env showed 20 neutralization activity against the closely related subtype C TV2 primary strain.

Example 12

Immunological Responses in Rhesus Macaques

Cellular and humoral immune responses were evaluated in three groups of 25 rhesus macaques (each group was made up of four animals) in an immunization study structured as shown in Table I. The route of administration for the immunizing composition was electroporation in each case. Antibody titers are shown in Table I for two weeks post-second immunization.

Table I

Group	Formulation of Immunizing Composition *	Animal #	Titer
1	pCMVgag (3.5 mg) + pCMVenv (2.0 mg)	A	3325
		B	4000
	C (previously immunized with HCV core ISCOMS, rVVC core E1)		1838
		D (previously immunized with HCV core ISCOMS, rVVC core E1)	1850
2	pCMVgag (3.5 mg) + pCMVpol (4.2 mg)	A (previously immunized with HCV core ISCOMS, rVVC core E1, p55gag _{LAI} (VLP))	525
		B	5313
		C	6450
		D	5713
5	3	A (previously immunized with HCV core ISCOMS, rVVC core E1, pCMVgagSF2)	0
		B (previously immunized with rVVC/E1, pCMV Epo-Epi, HIV/HCV-VLP, pCMVgagSF2, pUCgp120 SF2)	1063
		C	513

Group	Formulation of Immunizing Composition *	Animal #	Titer
		D (previously immunized with rVVC/E1, HIV/HCV-VLP)	713

* pCMVgag = pCMVKm2.GagMod Type C Botswana

pCMVenv = pCMVLink.gp140env.dV2.TV1 (Type C)

pCMVpol = pCMVKm2.p2Pol.mut.Ina Type C Botswana

pCMVgag-pol = pCMVKm2.gagCpol.mut.Ina Type C Botswana

5

Pre-immune sera were obtained at week 0 before the first immunization. The first immunization was given at week 0. The second immunization was given at week 4. The first bleed was performed at 2 weeks post-second immunization (i.e., at week 6). A third immunization will be given at week 8 and a fourth at week 16. Animals 10 2A, 3A, 3B and 3D had been vaccinated previously (approximately 4 years or more) with gag plasmid DNA or gag VLP (subtype B).

Bulk CTL, ⁵¹Cr-release assays, and flow cell cytometry methods were used to obtain the data in Tables J and K. Reagents used for detecting gag- and pol-specific T-cells were (i) synthetic, overlapping peptides spanning "gagCpol" antigen (n=377), typically the peptides were pools of 15-mers with overlap by 11, the pools were as follows, pool 1, n=1-82, pool 2, n=83-164, pool 3, n=165-271, pool 4, n=272-377, accordingly pools 1 and 2 are "gag"-specific, and pools 3 and 4 are "pol"-specific, and (ii) recombinant vaccinia virus (rVV), for example, rVVgag965, rVVp2Pol975 (contains p2p7gag975), and VV_{wr}parent.

20 Gag-specific IFN γ + CD8 + T-cells, Gag-specific IFN γ + CD4 + T-cells, Pol-specific IFN γ + CD8 + T-cells, and Pol-specific IFN γ + CD4 + T-cells in blood were determined for each animal described in Table I above, post second immunization. The results are presented in Tables J and K. It is possible that some of the pol-specific activity shown in Table K was directed against p2p7gag.

25

Table J
Gag Assay Results

5	Group/Animal	Immunizing Composition	Gag Specific CD4+ Responses				Gag Specific CD8+ Responses		
			LPA(SI)			Flow	CTL		Flow
			p55	Pool 1	Pool 2	IFNg+	Pool 1	Pool 2	IFNg+
	1A	pCMVgag pCMVenv	3.3	5.9	3.8	496	minus	minus	225
	1B	pCMVgag pCMVenv	11.8	4.4	1.5	786	minus	minus	160
	1C	pCMVgag pCMVenv	5.7	1.1	2.4	361	plus	plus	715
10	1D	pCMVgag pCMVenv	6.5	3.1	1.6	500	plus	?	596
	2A	pCMVgag pCMVpol	4.8	4.8	1.6	405	plus	minus	1136
	2B	pCMVgag pCMVpol	12.5	6.8	3.3	1288	plus	minus	2644
	2C	pCMVgag pCMVpol	6	3.8	2.1	776	minus	minus	0
	2D	pCMVgag pCMVpol	18.9	13.5	5.4	1351	minus	minus	145
15	3A	pCMV gagpol	12.2	7	1.5	560	plus	plus	3595
	3B	pCMV gagpol	2.7	5.6	1.3	508	plus	?	3256
	3C	pCMV gagpol	11.6	5	1.2	289	minus	?	617
	3D	pCMV gagpol	1.5	1.2	1.4	120	minus	minus	277

? = might be positive on rVVp2Pol.

Table K
Pol Assay Results

5	Group / Animal	Immunizing Composition	Pol Specific CD4+ Response			Pol Specific CD8+ Responses		
			LPA(SI)		Flow	CTL		Flow
			Pool 3	Pool 4	IFNg+	Pool 3	Pool 4	IFNg+
	1A	pCMVgag pCMVenv	1	1.2	0	minus	minus	0
	1B	pCMVgag pCMVenv	1	1	0	minus	minus	0
10	1C	pCMVgag pCMVenv	1	1.1	0	minus	minus	0
	1D	pCMVgag pCMVenv	1.2	1.3	0	minus	minus	262
	2A	pCMVgag pCMVpol	1.1	0.9	92	minus	minus	459
	2B	pCMVgag pCMVpol	2.5	1.8	107	minus	minus	838
	2C	pCMVgag pCMVpol	1.2	1.1	52	plus	minus	580
15	2D	pCMVgag pCMVpol	2.5	2.7	113	plus	plus	5084
	3A	pCMV gagpol	2.7	2.4	498	minus	minus	3631
	3B	pCMV gagpol	1.1	1	299	minus	minus	1346
	3C	pCMV gagpol	2.1	1.4	369	minus	minus	399
	3D	pCMV gagpol	1.3	1.8	75	minus	minus	510

20 These results support that the constructs of the present invention are capable of generating specific cellular and humoral responses against the selected HIV-polypeptide antigens.

Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.

What is claimed is:

1. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Gag* polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide comprises a sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; and SEQ ID NO:16.
2. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Gag* polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide comprises a sequence having at least 98% sequence identity to a sequence selected from the group consisting of SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; and SEQ ID NO:55.
3. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Gag* polypeptide, wherein the polynucleotide sequence encoding said *Gag* polypeptide comprises a sequence having at least 95% sequence identity to SEQ ID NO:17.
4. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Nef* polypeptide, wherein the polynucleotide sequence encoding said *Nef* polypeptide comprises a sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:33 and SEQ ID NO:34.
5. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Prot* polypeptide, wherein the polynucleotide sequence encoding said *Prot* polypeptide comprises a sequence having at least 98% sequence identity to SEQ ID NO:39.
- 30 6. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Tat* polypeptide, wherein the polynucleotide sequence

encoding said *Tat* polypeptide comprises a sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:42; SEQ ID NO:43; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:53; SEQ ID NO:54; SEQ ID NO:56; and SEQ ID NO:57.

5

7. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Rev* polypeptide, wherein the polynucleotide sequence encoding said *Rev* polypeptide comprises a sequence having at least 90% sequence identity to SEQ ID NO:45 or SEQ ID NO:45.

10

8. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Vif* polypeptide, wherein the polynucleotide sequence encoding said *Vif* polypeptide comprises a sequence having at least 90% sequence identity to at least 30 contiguous base pairs of SEQ ID NO:58.

15

9. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Vpr* polypeptide, wherein the polynucleotide sequence encoding said *Vpr* polypeptide comprises a sequence having at least 90% sequence identity to at least 20 contiguous base pairs of SEQ ID NO:59.

20

10. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Vpu* polypeptide, wherein the polynucleotide sequence encoding said *Vpu* polypeptide comprises a sequence having at least 90% sequence identity to at least 20 contiguous base pairs of SEQ ID NO:60.

25

11. A recombinant expression system for use in a selected host cell, comprising, an expression cassette of any of claims 1 to 10 or 57, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected host cell.

30

12. The recombinant expression system of claim 11, wherein said control elements are

selected from the group consisting of a transcription promoter, a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.

5

13. The recombinant expression system of claim 11, wherein said transcription promoter is selected from the group consisting of CMV, CMV+intron A, SV40, RSV, HIV-Ltr, MMLV-ltr, and metallothionein.

10 14. A cell comprising an expression cassette of any of claims 1 to 10 or 57, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected cell.

15. The cell of claim 14, wherein the cell is a mammalian cell.

15

16. The cell of claim 15, wherein the cell is selected from the group consisting of BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells.

17. The cell of claim 16, wherein said cell is a CHO cell.

20

18. The cell of claim 14, wherein the cell is an insect cell.

19. The cell of claim 18, wherein the cell is either *Trichoplusia ni* (Tn5) or Sf9 insect cells.

25

20. The cell of claim 14, wherein the cell is a bacterial cell.

21. The cell of claim 14, wherein the cell is a yeast cell.

30

22. The cell of claim 14, wherein the cell is a plant cell.

23. The cell of claim 14, wherein the cell is an antigen presenting cell.

24. The cell of claim 23, wherein the antigen presenting cell is a lymphoid cell selected from the group consisting of macrophages, monocytes, dendritic cells, B-cells, T-cells, 5 stem cells, and progenitor cells thereof.

25. The cell of claim 14, wherein the cell is a primary cell.

26. The cell of claim 14, wherein the cell is an immortalized cell.

10

27. The cell of claim 14, wherein the cell is a tumor-derived cell.

28. A method for producing a polypeptide including HIV *Gag* polypeptide sequences, said method comprising,

15

incubating the cells of claim 14, under conditions for producing said polypeptide.

29. A gene delivery vector for use in a mammalian subject, comprising a suitable gene delivery vector for use in said subject, wherein the vector 20 comprises an expression cassette of any of claims 1 to 10 or 57, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the subject.

30. A method of DNA immunization of a subject, comprising,

25

introducing a gene delivery vector of claim 29 into said subject under conditions that are compatible with expression of said expression cassette in said subject.

31. The method of claim 30, wherein said gene delivery vector is a nonviral vector.

30

32. The method of claim 30, wherein said vector is delivered using a particulate

carrier.

33. The method of claim 32, wherein said vector is coated on a gold or tungsten particle and said coated particle is delivered to said subject using a gene gun.

5

34. The method of claim 30, wherein said vector is encapsulated in a liposome preparation.

35. The method of claim 30, wherein said vector is a viral vector.

10

36. The method of claim 35, wherein said viral vector is a retroviral vector.

37. The method of claim 35, wherein said viral vector is an alphaviral vector.

15

38. The method of claim 35, wherein said viral vector is a lentiviral vector.

39. The method of claim 30, wherein said subject is a mammal.

40. The method of claim 39, wherein said mammal is a human.

20

41. A method of generating an immune response in a subject, comprising transfecting cells of said subject a gene delivery vector of claim 29, under conditions that permit the expression of said polynucleotide and production of said polypeptide, thereby eliciting an immunological response to said polypeptide.

25

42. The method of claim 41, wherein said vector is a nonviral vector.

43. The method of claim 41, wherein said vector is delivered using a particulate carrier.

30

44. The method of claim 43, wherein said vector is coated on a gold or tungsten

particle and said coated particle is delivered to said cell using a gene gun.

45. The method of claim 41, wherein said vector is encapsulated in a liposome preparation.

46. The method of claim 41, wherein said vector is a viral vector.

47. The method of claim 46, wherein said viral vector is a retroviral vector.

48. The method of claim 46, wherein said viral vector is an alphaviral vector.

49. The method of claim 46, wherein said viral vector is a lentiviral vector.

50. The method of claim 41, wherein said subject is a mammal.

51. The method of claim 50, wherein said mammal is a human.

52. The method of claim 41, wherein said transfecting is done *ex vivo* and said transfected cells are reintroduced into said subject.

53. The method of claim 41, wherein said transfecting is done *in vivo* in said subject.

54. The method of claim 41, where said immune response is a humoral immune response.

55. The method of claim 41, where said immune response is a cellular immune response.

56. The method of claim 41, wherein the gene delivery vector is administered intramuscularly, intramucosally, intranasally, subcutaneously, intradermally, transdermally, intravaginally, intrarectally, orally or intravenously.

57. An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV *Env* polypeptide, wherein the polynucleotide sequence encoding said *Env* polypeptide comprises a sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO: 63, and SEQ ID NO:64.
58. Use of a gene delivery vector of claim 29 in the manufacture of a preparation for the DNA immunization of a subject, wherein said preparation is effective when introduced into said subject under conditions that are compatible with expression of said expression cassette in said subject.
59. Use of claim 58, wherein said gene delivery vector is a nonviral vector.
60. Use of claim 58, wherein said preparation is effective when delivered using a particulate carrier.
61. Use of claim 60, wherein said vector is coated on a gold or tungsten particle and said preparation containing said coated particle is effective when delivered to said subject using a gene gun.
62. Use of claim 58, wherein said vector is encapsulated in a liposome preparation.
63. Use of claim 58, wherein said vector is a viral vector.
64. Use of claim 63, wherein said viral vector is a retroviral vector.
65. Use of claim 63, wherein said viral vector is an alphaviral vector.
66. Use of claim 63, wherein said viral vector is a lentiviral vector.

67. Use of claim 58, wherein said subject is a mammal.
68. Use of claim 67, wherein said mammal is a human.
69. A substance or composition for use in a method of generating an immune response in a subject, said substance or composition comprising a gene delivery vector of claim 29, and said method comprising transfecting cells of said subject with said substance or composition under conditions that permit the expression of said polynucleotide and production of said polypeptide, thereby eliciting an immunological response to said polypeptide.
70. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said vector is a nonviral vector.
71. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said substance or composition is delivered using a particulate carrier.
72. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said vector is coated on a gold or tungsten particle and said substance or composition containing said coated particle is delivered to said cell using a gene gun.
73. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said vector is encapsulated in a liposome preparation.
74. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said vector is a viral vector.
75. A substance or composition for use in a method of treatment or prevention of claim 74, wherein said viral vector is a retroviral vector.

76. A substance or composition for use in a method of treatment or prevention of claim 74, wherein said viral vector is an alphaviral vector.

77. A substance or composition for use in a method of treatment or prevention of claim 74, wherein said viral vector is a lentiviral vector.

78. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said subject is a mammal.

79. A substance or composition for use in a method of treatment or prevention of claim 78, wherein said mammal is a human.

80. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said transfecting is done *ex vivo* and said transfected cells are reintroduced into said subject.

81. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said transfecting is done *in vivo* in said subject.

82. A substance or composition for use in a method of treatment or prevention of claim 69, where said immune response is a humoral immune response.

83. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said immune response is a cellular immune response.

84. A substance or composition for use in a method of treatment or prevention of claim 69, wherein said substance or composition is administered intramuscularly, intramucosally, intranasally, subcutaneously, intradermally, transdermally, intravaginally, intrarectally, orally or intravenously.

85. An expression cassette according to any one of claims 1 to 10 or 57, substantially as herein described and illustrated.

86. An expression system according to any one of claims 11 to 13, substantially as herein described and illustrated.

87. A cell according to any one of claims 14 to 27, substantially as herein described and illustrated.

88. A method according to claim 28, substantially as herein described and illustrated.

89. A vector according to claim 29, substantially as herein described and illustrated.

90. A method according to any one of claims 30 to 56, substantially as herein described and illustrated.

91. Use according to any one of claims 58 to 68, substantially as herein described and illustrated.

92. A substance or composition for use in a method of treatment or prevention according to any one of claims 69 to 84, substantially as herein described and illustrated.

93. A new expression cassette, a new expression system, a new cell, a new method for producing a polypeptide, a new vector, a new non-therapeutic method of treatment, a new use of a vector as claimed in claim 29, or a substance or composition for a new use in a method of treatment or prevention, substantially as herein described.

8_5_ZA

1 TGGAAGGGTT AATTACTCC AAGAAAAGGC AAGAAATCCT TGATTTGTGG GTCTATCACA
 61 CACAAGGCTT CTTCCCTGAT TGGCAAAACT ACACACCGGG GCCAGGGTC AGATATCCAC
 121 TGACCTTG TGCTAC AAGCTAGTGC CAGTTGACCC AGGGGAGGTG GAAGAGGCCA
 181 ACGGAGGAGA AGACAACTGT TTGCTACACC CTATGAGCCA ACATGGAGCA GAGGATGAAG
 241 ATAGAGAAGT ATTAAAGTGG AAGTTTGACA GCCTCCTAGC ACGCAGACAC ATGGCCCGCG
 301 AGCTACATCC GGAGTATTAC AAAGACTGCT GACACAGAAG GGACTTTCCG CCTGGGACTT
 361 TCCACTGGGG CGTTCCGGGA GGTGTGGTCT GGGCGGGACT TGGGAGTGGT CAACCCTCAG
 421 ATGCTGCATA TAAGCAGCTG CTTTTCGCCT GTACTGGGT TCTCTCGGTA GACCAGATCT
 481 GAGCCTGGGA GCCCTCTGGC TATCTAGGGA ACCCACTGCT TAAGCCTCAA TAAAGCTTGC
 541 CTTGAGTGCT TTAAGTAGTG TGTGCCATC TGTTGTGTGA CTCTGGTAAC TAGAGATCCC
 601 TCAGACCCCT TGTGGTAGTG TGGAAAATCT CTAGCAGTGG CGCCCGAACCA GGGACCAGAA
 661 AGTGAAAGTG AGACCAAGAGG AGATCTCTCG ACGCAGGACT CGGCTTGCTG AAGTGCACAC
 721 GGCAAGAGGC GAGAGGGGGC GCTGGTGAGT ACGCCAATT TACTTGACTA GCGGAGGCTA
 781 GAAGGAGAGA GATGGGTGCG AGAGCGTCAA TATTAAGCGG CGGAAAATTA GATAAAATGGG
 841 AAAGAATTAG GTTAAGGCCA GGGGGAAAGA AACATTATAT GTTAAAACAT CTAGTATGGG
 901 CAAGCAGGGGA GCTGGAAAGA TTTCGACTTA ACCCCTGGCCT GTTAAAGAACCA TCAGAAGGCT
 961 GTAAACAAAT AATAAAACAG CTACAACCAAG CTCTTCAGAC AGGAACAGAG GAACTTAGAT
 1021 CATTATTCAA CACAGTAGCA ACTCTCTATT GTGTACATAA AGGGATAGAG GTACGAGACA
 1081 CCAAGGAAGC CTTAGACAAG ATAGAGGAAG AACAAAACAA ATGTCAGCAA AAAGCACAAC
 1141 AGGCAAAAGC AGCTGACGAA AAGGTCACTC AAAATTATCC TATAGTACAG AATGCCAAG
 1201 GGCAAATGGT ACACCAAGCT ATATCACCTA GAACATTGAA TGCACTGGATA AAAGTAATAG
 1261 AGGAAAAGGC TTTCAATCCA GAGGAAATAC CCATGTTAC AGCATTATCA GAAGGAGCCA
 1321 CCCCCAAGA TTTAAACACA ATGTTAAATA CAGTGGGGGG ACATCAAGCA GCCATGCAA
 1381 TGTTAAAAGA TACCATCAAT GAGGAGGCTG CAGAATGGGA TAGGACACAT CCAGTACATG
 1441 CAGGGCTGT TGCACCAAGC CAGATGAGAG AACCAAGGGG AAGTACATAA GCAGGAACTA
 1501 CTAGTACCCCT TCAGGAACAA ATAGCATGGA TGACAAGTAA TCCACCTATT CCAGTAGAAG
 1561 ACATCTATAA AAGATGGATA ATTCTGGGT TAAATAAAAT AGTAAGAATG TATAGCCCTG
 1621 TTAGCATTTC GGACATAAAA CAAGGGCCAA AAGAACCCCT TAGAGACTAT GTAGACCGGT
 1681 TCTTTAAAAC CTTAAGAGCT GAACAAGCTA CACAAGATGT AAAGAATTGG ATGACAGACA
 1741 CCTTGTGGT CAAAATGCG AACCCAGATT GTAAGACCAT TTTAAGAGCA TTAGGACAG
 1801 GGGCCTCATT AGAAGAAATG ATGACAGCAT GTCAGGGAGT GGGAGGACCT AGCCATAAAG
 1861 CAAGAGTGTG GGTGAGGCA ATGAGCCAAG CAAACAGTAA CATACTAGTG CAGAGAAGCA
 1921 ATTTTAAAGG CTCTAACAGA ATTATTAAT GTTCAACTG TGGCAAAGTA GGGCACATAG
 1981 CCAGAAATTG CAGGGCCCT AGGAAAAAGG GCTGTGGAA ATGTGGACAG GAAGGACACC
 2041 AAATGAAAGA CTGTACTGAG AGGCAGGCTA ATTTTTTAGG GAAAATTGG CCTTCCCACA
 2101 AGGGAGGCC AGGGAATTTC CTCCAGAAC GACCAGAGCC AACAGCCCCA CCAGCAGAAC
 2161 CAACAGCCCC ACCAGCAGAG AGCTTCAGGT TCGAGGAGAC AACCCCCCGTG CCGAGGAAGG
 2221 AGAAAGAGAG GGAACCTTTA ACTTCCCTCA AATCACTCTT TGGCAGCGAC CCCTTGTCTC
 2281 AATAAAAGTA GAGGGCCAGA TAAAGGAGGC TCTCTTAGAC ACAGGAGCAG ATGATAACAGT
 2341 ATTAGAAGAA ATAGATTGC CAGGGAAATG GAAACCAAAA ATGATAGGGG GAATTGGAGG
 2401 TTTTATCAA GTAAGACAGT ATGATCAAAT ACTTATAGAA ATTGTGGAA AAAAGGCTAT
 2461 AGGTACAGTA TTAGTAGGGC CTACACCACT CAACATAATT GGAAGAAATC TGTTAACTCA
 2521 GCTTGGATGC ACACAAATT TTCCAATTAG TCCTTATTGAA ACTGTACCAAG TAAAATTAAA
 2581 ACCAGGAATG GATGGCCCAA AGGTCAAACA ATGGCCATTG ACAGAAGAAA AAATAAAAGC
 2641 ATTAACAGCA ATTGTGAGG AATGGAGAA GGAAGGAAAA ATTACAAAAA TTGGCCCTGA
 2701 TAATCCATAT AACACTCCAG TATTGCCAT AAAAAGAAG GACAGTACTA AGTGGAGAAA
 2761 ATTAGTAGAT TTCAAGGGAAC TCAATAAAG AACTCAAGAC TTGGGGAAAG TTCAATTAGG
 2821 AATACCAACAC CCAGCAGGAT TAAAAAAGAA AAAATCACTG ACAGTGCAG ATGTGGGGGA
 2881 TGCATATTTC TCAGTTCCCT TAGATGAAAG CTTCAGGAAA TATACAGCAT TCACCATAACC

FIGURE 1A

2941 TAGTATAAAC AATGAAACAC CAGGGATTAG ATATCAATAT AATGTGCTGC CACAGGGATG
 3001 GAAAGGATCA CCAGCAATAT TCCAGAGTAG CATGACAAAA ATCTTAGAGC CCTTCAGAGC
 3061 AAAAAATCCA GACATAGTTA TCTATCAATA TATGGATGAC TTGTATGTAG GATCTGACTT
 3121 AGAAATAGGG CAACATAGAG CAAAAATAGA AGAGTTAAGG GAACATTTAT TGAAATGGGG
 3181 ATTTACAACA CCAGACAAGA AACATCAAAA AGAACCCCCA TTCTTTGGA TGGGGTATG
 3241 ACTCCATCCT GACAAATGGA CAGTACAACC TATACTGCTG CCAGAAAAGG ATAGTTGGAC
 3301 TGTCAATGAT ATACAGAAGT TAGTGGAAA ATTAAACTGG GCAAGTCAGA TTTACCCAGG
 3361 GATTAAAGTA AGGCACACTCT GTAAACTCCT CAGGGGGGCC AAAGCACTAA CAGACATAGT
 3421 ACCACTAATC GAAGAACGAG AATTAGAATT GCCAGAGAAC AGGGAAATT TAAGAGAAC
 3481 AGTACATGGA GTATATTATG ATCCATCAAA AGACTTGATA GCTGAAATAC AGAACACAGG
 3541 GCATGAACAA TGGACATATC AAATTTATCA AGAACCATTT AAAAATCTGA AAACAGGGAA
 3601 GTATGCAAAA ATGAGGACTA CCCACACTAA TGATGTAAAA CAGTTAACAG AGGCAGTGCA
 3661 AAAAAATAGCC ATGAAAGCA TAGTAATATG GGGAAAGACT CCTAAATTAA GACTACCCAT
 3721 CCAAAAAGAA ACATGGGAGA CATGGTGGAC AGACTATTGG CAAGCCACCT GGATCCCTGA
 3781 GTGGGAGTTT GTTAATACCC CTCCCCTAGT AAAATTATGG TACCAACTAG AAAAAGATCC
 3841 CATAGCAGGA GTAGAAACTT TCTATGTAGA TGGAGCAACT AATAGGGAAG CTAAAATAGG
 3901 AAAAGCAGGG TATGTTACTG ACAGAGGAAG GCAGAAAATT GTTACTCTAA CTAACACAAAC
 3961 AAATCAGAAG ACTGAGTTAC AAGCAATTCA GCTAGCTCTG CAGGATTCAAG GATCAGAAGT
 4021 AAACATAGTA ACAGACTCAC AGTATGCATT AGGAATCATT CAAGCACAAAC CAGATAAGAG
 4081 TGACTCAGAG ATATTTAACC AAATAATAGA ACAGTTAATA AACAGGAAA GAATCTACCT
 4141 GTCATGGGT A C CAGCACATA AAGGAATTGG GGGAAATGAA CAAGTAGATA AATTAGTAAG
 4201 TAAGGGAATT AGGAAAGTGT TGTTCCTAGA TGGAATAGAT AAAGCTCAAG AAGAGCATGA
 4261 AAGGTACCCAC AGCAATTGGA GAGCAATGGC TAATGAGTTT AATCTGCCAC CCATAGTAGC
 4321 AAAAGAAATA GTAGCTAGCT GTGATAAAATG TCAGCTAAAA GGGGAAGCCA TACATGGACA
 4381 AGTCGACTGT AGTCCAGGGG TATGGCAATT AGATTGTACC CATTAGAGG GAAAATCAT
 4441 CCTGGTAGCA GTCCATGTAG CTAGTGGCTA CATGGAAGCA GAGGTTATCC CAGCAGAAAC
 4501 AGGACAAGAA ACAGCATATT TTATATTAAA ATTAGCAGGA AGATGGCCAG TCAAAGTAAT
 4561 ACATACAGAC AATGGCAGTA ATTTCACCAG TACTGCTGTT AAGGCAGCCT GTTGGTGGC
 4621 AGGTATCCAA CAGGAATTG GAATTCCCTA CAATCCCCAA AGTCAGGGAG TGGTAGAATC
 4681 CATGAATAAA GAATTAAAGA AAATAATAGG ACAAGTAAGA GATCAAGCTG AGCACCTTAA
 4741 GACAGCAGTA CAAATGGCAG TATTCAATTCA CAATTTAAA AGAAAAGGGG GAATTGGGGG
 4801 GTACAGTGCA GGGGAAAGAA TAATAGACAT AATAGCAACA GACATACAAA CTAAGAATT
 4861 ACAAAAACAA ATTATAAGAA TTCAAAATT TCGGGTTTAT TACAGAGACA GCAGAGACCC
 4921 TATTGGAAA GGACCAGCCG AACTACTCTG GAAAGGTGAA GGGGTAGTAG TAATAGAAGA
 4981 TAAAGGTGAC ATAAAGGTAG TACCAAGGAG GAAAGCAAAA ATCATTAGAG ATTATGGAAA
 5041 ACAGATGGCA GGTGCTGATT GTGTGGCAGG TGGACAGGAT GAAGATTAGA GCATGGAATA
 5101 GTTTAGTAAA GCACCATATG TATATATCAA GGAGAGCTAG TGGATGGGTC TACAGACATC
 5161 ATTTGAAAG CAGACATCCA AAAGTAAGTT CAGAAGTACA TATCCCATTA GGGGATGCTA
 5221 GATTAGTAAT AAAACATAT TGGGGTTTGC AGACAGGAGA AAGAGATTGG CATTGGGTC
 5281 ATGGAGTCTC CATAGAATGG AGACTGAGAG AATACAGCAC ACAAGTAGAC CCTGACCTGG
 5341 CAGACAGCT AATTCACTG CATTATTG ATGTTTAC AGAATCTGCC ATAAGACAAAG
 5401 CCATATTAGG ACACATAGTT TTTCCTAGGT GTGACTATCA AGCAGGACAT AAGAAGGTAG
 5461 GATCTCTGCA ATACTTGGCA CTGACAGCAT TGATAAAACC AAAAAGAGA AAGCCACCTC
 5521 TGCCTAGTGT TAGAAAATA GTAGAGGATA GATGGAACGA CCCCCAGAAG ACCAGGGGCC
 5581 GCAGAGGGAA CCATACAATG AATGGACACT AGAGATTCTA GAAGAACTCA AGCAGGAAGC
 5641 TGTCAAGACAC TTTCCTAGAC CATGGCTCCA TAGCTTAGGA CAATATATCT ATGAAACCTA
 5701 TGGGGATACT TGGACGGGAG TTGAAGCTAT AATAAGAGTA CTGCAACAAAC TACTGTTCAT
 5761 TCATTTCAGA ATTGGATGCC AACATAGCAG AATAGGCATC TTGCGACAGA GAAGAGCAAG
 5821 AAATGGAGCC AGTAGATCCT AAACAAAGC CCTGGAACCA TCCAGGAAGC CAACCTAAA
 5881 CAGCTTGTAA TAATTGCTTT TGCAAAACT GTAGCTATCA TTGTCTAGTT TGCTTCAGA

FIGURE 1B

5941 CAAAAGGTTT AGGCATTCC TATGGCAGGA AGAAGCGGAG ACAGCGACGA AGCGCTCCCTC
 6001 CAAGTGGTGA AGATCATCAA AATCCTCTAT CAAAGCAGTA AGTACACATA GTAGATGTAA
 6061 TGGTAAGTTT AAGTTTATTT AAAGGAGTAG ATTATAGATT AGGAGTAGGA GCATTGATAG
 6121 TAGCACTAAT CATAGCAATA ATAGTGTGGA CCATAGCATA TATAGAATAT AGGAAATTGG
 6181 TAAGACAAAA GAAAATAGAC TGTTTAATTAA AAGAATTAG GGAAAGAGCA GAAGACAGTG
 6241 GCAATGAGAG TGATGGGAC ACAGAAGAAT TGTCAACAAT GTGGATATG GGGCATCTTA
 6301 GGCTTCTGGA TGCTAATGAT TTGTAACACG GAGGACTTGT GGGTCACAGT CTACTATGGG
 6361 GTACCTGTGT GGAGAGAAGC AAAAACTACT CTATTCTGTG CATCAGATGC TAAAGCATAT
 6421 GAGACAGAAG TGCATAATGT CTGGGCTACA CATGCTTGTG TACCCACAGA CCCCACCCCA
 6481 CAAGAAATAG TTTGGGAAA TGTAACAGAA AATTTTAATA TGTGGAAAAAA TAACATGGCA
 6541 GATCAGATGC ATGAGGATAT AATCAGTTA TGGGATCAAA GCCTAAAGCC ATGTGTAAAG
 6601 TTGACCCAC TCTGTGTCAC TTAAACTGT ACAGATACAA ATGTTACAGG TAATAGAACT
 6661 GTTACAGGTA ATACAAATGA TACCAATATT GCAAATGCTA CATATAAGTA TGAAGAAATG
 6721 AAAAATTGCT CTTTCAATGC AACCACAGAA TTAAGAGATA AGAAACATAA AGAGTATGCA
 6781 CTCTTTATA AACTTGATAT AGTACCACTT AATGAAAATA GTAACAACCT TACATATAGA
 6841 TTAATAAAATT GCAATACCTC AACCATAACA CAAGCCTGTC CAAAGGTCTC TTTGACCCG
 6901 ATTCTCTATAC ATTACTGTG TCCAGCTGAT TATGCGATT TAAAGTGTAA TAATAAGACA
 6961 TTCAATGGGA CAGGACCATG TTATAATGTC AGCACAGTAC AATGTACACA TGGAAATTAAG
 7021 CCAGTGGTAT CAACTCAACT ACTGTTAAAT GTAGTCTAG CAGAAGAAGG GATAATAATT
 7081 AGATCTGAAA ATTTGACAGA GAATACAAA ACAATAATAG TACATCTTAA TGAATCTGTA
 7141 GAGATTAATT GTACAAGGCC CAACAATAAT ACAAGGAAAA GTGTAAGGAT AGGACCAGGA
 7201 CAAGCATTCT ATGCAACAAA TGACGTAATA GGAAACATAA GACAAGCACA TTGTAACATT
 7261 AGTACAGATA GATGGAATAA AACTTTACAA CAGGTAATGA AAAAATTAGG AGAGCATTTC
 7321 CCTAATAAAA CAATAAAATT TGAACCACAT GCAGGAGGGG ATCTAGAAAT TACAATGCAT
 7381 AGCTTTAATT GTAGAGGAGA ATTTTCTAT TGCAATACAT CAAACCTGTT TAATAGTACA
 7441 TACTACCTA AGAATGGTAC ATACAAATAC AATGGTAAATT CAAGCTTACC CATCACACTC
 7501 CAATGCAAAA TAAAACAAAT TGTACGCTATG TGGCAAGGGG TAGGACAAGC AATGTATGCC
 7561 CCTCCCATTG CAGGAAACAT AACATGTAGA TCAAACATCA CAGGAATACT ATTGACACGT
 7621 GATGGGGAT TTAACAAACAC AAACAACGAC ACAGAGGAGA CATTGAGACC TGGAGGAGGA
 7681 GATATGAGGG ATAACCTGGAG AAGTGAATTAA TATAAAATATA AAGTGGTAGA AATTAAGCCA
 7741 TTGGGAATAG CACCCACTAA GGCAAAAAGA AGAGTGGTGC AGAGAAAAAA AAGAGCAGTG
 7801 GGAATAGGAG CTGTGTCCT TGGGTTCTTG GGAGCAGCAG GAAGCACTAT GGGCCAGCG
 7861 TCAATAACGC TGACGGTACA GGCCAGACAA CTGTTGTCG GTATAGTGCA ACAGCAAAGC
 7921 AATTGCTGA AGGCTATAGA GGCGCAACAG CATATGTTGC AACTCACAGT CTGGGGCATT
 7981 AAGCAGCTCC AGGGAGAGT CCTGGCTATA GAAAGATACC TAAAGGATCA ACAGCTCCTA
 8041 GGGATTTGGG GCTGCTCTGG AAGACTCATC TGCACCACTG CTGTCCTTG GAACTCCAGT
 8101 TGGAGTAATA AATCTGAAGC AGATATTG GATAACATGA CTTGGATGCA GTGGATAGA
 8161 GAAATTAAATA ATTACACAGA AACAATATTC AGGTGCTTG AAGACTCGCA AAACCAGCAG
 8221 GAAAAGAATG AAAAAGATT ATTAGAATTG GACAAGTGGG ATAATCTGTA GAATTGGTTT
 8281 GACATATCAA ACTGGCTGTG GTATATAAAA ATATTCTAA TGATAGTAGG AGGCTTGATA
 8341 GGTAAAGAA TAATTTTGC TGTCCTCT ATAGTGAATA GAGTTAGGCA GGGATACTCA
 8401 CCTTTGTCAT TTCAGACCTT TACCCCAAGC CCGAGGGGAC TCGACAGGCT CGGAGGAATC
 8461 GAAGAAGAAG GTGGAGAGCA ACACAGAGAC AGATCCATAC GATTGGTGAG CGGATTCTTG
 8521 TCGCTTGCTT GGGACGATCT GCGGAGCCTG TGCTCTTCA GCTACCACCG CTTGAGAGAC
 8581 TTCATATTAA TTGCACTGAG GGCACTGGAA CTTCTGGAC ACAGCAGTCT CAGGGACTA
 8641 CAGAGGGGT GGGAGATCCT TAAGTATCTG GGAAGTCTTG TGCAGTATIG GGGCTAGAG
 8701 CTAAGGAGAAGA GTGCTATTAG TCGCCTGAT ACCATAGCAA TAGCAGTAGC TGAAGGAACA
 8761 GATAGGATTA TAGAATTGGT ACAAAAGAATT TGTAGAGCTA TCCCAACAT ACCTAGGAGA
 8821 ATAAGACAGG GCTTTGAAGC AGCTTTGCTA TAAAATGGGA GGCAAGTGGT CAAAACGCAG
 8881 CATAGTTGGA TGGCCTGCAG TAAGAGAAAG AATGAGAAGA ACTGAGCCAG CAGCAGAGGG
 8941 AGTAGGAGCA GCGTCTCAAG ACTTAGATAG ACATGGGCA CTTACAAGCA GCAACACACC

FIGURE 1C

9001 TGCTACTAAT GAAGCTTGTG CCTGGCTGCA AGCACAAAGAG GAGGACGGAG ATGTTAGGCCT
9061 TCCAGTCAGA CCTCAGGTAC CTTTAAGACC AATGACTTAT AAGAGTGCAG TAGATCTCAG
9121 CTTCTTTTA AAAGAAAAGG GGGGACTGGA AGGGTTAATT TACTCTAGGA AAAGGCAAGA
9181 AATCCTTGAT TTGTGGGTCT ATAACACACA AGGCTTCTTC CCTGATTGGC AAAACTACAC
9241 ATCGGGGCCA GGGGTCCGAT TCCCACGTGAC CTTTGGATGG TGCTTCAAGC TAGTACCACT
9301 TGACCCAAGG GAGGTGAAAG AGGCAATGA AGGAGAAAGAC AACTGTTGC TACACCCAT
9361 GAGCCAACAT GGAGCAGAGG ATGAAGATAG AGAAGTATTA AAGTGGAAAGT TTGACAGCCT
9421 TCTAGCACAC AGACACATGG CCCGCGAGCT ACATCCGGAG TATTACAAAG ACTGCTGACA
9481 CAGAAGGGAC TTTCCGCTG GGACTTTCCA CTGGGGCGTT CCGGGAGGTG TGGTCTGGC
9541 GGGACTTGGG AGTGGTCACC CTCAGATGCT GCATATAAGC AGCTGCTTTT CGCTTGTA
9601 GGGTCTCTCT CGGTAGACCA GATCTGAGCC TGGGAGCTCT CTGGCTATCT AGGGAACCCA
9661 CTGCTTAGGC CTCAATAAAG CTTGCCTTGA GTGCTCTAAG TAGTGTGTGC CCATCTGTTG
9721 TGTGACTCTG GTAACTAGAG ATCCCTCAGA CCCTTTGTGG TAGTGTGGAA AATCTCTAGC
9781 A

FIGURE 1D

↓: is the regions for β-sheet deletions

*: is the N-linked glycosylation sites for subtype C TV1 and TV2. Possible mutation (N→ Q) or deletions can be performed.

		1		50
SF162	(1)	----MDAMKRLCCVLLICGAVFVSPSAVEKLWVTVVYGVPVWKEATIIL		
TV1.8_2	(1)	MRVMGTQKNCQQWWIWGILGFWMILMICNTEDLWVTVVYGVPVWWRDAKIST		
TV1.8_5	(1)	MRVMGTQKNCQQWWIWGILGFWMILMICNTEDLWVTVVYGVPVWREAKITI		
TV2.12-5/1	(1)	MRARGILKNRHHWIWGILGFWMILMMCNVKGLWVTVVYGVPVGREAKITI		
Consensus	(1)	MRVMGTQKNCQQWWIWGILGFWMILMICNVEDLWVTVVYGVPVWREAKITI		
		51	*	100
SF162	(47)	FCASDAKAYDTEVHNWATHACVPTDNPQEIIVLGNVTENFNMWKNNMV		
TV1.8_2	(51)	FCASDAKAYETEVHNWATHACVPTDNPQEIIVLGNVTENFNMWKNMD		
TV1.8_5	(51)	FCASDAKAYETEVHNWATHACVPTDNPQEIIVLGNVTENFNMWKNMD		
TV2.12-5/1	(51)	FCASDAKAYEKEVHNWATHACVPTDNPQEIIVLGNVTENFNMWKNMDV		
Consensus	(51)	FCASDAKAYETEVHNWATHACVPTDNPQEIIVLGNVTENFNMWKNMVD		
		101	↓	150
SF162	(97)	QMHEDIISLWDOSIKPCVKLTPICVTLNCTNLKNATNTK-----SSN--		
TV1.8_2	(101)	QMHEDIISLWDOSIKPCVKLTPICVTLNCTNLKNATNTKDTNVGNRTVTGNSTNNNTNG		
TV1.8_5	(101)	QMHEDIISLWDOSIKPCVKLTPICVTLNCTNLKNATNTKDTNVGNRTVTGNSTNNNTNG		
TV2.12-5/1	(101)	QMQEDIISLWDOSIKPCVKLTPICVTLNCTNLKNATVNYN-----NHS--		
Consensus	(101)	QMHEDIISLWDQSLKPCVKLTPICVTLNCTNLNVGNRTVTGNNSNSN A		
		151	* * *	*200
SF162	(139)	WKEMDRGEIKNGSAKWTTSRINKMKEYALFYKLDIVPLDN----DNTSN		
TV1.8_2	(151)	TGIVNIEEMKNGSENAITTELEDKKHKEYALFYKLDIVPLN--ENSDFNTY		
TV1.8_5	(151)	NATYKYEEMKNGSENAITTELEDKKHKEYALFYKLDIVPLN--ENSNNFTY		
TV2.12-5/1	(141)	-----KDMKNGSEWVTELEDKKKRENATMYPRLDIVPLNNRKNGNINNY		
Consensus	(151)	A Y EEMKNCSFNVTTTELRLDKHKEYALFYKLDIVPLNN ENSNNFTY		
		201	* ↓	250
SF162	(185)	KLTNCNTSVITQACPKVSEEPPTIHYCAPADENILKCNDIKENGSGPCIN		
TV1.8_2	(199)	RLLNCNTSTITQACPKVSEDPPTIHYCAPADENILKCNNKENGNGTGPCYN		
TV1.8_5	(199)	RLLNCNTSTITQACPKVSEDPPTIHYCAPADENILKCNNKENGNGTGPCYN		
TV2.12-5/1	(185)	RLLNCNTSAITQACPKVSEDPPTIHYCAPADENILKCNNKENGNGTGPCDN		
Consensus	(201)	RLLNCNTSTITQACPKVSEDPPTIHYCAPADENILKCNNKTFNGTGPCYN		
		251	* * *	300
SF162	(235)	VSTVQCTHGIKPVWSTOLLINGSLAEEGIVIRSENLTENTKTIIVELNES		
TV1.8_2	(249)	VSTVQCTHGIKPVWSTOLLINGSLAEEGIVIRSENLTENTKTIIVELNES		
TV1.8_5	(249)	VSTVQCTHGIKPVWSTOLLINGSLAEEGIVIRSENLTENTKTIIVELNES		
TV2.12-5/1	(235)	VSTVQCTHGIKPVWSTOLLINGSLAEEGIVIRSENLTENTKTIIVELNES		
Consensus	(251)	VSTVQCTHGIKPVWSTQLLINGSLAEEGIVIRSENLTENTKTIIVELNES		
		301*	* * * 350	*
SF162	(285)	VEINCTRPNNNTRKSITIGPGQAFYATGDIIGDITROAHGNESGEKNNNT		
TV1.8_2	(299)	VEINCTRPNNNTRKSITIGPGQAFYATNDVITGNTROAHGNISTDRWNKTE		
TV1.8_5	(299)	VEINCTRPNNNTRKSITIGPGQAFYATNDVITGNTROAHGNISTDRWNKTE		
TV2.12-5/1	(285)	VEINCTRPNNNTRKSITIGPGQAFYATGDIIGDITROAHGNESGEKNNNT		
Consensus	(301)	VEINCTRPNNNTRKSITIGPGQAFYATNDIIGNIRQAHCNISTDRWNKTL		

FIGURE 2A

		351	*	*	400	
SF162	(335)	KOTVTKLQAQEGNKE	-TVEKQSSGGDPEIVMHSFNCGGERFFYCNSTOLEM			
TV1.8_2	(349)	QQVMKKLGEHFPNKT	-IKFKPHAGGDLEITMHSFNORGERFFYCNTSNLEN			
TV1.8_5	(349)	QQVMKKLGEHFPNKT	-IKFEPHAGGDLEITMHSFNCRGEFFYCNTSNLEN			
TV2.12-5/1	(335)	QRVSQKIQELEPNSEIGIKFAPHSGGDLEITTHSENCGGFFYCNTEDEPN				
Consensus	(351)	QQVMKKLQEHPNKT	IKFKPHAGGDLEITMHSFNCRGEFFYCNTSNLFN			
401 * * * * β20/β21 ↓ 450						
SF162	(384)	STWNN-----TIGPN-NNGTITIIPGRIKQIINRQGEMVKMYAPPIRG				
TV1.8_2	(398)	STYHS---NNGHYKYNGNSSLPTILOCKIKQIIRVMWQGVQOATYAPPIAG				
TV1.8_5	(398)	STYMP---KNGTYKYNGNSSLPTILOCKIKQIIRVMWQGVQOAMYAPPIAG				
TV2.12-5/1	(385)	STYSNGTCTNGHICMSN--NTERIILQCRFQKLTINMWOEVGRAMYAPPIAG				
Consensus	(401)	STYHN	NGTYKYNGNSS	PITLQCKIKQIIRVMWQGVQAMYAPPIAG		
451 * * * * 500						
SF162	(427)	QIERCSSNITGILLTRDGGKEISNL--TEI	TERPAGGGDMRDINWRSELYKYKV			
TV1.8_2	(445)	NTTGRSNITGILLTRDGGFNTTNN--TET	TERPAGGGDMRDINWRSELYKYKV			
TV1.8_5	(445)	NTTGRSNITGILLTRDGGFNNNTNNDEET	TERPAGGGDMRDINWRSELYKYKV			
TV2.12-5/1	(433)	NTTGRSNITGILLTRDGGDNNTETI--	TERPAGGGDMRDINWRSELYKYKV			
Consensus	(451)	NTTGRSNITGILLTRDGGFNNNTNT	TETFRPAGGGDMRDINWRSELYKYKV			
501 550						
SF162	(475)	VKIEPLIGVAPTKAKRVRVOREKRAVTI	GAMELGELGAAGSTMGAASITLT			
TV1.8_2	(493)	MEIKPLGIAPTKAKRVRVOREKRAVGIGAVL	GELGAAGSTMGAASITLT			
TV1.8_5	(495)	VEIKPLGIAPTKAKRVRVORKRPAVGIGAVL	GELGAAGSTMGAASITLT			
TV2.12-5/1	(480)	MEIKPLGIAPTAAKRVRVOREKRAVGIGAVL	GELGAAGSTMGAASITLT			
Consensus	(501)	VEIKPLGIAPTKAKRVRVQREKRAVGIGAVFLGFLGAAGSTMGAASITLT				
551 600						
SF162	(525)	VOARQLLSGIVVOQSNLLKATEAQOHMLQT	WQGKIKOIGARVLAERYL			
TV1.8_2	(543)	VOARQLLSGIVVOQSNLLKATEAQOHMLQT	WQGKIKOIGARVLAERYL			
TV1.8_5	(545)	VOARQLLSGIVVOQSNLLKATEAQOHMLQT	WQGKIKOIGARVLAERYL			
TV2.12-5/1	(530)	VOARQLLSGIVVOQSNLLKATEAQOHMLQT	WQGKIKOIGARVLAERYL			
Consensus	(551)	VOARQLLSGIVVOQSNLLKATEAQOHMLQT	WQGKIKOIGARVLAERYL			
601 650						
SF162	(575)	DOOILIGIWCGSGKLICTTAIVPNASWSNKS	LDOIWNNTMILWMEWEREDNY			
TV1.8_2	(593)	DOOILIGIWCGSGKLICTTAIVPNSSWSNKS	EKDIDWDNMFTWQWDREISNY			
TV1.8_5	(595)	DOOILIGIWCGSGKLICTTAIVPNSSWSNKS	EADIDWDNMFTWQWDREISNY			
TV2.12-5/1	(580)	DOOILIGIWCGSGKLICTTNLWNSSWSNKS	TOSDIWDNMFTWQWDREISNY			
Consensus	(601)	DQQLLGIWCGSGKLICTTAIVPNSSWSNKS	SEADIWDNMFTWQWDREISNY			
651 700						
SF162	(625)	TNTIYTLESONGQEKNEQELD	DKWASGNNWEDESKLNWYIKIFIMI			
TV1.8_2	(643)	TGLTYNLEDSONGQEKNEKD	ELDCKWNNEWWNEDESNWPWYIKIFIMI			
TV1.8_5	(645)	TNTIYTLELEDSONGQEKNEKD	ELDCKWNNEWWNEDESNWPWYIKIFIMI			
TV2.12-5/1	(630)	TNTIYTLELEDSQGQERNEKD	ELDCKWNNEWWNEDESNWPWYIKIFIMI			
Consensus	(651)	TNTIYRLLEDSQNQQEKNED	KDLLELDCKWNNLWNWFDISNWLYIKIFIMI			
701 750						
SF162	(675)	VGGLIGVIRIIFAVLIVNVRVROGYSP	LSFQTRFPAAPRGPPRPEGIEEEGG			
TV1.8_2	(693)	VGGLIGVIRIIFAVLIVNVRVROGYSP	LSFQTRTSPERGLDRIGGIEEEGG			
TV1.8_5	(695)	VGGLIGVIRIIFAVLIVNVRVROGYSP	LSFQTRTSPERGLDRIGGIEEEGG			
TV2.12-5/1	(680)	VGGLIGVIRIIFAVLIVNVRVROGYSP	LSFQTRTSPERGLDRIGGIEEEGG			
Consensus	(701)	VGGLIGVIRIIFAVLIVNVRVROGYSP	LSFQTRTSPERGLDRIGGIEEEGG			

FIGURE 2B

		751			800
SF162	(725)	EQDRDRSPSPIVHGLIATIINDDILRSIGLFSVHRLRDLTIAARIVVELGR-			
TV1.8_2	(743)	EQDRDRSIRIVSGFESTIANDDIURNLIGRSVHRLRDFITIAVRAVELGHS			
TV1.8_5	(745)	EQDRDRSIRIVSGFISLANDDIURSICRSVHRLRDFITIAVRAVELGHS			
TV2.12-5/1	(730)	EQDSSESPIRIVSGFHTKAWDDILRSICLFCYVHRLRDFITIAVRAVELGHS			
Consensus	(751)	EQDRDRSIRLVSGFLSLAWDDILRSCLFSYHRLRDFILIAVRAVELLGHs			
		801			850
SF162	(774)	-----RGWHLKWKWGNLQIOTNIQELKNSAYSLFDATAIAVARGTDRIIE			
TV1.8_2	(793)	SLRGLORGWEILKYLGSIVQYWGLEDKKS AISLLDTIAIAVARGTDRIIE			
TV1.8_5	(795)	SLRGLORGWEILKYLGSIVQYWGLENKSAISPLDTIAIAVARGTDRIIE			
TV2.12-5/1	(780)	SLRGLORGWGTILKYLGSIVQYWGLENKSAISLLDTIAIAVARGTDRIIE			
Consensus	(801)	SLRGLORGWEILKYLGSIVQYWGLENKSAISLLDTIAIAVARGTDRIIE			
		851		876	
SF162	(818)	VADRIGRAFLHIPRTRQGFEAALL-			
TV1.8_2	(843)	LVQRICRAILNIPRTRQGFEAALL-			
TV1.8_5	(845)	LVQRICRAILNIPRTRQGFEAALL-			
TV2.12-5/1	(830)	FTONICRGIRNVPRTRQGFEAALL			
Consensus	(851)	LVQRICRAILNIPRTRQGFEAALL			

FIGURE 2C




FIG. 3

Figure 4




Figure 5




Figure 6
(Sheet 1 of 2)

GagComplPolmut.SF2 (Gag complete, RT mutated, Protease functional; all in frame)

GTGACGCCACCATGGCGCCGCCAGCGTGCTGAGCGGCCGGAGCT
GGACAAGTGGAGAAGATCCGCCTGCAGCCGGCAAGAAGAAGTAC
AAGCTGAAGCACATCGTGTGGCCAGCCGCAGCTGGAGCGCTCGCCGT
GAACCCCGGCCTGCTGGAGACCGAGCGAGGGCTGCCAGATCCTGGCC
AGCTGCAGCCCAGCCTGCAGACCGCAGCGAGGAGCTGCGCAGCCTGTAC
AACACCGTGGCCACCCCTGTACTGCGTCACCAGCGATCGACGTCAAGGA
CACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAGTCCAAG
AAGAAGGCCAGCAGGCCGCCGCCGCCGCCAGCAGCACAGCAGCC
AGGTGAGCCAGAACTACCCCATCGTGCAGAACCTGCAGGGCAGATGGT
CACCAGGCCATCAGCCCCCGCACCCCTGAACGCCTGGTGAAGGTGGTGA
GGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCG
AGGGGCCACCCCGAGGACCTGAACACGATGTTGAACACCGTGGCG
CACCAAGGCCAGCAGATGCTGAAGGAGACCATCAACGAGGAGGCC
CCGAGTGGGACCGCGTGCACCCGTGCAGCCGGCCCCATGCCCG
CAGATGCGCAGCCCCCGGGCAGCGACATGCCGGCACCACGACCC
GCAGGAGCAGATCGGCTGGATGACCAACAACCCCCCATCCCGTGGCG
AGATCTACAAGCGGTGGATCATCCTGGCCTGAACAAAGATCGTGC
GGATG
TACAGCCCCACCAGCATCCTGGACATCCGCCAGGGCCCAAGGAGCC
CCGCGACTACGTGGACCGCTTACAAGACCCCTGCGCGCTGAGCAGGCC
GCCAGGACGTGAAGAACTGGATGACCGAGACCCCTGCTGGTGCAGAACGC
CAACCCGACTGCAAGACCATCCTGAAGGCTCTGGCCCGGGCCACCC
TGGAGGAGATGATGACCGCCTGCCAGGGCGTGGCGGGCCACAA
GGCCCGCTGCTGGCGAGGCGATGAGCCAGGTGACGAACCCGG
ATCATGATGAGCGCGCAACTTCCGCAACCAGCGGAAGGACCGTCAAGTG
CTTCAACTGCGCAAGGAGGGCACACCGCCAGGAACCGCC
GCAAGAAGGGCTGCTGGCGCTGCGGCCGAGGGCCACAGATGAAGGA
CTGCACCGAGCGCCAGGCCAACCTCCTGGCAAGATCTGGCC
AGGCGCCGGCAACTTCCGCTTCCGCGAGGAGAAGACCAACCC
CCCGAGGAGAGCTTCCGCTTCCGCGAGGAGAAGACCAACCC
AGCAGGAGCCCAGCAGAACAGGAGCTGTACCCCTGACCG
CTGTTCCGCAACGACCCAGCAGCCAGAAAGAATTCAAGGCC
GGCGAGGCGATGAGCCAGGTGACGAACCCGGCAGCATCATGATGCAG
CGCGGCAACTTCCGCAACCAGCGGAAGACCGTCAAGTGCT
CAAGGAGGGCACACCGCCAGGAACAGCCGGCCACAG
TGCTGGCGCTGGCGCGAGGACACCAATGAAAGATTGCACTGAGA
GACAGGCTAATTCTCCGCGAGGACCTGGCCTTGCAGGGCAAGGCC
CGCGAGTTCAGCAGCGAGCAGACCCGCCAACAG
GCTGCAGGTGGGGCGCGAGAAACAACAGCCTGAGCGAGGCC
GACCGCCAGGGCACCGTGAAGCTCAACTTCCCCAGATCAC
CGGCCCTGGTGAACCATCAGGATCGGCCAGCTCAAGGAGGCC
TCGACACCGGCCGACGACACCGTGTGGAGGAGATGAACCTGCC
AAAGTGGAAAGCCCAAGATGATCGGCGGGATCGGGGGCTTC
GGCAGTACGACCAAGATCCCCGTGGAGGATCTGCC
ACAAGGCCATGGC

Figure 6
(Sheet 2 of 2)

ACCGTGCTGGTGGGCCCAACCCCGTGAACATCATCGGCCGAAACCTGCT
GACCCAGATCGGCTGACCCCTGAACCTCCCCATCAGCCCCATCGAGACGG
TGCCCCGTGAAGCTGAAGCCGGGGATGGACGGCCCCAAGGTCAAGCAGTG
GCCCTGACCGAGGGAGAAGATCAAGGCCCTGGTGGAGATCTGCACCGAG
ATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACA
ACACCCCCGTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAA
GCTGGTGGACTTCCCGAGCTGAACAAGCGCACCCAGGACTTCTGGGAGG
TGCAGCTGGGCATCCCCCACCCCGCCGGCTGAAGAAGAAGAAGAGCGTG
ACCGTGCTGGACGTGGCGACGCCTACTCAGCGTCCCCCTGGACAAAGGA
CTTCCGCAAGTACACCGCCTTACCATCCCCAGCATCAACAACGAGACCC
CCGGCATCCGCTACCAAGTACAACGTGCTGCCCAAGGGCTGGAAGGGCAGC
CCCGCCATCTCCAGAGCAGCATGACCAAGATCCTGGAGGCCCTCCGCAA
GCAGAACCCCGACATCGTACTACCAGGCCCTGTACGTGGCAGCG
ACCTGGAGATCGGCCAGCACCGCACCAAGATCGAGGAGCTGCCAGCA
CCTGCTGCGCTGGGCTTACCCACCCCGACAAGAACGACCAAGAGAAGGAGC
CCCCCTCCTGCCATCGAGCTGCACCCGACAAGTGGACCGTGCAGCCC
ATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAAAGCT
GGTGGGCAAGCTGAACTGGGCCAGCCAGATCTACGCCGGATCAAGGTGA
AGCAGCTGTGCAAGCTGCTGCCGGCACCAAGGCCCTGACCGAGGTGATC
CCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCGAGAACCGCGAGATCCT
GAAGGAGCCCGTGCACGAGGTGTACTACGACCCAGCAAGGACCTGGTG
GCCGAGATCCAGAACGAGGCCAGGGCCAGGGCCAGTGGACCTACCAGATCTACC
AGGAGCCCTCAAGAACCTGAAGACCGCAAGTACGCCGCATGCGCCGC
GCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAACGGTGA
GCACCGAGAGCATCGTATCTGGGCAAGATCCCCAAGTTCAAGCTGCC
ATCCAGAAGGAGACCTGGGAGGCCTGGTGGATGGAGTACTGGCAGGCC
CCTGGATCCCCAGTGGAGTTCGTGAACACCCCCCCCTGGTGAAGCTG
TGGTACCAAGCTGGAGAAGGAGGCCATCGTGGCGCCGAGACCTTCTACGT
GGACGGCGCCGCCAACCGAGACCAAGCTGGCAAGGCCGGCTACGTG
ACCGACCGGGGCCAGAACGGTGGAGCATCGCCGACACCACCAACC
AGAAGACCGAGCTGCAGGCCATCCACCTGCCCTGCAGGACAGCGGCCTG
GAGGTGAACATCGTACCGACAGCCAGTACGCCCTGGCATCATCCAGGC
CCAGCCCGACAAGAGCGAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAG
CTGATCAAGAAGGAGAAGGTGTACCTGGCCTGGGTGCCCCACAAGGG
CATCGGCCGCAACGAGCAGGTGGACAAGCTGGTGGAGGCCGGCATCCGC
AAGGTGCTGTTCTGAACGGCATCGATGGCGGCATCGTATCTACCAAGTA
CATGGACGACCTGTACGTGGCAGCGGCCCTAGGATCGATTAAAAGC
TTCCCGGGCTAGCACCGGTTAGA

Figure 7
(Sheet 1 of 2)

GagComplPolmutAtt.SF2 (Gag complete, RT mutated, Protease attenuated; all in frame)

GTGACGCCACCATGGCGCCCGCGCCAGCGTGCTGAGCGGCCAGCT
GGACAAAGTGGAGAAGATCCGCCCTGCGCCCCGGCGCAAGAAGAAGTAC
AAGCTGAAGCACATCGTGTGGCCAGCCCGAGCTGGAGCGCTTCGCCGT
GAACCCCGGCCTGCTGGAGACCAGCGAGGGCTGCCAGATCTGGGCC
AGCTGCAGCCCAGCCTGCAGACCGGCAGCGAGGAGCTGCGCAGCCTGTAC
AACACCGTGGCCACCCTGTACTGCGTGCACCAGCGATCGACGTCAAGGA
CACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCCAAG
AAGAAGGCCAGCAGGCCGCCGCCGCCGGCACCGCAACAGCAGCC
AGGTGAGCCAGAACTACCCCATCGTGCAGAACCTGCAGGGCCAGATGGTG
CACCAGGCCATCAGCCCCGACCCCTGAACGCCCTGGTGAAGGTGGTGG
GGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTCAGGCCCTGAGCG
AGGGGCCACCCCCCAGGACCTGAACACGATGTTAACACCGTGGCGGC
CACCAGGCCCATGCGATGCTGAAGGAGACCATCAACGAGGAGGCC
CCGAGTGGGACCGCGTGCACCCGTGACGCCGGCCCATGCCCGGCC
CAGATCGCGAGCCCCCGGGCAGCGACATGCCGGCACCAAGCACCCT
GCAGGAGCAGATCGGCTGGATGACCAACAACCCCCCATCCCCGTGGCG
AGATCTACAAGCGGTGGATCATCCTGGGCTGAACAAGATCGTGCAGGATG
TACAGCCCCACCAGCATCCTGGACATCCGCCAGGGCCCCAACGGAGGCC
CCGCGACTACGTGGACCGCTTACAAGACCCCTGCGCGCTGAGCAGGCC
GCCAGGACGTGAAGAACTGGATGACCGAGACCCCTGCTGGTGCAGAACGC
CAACCCGACTGCAAGACCATCCTGAAGGCTCTCGGCCCGGGCCACCC
TGGAGGAGATGATGACCGCTGCCAGGGCGTGGCGGCCAACAA
GGCCCGCGTGTGGCCAGGCGATGAGCCAGGTGACGAACCCGGGACC
ATCATGATGCAGCGCGCAACTCCGCAACCAGCGAACCGTCAAGTG
CTTCAACTGCGGCAAGGAGGCCACCCGCCAGGAACCGCCGG
GCAAGAAGGGCTGCTGGCGCTGCGGCCGAGGGCCACAGATGAAGGA
CTGCACCGAGCGCCAGGCCAACCTCCTGGCAAGATCTGGCCAGCTACA
AGGGCCGCCCGCAACTCCTGCAGAGGCCGGGAGGCCAACCGCCCC
CCCGAGGAGAGCTCCGCTTCCGCGAGGAGAACGCCACCCAGCCAGA
AGCAGGAGCCCATGACAAGGAGCTGACCCCTGACCGCTGCGCAGC
CTGTTGGCAACGACCCAGCAGCCAGAAAGAACGATCAAGGCC
GGCGAGGCGATGAGCCAGGTGACGAACCCGGCAGCATGATGCAG
CGCGGCAACTCCGCAACCAGCGGAAGACCGTCAAGTGCTCAACTGCGG
CAAGGAGGCCACACCGCCAGGAACGGCCGGGAGGCCAACAGCCCC
TGCTGGCGCTGCCCGAAGGACACAAATGAAAGATTGCACTGAGA
GACAGGCTAATTCTCCGCGAGGACCTGGCTTCTGCAGGGCAAGGCC
CGCGAGTTCAGCAGCGAGCAGACCCGCCAACAGCCCCACCGCC
GCTGCAGGTGTGGGGCGCGAGAACAAACAGCCTGAGCGAGGCC
GACCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCCGTGGCA
GCGCCCCCTGGTACCATCAGGATCGCGGCCAGCTCAAGGAGGCC
TCGACTCCGGCGCCAGCACCCGTGCTGGAGGAGATGAACCTGCC
AAAGTGGAAAGGCCAACAGATGATCGCGGGATCGGGGGCTTCATCAAGGTGC
GGCAGTACGACCAAGATCCCCGTGGAGATCTGCCGCCACAAGGCC
ATCGGC

Figure 7
(Sheet 2 of 2)

ACCGTGCTGGTGGGCCCAACCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAGATCGGCTGCACCCCTGAACCTCCCCATCAGCCCCATCGAGACGGTGCCCGTGAAGCTGAAGCCGGGATGGACGGCCCCAAGGTCAAGCAGTGCCCCCTGACCGAGGAGAAGATCAAGGCCCTGGAGATCTGCACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAAACCCCCGTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAA GCTGGTGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTTCTGGGAGG TGCAGCTGGGATCCCCCACCCGCCCTGAAGAAGAAGAAGAGCGTGACCGTGCTGGACGTGGCGACGCCCTACTTCAGCGTGCCTGGACAAGGA CTTCCGCAAGTACACCGCCTTACCATCCCCAGCATCAACAAACGAGACCCCGGCATCCGCTACCAGTACAACGTGCTGCCCAAGGGCTGGAAGGGCAGC CCCGCCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGCCCTCCGCAA GCAGAACCCCGACATCGTATCTACCAGGCCCCCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCACCGACCAAGATCGAGGAGCTGCGCCAGCA CCTGCTGCGCTGGGCTTACCAACCCCGACAAGAAGCACCAGAAGGAGC CCCCCCTCCTGCCATCGAGCTGCACCCGACAAGTGGACCGTGCAGCCC ATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAAGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCGCCGACCAAGGCCCTGACCGAGGTGATC CCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCGAGAACCGCGAGATCTGAAGGAGCCCGTGCACGAGGTGTACTACGACCCCAAGCAAGGACCTGGTGGCCGAGATCCAGAAGCTCAAGGAGACCTTCAAGAACCTGAAGACCGGCAAGTACGCCCGCATGCGCCGCCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAACGGTGA GCACCGAGAGCATCGTATCTGGGGCAAGATCCCCAAGTTCAAGCTGCCATCCAGAAGGAGACCTGGGAGGCCCTGGTGGAGCTGGCAGGCCA CCTGGATCCCCAGTGGAGTTCGTGAACACCCCCCCCCTGGTGAAGCTGTGGTACCTGGAGGCCATCGTGGCGCCGAGACCTTCTACGTGGACGGCGCCGCCAACCGCGAGACCAAGCTGGCAAGGCCGGCTACGTGACCGACGGGGCCGGCAGAACGGTGGAGCATCGCCGACACCACCAACCAGAACGGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGACATCGAGCAGCCAGGCCACAAGGAGATCAAGAAGGAGAAGGTGTACCTGGCCTGGGTGCCGCCACAAGGGCATCGGCCGGCAACGAGCAGGCCAGGTGGACAAGCTGGTGAAGCGCCGGCATCCGC AAGGTGCTGTTCTGAACGGCATCGATGGCGGCATCGTGAATCTACCAAGTACGGACCTGTACGTGGCAGCGGCCCTAGGATCGATTAAAAGCTTCCCGGGCTAGCACCCTGTTAGA

Figure 8
(Sheet 1 of 2)

GagComlPolmutIna.SF2 (Gag complete, RT mutated, Protease inactive; all in frame)

GTGACGCCACCATGGCGCCGCCAGCGTGCTGAGCGGGCGAGCTGGACAAGTGGAGAAGATCCGCCTGCGCCCCGGCGAAGAAGAAGTAC
AAGCTGAAGCACATCGTGTGGCCAGCCGCGAGCTGGAGCGCTTCGCCGT
GAACCCGGCCTGCTGGAGACCAGCGAGGGCTGCCAGATCCTGGCC
AGCTGCAGCCCAGCCTGCAGAACCGGAGCGAGGAGCTGCGCAGCCTGTAC
AACACCGTGGCCACCCGTACTGCGTGCACCAGCGCATCGACGTCAAGGA
CACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCCAAG
AAGAAGGCCAGCAGGCCGCCGCCGCCAGCAGCAGCC
AGGTGAGCCAGAACTACCCATCGTGCAGAACCTGCAGGGCCAGATGGT
CACCAAGGCCATCAGCCCCCGCACCCGTAAACGCCTGGTGAAGGTGGTGA
GGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCG
AGGGGCCACCCCCCAGGACCTGAACACGATGTTGAACACCGTGGGCC
CACCAAGGCCATGCAGATGCTGAAGGAGACCATCAACGAGGAGGCC
CCGAGTGGGACCGCGTGCACCCGTGCACGCCGCCATGCCGCC
CAGATGCGCAGCCCCCGCGCAGCGACATGCCGGCACCACCAGCACCC
GCAGGAGCAGATCGGCTGGATGACCAACAACCCCCCATCCCCGTGGCG
AGATCTACAAGCGGTGGATCATCCTGGCCTGAACAAGATCGTGCAGGATG
TACAGCCCCACCAGCATCCTGGACATCCGCCAGGGCCCCAACGGAGGCC
CCGCGACTACGTGGACCGCTTACAAGACCCGTGCCTGAGCAGGCC
GCCAGGACGTGAAGAACTGGATGACCGAGACCCGTGGTGCAGAACGC
CAACCCGACTGCAAGACCATCCTGAAGGCTCTCGGCCGGCCACCC
TGGAGGAGATGATGACCGCTGCCAGGGCGTGGCGGCCAACAA
GGCCCGGTGCTGGCCAGGGCGATGAGCCAGGTGACGAACCCGGCGACC
ATCATGATGAGCGCAGCAACTTCCGCAACCAGCGGAAGACCGTCAAGTG
CTTCAACTGCGCAAGGAGGGCCACACCAGCAGGAACCGCC
GCAAGAAGGGCTGCTGGCGCTGCCAGGGCCACCAGATGAAGGA
CTGCACCGAGCGCCAGGCCAACCTCCTGGCAAGATCTGGCCAGCTACA
AGGGCCGCCGGCAACTTCCCTGCAGAGCGCCGGCAGGCCACCGCCCC
CCCGAGGAGAGCTTCCGCTTCCGCGAGGAGAAGACCAACCCCCAGCCAGA
AGCAGGAGCCATCGACAAGGAGCTGTACCCCTGACCGCCTGCGCAGC
CTGTTGGCAACGACCCAGCAGCCAGAAAGAATTCAAGGCCCGTGT
GGCCGAGGCATGAGCCAGGTGACGAACCGCGACCATCATGATGCGAG
CGCGGCAACTTCCGCAACCAGCGGAAGACCGTCAAGTGTGTTCAACTGCGG
CAAGGAGGGCCACACCAGCAGGAACCGCCAGGAACAGCCTGAGCGAGGCC
TGCTGGCGTGGCGCGAAGGACACCAAATGAAAGATTGCACTGAGA
GACAGGCTAATTCTCCGCGAGGACCTGGCCTTGCAGGGCAAGGCC
CGCGAGTTCAGCAGCGAGCAGACCCCGGCCAACAGCCCCACCCGCC
GCTGCAGGTGTGGGGCGCGAAGAACACAACAGCCTGAGCGAGGCC
GACCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCCGTGGCA
GCGCCCCCTGGTGACCATCAGGATCGCGGCCAGCTCAAGGAGGCC
TCGCCACCGCGCCGACGACACCGTGCTGGAGGAGATGAACCTGCC
AAAGTGGAAAGCCCAAGATGATGGCGGATGGGGCTTCATCAAGGTGC
GGCAGTACGACCAGATCCCCGTGGAGATCTGCGGCCACAAGGCC
ACCGTGTGGTGGGCCACCCCGTGAACATCATCGGCCAACCTGCT

Figure 8
(Sheet 2 of 2)

GACCCAGATCGGCTGCACCTGAACCTCCCCATCAGCCCCATCGAGACGG
TGCCCGTGAAGCTGAAGCGGGGATGGACGGCCCCAAGGTCAAGCAGTG
GCCCTGACCGAGGAGAAGATCAAGGCCCTGGAGATCTGCACCGAG
ATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCCGAGAACCCCTACA
ACACCCCCGTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAA
GCTGGTGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTTCTGGGAGG
TGCAGCTGGCATCCCCCACCCGCCCTGAAGAAGAAGAAGAGCGTG
ACCGTGTGGACGTGGCGACGCCACTTCAGCGTCCCCTGGACAAAGGA
CTTCCGCAAGTACACCGCCTCACCATCCCCAGCATCAACAACGAGACCC
CCGGCATCCGCTACCAAGTACAACGTGCTGCCAGGGCTGGAAGGGCAGC
CCCGCCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGGCCCTCCGCAA
GCAGAACCCCGACATCGTATCTACCAAGGCCCCCTGTACGTGGCAGCG
ACCTGGAGATCGGCCAGCACCGCACCAAGATCGAGGAGCTGCGCCAGCA
CCTGCTGCGCTGGGCTTCACCACCCCCGACAAGAAGCACCAGAAGGAGC
CCCCCTTCCCTGCCATCGAGCTGCACCCGACAAGTGGACCCTGCAGCCC
ATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAAAGCT
GGTGGCAAGCTGAACTGGGCCAGCCAGATCTACGCCGGCATCAAGGTGA
AGCAGCTGTGCAAGCTGCTGCGCGCACCAAGGCCCTGACCGAGGTGATC
CCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCGAGAACCGCGAGATCCT
GAAGGAGCCCGTGCACGAGGTGTACTACGACCCCAGCAAGGACCTGGT
GCCGAGATCCAGAAGCAGGCCAGGGCCAGTGGACCTACCAGATCTACC
AGGAGCCCTCAAGAACCTGAAGACCGCAAGTACGCCGCATGCGCGGC
GCCACACCAACGACGTGAAGCAGCTGACCGAGGCCAGCAGAACGGTGA
GCACCGAGAGCATCGTATCTGGGCAAGATCCCCAAGTTCAAGCTGCC
ATCCAGAACGGAGACCTGGAGGCCCTGGATGGAGTACTGGCAGGCC
CCTGGATCCCCGAGTGGAGTTCGTGAACACCCCCCTGGTGAAGCTG
TGGTACCAAGCTGGAGAACGGAGGCCATCGTGGCGCCAGACCTTCTACGT
GGACGGCGCCGCCAACCGCAGACCAAGCTGGCAAGGCCGCTACGTG
ACCGACCGGGGCCAGAACGGTGGAGCATCGCCGACACCACCAACC
AGAAGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCTG
GAGGTGAACATCGTACCGACAGCCAGTACGCCCTGGCATCATCCAGGC
CCAGCCGACAAGAGCGAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAG
CTGATCAAGAACGGAGAACGGTGTACCTGGCCTGGTGGCCACAAAGGG
CATCGCGGGCAACGAGCAGGTGGACAAGCTGGTGGAGCCGCGCATCCGC
AAGGTGCTGTTCTGAACGGCATCGATGGCGGCATCGTATCTACCAAGTA
CATGGACGACCTGTACGTGGCGAGCGGCCCTAGGATCGATTAAAAGC
TTCCCGGGCTAGCACCGGTTAGA

Figure 9
(Sheet 1 of 2)

`gagCpolInaTatRevNef.opt_B`

```

GTCGACGCCACCATGGCGCCCGGCCAGCGTGTGAGCGCGAGCTGGACAAGTGGAGAAGATC
CGCCTGCGCCCCGGCGCAAGAAGAAGTACAAGCTGAAGCACATCGTGTGGCCAGCCGAGCTGGAG
CGCTTCGCGCTGAACCCGGCCTGCTGGAGACCAGCGAGGGCTGCCAGATCTGGGCCAGCTGCAG
CCCAGCCTGCAGACCGGCAGCGAGGAGCTGCAGCAGCTGTACAACACCGTGGCCACCCGTACTGCAG
CACCAAGCGCATCGACGTCAAGGACACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCC
AAGAAGAAGGCCAGCAGGCCGCCGCCGCCAGCGAACAGCAGCCAGGTGAGGCCAGAACACTAC
CCCATCGTCAGAACCTGCAGGGCCAGATGGTGCACCAGGCCATCAGCCCCCGCACCCGTGAACGCCCTGG
GTGAAGGTGGTGGAGGAGAACGGCCTTCAGCCCCGAGGTGATCCCCATGTTCAGCGCCCTGAGCGAGGGC
GCCACCCCCCAGGACCTGAACACGATGTTAACACCGTGGCGGCCACCAGGCCATGCAGATGCTG
AAGGAGACCATCAACGAGGAGGCCAGTGGGACCGCTGCACCCCGTGCACGCCGGCCCCATCGCC
CCCAGCAGATGCGCGAGCCCCGCGGGCAGCGACATGCCGGCACACCAGCACCCGTGAGGAGCAGATC
GGCTGGATGACCAACAACCCCCCATCCCCGTGGCGAGATCTACAAGCGGTGGATCATCCTGGCCTG
AACAAAGATCGTGGGATGTACAGCCCCACAGCATCTGGACATCCGCCAGGGCCCCAAGGAGGCCCTTC
CGCGACTACGTTGACCGCTTCTACAAGACCCCTGCGCGCTGAGCAGGCCAGGACGTGAAGAAACTGG
ATGACCGAGACCTGCTGGTGCAGAACGCCAACCCGACTGCAAGACCATCCTGAAGGCTCTGGGCC
GCCAGGCCCCACCTGGAGGAGATGATGACCGCCTGCAGGGCGTGGCGGGCCCCGGCCACAAGGCCGCGT
CTGGCGAGGCCATGAGCAGGATGACGAACCCGGCACCACATGATGTCAGCGCCCAACTTCCGCAAC
CAGCGGAAGACCGTCAAGTGCCTCAACTGCGCAAGGAGGCCACACCGCCAGGAACGTGCCGCCCCC
CGCAAGAAGGGCTGCTGGCGCTGCAGGGCCACCAGATGAAGGACTGCACCGAGGCCAGGCC
AACTCCTGGCAAGATCTGGCCAGCTACAAGGGCCCGGCCACTCCTGCAGAGGCCGCCCCGAG
CCCAACGCCCGAGGAGGAGCTTCCGCTTGGCGAGGAGAACACCCAGGCCAGAACGCCAGGAG
CCCACATGACAAGGAGCTGTACCCCCCTGACCGCCTGCGCACCTGTCAGGCAACGCCAGGCCAG
AAAGAATTCAAGGCCCGCTGCTGGCGAGGCGATGAGCCAGGTGACGAACCCGGCACCACATGATG
CAGCGCCGAACCTCCGCAACCAGCGGAAGACCGCTCAAGTGCCTCAACTGCGCAAGGAGGCCACACC
GCCAGGAACCTGGCGCCCGCAAGAAGGGCTGCTGGCGCTGCCCGCGAAGGACACCAATGAAA
GATTGCACTGAGAGACAGGCTAATTCTTCCGCGAGGACCTGGCCTTCTGCAGGGCAAGGCCGCGAG
TTCAGCAGCGAGCAGACCCCGGCCAACAGCCCCACCCGCCCGAGCTGAGGATCTGGCGGGATCGGG
AACAGCCTGAGCGAGGCCGGCGCCAGCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCC
TGGCAGCGCCCCCTGGTACCGATCAGGATCGGCCAGCTCAAGGAGGCCGCTGCTGCCACCGCGCC
GACGACACCGTGTGGAGGAGATGAACCTGCCCGCAAGTGGAGGCCAAGATGATCGGGGGATCGGG
GGCTCATCAAGGTGCGGCAGTACGACCGAGATCCCCGTGGAGATCTGGGGCCACAAGGCCATCGG
GTGCTGGTGGGGCCCCACCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAGATCGGCTGCACCC
AACTCCCCATCGACCGCTGAGACGGTGGCCAGCTGAAGCTGAAGGCCGGGATGGACGGCCCCAAGGTC
AAGCAGTGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGAGATCTGCACCGAGATGGAGAAGGAG
GGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCGTGTGACCCAGATCAAGAAGGAC
AGCACCAAGTGGCGCAAGCTGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTCTGGGAGGTG
CAGCTGGCATTCCCCACCCGCCCTGAAGAAGAAGAGCGTGAACCGCTGCTGGACGCTGGCGAC
GCCTACTTCAGCGTGGCCCTGGACAAGGACTTCCGCAAGTACACCGCCTTACCATCCCCAGATCAAC
AACGAGACCCCCGGCATCCGCTACCAAGTACACGTGCTGCCAGGGCTGGAAGGGCAGCCCCGCCATC
TTCCAGAGCAGCATGACCAAGATCTGGAGGCCCTCCGCAAGCAGAACCCCGACATGTGATCTACCAG
GCCCTGCTACGTGGCAGCGACCTGGAGATCGGCCAGCACCGCACAAGATCGAGGAGCTGCCAG
CACCTGCTGCCGTGGGCTTCACCAACCCCGACAAGAAGCACCAGAAGGAGGCCCTTCCCTGCCATC
GAGCTGCACCCGACAAGTGGACCGCTGCAGCCCATCATGCTGCCAGAAGGACAGCTGGACCGTGAAC
GACATCCAGAAGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAG
CTGTGCAAGCTGCTGCCGGCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGGCCGAGCTG
GAGCTGGCCAGAGACCGCGAGATCTGAAGGGAGCCGTGACGAGGTGACTACGACCCAGCAAGGAC
CTGGTGGCCAGAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTACCAAGATCTACAGGAGGCCCTCAAG
AACCTGAAGACCGCAAGTACGCCGCATGCCGGGCCACACCAACGACGTGAAGCAGCTGACCGAG
GCCGTGCAAGGGTGAAGCAGCGAGAGACATCGTGTCTGGGCAAGATCCCCAAGTCAAGCTGCCATC
CAGAAGGAGACCTGGGAGGCCCTGGTGAAGCTGTGGTACCAAGCTGGAGAAGGAGGCCATCGTGGCGAGACC
GTGAACACCCCCCCCCCTGGTGAAGCTGTGGTACCAAGCTGGAGAAGGAGGCCATCGTGGCGAGACC
TTCTACGTGGACGGCGCCCAACCGCAGACCAAGGACCAAGCTGGCAAGGCCGGCTACGTGACCGACCGGGC
CGGCAGAAGGTGGTGAAGCAGGCCACACCACCAACGAGACCGAGCTGCAAGGCCATCCACCTGGCC
CTGCAGGACAGCGGCCTGGAGGTGAACATCGTACCGACAGCCAGTACGCCCTGGCATCATCCAGGCC

```

Figure 9
(Sheet 2 of 2)

CAGCCCGACAAGAGCGAGAGCGAGCTGGTGAGCCAGATCATCGAGCAGCTGATCAAGAAGGAGAAGGTG
TACCTGGCCTGGGTGCCGCCACAAGGGCATCGCGGCAACGAGCAGGTGGACAAGCTGGTGAGCGC
GGCATCCGCAAGGTGCTGTTCTGAACGGCATCGATGGCGCATCGTATCTACCAAGTACATGGACGAC
CTGTACGTGGCAGCGGCCCTAGGGAGCCCGCTGGAGCCCTGGAGCCCTGGAGCAGCAGC
AGCCAGCCCAAGACCAGCCGCCACCAACTGCTACTGCAAGAAGTGCTGCTTCCACTGCCAGGTGAGCTTC
ATCACCAAGGGCCTGGGCATCAGCTACGGCGCAAGAAGCGCCGCCAGCGCCGCCGCCCCCCCCGAC
AGCGAGGTGACCCAGGTGAGCCTGCCAAGCAGCCGCCAGCCAGCCCCAGGGCGACCCACCGGCCCC
AAGGAGAGCAAGAAGAAGGTGGAGCGAGACCGAGACCGACCCCGTGACCCCGGGCGGGCGCAGC
GGCGACAGCGACGAGGAGCTGCTGCAGACCGTGCCTCATCAAGTCTGTACCAAGAGCAACCCCTG
CCCAGCCCCAAGGGCACCCGCCAGGGCACCTGAACCGCCGCCGCTGGCGAGCGCCAGCGCCAG
ATCCAGAGCATAGCGCCTGGATCATCAGCACCCACCTGGCCGAGCACCGAGCCGTGCCCTGAG
CTGCCCCCGACCTGCGCTGAACCTGGACTGAGCGAGGACTGCGGACCCAGCGGACCCAGGGCGTG
GGCAGCCCCCAGGTGCTGGCGAGAGCCCCGCCGTGCTGGACAGCGGACCAAGGAGCTGAGGGCGGC
AAGTGGAGCAAGCGCATGACGGCTGGAGCGCCGTGCGAGCGCATGAAGCGCCGAGCCGCCGAG
CCCAGGGCGACGGCGTGGCGCCGTGAGCGGCCAGCTGGAGAAGCACGGCGCCATCACAGCAGCAAC
ACCGCCGCCAACACCGGACTGCGCCTGGCTGGAGGCCCAGGAGGACGAGGACGTGGCTTCCCCGTG
CGCCCCCAGGTGCCCCCTGCGCCCATGACCTACAAGGCCGCCCTGGACCTGAGCCACTTCTGAAGGAG
AAGGGCGGCCCTGGAGGGCTGATCTACAGCCAGAAGCGCCAGGACATCCTGGACCTGTGGATCCACAC
ACCCAGGGCTACTTCCCCGGCTGGCAGAACTACACCCCGGCCCATCCGCTACCCCTGACCTTC
GGCTGGTGCTTCAGCTGGTGCCCGTGGACCCCGACTACGTGGAGGAGGCAACGCCGGCGAGAACAC
AGCCTGCTGCACCCCATGAGCCAGCAGGAGCTGAGCACCCGAGAAGGAGGTGCTGGTGCGCTTC
GACAGCCGCCCTGGCTTCCACCATGGCCCGAGCTGACCCCGAGTACTACAAGGACTGCGATTAA
AAGCTTCCCGGGCTAGCACCGGTTCTAGA

Figure 10
(Sheet 1 of 2)

GagPolmutAtt.SF2 (Gag, RT mutated, Protease attenuated; all in frame)

GTCGACGCCACCATGGCGCCCGCGCCAGCGTGCTGAGCGGCCAGCT
 GGACAAAGTGGGAGAAGATCCGCCTGCGCCCCGGCGCAAGAAGAAGTAC
 AAGCTGAAGCACATCGTGTGGGCCAGCCCGAGCTGGAGCGCTTCGCCGT
 GAACCCGGCCCTGCTGGAGACCAAGCGAGGGCTGCCGCAGATCCGGCC
 AGCTGCAGCCCAGCCTGCAGACCGGCAGCGAGGAGCTGCGCAGCCTGTAC
 AACACCGTGGCCACCCCTGTACTGCGTGCACCAGCGATCGACGTCAAGGA
 CACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCCAAG
 AAGAAGGCCAGCAGGCCGCCGCCGCCGGCACCGGAAACAGCAGCC
 AGGTGAGCCAGAACTACCCATCGTGAGAACCTGCAAGGGCCAGATGGT
 CACCAGGCCATCAGCCCCGACCCCTGAACGCCCTGGGTGAAGGTGGTGG
 GGAGAAGGCCTTCAGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCG
 AGGGGCCACCCCCCAGGACCTGAACACGATGTTGAACACCGTGGGCC
 CACCAGGCCCATGCAAGATGCTGAAGGAGACCATCAACGAGGAGGCC
 CCGAGTGGACCGCGTGCACCCGTGCACGCCGCCCATGCCGCC
 CAGATGCGCAGCCCCCGCCAGCGACATGCCGGCACCAACCAGCACCT
 GCAGGAGCAGATCGGCTGGATGACCAACAACCCCCCATCCCGTGGCG
 AGATCTACAAGCGGTGGATCATCCTGGGCTGAACAAGATCGTGCAG
 TACAGCCCCACCAGCATCCTGGACATCCGCCAGGGCCCAAGGAGCC
 CCGCGACTACGTGGACCGCTTCTACAAGACCCCTGCGCGCTGAGCAG
 GCCAGGACGTGAAGAACTGGATGACCGAGACCCCTGCTGGTGAGAAC
 CAACCCGACTGCAAGACCATCCTGAAGGCTCTGGGCCGCCACCC
 TGGAGGAGATGATGACCGCCTGCCAGGGCGTGGCGGCCACAA
 GGCCCGCTGCTGGCGAGGCGATGAGCCAGGTGACGAACCCGGGAC
 ATCATGATGCAAGCGGCCACTTCCGCAACCAGCGGAAGACCGTCAAG
 CTTCAACTGCGCAAGGAGGGCACACCGCCAGGAACGCGCC
 GCAAGAAGGGCTGCTGGCGCTGCCAGGCCAGAACACCAAATGAAAGA
 TTGCACTGAGAGACAGGTAATTCTCCGCGAGGACCTGGCCTTC
 GCAAGAAGGGCGAGITCAGCAGCGAGCAGACCCCGCCAAACAG
 ACCCGCCGCGAGCTGCAGGTGTGGGGCGCGAGAACAAACAGC
 AGGCCGGCGCCACCAGGCCAGGGCACCGTGAGCTCAACT
 ACCCTGTGGCAGCGCCCCCTGGTGACCATCAGGATCGCGGCC
 GGAGGCCTGCTCGACTCCGGCGCCAGCACCCGTGCTGGAGGAGATGA
 ACCTGCCCGCAAGTGAAGCCAAGATGATCGCGGGATCGGGGCTTC
 ATCAAGGTGCGGCAGTACGACCAAGATCCCCGTGGAGATCTGCC
 GGCCATCGGCACCGTGTGGTGGCCCCACCCCGTGAACATCATGCC
 GCAACCTGCTGACCCAGATCGCGCTGCACCCGTGAACCT
 ATCGAGACGGTCCCCTGAAGCTGAAGCCGGGATGGACGGCC
 TCAAGCAGTGGCCCTGACCGAGGAGAGATCAAGGCC
 TGCACCGAGATGGAGAAGGAGGGCAAGATCAGCAAG
 ACCCCTACAACACCCCCGTGTTGCCATCAAGAACAG
 TGGCGCAAGCTGGACTTCCGCGAGCTGAACAAGCGCACCC
 CTGGGAGGTGAGCTGGCATCCCCACCCGCCGGCTGAAGAAC
 AGAGCGTGACCGTGCTGGACGTGGCGACGCC
 GACAAGGACTTCCGCAAGTACACCGCCTTC
 ACCATCCCCAGC
 CGAAC
 CGACCGCTACCA
 CGAGACCCCCGG
 CATCCGCTACCAGTACA
 AACGTGCTGCC
 CAGGGCTGGA

Figure 10
(Sheet 2 of 2)

AGGGCAGCCCCGCCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGCCC
TTCCGCAAGCAGAACCCCGACATCGTATCTACCAGGGCCCCCTGTACGT
GGGCAGCGACCTGGAGATCGGCCAGCACCGCACCAAGATCGAGGAGCTG
CGCCAGCACCTGCTGCCTGGGGCTTCACCACCCCGACAAGAACGACCA
GAAGGAGCCCCCTTCTGCCATCGAGCTGCACCCCGACAAGTGGACCG
TGCAGCCCATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATC
CAGAAGCTGGTGGCAAGCTGAACCTGGGCCAGCCAGATCTACGCCGGCAT
CAAGGTGAAGCAGCTGTGCAAGCTGCTGCCTGGGGCACCAAGGCCCTGACCG
AGGTGATCCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCGAGAACCG
CGAGATCCTGAAGGAGCCCGTGCACGAGGTGTACTACGACCCAGCAAGG
ACCTGGTGGCCGAGATCCAGAACGAGGCCAGGGCCAGTGGACCTACCA
GATCTACCAGGAGGCCCTCAAGAACCTGAAGAACGGCAAGTACGCCCGCA
TGCCTGGCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCA
GAAGGTGAGCACCGAGAGCATCGTATCTGGGGCAAGATCCCCAAGTTCA
AGCTGCCATCCAGAAGGAGACCTGGGAGGCCCTGGTGGATGGAGTACTGG
CAGGCCACCTGGATCCCCGAGTGGAGTTCGTGAACACCCCCCTGGT
GAAGCTGTGGTACCTGGAGAAGGAGGCCATCGTGGCGCCGAGACCT
TCTACGTGGACGGCGCCGCCAACCGCGAGACCAAGCTGGCAAGGCCGG
CTACGTGACCGACCGGGGCCAGAACGGTGGTGGAGCATGCCGACACC
ACCAACCAGAACGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAG
CGGCCTGGAGGTGAACATCGTGAACGCCAGTACGCCCTGGCATCA
TCCAGGCCAGCCGACAAGAGCGAGAGCGAGCTGGTGGAGCCAGATCAT
CGAGCAGCTGATCAAGAAGGAGAACGGTGTACCTGGCCCTGGTGGCCGCC
ACAAGGGCATGGCGCAACGAGCAGGTGGACAAGCTGGTGGAGCGCCGG
CATCCGCAAGGTGCTGTTCCCTGAACGGCATCGATGGCGGCATCGTATCT
ACCAAGTACATGGACGACCTGTACGTGGGAGCGGGGCCCTAGGATCGAT
TAAAAGCTTCCGGGGTAGCACCGGTGAATT

Figure 11
(Sheet 1 of 2)

GagPolmutIna.SF2 (Gag, RT mutated, Protease inactive; all in frame)

GTCGACGCCACCATGGGCGCCCGGCCAGCGTGTGAGCGGCCGGAGCT
 GGACAAGTGGGAGAAGATCCGCCTGCGCCCCGGCGCAAGAAGAAGTAC
 AAGCTGAAGCACATCGTGTGGGCCAGCCGCGAGCTGGAGCGCTTCGCCGT
 GAACCCCGGCCCTGCTGGAGACAGCGAGGGCTGCCGCCAGATCCGGCC
 AGCTGCAGCCCAGCCTGCAGACCGGCAGCGAGGAGCTGCGCAGCCTGTAC
 AACACCGTGGCCACCCTGTACTGCGTGCACCAGCGATCGACGTCAAGGA
 CACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCCAAG
 AAGAAGGCCAGCAGGCCGCCGCCGGCACCGGAAACAGCAGCC
 AGGTGAGCCAGAACTACCCCATCGTGCAGAACCTGCAGGGCCAGATGGT
 CACCAGGCCATCAGCCCCGCAACCTGAACGCCCTGGTGAAGGTGGTGG
 GGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCG
 AGGGGCCACCCCCCAGGACCTGAACACAGATGTTGAACACCGTGGCGGC
 CACCAGGCCCATGCAAGATGCTGAAGGAGACCATCAACGAGGAGGCC
 CCGAGTGGGACCGCGTGCACCCGTGCACGCCGCCCATGCCGCC
 CAGATGCGCAGCCCCCGGCAGCGACATGCCGGCACCAAGCACCT
 GCAGGAGCAGATGGCTGGATGACCAACAACCCCCCATCCCCGTGGCG
 AGATCTACAAGCGGTGGATCATCCTGGGCTGAACAAGATCGTGCAGGATG
 TACAGCCCCACCAGCATCCTGGACATCCGCCAGGGCCAAGGAGGCC
 CCGCGACTACGTGGACCGCTTCTACAAGACCTGCGCCTGAGCAGGCC
 GCCAGGACGTGAAGAACTGGATGACCGAGACCTGCTGGTGCAGAACGC
 CAACCCGACTGCAAGACCATCCTGAAGGCTCTGGCCCCGCCACCC
 TGGAGGAGATGATGACCGCTGCCAGGGCGTGGCGGCCACAA
 GGCCCGCTGCTGGCGAGGCGATGAGCCAGGTGACGAACCCGGGACCC
 ATCATGATGCAAGCGCAACTTCCGCAACCAGCGGAAGACCGTCAAGTG
 CTTCAACTGCGCAAGGAGGGCACACCGCCAGGAACCTGCCGCC
 GCAAGAAGGGCTGCTGGCGCTGCCAGGGCGAACAGACACAAATGAAAGA
 TTGCACTGAGAGACAGGCTAATTCTCCGCGAGGACCTGGCTTCTGCA
 GGGCAAGGCCCGAGTTCAGCAGCGAGCACCCGCCAACAGCCCC
 ACCCGCCGCGAGCTGCAGGTGTGGGCGCGAGAACACAGCCTGAGCG
 AGGCCGGCGCCGACCGCCAGGGCACCGTGAGCTCAACTCCCCAGATC
 ACCCTGTGGCAGCGCCCCCTGGTACCATCAGGATCGCGGCCAGCTCAA
 GGAGGCCTGCTGCCACCGCGCCAGCACCCGTGCTGGAGGAGATG
 AACCTGCCGGCAAGTGGAAAGCCAAGATGATCGCGGGATCGGGGCTT
 CATCAAGGTGCCAGTACGACCAAGATCCCCGTGGAGATCTGCCGCCACA
 AGGCCATCGGCACCGTGCTGGTGGGCCACCCCGTGAACATCATCGGC
 CGCAACCTGCTGACCCAGATCGGCTGCACCCGTAACTCCCCATGCC
 ATCGAGACGGTGGCCGTGAAGCTGAAGCCGGGATGGACGGCCCCAAGG
 TCAAGCAGTGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGGAGATC
 TGCACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGA
 ACCCCTACAACACCCCCGTGTCGCCATCAAGAAGAAGGACAGCACCAAG
 TGGCGCAAGCTGGTGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTT
 CTGGGAGGTGCAAGCTGGCATCCCCCACCCGCCGGCCTGAAGAAGAAGA
 AGAGCGTGAACCGTGCTGGACGTGGCGACGCCACTTCAGCGTCCC
 GACAAGGACTTCCGCAAGTACACCGCCTCACCATCCCCAGCATCAACAA
 CGAGACCCCGGCATCCGCTACCAAGTACAACGTGCTGCCAGGGCTGGA

Figure 11
(Sheet 2 of 2)

AGGGCAGCCCCGCCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGCCC
TTCCGCAAGCAGAACCCCGACATCGTGTACCTACCAGGCCCCCTGTACGT
GGGCAGCGACCTGGAGATCGGCCAGCACCGCACCAAGATCGAGGAGCTG
CGCCAGCAGCACCTGCTGCGCTGGGGCTTCACCACCCCCGACAAGAACACCA
GAAGGAGCCCCCTTCCTGCCATCGAGCTGCACCCGACAAGTGGACCG
TGCAGCCCATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATC
CAGAACGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATCTACGCCGGCAT
CAAGGTGAAGCAGCTGTGCAAGCTGCTGCGCGGACCAAGGCCCTGACCG
AGGTGATCCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCGAGAACCG
CGAGATCCTGAAGGAGCCCCTGCACGAGGTGACTACGACCCAGCAAGG
ACCTGGTGGCCGAGATCCAGAACGAGGGCCAGGGCCAGTGGACCTACCA
GATCTACCAGGAGGCCCTCAAGAACCTGAAGACCGGCAAGTACGCCCGCA
TGCAGGGCGCCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCA
GAAGGTGAGCACCGAGAGCATCGTGTACCTGGGCAAGATCCCCAAGTCA
AGCTGCCCATCCAGAACGGAGACCTGGGAGGCCCTGGTGGATGGAGTACTGG
CAGGCCACCTGGATCCCCGAGTGGAGTTCGTGAACACCCCCCCCCCTGGT
GAAGCTGTGGTACCAAGCTGGAGAACGGAGCCCATCGTGGCGCCGAGACCT
TCTACGTGGACGGCGCCGCAACCGCGAGACCAAGCTGGCAAGGCCGG
CTACGTGACCGACCGGGGCCGGCAGAACGGTGGTGGAGCATGCCGACACC
ACCAACCAGAACGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAG
CGGCCTGGAGGTGAACATCGTGACCGACAGCCAGTACGCCCTGGGCATCA
TCCAGGCCAGCCGACAAGAGCGAGAGCGAGCTGGTGGAGCCAGATCAT
CGAGCAGCTGATCAAGAACGGAGAACGGTGTACCTGGCCCTGGGTGCCCGCC
ACAAGGGCATGGCGGCAACGAGCAGGTGGACAAGCTGGTGGAGCGCCGG
CATCCGCAAGGTGCTGTTCTGAACGGCATCGATGGGGCATCGTGTACCT
ACCAAGTACATGGACGACCTGTACGTGGGAGCGGGCGGCCCTAGGATCGAT
TAAAAGCTTCCCAGGGCTAGCACCGGTGAATT

Figure 12
(Sheet 1 of 2)

GagProtInaRTmut.SF2 (Gag, Protease inactive, RT mutated; all in frame fusion protein)

GCCACCATGGCGCCCGCCAGCGTGCTGAGCGGCGGCGAGCTGGACA
 AGTGGGAGAAGATCCGCCTGCGCCCCGGCGCAAGAAGAAGTACAAGCT
 GAAGCACATCGTGTGGCCAGCCGGAGCTGGAGCGCTTGGCGTGAAGC
 CCGGCCTGCTGGAGACCAGCGAGGGCTGCCGCCAGATCCTGGGCCAGCTG
 CAGCCCAGCCTGCAGACCGGCAGCGAGGAGCTGCGCAGCCTGTACAACAC
 CGTGGCCACCCCTGTACTGCGTGCACCAGCGCATCGACGTCAAGGACACCA
 AGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCCAAGAAGAA
 GGCCCAGCAGGCCGCGCCGCCGGCACCGCAACAGCAGCCAGGTG
 AGCCAGAACTACCCCATCGTGCAGAACCTGCAGGGCCAGATGGTGCACCA
 GGCCATCAGCCCCCGCACCTGAACGCCCTGGTGAAGGTGGTGGAGGAGA
 AGGCCTTCAGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCGAGGGC
 GCCACCCCCCAGGACCTGAACACGATGTTAACACCGTGGCGGCCACCA
 GGCGCCATGCAGATGCTGAAGGAGACCATCAACGAGGAGGCCGCGAG
 TGGGACCGCGTGCACCCGTGCACGCCGGCCCATGCCCGGGCCAGAT
 GCGCGAGCCCCCGGGCAGCGACATGCCGGCACCACCGACCCCTGCAGG
 AGCAGATCGGCTGGATGACCAACAACCCCCCATCCCCGTGGCGAGATC
 TACAAGCGGTGGATCATCCTGGCCTGAACAAGATCGTGCAGGATGTACAG
 CCCCACCAGCATCCTGGACATCCGCCAGGGCCCCAAGGAGGCCCTCCGCG
 ACTACGTGGACCGCTTCTACAAGACCCCTGCGCGCTGAGCAGGCCAGCCAG
 GACGTGAAGAACTGGATGACCGAGACCCCTGCTGGTGCAGAACGCCAACCC
 CGACTGCAAGACCATCCTGAAGGCTCTCGGCCGGCCACCGTGGAGG
 AGATGATGACCGCCTGCCAGGGCGTGGCGGGCCCCGCCACAAGGCCGC
 GTGCTGGCGAGGCAGATGAGCCAGGTGACGAACCGCGACCATCATGAT
 GCAGCGCGCAACTCCGCAACCAGCGGAAGACCGTCAAGTGCCTCAACT
 GCGGCAAGGAGGGCCACACCGCCAGGAACCTGCCGCCGGCCACCGTGGAGG
 GGGCTGCTGGCGCTGCCGGCGAGGGCCACAGATGAAGGACTGCACC
 GAGGCCAGGCCACTTCCTGGCAAGATCTGGCCCAGCTACAAGGCCCG
 CCCCAGCAACTTCCTGCAGAGGCCCCCCGAGGCCACCGCCCCCGAGG
 AGAGCTTCCGCTTCGGCGAGGAGAAGACCAACCCAGCCAGAACAGGAGA
 GCCCATCGACAAGGAGCTGTACCCCTGACCGCCTGCGCAGCCTGTTCG
 GCAACGACCCAGCAGCCAGAAAGAATTCCCCAGATCACCCCTGTCAG
 CGCCCCCTGGTGCACCATCAGGATCGGCCGCCAGCTCAAGGAGGCCGCTGCT
 CGCCACCGGCCGACGACACCGTGTGGAGGAGATGAACCTGCCGGCA
 AGTGGAAAGCCAAGATGATCGCGGGATCGGGGCTTCATCAAGGTGCG
 GCAGTACGACCAAGATCCCCGTGGAGATCTGCCGCCACAAGGCCATCGCA
 CCGTGTGGTGGCCCCACCCCGTGAACATCATGCCGCCAACCTGCTG
 ACCCAGATCGGCTGCACCCCTGAACCTCCCCATCAGCCCCATCGAGACGGT
 GCCCGTGAAGCTGAAGGCCGGATGGACGCCAACAGTCAAGCAGTGG
 CCCCTGACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGCACCGAGAT
 GGAGAAGGAGGGCAAGATCAGCAAGATCGGCCGCCAGAACCCCTACAAC
 ACCCCCGTGTTCGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCT
 GGTGGACTTCGCGAGCTGAACAAAGCGCACCCAGGACTTCTGGAGGTGC
 AGCTGGCATCCCCACCCCGCCGGCTGAAGAAGAAGAAGAGCGTGAC
 CGTGTGGACGTGGCGACGCCACTTCAGCGTGCCTGGACAAGGACT

Figure 12
(Sheet 2 of 2)

TCCGCAAGTACACCGCCTCACCATCCCCAGCATCAACAACGAGACCCCC
GGCATCCGCTACCAGTACAACGTGCTGCCCAAGGGCTGGAAGGGCAGCCC
CGCCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGCCCTCCGCAAGC
AGAACCCCCGACATCGTATCTACCAGGCCCCCTGTACGTGGCAGCGAC
CTGGAGATCGGCCAGCACCACCAAGATCGAGGAGCTGCGCCAGCACCT
GCTGCGCTGGGGCTTCACCACCCCCGACAAGAACGACCAAGAACGGAGCCC
CCTTCCTGCCCATCGAGCTGCACCCGACAAGTGGACCGTGCAGCCCATC
ATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGT
GGGCAAGCTGAACCTGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAG
CAGCTGTGCAAGCTGCTGCGGGCACCAAGGCCCTGACCGAGGTGATCCC
CCTGACCGAGGAGGCCAGCTGGAGCTGGAGCTGGCCGAGAACCGCGAGATCCTG
AAGGAGCCCCTGCACGAGGTGTACTACGACCCAGCAAGGACCTGGTGGC
CGAGATCCAGAACGAGGGCCAGGGCAGTGGACCTACCAGATCTACCAG
GAGCCCTCAAGAACCTGAAGACCGGCAAGTACGCCCGATGCGCGGCCGC
CCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAACGGTGAGC
ACCGAGAGCATCGTATCTGGGGCAAGATCCCCAAGTTCAAGCTGCCCAT
CCAGAAGGAGACCTGGGAGGCCCTGGTGGATGGAGTACTGGCAGGCCACC
TGGATCCCCGAGTGGAGTTCGTGAACACCCCCCCCCTGGTGAAGCTGTG
GTACCAAGCTGGAGAACGGAGCCCATCGTGGCCCGAGACCTTCTACGTGG
ACGGCGCCGCCAACCGCGAGACCAAGCTGGCAAGGCCGGTACGTGAC
CGACCGGGGCCGGCAGAACGGTGAGCATGCCGACACCACCAACCAG
AAGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGA
GGTGAACATCGTGAACGCCAGTACGCCCTGGGATCATCCAGGCC
AGCCCGACAAGAGCGAGAGCGAGCTGGTGAAGCCAGATCATCGAGCAGCT
GATCAAGAACGGAGAACGGTGTACCTGGCCTGGTGGCCCAACAAGGGC
ATCGGCGGCAACGAGCAGGTGGACAAGCTGGTGAAGCGCCGGCATCCGCA
AGGTGCTCTAAATCTAGA

Figure 13
(Sheet 1 of 2)

GagProtInaRTmutTatRevNef.opt_B

```

GCCACCATGGCGCCGCCAGCGTGTGAGCGGGCGAGCTGGACAAGTGGAGAAGATCCGCCTG
CGCCCCGGCGCAAGAAGAAGTACAAGCTGAAGCACATCGTGTGGCCAGCCCGAGCTGGAGCGCTTC
GCCGTGAACCCCGGCCCTGCTGGAGACAGCGAGGGCTGCCAGATCCTGGGCCAGCTGCAGCCCAGC
CTGCAGACCGCAGCGAGGAGCTGCCAGCCTGTACAACACCGTGGCCACCTGTACTGCCGTGACCCAG
CGCATCGACGTCAAGGACACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAACTCAAGAAG
AAGGCCAGCAGGCCGCCGCCGGCACGGCAACAGCAGCCAGGTGAGCCAGAACTACCCCATC
GTGCAGAACCTGCAGGCCAGATGGTGCACCAGGCCATAGCCCCCGCACCTGAACGCCCTGGGTGAAG
GTGGTGGAGGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTAGGCCCTGAGCGAGGGGCCACC
CCCCAGGACCTGAAACACGATGTTGAAACACCGTGGCGGCCACCAAGGCCCATGAGATGCTGAAGGAG
ACCATCAACGAGGAGGCCCGAGTGGGACCGCGTGCACCCCGTGCAGGCCGCCCATGCCCGGCC
CAGATGCGCAGGCCCGCAGCGACATCGCCCGACCACCGACCCCTGAGGAGCAGATCGCTGG
ATGACCAACAACCCCCCATCCCCGTGGCGAGATCTACAAGCGGTGGATCATCTGGGCTGAACAAG
ATCGTGCAGGATGTCAGCCCCACCGACATCCGTGGACATCCCCCAGGGCCCAAGGAGCCCCCTCCGCGAC
TACGTGGACCGCTTCTACAAGACCTGCGCCTGAGCAGGCCAGGACGTGAAGAACTGGATGACC
GAGACCTGCTGGTGCAGAACGCCAACCCGACTGCAAGACCATCTGAAGGCTCTGGGCCGGCC
ACCTGGAGGAGATGATGACCGCCCTGCCAGGGCGTGGCGGCCACAAGGCCCGGTGCTGGCC
GAGCGATGAGCCAGGTGACGAACCCGGCACCACATGATGCCAGGCCAACTTCCGCAACCCAGCGG
AAGACCGTCAAGTGTTCACTGCGGAAGGAGGCCACACCGCCAGGAACCTGCCGCCCCCGCAAG
AAGGGCTGCTGGCGCTGCGCCCGAGGGCCACCCAGATGAAGGACTGACCCGAGGCCAGCTCAAGGAGGCG
CTGGCAAGATCTGGCCAGCTACAAGGCCGCCCGCAACTTCTGAGGCCGCCCCGAGCCACC
GCCCGGCCAGGGAGAGCTCCGCTGGCGAGGAGAACGCCACCCCGAGCCAGAACGCCAGGAGCCATC
GACAAGGAGCTGTACCCCTGACCAGCCTGCGCAGCCTGTTGGCAACGACCCAGCAGCCAGAAAGAA
TTCCCCCAGATCACCCGTGGCAGCGCCCGTGGTACCATCAGGATCGGCCAGCTCAAGGAGGCG
CTGCTGCCACCGCGCCGACACCGTGTGGAGGAGATGAACCTGCCCGCAAGTGGAGGCCAG
ATGATCGCGGGATCGGGGCTTCATCAAGGTGCGCAGTACGACCAGATCCCCGTGGAGATCTGCGC
CACAAGGCCATCGGCACCGTGTGGGCCACCCCGTGAACATCATGGCCGCAACCTGCTGACC
CAGATCGGCTGACCCCTGAACCTCCCATCAGCCCCATCGAGACGGTGGCCGTGAAGCTGAAGGCCGGG
ATGGACGGCCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAACATCAAGGCCCTGGTGGAGATCTG
ACCGAGAGATGGAGAAGGAGGCCAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCGTGTTC
GCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGACTTCCGCGAGCTGAACAAGCGCACC
CAGGAATTCTGGGAGGTGCAAGCTGGGATCCCCCACCCCGCCGCTGAAGAAGAAGAGCGTGCACC
GTGCTGGACGTGGCGACGCCACTTCAGCGTGGCCCTGGACAAGGACTTCCGCAAGTACACCGCCTTC
ACCATCCCCAGCATCAACAAGGAGACCCCGGATCCGCTACCAAGTACACGTGCTGCCAGGGCTGG
AAGGGCAGCCCCGCGATCTCCAGAGCAGCATGACCAAGATCTGGAGCCCTCCGCAAGCAGAACCCC
GACATCGTGTACCAAGGCCCGTGTACGTTGGCAGCGACCTGGAGATGGCCAGCCAGCGACCAAG
ATCGAGGAGCTGCCAGCACCTGCGCTGGGCTTCACCAACCCCGACAAGAACGCCAGAGGAG
CCCCCTCCTGCCATCGAGCTGCACCCCGACAAGTGGACCGTGCAGGCCATCATGCTGCCAGGGCTGG
GACAGCTGGACCGTGAACGACATCCAGAAGCTGGTGGCAAGCTGAACCTGGGAGCCAGATCTACGCC
GGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCCGACCAAGGCCCTGACCGAGGTGATCCCCCTG
ACCGAGGAGGCCAGCTGGAGCTGGCGAGAACCCCGAGATCTGAAGGAGGCCGTGCACGAGGTGTAC
TACGACCCAGCAAGGACCTGGTGGCCAGATCCAGAAGCAGGCCAGGGCCAGTGGACCTACCAAGATC
TACCAAGGAGGCCCTTCAGAAGACCTGAAGGAGACATCCAGAAGCTGGTGGCAAGCTGGGAGGCC
GTGAAGCAGCTGACCGAGGGCGTGCAGAAGGTGAGGACCGAGAGCATCGTGTACGGGAGATCCCC
AAGTCAAGCTGCCCATCCAGAAGGAGACCTGGGAGGCCCTGGTGGAGTACTGGCAGGCCACCTGG
ATCCCCGAGTGGGAGTTGTGAACACCCCCCCCCTGGTGAAGCTGTGGTACCATGCTGGAGAAGGCC
ATCGTGGGCGCCAGACCTCTACGTGGACGGCGCCAAACCGCGAGGACCAAGCTGGCAAGGCCGGC
TACGTGACCGACCGGGCGCAGAAGGTGGTGAACGATCGCCGACACCACCAAGGAGGCCAGCTG
CAGGCCATCCACCTGCCCTGACCGACAGCGGCCCTGGAGGTGAACATCGTACCGACAGCCAGTACGCC
CTGGGCATCATCCAGGCCAGGCCGACAAGAGCGAGAGCGAGCTGGTGGCAAGATCATGAGCAGCTG
ATCAAGAAGGAGAAGGTGACCTGGCTGGGTGCCAGAAGGTGCTCAAGCTGAGGCCCTGGAGGCC
GACAAGCTGGTGAACGCGCCGACCCGAGGCCAGGAGGCCACCAACTGCTACTGCAAGAAGTGTGCTG
TGGAAGCACCCCGCAGCCAGGCCAAGACCAGGCCACCAACTGCTACTGCAAGAAGTGTGCTG
TGCCAGGTGAGCTTCATCAGCTACGCCAGGCCAGGAGGTGACGCCAGGCCAGGCCAGGCCAGGGC
CGGCCACCCCGACAGCGAGGTGACCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGCCAGGGC

```

Figure 13
(Sheet 2 of 2)

GACCCCACCGGCCCAAGGAGAGCAAGAAGAAGGTGGAGCGCGAGACCGAGACCGACCCCGTGCACCCC
GGGGCCGGCCGCAGCGGCACAGCGACAGCAGGAGCTGCTGCAGACCGTGCCTTCATCAAGTCCCTGTAC
CAGAGCAACCCCCCTGCCAGCCCCAAGGGCACCCGCCAGGGCAGCTGAACCGCCGCCGCTGGCGC
GAGGCCAGGCCAGATCCAGAGCATCAGGCCCTGGATCATCAGCACCCACCTGGGCCAGCACCGAG
CCCGTGCCTCTGCAGCTGCCCGACCTGCGCTGAACCTGGACTGCAGCAGGACTGCAGGCCACCAGC
GGCACCCAGGGCGTGGGAGCCCCCAGGTGCTGGCGAGAGCCCCCGCGTGGACAGCGGCCACCAAG
GAGCTCGAGGCCGGCAAGTGGAGCAAGCGCATGAGCGGCTGGAGCGCCGTGCGAGCGCATGAAGCGC
GCCGAGCCCCGCCAGCCCCGCCGACGGCGTGGCGCCGTGAGCCCGACCTGGAGAAGCACGGCGCC
ATCACCAAGCAGAACACCGCCGCCAACAACGCCGACTGCCCTGGCTGGAGGCCAGGAGGACGAGGAC
GTGGCTTCCCCGTGCGCCCCCAGGTGCCCTGCGCCCCATGACCTACAAGGCCGCCCTGGACCTGAGC
CACTCCCTGAAGGAGAACGGCGGCCCTGGAGGGCTGTATCTACAGCCAGAACGCCAGGACATCCGAC
CTGTGGATCCACCAACACCCAGGGCTACTTCCCCGCTGGCAGAACTACACCCCCGGCCGCATCCGC
TACCCCCCTGACCTTCGGCTGGTGCTTCAGCTGGTCCCCGTGGACCCCCGACTACGTGGAGGAGGCCAAC
GCCGGCGAGAACAAACAGCCTGCTGCACCCCATGAGCCAGCACGGCATGGACGACCCGAGAACGGAGGTG
CTGGTGTGGCGCTTCGACAGCCGCTGGCTTCACCACATGGCCCGAGCTGCACCCGAGTACTAC
AAGGACTGCTAA

Figure 14
(Sheet 1 of 2)

GagRTmut.SF2 (Gag, RT mutated; all in frame fusion protein)

GTCGACGCCACCATGGCGCCCGGCCAGCGTGTGAGCGGCCGGGAGCT
 GGACAAGTGGGAGAAGATCCGCCTGCGCCCCGGCGCAAGAAGAAGTAC
 AAGCTGAAGCACATCGTGTGGGCCAGCCGCGAGCTGGAGCGCTTCGCCGT
 GAACCCCGCCTGCTGGAGACCAGCGAGGGCTGCCGCCAGATCCTGGGEE
 AGCTGCAGCCCAGCCTGCAGACCAGCGAGCTGGAGCGCAGCCTGTAC
 AACACCGTGGCCACCCCTGTACTCGCTGCACCAGCGCATCGACGTCAAGGA
 CACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAGTCCAAG
 AAGAAGGCCAGCAGGCCGCCGCCGCCGCCAGGGCAACAGCAGCC
 AGGTGAGCCAGAACTACCCCATCGTGCAGAACCTGCAGGGCAGATGGT
 CACCAGGCCATCAGCCCCGCAACCGCTGGGTGAAGGTGGTGG
 GGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTCAGGCCCTGAGCG
 AGGGGCCACCCCGAGGACCTGAACACGATGTTGAACACCGTGGGCC
 CACCAGGCCGATGCAGATGCTGAAGGAGACCATCAACGAGGAGGCC
 CCGAGTGGGACCGCGTGCACCCGTGCAGGCCGCCATGCCGCC
 CAGATCGCGAGCCCCCGGCAGCGACATGCCGGCACCAAGCACCCT
 GCAGGAGCAGATCGGCTGGATGACCAACAACCCCCCATCCCCGTGGCG
 AGATCTACAAGCGGTGGATCATCCTGGCCTGAACAAGATCGTGCAG
 TACAGCCCCACCAAGCATTGGACATCCGCCAGGGCCCAAGGAGGCC
 CCGCGACTACGTGGACCGCTTACAAGACCCCTGCAGCTGAGCAGGCC
 GCCAGGACGTGAAGAACTGGATGACCGAGACCCCTGCTGGTGCAG
 CAACCCGACTGCAAGACCATCCTGAAGGCTCTGGGCCGCCACCC
 TGGAGGAGATGATGACCGCTGCCAGGGCTGGCGGGCCACAA
 GGCGCGTGCCTGGCGAGGCGATGAGCCAGGTGACGAACCCGGGAC
 ATCATGATGCAGCGCGCAACTCCGCAACCAGCGGAAGACCGTCAAG
 CTTCAACTGCAGGCAAGGAGGGCACACCGCCAGGAACGCCGCC
 GCAAGAAGGGCTGCTGGCGTGCAGGCCAGGGCACCAAGATGAAG
 CTGCACCGAGGCCAGGCCAACTTCCCTGGCAAGATCTGGCCAGCT
 AGGGCCGCCCGCAACTTCCCTGCAGAGCCGCCAGGCCACCGCC
 CCCGAGGAGAGCTTCCGCTTCCGGAGGAGAACGCCACCCAGCC
 AGCAGGAGCCATCGACAAGGAGCTGTACCCCTGACCAAGCCTG
 CTGTTCCGCAACGACCCAGCAGCCAGAAAGAATTCCCCAT
 CGAGACGGTGGCCGTGAAGCTGAAGCCGGGATGGACGGCCCAAG
 AAGCAGTGGCCCTGACCGAGGAGAACATCAAGGCCCTGGAG
 GCACCGAGATGGAGAACGGAGGGCAAGATCAGCAAGATCG
 CCCCTACAACACCCCGTGTTCGCCATCAAGAAGAACGG
 AGCAGGCCAGCTGGACTTCCCGAGCTGAACAAGCGCACCC
 AGGACTTC
 TGGGAGGTGAGCTGGCATCCCCCACCCGCCGGCCTGAAGAAC
 AGAGCGTGACCGTGCTGGACGTGGCGACGCCACTTCAGCG
 GACAAAGGACTTCCGCAAGTACACCGCCTTCACCAT
 CCCAGCATCAACAA
 CGAGACCCCGGCATCCGCTACCAAGTACAACGTG
 CTGCCAGGGCTGGAG
 AGGGCAGCCCCGCCATTTCCAGAGCAGCAT
 GACCAAGAAC
 ATCCTGGAGGCC
 TTCCGCAAGCAGAACCCGACATCGT
 GATCTACCAAGGCC
 CCCAGCGACCTGGAGATCGGCCAGC
 ACCGCACCAAG
 ATCGAGGAGCTG
 CGCCAGC
 ACCCTGCTGCC
 GCTGGGCTTCA
 ACCACCCCGACAAGAAC
 GACCAAG
 GAGCCCCCTT
 CCTGCC
 CATCGAGCTG
 CACCCGACAAGTGGACCG

Figure 14
(Sheet 2 of 2)

TGCAGCCCATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATC
CAGAAGCTGGTGGCAAGCTGAACCTGGGCCAGCCAGATCTACGCCGGCAT
CAAGGTGAAGCAGCTGTGCAAGCTGCTGCGCGGACCAAGGCCCTGACCG
AGGTGATCCCCCTGAACCGAGGAGGCCGAGCTGGAGCTGGCCGAGAACCG
CGAGATCCTGAAGGAGCCC GTGCACGAGGTGTACTACGACCCCAGCAAGG
ACCTGGTGGCCGAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTACCA
GATCTACCAGGAGGCCCTCAAGAACCTGAAGACCGGCAAGTACGCCCGCA
TGC CGGGCGCCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCA
GAAGGTGAGCACCGAGAGCATCGTGAATCTGGGGCAAGATCCCCAAGTTCA
AGCTGCCCATCCAGAAGGAGACCTGGGAGGCCCTGGTGGATGGAGTACTGG
CAGGCCACCTGGATCCCCGAGTGGGAGTTCGTGAACACCCCCCCCCTGGT
GAAGCTGTGGTACCAAGCTGGAGAAGGAGCCATCGTGGCGCCGAGACCT
TCTACGTGGACGGCGCCCAACCGCGAGACCAAGCTGGCAAGGCCGG
CTACGTGACCGACCGGGGCCGGCAGAAGGTGGT GAGCATGCCGACACC
ACCAACCAAGACCGAGCTGCAGGCCATCCACCTGCCCTGCAGGACAG
CGGCCCTGGAGGTGAACATCGT GACCGACAGCAGTACGCCCTGGCATCA
TCCAGGCCAGCCCACAAGAGCGAGAGCGAGCTGGT GAGCCAGATCAT
CGAGCAGCTGATCAAGAAGGAGAAGGTGTACCTGGCCTGGGTGCCGCC
ACAAGGGCATCGCGGCAACGAGCAGGTGGACAAGCTGGT GAGCGCCGG
CATCCGCAAGGTGCTAAATCTAGA

Figure 15
(Sheet 1 of 1)

GagTatRevNef.opt_B

GCCACCATGGCGCCGCCAGCGTGTGAGCGGGCGAGCTGGACAAGTGGAGAAGATCCGCCTG
 CGCCCGGCGCAAGAAGAAGTACAAGCTGAAGCACATCGTGTGGGCCAGCCGCGAGCTGGAGCGCTTC
 GCCGTGAACCCCGGCTGCTGGAGACCAGCGAGGGCTGCCGCCAGATCCTGGGCCAGCTGCAGCCCAGC
 CTGCAGACCGCAGCGAGGAGCTGCCAGCCTGTACAACACCGTGGCCACCTGTACTGCGTGCACCAG
 CGCATCGACGTCAGGACACCAAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAGTCAAGAAG
 AAGGCCAGCAGGCCGCCGCCGCCGGCACCGCAACAGCAGCCAGGTGAGCCAGAACACTACCCCATC
 GTGCAGAACCTGCAGGCCAGATGGTGCACCAGGCCATCAGCCCCCGCACCTGTACGCCTGGGTGAAG
 GTGGTGGAGGAGAAGGCCCTCAGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCGAGGGGCCACC
 CCCAGGACCTGAACACGATGTTGAAACACCGTGGCGGCCACCAGGCCCATGCAGATGCTGAAGGAG
 ACCATCAACGAGGAGGCCCGAGTGGGACCGCGTGCACCCGTGCACGCCGCCCATGCCCGGCC
 CAGATGCGCGAGCCCCCGGGCAGCAGCACATGCCGCCACCAGCACCCGTGCAGGAGCAGATCGGCTGG
 ATGACCAACAACCCCCCATCCCCGTGGCGAGATCTACAAGCGGTGGATCATCTGGCTGAACAAG
 ATCGTGCAGGATGTCAGCCCCACCAGCATCCTGGACATCCGCCAGGGCCCAAGGAGGCCCTCCGCCAC
 TACGTGGACCGCTTCTACAAGACCTGCAGCTGAGCAGGGCAGCCAGGACGTGAAGAACTGGATGACC
 GAGACCTGCTGGTGCAGAACGCCAACCCGACTGCAAGAACCATCTGAAGGCTCTGGGCCCGGCC
 ACCCTGGAGGAGATGATGACCGCCTGCCAGGGCGTGGGCCACAAGGCCCGGTGCTGGCC
 GAGCCGATGAGCCAGGTGACGAACCCGGCAGCATCATGATGCAAGGCCGCAACTTCCGAAACCAGCG
 AAGACCGTCAAGTGTTCACAGCGCAAGGAGGGCACACCGCCAGGAACCTGCCGCCCCCGCAAG
 AAGGGCTGCTGGCCTGCCGGCGAGGGCCACAGATGAAGGACTGCAACGCCAGGCAACTTC
 CTGGCAAGATCTGGCCAGCTACAAGGGCCCGGCCACTTCTGCAGAGGCCGCCCCGAGCCCACC
 GCCCCCCCCGAGGAGAGCTCCGCTTCCGGAGAGAACACCAGCCAGAAGCAGGAGGCCATC
 GACAAGGAGCTGTACCCCTGACCAAGCCTGCCAGCGCAGCCAGCTGTTGGCAACGACCCAGCAGCCAGGAATTC
 GAGCCCGTGGACCCCGCCTGGAGGCCCTGGAAGCACCCCGGCAGCCAGGCCAACGCCGCCACCAAC
 TGCTACTGCAAGAAGTGTCTTCACTGCCAGGTGAGCTTCATCAGGACGGCTGGCATCAGCTAC
 GGCCGCAAGAAGGCCGCCAGGCCAGGGAGACCCACCGGCCAACAGCGAGGTGCAACAGGCTGAGCC
 AAGCAGCCGCCAGCCAGGGAGACCCACCGGCCAACAGGCCAACAGCGAGGAGCAAGAAGAAGGTTGAGCG
 GAGACCGAGACCCGACCCGTGCACCCGGGGCCGCCAGCGGCCACAGCGACGAGGAGCTGCTGCAG
 ACCGTGCGTTCATCAAGTTCTGTACCAAGAGCAACCCCTGCCAGGCCAACGCCAGGCC
 GACCTGAACCGCCGCCGCGAGCGCAGCGCCAGATCCAGAGCATCAGGCCCTGGATCATC
 AGCACCCACCTGGGCCAGCACCGAGCCCGTGGCCCTGCACTGCCGCCCCGACCTGCCCTGAACCTG
 GACTGCAAGGACTGCCAGCAGGCCACCCAGGGCGTGGCAGCCAGGTGCTGGCGAGAGC
 CCCGGCGTGTGGACAGCGGCCACCAAGGAGCTCGAGGCCGCCAGTGGAGCAAGCGCATGAGCGCTGG
 AGCGCCGTGCGAGCGCATGAAGCGCCGCCAGGCCAGATCCAGAGCATCAGGCCCTGGATCATC
 AGCCGCGACCTGGAGAAGCACGGCGCATCACCAGCAGCACACCGCCGCCAACACGCCGACTGCC
 TGGCTGGAGGCCAGGAGGACGAGGACGTGGCTCCCGTGCAGCCAGGTGCTGGCGAGAGC
 ACCTACAAGGCCGCCCTGGACCTGAGCCACTTCTGAAGGAGAAGGGCGGCCCTGGAGGGCTGATCTAC
 AGCCAGAACGCCAGGACATCCTGGACCTGTGGATCCACCAACCCAGGGCTACTTCCCGGCTGGCAG
 AACTACACCCCCGGCCCCGGCATCCGCTACCCCTGACCTTGGCTGGCTTCAAGCTGGTGCCCGTG
 GACCCGACTACGTGGAGGAGGCCAACGCCGGCAGAACACAGCCTGCTGCACCCCATGAGCCAGCAC
 GGCATGGACGACCCGAGAAGGAGGTGCTGGTGGCGCTTCGACAGCCGCCCTGGCTTCCACCATG
 GCCCGCAGCTGCACCCGAGTACTACAAGGACTGCTAA

Figure 16
(Sheet 1 of 1)

gp140.modSF162.CwtLmod

```

1 atgcgcgtga tgggcaccca gaagaactgc cagcagtggt ggatctgggg catcctggc
61 ttctggatgc ttagatctg cagcgcgtg gagaagctgt gggtgaccgt gtactacggc
121 gtgcccgtgt ggaaggaggc caccaccacc ctgttctgcg ccagcgacgc caaggcctac
181 gacaccgagg tgcacaacgt gtggggccacc cacgcgtgcg tggccaccga ccccaacccc
241 caggagatcg tgctggagaa cgtgaccgag aacttcaaca tggtaagaa caacatggtg
301 gagcagatgc acgaggacat catcagcctg tgggaccaga gcctgaagcc ctgcgtgaag
361 ctgacccccc tgcgtgtac cctgcactgc accaacctga agaacgcac caacaccaag
421 agcagcaact ggaaggagat ggaccgcggc gagatcaaga actgcagctt caaggtgacc
481 accagcatcc gcaacaagat gcagaaggag tacgcctgt tctacaagct ggacgtggtg
541 cccatcgaca acgacaacac cagctacaag ctgatcaact gcaacaccag cgtgatcacc
601 caggcctgco ccaaggttag cttcgagccc atccccatcc actactgcgc ccccgccggc
661 ttgcctatcc tgaagtgc aa cgcacaagaag ttcaacggca gggccctgt caccaacgtg
721 agcaccgtgc agtgcaccca cggcattccgc cccgtggta gcaaccagct gctgctgaac
781 ggcagcctgg ccgaggaggg cgtggtagtc cgcagcgaga acttccacca caacgcctaag
841 accatcatcg tgcagctgaa ggagagcgtg gagatcaact gcaaccgcggc caacaacaac
901 acccgcaaga gcatcaccat cggcccccggc cggcccttct acggccacgg cgacatcatc
961 ggcgacatcc gccaggccca ctgcaacatc agcggcgaga agtggaaacaa caccctgaag
1021 cagatcgta ccaagctgca gcccagttc ggcaacaaga ccatcggtt caagcagagc
1081 agcggcggcg accccagat cgtgatgcac agcttcaact gccggcggcga gttcttctac
1141 tgcacagca cccagctgtt caacagcacc tggaaacaaca ccatcgccca caacaacacc
1201 aacggcacca tcacccctgcc ctgcccgcatt aagcagatca tcaaccgctg gcaggagggt
1261 ggcacaggcca tgcgtgtcc cccatccgc ggcagatcc gtcgcagcag caacatcacc
1321 ggctctgtc tgaccccgca cggcggcaag gagatcagca acaccaccga gatctccgc
1381 cccggcggcg ggcacatgcg cgacaaactgg cgacgcgagc tgcacaaagta caaggtggtg
1441 aagatcgagc ccctggcggt gggcccccacc aaggccaaagc gccgcgtggt gcagcgcgag
1501 aagcgcgcgc tgacccctggg cccatgttc ctgggcttcc tgggcgcgcgc cggcagcacc
1561 atgggcgcacc gcaagctgac cctgaccgtg caggcccgcc agctgctgag cggcatcg
1621 cagcagcaga acaacctgct ggcgcgcatt gaggcccagc agcacctgct gcagctgacc
1681 gtgtgggca tcaagcagct gcaggccgcgt gtgcgtgcgc tggagcgtta cctgaaggac
1741 cagcagctgc tggcgtctgc gggctgcagc ggcaagctga tctgcaccac cggcgtccccc
1801 tggaaacgcaca gctggagcaa caagacccgtg gaccagatct ggaacaacat gacctggatg
1861 gagtgggagc gcgagatcga caactacacc aacctgatct acaccctgat cgaggagagc
1921 cagaaccagc aggagaagaa cgacgcaggag ctgcgtggcgt gggacaagtg ggccagcctg
1981 tggaaactgtt tcgacatcag caagtggctg tggtaatct aactcgag

```

Figure 17
(Sheet 1 of 1)

gp140.modSF162.CwtLnat

1 atgagagtga tggggacaca gaagaattgt caacaatggt ggatatgggg catcttaggc
 61 ttctggatgc taatgatttg tagcccggt gagaagctgt gggtaccgt gtactacggc
 121 gtccccgtgt ggaaggaggc caccaccacc ctgttctgcg ccacgcacgc caaggctac
 181 gacaccgagg tgcacaacgt gtggccacc caccgcgtcg tgccaccga ccccaacccc
 241 caggagatcg tgctggagaa cgtgaccgag aacttcaaca tggaaagaa caacatggtg
 301 gaggagatgc acgaggacat catcagcctg tggaccaga gcctgaagcc ctgcgtgaag
 361 ctgacccccc tgcgtgac cctgcactgc accaacctga agaacgccac caacaccaag
 421 agcagcaact ggaaggagat ggaccgcggc gagatcaaga actgcagctt caaggtgacc
 481 accagcatcc gcaacaagat gcagaaggag tacgcctgt tctacaagct ggacgtggtg
 541 cccatcgaca acgacaacac cagctacaag ctgatcaact gcaacaccag cgtgatcacc
 601 caggcctgcc ccaagggtgag ctgcgtgac atcccccattc actactgcgc cccgcggc
 661 ttgcctatcc tgaagtgcaa cgacaagaag ttcaacggca gcccggctg caccacgtg
 721 agcaccgtgc agtgcaccca cggcattccgc cccgtggta gcacccagct gtcgtgaac
 781 ggcagcctgg ccgaggaggg cgtgggtgatc cgcagcggaa acttcaccga caacgc当地
 841 accatcatcg tgcagctgaa ggagagcgtg gagatcaact gcacccggcc caacaacaac
 901 acccgcaaga gcatcaccat cggccggc cgcgccttct acgccaccgg cgacatcatc
 961 ggcgacatcc gccaggccca ctgcaacatc agcggcgaga agtggaaacaa caccctgaag
 1021 cagatcgta ccaagctgca ggcccagtgc ggcaacaaga ccatcggtt caagcagagc
 1081 agccggccgc acccccgagat cgtgatgcac agcttcaact gggccggcga gttcttctac
 1141 tgcaacagca cccagctttt caacagcacc tggaaacaaca ccatcgccc caacaacacc
 1201 aacggcacca tcaccctgccc ctggcgcatc aagcagatca tcaaccgctg gcaggaggtg
 1261 ggcaggccca tgcacccccc cccatccgc ggccagatcc gtcgcagcag caacatcacc
 1321 ggcctgctgc tgaccccgca cggccggcaag gagatcagca acaccaccga gatctccgc
 1381 cccggccggc ggcacatcg cgcacactgg cgcagcggc tgcataagta caaggtggtg
 1441 aagatcgagc ccctggcggt ggcccccacc aaggccaaagc gcccgtggc gcagcgc当地
 1501 aagcgcgc当地 tgacccctgg cgcacatgtc ctggcgttcc tggccggcc cggcagcacc
 1561 atggccccc gcagcctgac cctgaccgtg caggccccc agctgctgag cggcatcg
 1621 cagcagcaga acaacctgtc ggcgcaccat gaggccccc agcacctgtc gcagctgacc
 1681 gtgtgggca tcaaggcagtc gcaggccgc gtgcgtggcc tggagcgtca cctgaaggac
 1741 cagcagctgc tggccatctg gggctgcagc ggcaagctga tctgcaccac cggcgtccc
 1801 tggaaacgcca gctggagcaa caagagcctg gaccagatct ggaacaacat gacctggatg
 1861 gagtgggagc gcgagatcga caactacacc aacctgtatc acacccctgtc cgaggagagc
 1921 cagaaccagc aggagaagaa cgagcaggag ctgcgtggagc tggacaagtg ggccagcctg
 1981 tggaaactgggt tcgacatcg caagtggctg tggatcatct aactcgag

Figure 18
(Sheet 1 of 1)

gp160.modSF162.delV2.mut7

```

1 atggatgcaa tgaagagagg gctctgtgt gtgctgtgc tgggtggagg agtcttcgtt
61 tcgcccagcg ccgtggagaa gctgtgggtg accgtgtact acggcgtgcc cggtgtgaag
121 gaggccacca ccaccctgtt ctgcgcgcagc gacgccaagg cctacgacac cgaggtgcac
181 aacgtgtgg ccacccacgc ctgcgtgccc accgacccca acccccagga gatcgtgctg
241 gagaacgtga ccgagaactt caacatgtgg aagaacaaca tgggtggagca gatgcacgag
301 gacatcatca gcctgtggga ccagagcctg aagccctgcg tgaagctgac ccccctgtgc
361 gtgaccctgc actgcaccaa cctgaagaac gccaccaaca ccaagagcag caactggaag
421 gagatggacc gcgccgagat caagaactgc agcttcaagg tgggcgcgg caagctgatc
481 aactgcaaca ccagcgtgat caccaggcc tgccccaagg tgagcttcga gccccatcccc
541 atccactact gcgcccccgc cggcttcgccc atccctgaagt gcaacgacaa gaagttcaac
601 ggcagcggcc cctgcaccaa cgtgagcacc gtgcagtgca cccacggcat cggcccccgtg
661 gtgagcaccc agctgctgct gaacggcagc ctggccgagg agggcgtggt gatccgcagc
721 gagaacttca ccgacaacgc caagaccatc atcgtgcagc tgaaggagag cgtggagatc
781 aactgcaccc gccccaaacaa caacacccgc aagagcatca ccatcgccccc cggccgcgc
841 ttctacgcca cccggcagat catcgccgac atccgcagg cccactgcaa catcagcggc
901 gagaagtgg acaacacccct gaagcagatc gtgaccaagc tgcaggccca gttcggcaac
961 aagaccatcg tggtaagca gaggccgc ggcaccccg agatcgtgat gcacagcttc
1021 aactgcggcg gcgagttctt ctactgcac accatcgccgat tggtaacag cacctgaaac
1081 aacaccatcg gccccaaacaa caccacccgc accatcaccct tgccctgccc catcaagcag
1141 atcatcaacc gctggcagga ggtgggcaag gccatgtacg ccccccccat cgcggccag
1201 atccgctgca gcagcaacat caccggctg ctgctgaccc gcacggccgg caaggagatc
1261 agcaacacca ccgagatctt ccgcggccgc ggcggcgaca tgcgcgacaa ctggcgcagc
1321 gagctgtaca agtacaaggt ggtgaagatc gagccctgg gctggggccc caccaggcc
1381 atcagcagcg tggtgccagcg cgagaagagc gccgtgaccc tggcgcccat gttcctggc
1441 ttctggcgcc cccggcagc caccatgggc gcccgcagcc tgaccctgac cgtgcaggcc
1501 cgccagctgc tggcgccat cgtgcagcagc cagaacaacc tgctgcgcgc catcgaggcc
1561 cagcagcacc tgctcagct gaccgtgtgg ggcaccaacg agctgcaggc cgcgtgtgc
1621 gccgtggaggc gctacctgaa ggaccaggcag ctgctggca tctggggctg cagcggcaag
1681 ctgatctgca ccaccggcg tggctggaaac gccagctgga gcaacaagag cctggaccag
1741 atctggaaaca acatgacccgt gatggagttt gaggcgaga tcgacaacta caccacccctg
1801 atctacaccc tgatcgagga gagccagaac cagcaggaga agaacgagca ggagctgctg
1861 gagctggaca agtggggccag cctgtggaaac tggttcgaca tcagcaagtg gctgtggta
1921 atcaagatct tcatcatgat cgtggccggc ctggctggcc tgccatcgat gttcaccgtg
1981 ctgagcatcg tggatcccgat ggcgcggcc tacacccccc tgaccccttcca gacccgcctc
2041 cccggccccc gggcccccga ccgcggccgg ggcaccccgat gggaggccgg cgacgcgcac
2101 cgcgaccgca gcaacccctt ggtgcacggc ctgctggccc tgatctggga cgacccgcgc
2161 agcctgtgcc tggatcccgat ccaccggctg cgcgcacccgt tggatcccgat gggccatcgatc
2221 gtggagctgc tggccgcgg cggctggag gcccctgaatg actggggcaa cctgctgcag
2281 tactggatcc aggagctgaa gaaacaggcc gtcggccctgt tggatcccgat cgcacatcgcc
2341 gtggccgagg gcaccggaccg catcatcgat gtcggcccgat gatcggcccg cgccttcctg
2401 cacatcccccc gccgcaccccg ccaggccctc gaggcccgatc gacccatcgcc
```

Figure 19
(Sheet 1 of 1)

gp160.modSF162.delV2.mut8

```

1 atggatgcaa tgaagagagg gctctgctgt gtgctgctgc tttgtggagg agtcttcgtt
61 tcgcccagcg ccgtggagaa gctgtgggtg accgtgtact acggcggtgcc cgtgtggaaag
121 gagccacca ccaccctgtt ctgcgccagc gacgccaagg cctacgacac cgagggtgcac
181 aacgtgtggg ccacccacgc ctgcgtgccc accgacccca acccccagga gatcgtgctg
241 gagaacgtga ccgagaactt caacatgtgg-aagaacaaca tggtggagca gatgcacgag
301 gacatcatca gcctgtggga ccagagcctg aagccctgcg tgaagctgac cccctgtgc
361 gtgaccctgc actgcaccaa cctgaagaac gccaccaaca ccaagagcag caactggaag
421 gagatggacc gcccgcgagat caagaactgc agcttcaagg tgggcgcgg caagctgatc
481 aactgcaaca ccagcggtat caccaggcc tggcccaagg tgagcttcga gcccattcccc
541 atccactact gcccggcccg cggcttcgccc atcctgaagt gcaacgacaa gaagttcaac
601 ggcagcggcc cctgcaccaa cgtgagcacc gtgcagtgca cccacggcat cggcccccgt
661 gtgagcacc cagtcgtgtc gaacggcagc ctggccgagg agggcgtgg gatccgcagc
721 gagaacttca ccgacaacgc caagaccatc atcgtgcagc tgaaggagag cgtggagatc
781 aactgcaccc gcccccaacaa caacacccgc aagagcatca ccatcgcccc cggccgcgcc
841 ttctacgcca ccggcgacat catcgccgac atccgcagg cccactgcaa catcagcgcc
901 gagaagtgg acaacacccct gaagcagatc gtgaccaagg tgcaggccca gttcggcaac
961 aagaccatcg tttcaagca gaggcgccg ggcgaccccg agatcgatc gcacagcttc
1021 aactgcggcg gcgagttctt ctactgcaac agcaccacgc tttcaacag cacctggAAC
1081 aacaccatcg gcccccaacaa caccaacggc accatcaccc tggccctgccc catcaagcag
1141 atcatcaacc gctggcagga gttggcggaa gccatgtacg ccccccggcat cggccggccag
1201 atccgctgca gcagcaacat caccggcctg ctgctgaccc ggcacggcgg caaggagatc
1261 agcaacacca ccgagatctt cggccggccg ggcggcgaca tggcgacaa ctggcgccagc
1321 gagtcgtaca agtacaagg ggtgaagatc gagccctgg gctgtggcccc caccatcgcc
1381 atcagcagcg tggtgcagag cgagaagagc gccgtgaccc tggcgcccat gttcctggc
1441 ttctggcgcc cccggcccg caccatgggc gcccgcagcc tgaccctgac cgtgcaggcc
1501 cgccagctgc tgagcgccat cgtgcagcag cagaacaacc tgctgcgcgc catcgaggcc
1561 cagcagcacc tgctgcagct gaccgtgtgg ggcaccaagg agtgcaggc cccgtgtcg
1621 gcccgtggc gctacctgaa ggaccaggcag ctgctggca tctgggctg cagcggcaag
1681 ctgatctgca ccaccggcg gccctggaaac gccagctgg gcaacaaggag cctggaccag
1741 atctggaaaca acatgacctg gatggagtgg gagcgcgaga tcgacacaacta caccacactg
1801 atctacaccc tcatcgagga gagccagaac cagcaggaga agaacagagca ggagctgtcg
1861 gagtcggaca agtggccag cctgtggaaac tggttcgaca tcagcaagt gctgtggatc
1921 atcaagatct tcatcatgtat cgtggcgccg ctggggccg tgcgcacatcg tttcaccgt
1981 ctgagcatcg tgaaccggcg ggcacccggc tacagccccc ttagcttcca gaccgcgttc
2041 cccggccccc gggcccccga cccggcccgag ggcacatcgagg aggaggggcgg cgagcgcgac
2101 cgcgaccgca gcagcccccgtt ggtgcacggc ctgtggccc ttagctggaa cgaccgtgc
2161 agcctgtgcc tttcagcta ccaccggcg cgcgcacatcg tcctgatcg cggccgcac
2221 gtggagctgc tggccggccg cggctggag gcccctgaagt actggggcaa cctgctgcag
2281 tactggatcc aggagctgaa gaacagcgcc gtgagcctgt tgcacgcacat cggccatcgcc
2341 gtggccgagg gcaccgaccg catcatcgag gtggcccgac gcatcgcccg cggcccttc
2401 cacatcccccc gccgcacatcg ccaggcgcc tgcgtgtaa

```

Figure 20
(Sheet 1 of 1)

int.opt.mut.SF2

```
TTCCCTGAAACGGCATCGACAAGGCCCAAGGAGGAGCACGAGAACTTACACAGCAACTGGCGGCCATGGCC
AGCGACTCTAACCTGCCCCCGTGGTGGCCAAGGAGATCGTGGCCAGCGCCGACAAGTGCCAGCTGAAG
GGCGAGGCCATGCACGGCCAGGTGGACTGCAGCCCCGGCATCTGGCAGCTGGCCTGCACCCACCTGGAG
GGCAAGATCATCCTGGTGGCCGTGCACGTGGCCAGCGGCTACATCGAGGCCGAGGTGATCCCCGCCGAG
ACCGGCCAGGAGACCGCTACTTCCCTGCTGAAGCTGGCCGGCGCTGGCCCGTGAAGACCATCCACACC
GCCAACGGCAGCAACTTCACCAGCACCAACCGTGAAGGCCGCTGCTGGTGGCCGGCATCAAGCAGGAG
TTCGGCATCCCCTACAACCCCCAGAGCCAGGGCGTGGTGGCGAGCATGAACAACGAGCTGAAGAACATC
ATCGGCCAGGTGCGCGACCAGGCCGAGCACCTGAAGACCGCCGTGCAGATGGCCGTGTTCATCCACAAC
TTCAAGCGCAAGGGCGGCATCGCGGCTACAGCGCCGGCGAGCGCATCGTGGACATCATGCCACCGAC
ATCCAGACCAAGGAGCTGCAGAAGCAGATCACCAAGATCCAGAACTTCCGCGTGTACTACCGCGACAAC
AAGGACCCCTGAAGGGCCCCGCCAAGCTGCTGGAAGGGCGAGGGCGCGTGGTGATCCAGGACAAC
AGCGACATCAAGGTGGTGGCCAGCCGCCAGGACGAGGAC
GACGACTGCCTGGCCAGCCGCCAGGACGAGGAC
```

Figure 21
(Sheet 1 of 1)

int.opt.SF2

```
TTCCCTGAACGGCATCGACAAGGCCAGGAGGAGCACGAGAAGTACCAAGCAACTGGCGGCCATGGCC
AGCGACTTCAACCTGCCCGGTGGTGGCCAAGGAGATCGTGGCCAGCTGCGACAAGTGCCAGCTGAAG
GGCGAGGCCATGCACGGCCAGGTGGACTGCAGCCCCGGCATCTGGCAGCTGGACTGCACCCACCTGGAG
GGCAAGATCATCCTGGTGGCCGTGACGTGGCCAGGGCTACATCGAGGCCAGGGTATCCCCGCCAG
ACCGGCCAGGAGACCGCCTACTTCTGCTGAAGCTGGCCGGCCCTGGCCCGTGAAGACCATCCACACC
GACAACGGCAGCAACTTCACCAAGCACCACCGTGAAGGCCGCTGCTGGTGGGCCATCAAGCAGGAG
TTCGGCATCCCCATAACCCCCAGAGCCAGGGCGTGGAGACATGAACAACGAGCTGAAGAAGATC
ATCGGCCAGGTGCGCGACCAGGCCGAGCACCTGAAGACCGCCGTGCAGATGGCCGTGTCATCCACAAC
TTCAAGCGCAAGGGCGGCATGGCGGCTACAGCGCCCGAGGCCATCGTGGACATCATGCCACCGAC
ATCCAGACCAAGGAGCTGCAGAAGCAGATACCAAGATCCAGAACTTCCGCGTGTACTACCGCGACAAC
AAGGACCCCTGTGGAAGGGCCCCGCCAAGCTGCTGGAAGGGCGAGGGCGCCGTGGTATCCAGGAC
AACAGCGACATCAAGGTGGTGGCCAGGCCAGGACGAGGAC
GGCGACGACTGCGTGGCCAGGCCAGGAC
```

Figure 22
(Sheet 1 of 1)

nef.D125G.-myr.opt.SF162

```
ATGGCCGGCAAGTGGAGCAAGCGCATGAGCGGCTGGAGCGCCGTGCGCGAGCGCATGAAGCGCGCCGAG
CCCGCCGAGCCCGCCCGACGGCGTGGCGCCGTGAGCGCGACCTGGAGAAGCACGGCGCCATCACC
AGCAGCAACACCGCCGCCAACAACGCGACTGCGCCTGGCTGGAGGCCAGGGAGGACGAGGACGTGGGC
TTCCCCGTGCGCCCCCAGGTGCCCCATGACCTACAAGGCCGCCCTGGACCTGAGCCACTTC
CTGAAGGAGAAGGGCGGCCTGGAGGGCTGATCTACAGCCAGAAGCGCCAGGACATCCTGGACCTGTGG
ATCCACCAACACCCAGGGCTACTTCCCCGGCTGGCAGAACTACACCCCCGGGCCATCCGCTACCCC
CTGACCTTCGGCTGGTGTCAAGCTGGTGCCTGGACCCCCGACTACGTGGAGGAGGCCAACGCCGGC
GAGAACACAGCCTGCTGCACCCATGAGCCAGCACGGCATGGACGACCCCCGAGAAGGAGGTGCTGGTG
TGGCGCTTCGACAGCCGCCTGGCCTCCACCACATGGCCCGAGCTGCACCCCGAGTACTACAAGGAC
TGC
```

Figure 23
(Sheet 1 of 1)

nef.D107G.-myr18.opt.SF162 (dbl.mutant)

```
ATGAAGCGCGCCGAGCCCGCCGAGCCCGCCGACGGCGTGGCGCCGTGAGCCGC
GACCTGGAGAAGCACGGCGCCATCACCAAGCAGCAACACCGCCGCAACAACGCCGAC
TGCCTGGCTGGAGGCCAGGAGGACGAGGACGTGGCTTCCCGTGCGCCCGAG
GTGCCCTGGCCCATGACCTACAAGGCCCTGGACCTGAGCCACTTCCTGAAG
GAGAAGGGCGGCCCTGGAGGGCTGATCTACAGCCAGAACAGGCCAGGACATCCTGGAC
CTGTGGATCCACCACACCCAGGGCTACTTCCCGGCTGGCAGAACTACACCCCCGGC
CCCGGCATCCGCTACCCCTGACCTTCGGCTGGCTTCAAGCTGGTGGCGCTTGACAGC
CCCGACTACGTGGAGGAGGCCAACGCCGGCAGAACAAACAGCCTGCTGCACCCCATG
AGCCAGCACGGCATGGACGACCCGAGAAGGAGGTGCTGGTGTGGCGCTTCGACAGC
CGCCTGGCCTTCCACCATGGCCCGAGCTGCACCCGAGTACTACAAGGACTGC
```

Figure 24
(Sheet 1 of 1)

nef.opt.D125G.SF162

```
ATGGGCGCAAGTGGAGCAAGCGCATGAGCGGCTGGAGCGCCGTGCGCGAGCGCATGAAGCGCGCCGAG
CCCGCCGAGCCCGCCCGACGGCGTGGCGCCGTGAGCCGCACCTGGAGAAGCACGGCGCCATCACC
AGCAGCAACACCGCCGCCAACAACGCCGACTGCGCCTGGCTGGAGGCCAGGAGGACGAGGACGTGGC
TTCCCCGTGCGCCCCCAGGTGCCCTGCGCCCCATGACCTACAAGGCCGCTGGACCTGAGCCACTTC
CTGAAGGAGAAGGGCGGCCTGGAGGGCCTGATCTACAGCCAGAAGCGCCAGGACATCTGGACCTGTGG
ATCCACCACACCCAGGGCTACTTCCCCGGCTGGCAGAACTACACCCCCGGCCCGGCATCCGCTACCCCC
CTGACCTTCGGCTGGTGTCAAGCTGGTCCCCGTGGACCCCCGACTACGTGGAGGAGGCCAACGCCGGC
GAGAACAAACAGCCTGCTGCACCCCATGAGCCAGCACGGCATGGACGACCCCCGAGAAGGAGGTGCTGGT
TGGCGCTTCGACAGCCGCCTGGCCTTCCACCATGGCCCGAGCTGCACCCCGAGTACTACAAGGAC
TGC
```

Figure 25
(Sheet 1 of 1)

nef.opt.SF162

```
ATGGGCGGCAAGTGGAGCAAGCGCATGAGCGGCTGGAGCGCCGTGCGCGAGCGCATGAA
GCGCGCCGAGCCCGCCGAGCCCGCCGACGGCGTGGCGCCGTGAGCCCGACCTGG
AGAAGCACGGCGCATCACCAAGCAGCAACACCGCCGCAACAACGCCGACTGCGCTGG
CTGGAGGCCAGGAGGACGAGGACGTGGGCTTCCCGTGCGCCCGAGGTGCCCTGCGC
CCCAGTACAGGCCGCTGGACCTGAGCCACTTCTGAAGGAGAAGGGCGGCCTG
GAGGGCCTGATCTACAGCCAGAAGCGCCAGGACATCCTGGACCTGGATCCACCACACC
CAGGGCTACTTCCCGACTGGCAGAACTACACCCCCGGCCCGCATCCGCTACCCCTG
ACCTTCGGCTGGTCTCAAGCTGGTCCCCGTGGACCCCGACTACGTGGAGGAGGCAAC
GCCGGCGAGAACAAACAGCCTGCTGCACCCCATGAGCCAGCACGGCATGGACGACCCGA
GAAGGAGGTGCTGGTGTGGCGCTTCGACAGCCGCTGGCCTCCACCACATGGCCCGCGA
GCTGCACCCGAGTACTACAAGGACTGC
```

Figure 26
(Sheet 1 of 1)

p15RnaseH.opt.SF2

```
TACGTGGACGGCGCCGCAACCGCGAGACCAAGCTGGCAAGGCCGGTACGTGACCGA
CCGGGGCGGGCAGAAGGTGGTGAGCATGCCGACACCACCAACCAGAAGACCGAGCTGC
AGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTACCGACAGCC
AGTACGCCCTGGGCATCATCCAGGCCAGCCCCACAAGAGCGAGAGCGAGCTGGTGAGC
CAGATCATCGAGCAGCTGATCAAGAAGGAGAAGGTGTACCTGGCCTGGGTGCCGCCAC
AAGGGCATCGCGGCAACGAGCAGGTGGACAAGCTGGTGAGCGCCGGATCCGCAAGGT
GCTG
```

Figure 27
(Sheet 1 of 1)

p2Pol.opt.YMWM.SF2

GGCACCATGGCCGAGCGCATGAGCCAGGTACGAACCCGGCGACCATCATGATGCAGCGCGGAACTTC
CGCAACCAGCGGAAGACCGTCAACTGCTTCAACTGCGGCAAGGAGGGCCACACCGCCAGGAACCGCCGC
GCCCCCGCAAGAAGGGCTGCTGGCGCTGGCCGCGAAGGACACCAAATGAAAGATTGCACTGAGAGA
CAGGCTAATTCTTCCCGAGGACCTGGCTTCTGCAAGGGCAAGGCCGCGAGTTCAAGCAGCGAGCAG
ACCCGCGCAACAGCCCCACCCCGCGAGCTGCAGGTGTGGGCGGGAGAACAAACAGCCTGAGCGAG
GCCGGCGCCGACCGCCAGGGCACCGTGAGCTCAACTTCCCCCAGATCACCTGTGGCAGCGCCCCCTG
GTGACCATCAGGATCGCGGCCAGCTCAAGGAGGCGTGCCTGCCACCGGGCGCGACGACACCGTGTG
GAGGAGATGAACTGCCCAGCAAGTGGAAAGCCAAAGATGATCGGGGATCGGGGCTTCATCAAGGTG
CGGAGTACGACCAGATCCCCGTGGAGATCTGCGGCCACAAGGCCATGGCACCGTGTGACCCCTGAAC
ACCCCGTGAACATCATCGGCCGCAACCTGTCGACCCAGATCGGTGACCCCTGAACCTCCCCATCAGC
CCCATCGAGACGGTGGCCGTGAAGCTGAAGCCGGGATGGACGGCCCAAGGTCAAGCAGTGGCCCTG
ACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGCAACCGAGATGGAGAAGGAGGGCAAGATCAGCAAG
ATCGGCCCCGAGAACCCCTACAAACACCCCCGTGTCGCATCAAGAAGAAGGACAGCACCAAGTGGCGC
AAGCTGGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTCTGGGAGGTGCAGCTGGCATCCCC
CACCCCGCCGGCCTGAGAAGAAGAAGAGCGTGAACCGTGTGGACGTGGCGACGCCTACTTCAGCGT
CCCCCTGGACAAGGACTTCCGCAAGTACACCGCTTCACCATCCCCAGCATCAACAACGAGACCCCCGGC
ATCCGCTACCAAGTACAACGTGCTGCCCCAGGGCTGAAAGGGCAGCCCCGCATCTTCCAGAGCAGCATG
ACCAAGATCCTGGAGCCCTTCCGCAAGCAGAACCCCCGACATCGTGTACCTACAGGCCCCCTGTACGTG
GGCAGCGACCTGGAGATCGGCCAGCACCACCGAACAGATCGAGGAGCTGCGCCAGCACCTGCTGCGCTGG
GGCTTCACCAAGGACCCCCGACAAGAAGCACCAGAAGGAGCCCCCTTCCCTGGCCATCGAGCTGCAACCCGAC
AAGTGGACCGTGCAGCCCACATGCTGCCCCAGAGAACAGCTGGACCGTGAACGACATCCAGAACGCTG
GTGGGCAAGCTGAACTGGGCCAGCCAGATCTACCGGGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTG
CGCGGCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGCTGGAGCTGGCGAGAAC
CGCGAGATCCTGAAGGAGCCGTGACGGTGTACTACGACCCAGCAAGGACCTGGTGGCGAGATC
CAGAAGCAGGCCAGGGCCAGTGGACCTACCAAGATCTACAGGAGGCCCTCAAGAACCTGAAGACCGGC
AAGTACGCCGCATCGCGGGGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAAGAAC
AGCACCGAGAGCATCGTGTACCTGGGCAAGATCCCCAAGTCAAGCTGCCCATCCAGAAGGAGACCTGG
GAGGCCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGGAGTTCGTGAACACCCCCCCC
CTGGTGAAGCTGTGGTACCGCTGGAGAAGGAGGCCATCGTGGGCGCCGAGACCTTCTACGTGGACGGC
GCCGCCAACCGCGAGACCAAGCTGGCAAGGCCGCTACGTGACCGACCGGGGCCAGAACGGTGGT
AGCATCGCCGACACCAACCAGAACAGACCGAGCTGCAAGGCCATCCACCTGGCCCTGCAAGGACAGCGGC
CTGGAGGTGAACATCGTGAACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGCCAGAACAGAC
GAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAGCTGATCAAGAAGGAGAACGGTGTACCTGGCCTGGT
CCCGCCACAAGGGCATCGCGGCCAGAGCAGGTGACAAGCTGGTGGAGCGCCGGCATCCGCAAGGTG
CTGTTCCCTGAACGGCATCGATGGCGGCATCGTGTACCTACAGTACATGGACGACCTGTACGTGGCAGC
GGCGGCCCTAGGATCGATTAAAGCTTCCGGGCTAGCACCGGT

Figure 28
(Sheet 1 of 1)

p2PolInaopt.YM.SF2

GGCACCATGGCCGAGGCAGATGAGCCAGGTGACGAACCGGGGACCATCATGATGCAGCGCGGCAACTTC
CGCAACCAGCGGAAGACCGTCAAGTGCTTCAACTGCCGCAAGGAGGGCACACCGCCAGGAACCTGCCGC
GCCCGCCCAAGAAGGGCTGCTGGCGCTGCCGCGAAGGACACCAAATGAAAGATTGCACTGAGAGA
CAGGCTAATTCTCCGCGAGGACCTGCCCTCCTGCAGGGCAAGGCCGCGAGTTCAGCAGCGAGCAG
ACCCGCCAACAGCCCCACCCGCCGAGCTGCAGGTGAGGGCGAGAACAAACAGCCTGAGCGAG
GCCGGCGCCGACCGCCAGGGCACCGTGAGCTTCAACTCCCCAGATCACCTGTGGCAGCGCCCCCTG
GTGACCATCAGGATCGGCGGCCAGCTCAAGGAGGCCTGCTGCCACCGGCCGACGACACCGTGCTG
GAGGAGATGAACTGCCGGCAAGTGGAAAGCCAAGATGATCGGCGGGATCGGGGCTTCATCAAGGTG
CGGCAGTACGACCAGATCCCCGTGGAGATCTGCCACAAAGCCATGGCACCGTGCACCTGAACCTCCCCATCAGC
ACCCCGTGAACATCATCGGCCAACCTGCTGACCCAGATCGGCTGCACCTGAACCTCCCCATCAGC
CCCATCGAGACGGTGGCGTGAAGCTGAAGCCGGGATGGACGGCCCCAAGGTCAAGCAGTGGCCCCCTG
ACCGAGGAGAAGATCAAGCCCTGGTGGAGATCTGACCCGAGATGGAGAAGGAGGGCAAGATCAGCAAG
ATCGGCCCCGAGAACCCCTACACACACCCCCGTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGC
AAGCTGGTGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTCTGGGAGGTGAGCTGGCATCCCC
CACCCCGCCGGCCTGAAGAAGAAGAGCGTGACCGTGTGGAGCTGGCAGCGCTACTTCAGCGT
CCCCTGGACAAGGACTTCCGCAAGTACACCCCTTCACCATCCCCAGCATCAACAAACGAGACCCCCGGC
ATCCGCTACCAAGTACAACGTGCTGCCCCAGGGCTGGAAAGGGCAGCCCCGCCATCTTCCAGAGCAGCATG
ACCAAGATCCTGGAGCCCTTCCGCAAGCAGAACCCCCGACATCGTGTACCTACAGGCCCCCTGTACGTG
GGCAGCGACCTGGAGATCGGCCAGCCGACCAAGATCGAGGAGCTGCCAGCACCTGCTGCCTGG
GGCTTCACCAACCCCGACAAGAACGACCCAGAACAGGAGCCCCCTTCCGTGGATGGCTACGAGCTGCAC
CCCGACAAGTGGACCGTGCAGCCCACATGCTGCCAGAACGGAGCAGCTGGAGCTGAACGACATCCAG
AAGCTGGTGGCAAGCTGAACTGGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTGTCAAG
CTGCTGCCGGCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGCCGAGCTGGAGCTGGCC
GAGAACCGCGAGATCTGAAGGAGCCGTGCACGAGGTGACTACGACCCAGCAAGGACCTGGTGGCC
GAGATCCAGAACGAGGGCCAGGGCCAGTGGACCTACCAAGATCTACCCAGGAGGCCCTTAAGAACCTGAAG
ACCGGCAAGTACGCCGCATGCCGGCGCCACACCAACGACGTGAAGCAGCTGACCCAGGCCGTGCAG
AAGGTGAGCACCGAGAGCATCGTGTACCTGGGCAAGATCCCCAAGTCAAGCTGCCATCCAGAACGGAG
ACCTGGGAGGCCTGGTGGAGTGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCGTGAACACC
CCCCCCCCTGGTGAAGCTGTGGTACAGCTGGAGAACGGAGCCCATCGTGGGCCAGAACCTTCTACGTG
GACGGCGCCGCCAACCGCAGAACAGCTGGCAAGGCCGGCTACGTGACCGACCGGGGCCGGCAGAAC
GTGGTGAGCATGCCGACACCAACCAAGAACGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGAC
AGCGGCCTGGAGGTGAACATCGTACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGGCCAC
AAGAGCGAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAGCTGATCAAGAACGGAGAACGGTGTACCTGGCC
TGGGTGCCGCCAACAGGGCATCGGCCAACGAGCAGGAGCTGGACAAGCTGGTGGAGCAGGCCGGCATCCGC
AAGGTGCTGTTCCCTGAACGGCATCGATGGGGCATCGTGTACCTACAGTACATGGACGACCTGTACGTG
GGCAGCGGGCGGCCCTAGGATCGATTAAAGCTTCCCCGGCTAGCACCGGT

Figure 29
(Sheet 1 of 1)

p2Polopt.SF2

GGCACCATGGCGAGGCGATGAGCCAGGTACGAACCGGGCACCATCATGATGCAGCGCGGCAACTTC
CGCAACCAGCGGAAGACCGTCAAGTCTCAACTGCGGCAAGGAGGCCACACCGCCAGGAACCTGCCGC
GCCCCCGCAAGAAGGGCTGCTGGCGCTGCGCCGCGAAGGACACCAATGAAAGATTGCACTGAGAGA
CAGGCTAATTCTCCGCGAGGACCTGGCCTTCCTGCAAGGGCAAGGCCCGCGAGTTCAGCAGCGAGCAG
ACCCGCGCAACAGCCCCACCGCCGCGAGCTGCAGGTGTGGGGCGAGAACAAACAGCCTGAGCGAG
GCCGGCGCCGACCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCTGTGGCAGCGCCCCCTG
GTGACCATCAGGATCGCGGCCAGCTCAAGGAGGCGCTGCTGACACCGGCCGACGACACCGTGCTG
GAGGAGATGAACTGCCCCGGCAAGTGAAGGCCAAGATGATGCGGGGATCGGGGCTTCATCAAGGTG
CGGCAGTACGACCAAGATCCCCGTGGAGATCTGCGGCACAAGGCCATCGGACCGTGTGGGGCCCC
ACCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAGATCGGCTGCACCCCTGAACTTCCCCATCAGC
CCCATCGAGACGGTCCCCTGAAGCTGAAGCCGGGATGGACGGCCCAAGGTCAAGCAGTGGCCCCCTG
ACCGAGGAGAAGATCAAGGCCCCGGGAGATCTGCAACCGAGATGGAGAAGGAGGCCAAGATCAGCAAG
ATCGGCCCCGAGAAGACCCCTACAACACCCCCCGTGTGCCCCATCAAGAAGAAGGACAGCACCAAGTGGCGC
AAGCTGGTGGACTTCCGCGAGCTGAACAAGCGCACCCAGGACTCTGGGAGGTGCAAGCTGGGATCCCC
CACCCCGCCGGCCTGAAGAAGAAGAGCGTGACCGTGTGGACGTGGGAGGTGCAAGCCTACTTCAGCGT
CCCCCTGGACAAGGACTTCCGCAAGTACACCGCCTTACCATCCCCAGCATCAACACGGAGACCCCCGGC
ATCCGCTACCACTGCTGCCCCAGGGCTGGAAGGGCAGCCCCGCCATCTCCAGAGCAGCATG
ACCAAGATCCTGGAGCCCTTCCGCAAGCAGAACCCCCGACATCGTGATCTACCACTGAGCTGGACGACCTG
TACGTGGCAGCGACCTGGAGATCGGCCAGCACCACAGATCGAGGAGCTGCGCCAGCACCTGCTG
CGCTGGGCTTCACCACCCCCGACAAGAAGCACCAGAAGGAGCCCCCTTCTGTGGATGGCTACGAG
CTGCACCCGACAAGTGGACCGTGCAAGCCATCATGCTGCCCCAGAGAAGGACAGCTGGACCGTGAACGAC
ATCCAGAAGCTGGTGGCAAGCTGAAGCTGGCCAGCAGATCTACGCCGGCATCAAGGTGAAGCAGCTG
TGCAAGCTGCTGCGCGGCCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGGCCAGCTGGAG
CTGGCCGAGAAGCAGCGAGATCTGAAGGAGCCGTGACGAGGTGTACTACGACCCAGCAAGGACCTG
GTGGCCGAGATCCAGAAGCAGGGCCAGGGCAGTGGACCTACAGATCTACAGGAGCCCTCAAGAAC
CTGAAGACCGGCAAGTACGCCCATGCGCGGCCACACCAACGACGTGAAGCAGCTGACCGAGGCC
GTGCAGAAGGTGAGCAGCAGAGCATCGTGATCTGGGCAAGATCCCCAAGTTCAAGCTGCCCATCCAG
AAGGAGACCTGGGAGGCCCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCTG
AACACCCCCCCCCTGGTGAAGCTGTGGTACCACTGCTGGAGAAGGAGCCATCGTGGGCGCCAGACCTTC
TACGTGGACGGCGCCCAACCGCGAGACCAAGCTGGCAAGGCCGGTACGTGACCGACCGGGGGGG
CAGAAGGTGGTGAGCATGCCGACACCACCAACAGAAGACCGAGCTGCAGGCCATCCACCTGGCCCTG
CAGGACAGCGGCCTGGAGGTGAACATCGTGACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAG
CCCGACAAGAGCGAGAGCGAGCTGGTGAGGCCAGATCATGAGCAGCTGATCAAGAAGGAGAAGGTGTAC
CTGGCCTGGGTGCCGCCACAAGGGCATGGCGCAACGAGCAGGTGGACAAGCTGGTGAAGCGGCCGG
ATCCGCAAGGTGCTGTTCTGAACGGCATCGATGGCGGATCGTGATCTACCACTGAGCTACGACCTG
TACGTGGCAGCGCGGCCCTAGGATCGATCAAAGCTTCCGGGGCTAGCACCAGGT

Figure 30
(Sheet 1 of 1)

p2PolTatRevNef.opt.native_B

ATGGCCGAGGCGATGAGCCAGGTGACGAACCGGGCACCATCATGATGCAAGCGCGCAACTTCCGCAAC
CAGCGGAAGACCGTCAAGTGTCTCAACTGCGCAAGGAGGGCCACACCGCCAGGAACCTGCGCGCCCC
CGCAAGAAGGGCTGCTGGCGCTGGGCCGAGGACACCAATGAAAGATTGCACTGAGAGACAGGCT
AATTCTTCCCGCAGGGACCTGGCCTTCTGCAGGGCAAGGCCCGAGTTCAGCAGCGAGCAGACCCCG
GCCAACAGCCCCACCGCGAGCTGAGGTGTGGGGGGAGAACAAACAGCCTGACCGAGGGCGGG
GCCGACCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCTGTGGCAGCGCCCCCTGGTGACC
ATCAGGATCGGGGCCAGCTCAAGGAGGCCTGACACCCGGCGAGCACCCGTCTGGAGGAG
ATGAACCTGCCCAGCTGAAGTGGAAAGCCAAGATGATCGGGGGATCGGGGCTTCATCAAGGTGGCAG
TACGACCGAGATCCCCGTGGAGATCTGCGCCACAAGGCCATCGGCACCGTGCTGGGGCCCCACCCCC
GTGAACATCATCGGGCGCAACCTGCTGACCCAGATCGGCACCCCTGAACCTTCCCCATCAGCCCCATC
GAGACGGTGGCCGTGAAGCTGAAGCCGGATGGACGGCCCCAAGGTCAAGCAGTGGCCCTGACCGAG
GAGAAGATCAAGGCCCTGGTGGAGATCTGACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGC
CCCGAGAACCCCTACAACACCCCCGTGTCGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTG
GTGGACTTCCCGCAGCTGAACAAAGCGCACCCAGGACTCTGGAGGTGCACTGGCATTCCCCACCCCC
GCCGGCCTGAAGAAGAAGAGCGTGGACCGTGCTGGACGTGGCAGCCTACTTCAGCGTCCCCCTG
GACAAGGACTTCCGCAAGTACACCGCCTCACCATCCCCAGCATCAACAAAGAGACCCCCGGATCCCG
TACCGTACAACGTGCTGCCCAAGGGCTGGAGGGCAGCCCCCGCCATCTTCAGAGCAGCATGACCAAG
ATCCCTGGAGCCCTTCCGCAAGCAGAACCCCGACATCGTATCTACCGTACATGGACGACCTGTACGTG
GGCAGCGACCTGGAGATCGGCCAGCACCGCCAAGATCGAGGAGCTGGCAGCACCTGCTGCGCTGG
GGCTTCACCAACCCCCGACAAGAAGCACCAGAGGGGCCCCCTTCTGTGGATGGCTACGAGCTGGCAC
CCCGACAAGTGGACCGTGCAGCCCATCATGCTGCCAGAGAACAGCTGGACCGTGAACGACATCCAG
AAGCTGGGGCAAGCTGAACTGGCCAGCCAGATCTACGCCGCATCAAGGTGAAGCAGCTGTGCAAG
CTGCTGCCGGCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGGGCAGCTGGAGCTGGC
GAGAACCCGGAGATCTGAAGGAGCCCCGTGACCGAGGTGACTACGACCCAGCAAGGACCTGGGGC
GAGATCCAGAAGCAGGGCAGGGCAGTGGACCTACAGATCTACCGAGGCCCTTCAAGAACCTGAAAG
ACCGGCAAGTACGCCGCATGCCGGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAAG
AAGGTGAGCACCGAGAGCATCGTATCTGGGCAAGATCCCCAAGTCAAGCTGCCATCCAGAAGGAG
ACCTGGGAGGGCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCTGTGACACC
CCCCCCCCCTGGTGAAGCTGTGGTACCAAGCTGGAGAAGGAGGCCATCGTGGGGCGCCGAGACCTCTACGTG
GACGGGCCGCCAACCGCGAGACCAAGCTGGGCAAGGCCGGCTACGTGACCGAGCAGGGGGCGGAGAAG
GTGGTGAACATGCCGACACCAACCAACAGAACGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAAGGAC
AGCGGCCTGGAGGTGAACATCGTGCACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGCCGAC
AAGAGCGAGAGCGAGCTGGTAGGCCAGATCATGAGCAGCTGATCAAGAAGGAGAAGGTGTACCTGGCC
TGGGTGCCCGCCACAAGGGCATCGCGCGCAACGAGCAGGTGGACAAGCTGGTGGAGGCCGAGCCGATCCGC
AAGGTGCTGgattcGAGCCCGTGGACCCCCGGCTGGAGGCCCTGGAGACCCCCGGCAGCCAGCCAAAG
ACCGCCTGCACCAACTGCTACTGCAAGAAGTGTCTCCACTGCCAGGTGTGCTTCATCACCAAGGGC
CTGGGCATCAGCTACGGCGCAAGAAGCGCCAGCGCCGCCGCCCCCCCCCGACAGCGAGGTGCAAC
CAGGTGAGCCTGCCAAGCAGGCCAGCCAGGCCAGGGCAGCCCCACGGGCCCCAAGGAGAGCAAG
AAGAAGGTGGAGCGCGAGACCGAGACCGACCCCGTGCACCCCCGGCGGCCAGCGAGCAGCGAC
GAGGAGCTGCTGCAGACCGTGCCTCATCAAGTCCGTACCAAGAGCAACCCCCCTGCCAGCCCAAG
GGCACCCGCCAGGCCGCCAACCGCCGCCGCTGGCGAGCGCCAGCGCCAGATCCAGAGCATC
AGCGCCTGGATCATCAGCACCCACCTGGCCCGCAGACCGAGGCCGTGCCCCCTGCAGCTGCCCTG
GAGCGCCTGAACCTGGACTGCAGCGAGGACTGCACCGCAGGCCAGGGCTGGCAGCCCCCAG
GTGCTGGCGAGAGCCCCGCCGTGCTGGACAGCGGCACCAAGGAGCTCGAGGGCGCAAGTGGAGCAAG
CGCATGAGCGGCTGGAGCGCGTGCAGCGAGCGCATGAAGCGCCCGAGGCCGCCGAGCCGCCAG
GGCGTGGCGCCGTGAGCGCGACCTGGAGAAGCACGGGCCATCACAGCAGCAACACGCCGCCAAC
AACGCCGACTGCGCCTGGCTGGAGGCCAGGAGGACGAGGACGGTGGCTTCCCCGTGCGCCCCCAGGTG
CCCCCTGCCCTGACCTACAAGGCCGCCCTGGACCTGAGCCACTTCCCTGAAGGAGAAGGGCGCCCTG
GAGGGCCTGATCTACAGCCAGAACGGCCAGGACATCTGGACCTGTGGATCCACCAACCCAGGGCTAC
TTCCCCGACTGGCAGAACTACACCCCCGGCCCCGGCATCCGCTACCCCCCTGACCTTCCGCTGGTGTCTC
AAGCTGGTCCCCGTGGACCCCCGACTACGTGGAGGAGGCCAACGCCGGCAGAACACAGCTGCTGCA
CCCCATGAGCCAGCACGGCATGGACCCCCGAGAAGGAGGTGCTGGTGTGGCGCTTCGACAGCCGCTG
GCCCTTCCACCATGGCCCGAGCTGACCCCCGAGTACTACAAGGACTG

Figure 31
(Sheet 1 of 2)

p2Po1TatRevNef.opt_B

```

GCCACCATGGCCGAGGCGATGAGCCAGGTGACGAACCCGGGACCATCATGATGCAGCGGGCAACTTC
CGCAACCAGCGGAAGACCGTCAAGTGCCTCAACTGCGCAAGGAGGGCACACCGCCAGGAACGTGCCGC
GCCCGCGCAAGAAGGGCTGCTGGCGTGCAGGACACCAAAATGAAAGATTGCACTGAGAGA
CAGGCTAATTCTCCCGAGGACCTGGCTTCTGCAGGGCAAGGCCCGAGTCAGCAGCGAGCAG
ACCCCGGCCAACAGCCCCACCCGCCCGAGCTGCAGGTGTGGGGGGGAGAACACAACAGCCTGAGCGAG
GCCGGCGCCGACCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCTGTTGCAGCGCCCCCTG
GTGACCATCAGGATCGCGGCCAGCTCAAGGAGGCCTGCTGCCACCGGCCGACGACACCGTGCTG
GAGGAGATGAACCTGCCCGCAAGTGGAAAGCCAAGATGATCGCGGGATCGGGGCTTCATCAAGGTG
CGCAGTACGACAGATCCCCGTGGAGATCTGCGGCCACAAGGCCATCGGCACCGTGCTGGGGCCCC
ACCCCGTGAACATCATCGCCGCAACCTGCTGACCCAGATCGGCTGCACCCCTGAACCTCCCCATCAGC
CCCATCGAGACGGTCCCCGTGAAGCTGAAGCCGGGATGGACGGCCCAAGGTCAAGCAGTGGCCCCCTG
ACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGCACCGAGATGGAGAACAGGAGGCCAGATCAGCAAG
ATCGGCCCCGAGAACCCCTACAACACCCCCGTGTCGCCATCAAGAAGAACAGCACCAAGTGGCGC
AAGCTGGTGGACTTCCCGAGCTGAACAAGCGCACCCAGGACTCTGGGAGGTGCAAGCTGGGATCCCC
CACCCCGCCGGCCTGAAGAAGAACAGAGCGTGACCGTGCTGGACGTGGCGACGCCACTTCAGCGTG
CCCCCTGGACAAGGACTTCCGCAAGTACACCGCCTTCACCATCCCCAGCATCAACACGAGACCCCCGGC
ATCCGCTACCAGTACAACGTGCTGCCAGGGCTGGAAGGGCAGCCCCGCCATCTCCAGAGCAGCATG
ACCAAGATCCTGGAGCCCTTCCGCAAGCAGAACCCGACATCGTATCTACCAAGGCCCCCTGTACGTG
GGCAGCGACCTGGAGATCGGCCAGCACCACAGATCGAGGAGCTGGCCAGCACCTGTCGCGCTGG
GGCTTCAACCACCCCGACAAGAACGACCAAGAACGGAGCCCCCTTCCTGCCATCGAGCTGCAACCCGAC
AAAGTGGACCGTGAGCCATCATGCTGCCAGAACGGACAGCTGGACCGTGAACGACATCCAGAACGCTG
GTGGGCAAGCTGAACCTGGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTG
CGCGGCACCAAGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCAGAAC
CGCAGAGATCCTGAAGGAGCCCCTGACCGAGGTGACTACGACCCCCAGCAAGAACCTGGTGGCCAGATC
CAGAACGAGGGCCAGGGCAGTGGACCTACAGATCTACCAAGGAGCCCTCAAGAACCTGAAGAACGGG
AAAGTACGCCGCATGCGCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGAGAACGGT
AGCACCGAGAGCATTGATCTGGGCAAGATCCCCAAGTCAAGCCTGCCATCCAGAACGGAGACCTGG
GAGGCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCTGTGAACACCCCCCCC
CTGGTGAAGCTGTGGTACCAAGCTGGAGAACGGGCCATCGTGGCGCCAGACCTCTACGTGGACGGC
GCCGCAACCGCGAGACCAAGCTGGCAAGGCCGGCTACGTGACCGACGGGGCCGGCAGAACGGTGGT
AGCATGCCGACACCACCAACCAGAACGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGC
CTGGAGGTGAACATCGTACCGACAGCCAGTACCCCTGGCATCATCCAGGCCAGCCCCGACAAGAGC
GAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAGCTGATCAAGAACGGAGAACGGTGTACCTGGCTGGGTG
CCCGCCACAAAGGGCATCGCGGCCACCGAGCAGCAGGGACAAGCTGGTGGAGCGCCGGCATCCGAAGGTG
CTGTTCTGAACCGCATCGATGGCGCATCGTGAATCTACCAAGTACATGGACGACCTGTACGTGGCGAGC
GGCGGCCCTAGGGAGGCCGTGGACCCCCGCCCTGGAGGCCAGCAGCCCCGGCAGCCAGCCCCAAGACC
GCCGGCACCAACTGCTACTGCAAGAACGTGCTTCACTGCCAGGTGAGCTTCATCACCAAGGGCTG
GGCATCAGCTACGGCCGCAAGAACGCCAGCGCCGCCAGCGCCGCCGCCCCCCCCGACAGCGAGGTGCACCAG
GTGAGCCTGCCAACGAGCCGCCAGCCAGGCCAGGGCAGCCCCACGGGCCAACGGAGAGCAAGAAC
AAAGTGGAGCGCAGACCGAGACCGACCCGTGACCCCGGGGCCGGCAGCGGCACAGCGACAG
GAGCTGCTGCAGACCGTGCGCTTCATCAAGTCTGTACCAAGAGAACCCCCCTGCCAGCCCCAAGGGC
ACCCGCCAGGCCACCTGAACCGCCGCCGCTGGCGAGCGCCAGCGCCAGATCCAGAGCATCAGC
GCCTGGATCATCAGCACCCACCTGGCCGCAAGCACCGAGCCCTGCCCCCTGCAGCTGCCCTGGACCTG
CGCCTGAACCTGGACTGCAGCGAGGACTGCAGGCCAGCGGCCACCGAGGGCTGGCAGCCCCCAGGTG
CTGGGCGAGAGCCCCGCCGTGCTGGACAGCGGCCAGCAAGGAGCTCGAGGCCAGGCAAGTGGAGCAAGCGC
ATGAGCGGCTGGAGCGCCGTGCGCGAGCGCATGAAGCGCGCCAGGCCAGGCCACCGGCCAGGGCAGCGC
GTGGGCGCCGTGAGCGCGCACCTGGAGAACGACCGCGCCATCACAGCAGCAACACCGCCGCCAACAAAC
GCCGACTGCCCTGGCTGGAGGCCAGGGAGGACGAGGACGTGGCTTCCCGTGCCTGGGCCAGGGT
CTGCGCCCCATGACCTACAAGGCCCTGGACCTGAGCCACTTCCTGAAGGAGAACGGGCCGGCTGGAG
GGCCTGATCTACAGCCAGAACGCCAGGACATCTGGACCTGTGGATCCACCACACCCAGGGCTACTTC
CCCCGCTGGCAGAACACTACACCCCCGGGCCATCGCTACCCCTGACCTTCGGCTGGTGGCTTCAG
CTGGTGGCCGTGGAGCCCCGACTACGTGGAGGAGGCCAACGCCGGAGAACACAACAGCCTGCTGCACCC
ATGAGCCAGCAGCGCATGGACGACCCCGAGAACGGAGGTGCTGGTGTGGCGCTTCAGGCCCTGGCC

```

Figure 31
(Sheet 2 of 2)

TTCCACCACATGGCCCGCGAGCTGCACCCCGAGTACTACAAGGACTGCGATTAAAGCTTCCCGGGGCT
AGCACCGGT

Figure 32
(Sheet 1 of 1)

pol.opt.SF2 (native, start at p6Pol until 6aa Integrase)

TTCTTCCGCGAGGACCTGGCCTTCTGCAGGGCAAGGCCCCGCGAGTTCAGCAGCGAGCAGACCCGCGCC
AACAGCCCCACCCGCCGCGAGCTGCAGGTGTGGGGCGGGCGAGAACAAACACCCCTGAGCGAGGCCGGCGCC
GACCGCCAGGGCACCGTGAGCTCAACTTCCCCAGATCACCCCTGTCAGCGCCCCCTGGTGACCATC
AGGATCGCGGCCAGCTCAAGGAGGCGCTGCTGACACCGGCCGACGACACCCTGCTGGAGGAGATG
AACCTGCCGGCAAGTGGAGGCCAAGATGATCGGCGGGATCGGGGCTTCATCAAGGTGCGGCAGTAC
GACCAAGATCCCCGGAGATCTGCGGCCACAAGGCCATCGGCACCGTGTGGTGGGCCCCACCCCGTG
AACATCATCGGCCGCAACCTGCTGACCCAGATCGGCTGCACCCATGAACTTCCCCATCAGCCCCATCGAG
ACGGTGCCCGTGAAGCTGAAGCCGGGATGGACGCCAAGGTCAGCAGTGGCCCTGACCGAGGAG
AAGATCAAGGCCCTGGAGATCTGCACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCC
GAGAACCCCTACAACACCCCCCGTGTGCGGCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTG
GACTTCCCGAGCTGAACAAGCGCACCCAGGACTCTGGAGGTGCAAGCTGGGATCCCCACCCCGCC
GGCCTGAAGAAGAAGAGCGTGAACCGTGGCTGGACCTGGGAGGCTGACGCTGGGATCCCCACCCCGCC
AAGGACTTCCGCAAGTACACCGCCTTCACCATCCCCAGCATCAACAACAGAGACCCCCGGCATCCGCTAC
CAGTACAACGTGCTGCCCCAGGGCTGGAAGGGCAGCCCCGCCATCTCCAGAGCAGCATGACCAAGATC
CTGGAGCCCTTCCGCAAGCAGAACCCCGACATCGTGAATCTACCAGTACATGGACGACCTGTACGGG
AGCGACCTGGAGATGGGACGCCAGCACCAAGATCGAGGAGCTGGCCAGCACCTGCTGCGCTGGG
TTCACCAACCCCCGACAAGAACCCAGAGAAGGAGCCCCCTTCCCTGTTGGATCGGCTACGAGCTGCAACCC
GACAAGTGGACCGTGCAAGCCCATCATGCTGCCCCGAGAAGGACAGCTGGACCGTGAAAGCACATCCAGAAG
CTGGTGGCAAGCTGAACTGGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTGTGCAAGCTG
CTGGCGGCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCGAG
AACCGCGAGATCTGAAGGAGGCCCTGACCGAGGTGACTACGACCCAGCAAGGACCTGGTGGCGAG
ATCCAGAAGCAGGGCCAGGGCAGTGGACCTACCAGATCTACCAAGGAGGCCCTCAAGAACCTGAAGACC
GGCAAGTACGCCCGCATGCGCGGCCAACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAAG
GTGAGCACCGAGAGCATCGTGAATCTGGGCAAGATCCCCAAGTTCAAGCTGCCATCCAGAAGGAGACC
TGGGAGGCCCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCAGTGGAGTTCTGTGAACACCC
CCCCCTGGTGAAGCTGTGGTACCAAGCTGGAGAAGGAGGCCATCGTGGCGCCAGACCTTCTACGTGGAC
GGCGCCGCAACCGCGAGACCAAGCTGGCAAGGCCGCTACGTGACCGACCGGGGCCAGAAGGTG
GTGAGCATGCCGACACCACCAACAGAACAGCCAGCTGCAGGCCATCCACCTGGCCCTGCAAGGACAGC
GGCCTGGAGGTGAACATCGTGAACCGACAGCCAGTACGCCCTGGCAGTACCCAGGCCAGCCGACAAG
AGCGAGAGCGAGCTGGTGAGCCAGATCATCGAGCAGCTGATCAAGAACAGGAGAAGGTGACCTGGCTGG
GTGCCCCCCCACAAGGGCATCGCGGCCAACAGAGCAGGTGGACAAGCTGGTGAAGCGCCGGCATCCGCAAG
GTGCTG

Figure 33
(Sheet 1 of 1)

prot.opt.SF2 (native):

CCCCAGATCACCCCTGTGGCAGCGCCCCCTGGTGACCATCAGGATCGGCGGCCAGCTCAAGGAGGCCTG
CTCGACACCGGGCGCCGACGACACCGTGCTGGAGGAGATGAACCTGCCCGGAAGTGGAAAGCCAAGATG
ATCGGCAGGATCGGGGGCTTCATCAAGGTGCAGTACGACCAGATCCCCGTGGAGATCTGCAGGCCAC
AAGGCCATCGGCACCGTGCTGGTGGGCCACCCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAG
ATCGGCTGCACCCCTGAACCTTC

Figure 34
(Sheet 1 of 1)

protIna.opt.SF2 (mutant, Protease non-functional):

```
CCCCAGATCACCCCTGTGGCAGCGCCCCCTGGTGACCATCAGGATCGGCGGCCAGCTCAAGGAGGCGCTG
CTCGCCACCGGGCGCCGACGACACCGTGCTGGAGGAGATGAACCTGCCCAGCAAGTGGAAAGCCCAAGATG
ATCGGGGGATCGGGGGCTTCATCAAGGTGCGGCAGTACGACCAGATCCCCGTGGAGATCTGCGGCCAC
AAGGCCATCGGCACCGTGCTGGTGGGCCCCACCCCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAG
ATCGGCTGCACCCCTGAACCTTC
```

Figure 35
(Sheet 1 of 1)

protInaRT.YM.opt.SF2

CCCCAGATCACCCCTGTGGCAGCGCCCCCTGGTGACCATCAGGATCGCGGCCAGCTCAAGGAGGCCGTG
CTCGCCACCGGCGCGACGACACCGTGCTGGAGGAGATGAACCTGCCCGOAAGTGGAAAGCCCAAGATG
ATCGGCGGGATCGGGGCTTCATCAAGGTGGCGCAGTACGACCAGATCCCGTGGAGATCTGCGGCCAC
AAGGCCATCGGCACCGTGCTGGTGGGCCACCCCGTGAACATCATGGCCCAACCTGCTGACCCAG
ATCGGCTGCACCCCTGAACCTCCCCATCAGCCCCATCGAGACGGTGGCCCGTGAAGCTGAAGGCCGGGATG
GACGGCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGCA
GAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACACCCCGTGGCC
ATCAAGAAGAAGGACAGCACCAAGTGGCGAAGCTGGTGGACTTCCCGAGCTGAACAAGCGCACCCAG
GACTTCTGGGAGGTGCAGCTGGCATCCCCCACCCCGCCCTGAAGAAGAAGAAGAGCGTGACCGTG
CTGGACGTGGCGACGCCTACTTCAGCGTCCCCCTGGACAAGGACTTCCGCAAGTACACCGCCTTCACC
ATCCCCAGCATCAACAACGAGACCCCGCATCCGCTACCAAGTACAACGTGCTGCCCAAGGCTGGAAG
GGCAGCCCCGCATCTTCAGAGCAGCATGACCAAGATCCTGGAGCCCTCCGCAAGCAGAACCCGAC
ATCGTGAATCTACCAGGCCCCCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCAGCACCAAGATC
GAGGAGCTGCCAGCACCTGCTGCGCTGGGCTTCACCAACCCCGACAAGAAGCACCAGAAGGAGCC
CCCTCCTGTGGATGGGCTACGAGCTGCACCCCGACAAGTGGACCCTGCAGCCATCATGCTGCCAG
AAGGACAGCTGGGACCGTGAACGACATCCAGAAGCTGGTGGCAAGCTGAACCTGGCCAGGAGATCTAC
GCCGGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCCGGACCAAGGCCCTGACCGAGGTGATCCCC
CTGACCGAGGAGGCCAGCTGGAGCTGGCGAGAACCGCGAGATCCTGAAGGAGCCGTGCACGAGGTG
TACTACGACCCAGAAGGACCTGGTGGCCAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTACCA
ATCTACCAGGAGCCCTCAAGAACCTGAAGACCGCAAGTACGCCGCATGCCGGGCCCCACACCAAC
GACGTGAAGCAGCTGACCGAGGCCGTGCAGAAGGTGAGCACCAGAGACATCGTGAATCTGGGCAAGATC
CCCAAGTTCAAGCTGCCCATCCAGAAGGAGACCTGGGAGGCCCTGGTGGATGGAGTACTGGCAGGCCACC
TGGATCCCCGAGTGGGAGTTCGTGAACACCCCCCCCCCTGGTGAAGCTGTGGTACAGCTGGAGAAGGAG
CCCACATCGTGGCGCCGAGACCTCTACGTGGACGGCGCCCAACCGCGAGACCAAGCTGGGCAAGGCC
GGCTACGTGACCGACCGGGGCCGGCAGAAGGTGGTGAGCATGCCGACACCACCAAGGAGACCGAG
CTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTGAACCGACAGCCAGTAC
GCCCTGGGCATCATCCAGGCCAGCCGACAAGAGCGAGAGCGAGCTGGTGGCCAGATCATGAGCAG
CTGATCAAGAAGGAGAAGGTGTACCTGGCTGGGTGCCGCCACAAGGGCATCGCGCAACGAGCAG
GTGGACAAGCTGGTGGCGCCGGATCCGCAAGGTGCTG

Figure 36
(Sheet 1 of 1)

protInaRT.YMWM.opt.SF2

CCCCAGATCACCCCTGGCAGCGCCCCCTGGTGACCATCAGGATCGCGGCCAGCTCAAGGAGGCCCTG
CTCGCCACCGGCGCCGACGACACCGTGTGGAGGAGATGAACCTGCCCCAAGTGGAGGCCAAGATG
ATCGGCGGGATCGGGGCTTCATCAAGGTGGCAGTACGACCAAGATCCCCGTGGAGATCTGCGGCCAC
AAGGCCATCGGCACCGTGCTGGGGCCCCACCCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAG
ATCGGCTGACCCCTGAACCTCCCCAGATCACCCCTGGCAGGCCCTGGTGAACATCAGGATCGGC
GGCCAGCTCAAGGAGGCCGCTGCTGACACCCGGCGACGACACCGTGTGGAGGAGATGAACCTGCC
GGCAAGTGGAAAGCCCAAGATGATCGGGGATCGGGGCTTCATCAAGGTGGCAGTACGACCAAGATC
CCCGTGGAGATCTCGGCCACAAGGCCATCGCACCGTGTGGGGCCCCACCCCCGTGAACATCATC
GGCCGCAACCTGCTGACCCAGATCGGCTGACCCCTGAACCTCCCCATCGAGACGGTGGCC
GTGAAGCTGAAGCCGGGATGGACGGCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAAGATCAAG
GCCCTGGTGGAGATCTGACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCC
TACAACACCCCCGTGGCCATCAAGAAGAAGGACAGCACCAGTGGCGCAAGCTGGTGGACTTCCGC
GAGCTGAACAAGCGCACCCAGGACTCTGGGAGGTGAGCTGGCATCCCCACCCGCCGGCTGAAG
AAGAAGAAGAGCGTGTGGACCGTGTGGACGTGGCGACGCCCTACTTCAGCGTGGCCCTGGACAAGGACTTC
CGCAAGTACACCGCCTTCACCATCCCCAGCATCAACACAGGACCCCCGGCATCCGCTACCAAGTACAAC
GTGCTGCCCAAGGGCTGGAAGGGCAGCCCCCGCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGCCC
TTCCGCAAGCAGAACCCCGACATCGTGTACCTACAGGCCCTGTACGTGGCAGCGACCTGGAGATC
GGCCAGCACCGCACCAAGATCGAGGAGCTGCGCCAGCACCTGCGCTGGGCTTCACCACCCCCGAC
AAGAAGCACCAGAAGGAGCCCCCTTCTGCCCCATCGAGCTGACCCCCGACAAGTGGACCGTGCAGCCC
ATCATGCTGCCAGAGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTGAACCTGG
GCCAGCCAGATCTACGCCGCATCAAGGTGAAGCAGCTGTCAAGCTGCTGCCGGCACCAAGGCCCTG
ACCGAGGTGATCCCCCTGACCGAGGAGGCCGAGCTGGAGCTGGCGAGAACCGCGAGATCCTGAAGGAG
CCCGTGCACGAGGTGACTACGACCCCAGCAAGGACTCTGGTGGCGAGATCCAGAACGGCAGGGC
CAGTGGACCTACCAAGATCTACCAAGGCCCTCAAGAACGCTGAAGACCGGCAAGTACGCCGCATGCC
GGCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGAGAACGGTGGAGCACCAGAGCATCGT
ATCTGGGCAAGATCCCAAGTTCAAGCTGCCATCCAGAACGGAGACCTGGGAGGCCCTGGTGGAG
TACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCTGTGAACACCCCCCTGGTGAAGCTGTGGTAC
CAGCTGGAGAACGGAGGCCATCGTGGCGCCGAGACCTCTACGTGGACGGCGCCAACCGCGAGACC
AAGCTGGCAAGGCCGGCTACGTGACCGACCGGGGCCGGCAGAACGGTGGTAGCATGCCGACACCACC
AACCAAGAACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGT
ACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGCCCCGACAAGAGCGAGAGCGAGCTGGTGG
CAGATCATCGAGCAGCTGATCAAGAACGGAGAACGGTGTACCTGGCCTGGGTGCCGCCACAAGGGC
GGCGGCAACGAGCAGGTGGACAAGCTGGTGAAGCGCCGGCATCCGCAAGGTGCTG

Figure 37
(Sheet 1 of 1)

ProtInaRTmut.SF2 (Protease inactive, RT mutated)

GTGACGCCACCATGCCAGATCACCTGTGGCAGCGCCCCCTGGTGAC
CATCAGGATCGGCGGCCAGCTCAAGGAGGCGCTGCTGCCACCGCGCCG
ACGACACCGTGCTGGAGGAGATGAACCTGCCGGCAAGTGGAAAGCCCAA
GATGATCGGCGGGATCGGGGCTTCATCAAGGTGCGGCAGTACGACCAGA
TCCCCGTGGAGATCTCGGCCACAAGGCCATCGGCACCGTGCTGGTGGC
CCCACCCCCGTGAACATCATCGGCCAACCTGCTGACCCAGATCGGCTG
CACCTGAACCTCCCCATCAGCCCCATCGAGACGGTGGCCGTGAAGCTGA
AGCCGGGATGGACGCCAACGGTCAAGCAGTGGCCCTGACCGAGGA
GAAGATCAAGGCCCTGGAGATCTGCACCGAGATGGAGAAGGAGGGC
AAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCCGTGTCGC
CATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGACTTCCGC
GAGCTGAACAAGCGCACCCAGGACTCTGGAGGTGCAGCTGGCATCCC
CCACCCCGCCGGCCTGAAGAAGAAGAGCGTGACCGTGTGGACGTG
GGCGACGCCTACTTCAGCGTCCCCCTGGACAAGGACTTCCGCAAGTACAC
CGCCTTCACCATCCCCAGCATCAACAACGAGACCCCCGGCATCCGCTACC
AGTACAACGTGCTGCCAGGGCTGGAAGGGCAGCCCCGCCATCTCCAG
AGCAGCATGACCAAGATCCTGGAGCCCTCCGCAAGCAGAACCCGACAT
CGTGAATCTACCAGGCCCCCTGTACGTGGCAGCGACCTGGAGATCGGCC
AGCACCGCACCAAGATCGAGGAGCTGCGCCAGCACCTGCTGCGCTGGGGC
TTCACCAACCCCCGACAAGAACGACCAAGAACGGAGCCCCCTTCCTGCCAT
CGAGCTGCACCCCGACAAGTGGACCGTGCAGGCCATCATGCTGCCGAGA
AGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTGAA
CTGGGCCAGCCAGATCTACGCCGCATCAAGGTGAAGCAGCTGTGCAAGC
TGCTGCGCGGCCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAG
GCCGAGCTGGAGCTGGCGAGAACCGCGAGATCCTGAAGGAGCCGTGC
ACGAGGTGTACTACGACCCAGCAAGGACCTGGTGGCCGAGATCCAGAA
GCAGGGCCAGGGCCAGTGGACCTACCAAGATCTACCAAGGAGCCCTCAAGA
ACCTGAAGACCGCAAGTACGCCGCATGCGCGGCCACACCAACGAC
GTGAAGCAGCTGACCGAGGCCGTGAGAACGGTGAAGCAGCTGAGCATCG
TGATCTGGGCAAGATCCCCAAGTCAAGCTGCCATCCAGAACGGAGACC
TGGGAGGCCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTG
GGAGTCGTGAACACCCCCCCCCTGGTGAAGCTGTGGTACCGAGCTGGAGA
AGGAGCCCATCGTGGCGCCGAGACCTCTACGTGGACGGCGCCGCAAC
CGCGAGACCAAGCTGGCAAGGCCGTACGTGACCGACCGGGGCCGGC
AGAAGGTGGTGAAGCATGCCGACACCACCAACCAGAACGACCGAGCTGCA
GGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTGA
CCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGCCGACAAGAGC
GAGAGCGAGCTGGTGAAGCCAGATCATGAGCAGCTGATCAAGAACGGAGA
AGGTGTACCTGGCCTGGGTGCCCCACAAGGGCATCGCGGCAACGAG
CAGGTGGACAAGCTGGTGAAGGCCGGCATCCGCAAGGTGCTCTAAATCTA
GA

Figure 38
(Sheet 1 of 1)

protRT.opt.SF2

CCCCAGATCACCTGTGGCAGCGCCCCCTGGTGACCATCAGGATCGGCGGCAGCTCAAGGAGGCCTG
CTCGACACCGGCGCCGACGACACCGTGTGGAGGAGATGAACCTGCCGCCAAGTGGAGGCCAAGATG
ATCGGCGGGATCGGGGCTTCATCAAGGTGCGGAGTACGACCAGATCCCCGTGGAGATCTGCCAC
AAGGCCATCGGCACCGTGTGGTGGGCCACCCCCGTGAACATCATGGCCGCAACCTGCTGACCCAG
ATCGGCTGCACCCCTGAACCTCCCCATCAGCCCCATCGAGACGGTGCCTGAAGCTGAAGGCCGGGATG
GACGGCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGCACC
GAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCCGTGTCGCC
ATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGACTTCCGCGAGCTGAACAAGCGCACCCAG
GACTTCTGGGAGGTGCAGCTGGGCATCCCCCACCCCGCCGGCCTGAAGAAGAAGAAGAGCGTGACCGTG
CTGGACGTGGCGACGCCTACTTCAGCGTGCCTGACAAGGACTTCCGCAAGTACACCGCCTTCACC
ATCCCCAGCATCAACAACGAGACCCCGGCATCCGCTACCAGTACAACGTCTGCCCGAGGCTGGAAG
GGCAGCCCCGCATCTTCCAGAGCAGCATGACCAAGATCTGGAGCCCTCCGCAAGCAGAACCCCGAC
ATCGTGTACTACCAAGTACATGGACGACCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCACC
AAGATCGAGGAGCTGCACCGACCTGCTGCCTGGGCTTCACCAACCCCGACAAGAACGACCAAG
GAGCCCCCTTCTGTGGATGGCTACGAGCTGCACCCGACAAGTGGACCGTGCAGCCCATGCTG
CCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAAGCTGGTGGCAAGCTGAACTGGCCAGCCAG
ATCTACGCCGGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCCGGCACCAGGCCCTGACCGAGGTG
ATCCCCCTGACCGAGGAGGCCGAGCTGGAGCTGGCCGAGAACCCGAGATCTGAAGGAGCCGTGCAC
GAGGTGTACTACGACCCCAGCAAGGACCTGGTGGCCGAGATCCAGAAGCAGGGCCAGGGCAGTGGACC
TACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAAGGTGAGCACCAGCATCGTGTACTGGCAG
AAGATCCCCAAGTTCAAGCTGCCATCCAGAAGGAGACCTGGGAGGCTGGTGGATGGAGTACTGGCAG
GCCACCTGGATCCCCAGTGGAGTTCGTGAACACCCCCCTGGTGAAGCTGTGGTACCAAGCTGGAG
AAGGAGCCCACGTGGCGCCGAGACCTTCTACGTGACGGCGCCGCAACCGCGAGACCAAGCTGGC
AAGGCCGGCTACGTGACCGACCGGGGCCGAGAAGGTGGTGAGCATGCCGACACCACCAACCAGAAG
ACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTACCGACAGC
CACTACGCCCTGGCATCCAGGCCAGCCCCACAAGAGCGAGAGCGAGCTGGTGGACCGAGATCATC
GAGCAGCTGATCAAGAAGGAGAAGGTGTACCTGGCTGGGTGCCCCACAAGGGCATCGCGGCAAC
GAGCAGGTGGACAAGCTGGTGGACCGCCGGCATCCGCAAGGTGCTG

Figure 39
(Sheet 1 of 1)

ProtRT.TatRevNef.opt_B

```

ATGCCCCAGATCACCTGTGGCAGCGCCCCCTGGTGACCATCAGGATCGGCGGCCAGCTCAAGGAGGCC
CTGCTCGCCACCGGCCGACGACACCGTGCTGGAGGAGATGAACCTGCCCCGCAAGTGGAAAGGCCAAG
ATGATCGGGGATCGGGGCTCATCAAGGTGCGGAGTACGACCAGATCCCCGTGGAGATCTGGGC
CACAAGGCCATCGCACCGTGCTGGTGGGGCCCACCCCGTGACATCATCGGCCGCAACCTGCTGACC
CAGATCGGCTGCACCCATGAACTCCCCATCGAGACGGTGCCCGTGAAGCTGAAGGCCGGGG
ATGGACGGCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGTGGAGATCTGC
ACCGAGATGGAGAAGGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCGTGTTC
GCCATCAAGAAGAAGGGACAGCACCAAGTGGCGCAAGCTGGTGGACTTCCGCGAGCTGAACAAGCGACC
CAGGACTTCTGGGAGGGTGAGCTGGCATCCCCCACCCGCCCTGAAGAAGAAGAGCGTGACC
GTGCTGGACGTGGCGACGCCTACTTCAGCGTGGCCCTGGACAAAGGACTTCCGCAAGTACACCGCCTTC
ACCATCCCCAGCATCAACAACGAGACCCCCGGCATCCGCTACCAAGTACAACGTGCTGCCCAAGGGCTGG
AAGGGCAGCCCCCCTCTTCCAGAGCAGCATGACCAAGATCTGGAGCCCTTCCGCAAGCAGAACCCC
GACATCGTATCTACAGGCCCCCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCACGCCACCAAG
ATCGAGGAGCTGCGCCAGCACCTGCTGCGTGGGCTTCACCAACCCCGACAAGAACGACAGAACGGAG
CCCCCCTTCCTGCCCCATCGAGCTGCACCCGACAAGTGGACCGTGCAGGCCATCATGCTGCCAGAACG
GACAGCTGGACCGTGAACGACATCCAGAAAGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATCTACGCC
GGCATCAAGGTGAAGCAGCTGTCAAGCTGCTGCGGGCACCAAGGCCATGCCGGGCCACACCAACGAC
ACCGAGGAGGCCGAGCTGGAGCTGGCGAGAACCGCAGAGATCTGAAGGGAGGCCGTGACGAGGTGTAC
TACGACCCAGCAAGGACCTGGTGGCCGAGATCCAGAAGCAGGCCAGGGCAGTGGACCTACCAAGATC
TACCAAGGAGCCCTCAAGAACCTGAAGAGACCGCAAGTACGCCCATGCCGGGCCACACCAACGAC
GTGAAGCAGCTGACCGAGGCCGTGCAGAAAGGTGAGCACCGAGAACATCGTATCTGGGCAAGATCCCC
AAGTTCAAGCTGCCCATCCAGAAGGAGACCTGGGAGGCCCTGGTGGAGTACTGGCAGGCCACCTGG
ATCCCCGAGTGGAGCTGTGAACACCCCCCCTGGTGAAGCTGTGGTACAGCTGGAGAACGGAGGCC
ATCGTGGCGCCGAGACCTTCTACGTGGACGGCGCCAACCGCAGACCAAGCTGGCAAGGCCGGC
TACGTGACCGACCGGGGCCGAGAACGGTGTGAGCATCGCGACACCACCAAGAACGACCGAGCTG
CAGGCCATCCACCTGGCCCTGCAGGACAGGCCCTGGAGGTGAACATCGTACCGACAGCCAGTACGCC
CTGGGCATCATCCAGGCCAGCCGACAAGAGCGAGAGCGAGCTGGTGGAGCCAGATCATGAGCAGCTG
ATCAAGAAGGAGAACGGTGTACCTGGCCTGGTGCCGCCACAAGGGCATCGCGGCAACGAGCAGGTG
GACAAGCTGGTGGAGCGCCGGCATCCGCAAGGTGCTCGAATTGAGGCCGTGGACCCCGCTGGAGGCC
TGGAGCACCCGGCAGCCAGCCAAGACGCCGGCACCAACTGCTACTGCAAGAAGTGTGCTTCCAC
TGCCAGGTGAGCTCATACCAAGGGCCTGGCATCAGCTACGCCGCAAGAACGCGCCAGCGCCGC
CGCGCCCCCCCCGACAGCGAGGTGCACCGGTGAGCTGCCAACGAGGCCAGCCAGCCCCAGGGC
GACCCCAACGGGCCCCAAGGAGAGCAAGAACGAGGCCAGGCCAGGGAGACCGAGGCCAGGGCACCC
GGGGCGGGCCGAGCGCGACAGCGAGGGAGCTGTCAGACCGTGCCTCATCAAGTCCGTAC
CAGAGCAACCCCTGCCAGCCCAAGGGCACCCGCCAGGCCAGCTGAACCGCCGCCGCTGGCGC
GAGGCCAGCGCCAGATCCAGAGCATCAGGCCCTGGATCATCAGCACCCACCTGGGCCAGCACCGAG
CCCGTGCCTGCAGCTGCCCTGGACCTGCGCTGAACCTGGACTGCAAGCGAGGACTGCGGCACCAAG
GGCACCCAGGGCGTGGGAGGCCCTGGAGAGGCCAGGCCAGGCCAGCGCAGGCCAGGCCAGCGC
GAGCTCGAGGCCGGCAAGTGGAGCAAGCGCATGAGCGGCTGGAGCGCCGTGCGCAGGCCAGTGAAGCGC
GCCGAGGCCGCCAGGCCGCCGACGGCGTGGGCCGTGAGCCCGCAGCTGGAGAACGACGGGCC
ATCACCAAGCAGCAACACCGCCGCCAACACGCCGACTGCGCTGGCTGGAGGCCAGGAGGACGAGGAC
GTGGGCTTCCCCGTGCGCCCCCAGGTGCCCTGCGCCCATGACCTACAAGGCCGCCCTGGACCTGAGC
CACTTCCCTGAAGGAGAACGGCGGCCCTGGAGGGCCTGATCTACAGCCAGAACGCCAGGACATCTGGAC
CTGTGGATCCACCACACCCAGGGCTACTTCCCCGGCTGGCAGAACTACACCCCCGGCCGGCATCCGC
TACCCCCCTGACCTTCGGCTGGTGTCAAGCTGGTGGCCGTGGACCCGACTACGTGGAGGAGGCCAAC
GCCGGCGAGAACAAACAGCCTGTCACCCCATGAGCCAGCACGGCATGGAGCACCCGAGAACGGAGGTG
CTGGTGTGGCGCTTCGACAGGCCCTGGCCTTCCACCATGGGCCGAGCTGACCCGAGTACTAC
AAGGACTGC

```

Figure 40
(Sheet 1 of 1)

ProtRTTatRevNef.opt_B

GCCACCATGCCCATGCCACCGCCAGATCACCCCTGTGGCAGGCCCTGGTGACCATCAGGATGGCGGCCAGCTCAAG
 GAGGCCTGCTCGCCACCGCGCCAGCACACCGTGTGGAGGAGATGAACCTGCCGGCAAGTGGAG
 CCCAAGATGATCGGCGGGATCGGGGCTTCATCAAGGTGCCAGTACGACCAGATOCCCCTGGAGATC
 TGGGCCACAAGGCCATCGGCACCGTGTGGTGGGCCACCCCGTGAACATCATCGGCCCAACCTG
 CTGACCCAGATCGGCTGCCACCTGAACCTCCCGATGCCATCGAGACGGTGECCGTGAAGCTGAAG
 CGGGGATGGACGGCCCCAAGGTCAAGCAGTGGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGTGGAG
 ATCTGACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCC
 GTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGACTTCCGAGCTGAACAAG
 CGCACCCAGGACTCTGGGAGGTGCAGCTGGGCATCCCCCACCCGCCCTGAAGAAGAAGAGC
 GTGACCGTGTGGACGTGGCGACGCTACTTCAGCGTGGCCCTGGACAAGGACTCCGCAAGTACACC
 GCCTCACCATCCCCAGCATCAACACGAGACCCCCGGCATCCGCTACCAGTACAACGTGCTGCC
 GGCTGGAAGGGCAGCCCCGCCATCTTCAGAGCAGCATGACCAAGATCTGGAGCCCTCCGCAAGCAG
 AACCCCACATCGTGTACCTACAGGCCCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCACGC
 ACCAAGATCGAGGAGCTGCCAGCACCTGCTGCCCTGGCTTCACCACCCCCGACAAGAAGCAC
 AAGGAGCCCCCTTCCTGCCCATCGAGCTGCACCCGACAAGTGGACCGTGCAGCCATCATGCTGCC
 GAGAAGGACAGCTGGACCGTGAACGACATCCAGAAGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATC
 TACGCCGCATCAAGGTGAAGCAGCTGTCAAGCTGCTGCCGGCACCAAGGCCCTGACCGAGGTGATC
 CCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCGAGAACCGCAGATCCTGAAGGAGGCCGTGCACGAG
 GTGTACTACGACCCCAGCAAGGACCTGGTGGCCGAGATCCAGAAGCAGGGCCAGGGCCAGTGGACCTAC
 CAGATCTACCAGGAGCCCTCAAGAACCTGAAGACCGGCAAGTACGCCGCATGCCGGCAGCCACACC
 AACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAAGGTGAGCACCAGAGACATCGTATCTGGGCAAG
 ATCCCCAAGTTCAAGCTGCCATCCAGAAGGAGACCTGGGAGCTGGTGAACACCCCCCTGGTGAAGCTGTGG
 ACCTGGATCCCCAGTGGGAGTTCTGCAAGGACCTTCTACGTGGACGGGGCCAAACCGCAGACCAAGCTGG
 GAGCCCATCGTGGGCCGAGACCTTCTACGTGGACGGGGCCAAACCGCAGACCAAGCTGG
 GCCGGCTACGTGACCGACGGGGCCGGCAGAAGGTGGTAGCATGCCGACACCACCAAGAACGACC
 GAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTACCGACAGCC
 TACGCCCTGGGCATCATCCAGGCCAGCCCAGACAGAGCGAGAGCGAGCTGGTGGACCCAGATCATCGAG
 CAGCTGATCAAGAAGGAGAAGGTGTACCTGGCCTGGGTGCCCAACAGGCATCGGCCAACGAG
 CAGTGGACAAGCTGGTGGACGCCGAGCATCCGCAAGGTGCTCGAATTGAGCCGTGGACCCCCCG
 GAGCCCTGGGAAGCACCCGGCAGCCAGCCCAGACAGGAGCTGCTGAGACCGTGGCAGGCCAGATCATCG
 TTCCACTGCCAGGTGAGCTTCATCACCAGGGCTGGCATCGTACGGCCGCAAGAACGCGCCAG
 CGCCGCCGCGCCCCCGACAGCGAGGTGCAACAGGTGAGCCTGCCCAAGGCATCGGCCAACGAG
 CAGGGCAGCCCACCGGCCCAAGGAGAGCAAGAACGAGGTGGAGCGCAGACCGAGACCGAC
 CACCCGGGGCCGGCCGAGCGGCCAGCGAGAGCTGCTGAGACCGTGGCCTTCATCAAGTTC
 CTGTACCAAGGCAACCCCTGCCAGCCCCAACGGCACCCGCCAGGCCACCTGAACGCCGCC
 TGGCGCAGCGCCAGCGCCAGATCCAGGACATCAGGCCCTGGATCATCAGCACCAACCTGGGCC
 ACCGAGCCGTGCCCTGCAGCTGCCCTGGCAGCCCCCAGGTGCTGGCGAGAGCCCCGCC
 ACCAGCGGCACCCAGGGCTGGGAGCCCCCAGGTGCTGGCGAGAGCCCCGCC
 ACCAAGGAGCTCGAGGCCGCAAGTGGAGCAAGCGCATGAGCGCTGGAGCGCC
 AAGCGCCGAGCCCCGCCAGCGCCAGCGCCAGCGACCTGGAGGAAGCAC
 GGCGCCATCACAGCAGCAACACGCCGCAACACGCCGACTGCCCTGGAGGAAGCAC
 GAGGACGTGGCTTCCCGTGCAGGCCCTGGAGGGCCATGACCTACAAGGCC
 CTGAGCCACTTCTGAAGGAGAAGGGGGCTGGAGGGCCTGAGACTACAG
 CTGGACCTGTGGATCCACCAACCCCCAGGGCTACTTCCCGTGGCAGAAC
 TACACCCCCGGCCGG
 ATCCGCTACCCCTGACCTCGGCTGGTCTCAAGCTGGTGGCCGTGGAC
 GCCAACGCCGGGAGAACAACAGCCGCTGCACCCCATGAGCCAGC
 GAGGGTGTGGTGGCGCTCGACAGCCGCC
 TGGCCTGGCC
 TACTACAAGGACTGCGATTAA

Figure 41
(Sheet 1 of 1)

rev.exon1_2.M5/10.opt.SF162

```
ATGGCCGGCCGCAGCGCGACAGCGACGAGGAGCTGCTGCAGACCGTGCCTTCATCAAGTTCCGTAC
CAGAGCAACCCCCCTGCCAGCCCCAAGGGCACCCGCCAGGCCACCTGAACCGCCGCCGCTGGCGC
GAGCGCCAGCGCCAGATCCAGAGCATCAGCGCCTGGATCATCAGCACCCACCTGGCCGCAGCACCGAG
CCCGTGCCCCCTGCAGCTGCCCGACCTGCCTGAACCTGGACTGCAGCGAGGACTGCACCGCAGCAGC
GGCACCCAGGGCGTGGGCAGCCCCCAGGTGCTGGCGAGAGCCCCCGCTGGACAGCGGCACCAAG
GAG
```

Figure 42
(Sheet 1 of 1)

rev.exon1_2.opt.SF162

ATGGCCGGCCGCAGCGGCACAGCGACGGAGCTGCTGCAGACCGTGCCTTCATCAAGTTCTGTAC
CAGAGCAACCCCTGCCAGCCCCAAGGGCACCCGCCAGGCCCGCAACCGCCGCCGCTGGCGC
GAGCGCCAGGCCAGATCCAGAGCATCAGCGCCTGGATCATCAGCACCCACTGGGCCGAGCACCCGAG
CCCGTGCCCCCTGCAGCTGCCCTGGAGCGCCTGAACCTGGACTGCAGCGAGGACTGCGGACCCAGC
GGCACCCAGGGGTGGCAGCCCCCAGGTGCTGGCGAGAGCCCCGCCGTGGACAGCGGACCCAAG
GAG

Figure 43
(Sheet 1 of 1)

RT.opt.SF2 (mutant)

GCCACCATGCCCAAGATCACCTGTGGCAGCGCCCCCTGGTACCATCAGGATCGGCAGCTCAAG
GAGGCGCTGCTGCCACCGGCCGACGACACCGTGTGGAGGAGATGAACCTGCCGGCAAGTGGAG
CCCAAGATGATCGGGGGATCGGGGGCTTCATCAAGGTGCGCAGTACGACCAGATCCCCGTGGAGATC
TGGGCCACAAGGCCATCGGCACCGTGTGGTGGGCCACCCCCGTGAACATCATGGCCGAACTG
CTGACCCAGATCGGCTGACCCCTGAACCTCCCCATCAGCCCCATCGAGACGGTGCCGTGAAGCTGAAG
CGGGGGATGGACGGCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAAAGATCAAGGCCCTGGTGGAG
ATCTGCACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCCCC
GTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGACTTCCGAGCTGAACAAG
CGCACCCAGGACTCTGGAGGTGCAGCTGGCATCCCCACCCCGCCGGCTGAAGAAGAAGAAGAGC
GTGACCGTGCTGGACGTGGCGACGCCCTACCTCAGCGTGGCCCTGGACAAGGACTTCCGCAAGTACACC
GCCTTCACCATCCCCAGCATCAACAACGAGACCCCCGGCATCCGCTACCAGTACAACGTGCTGCCAG
GGCTGGAAGGGCAGCCCCGCATCTCCAGAGCAGCATGACCAAGATCTGGAGCCCTCCGCAAGCAG
AACCCCCGACATCGTATCTACCAAGGCCCCCTGTACGTGGCAGCAGCTGGAGATCGGCCAGCAGC
ACCAAGATCGAGGAGCTGCGCCAGCACCTGCGCTGGGCTTCACCACCCCCGACAAGAAGCACCAG
AAGGAGCCCCCTTCTGCCATCGAGCTGCACCCGACAAGTGGACCGTGCAGCCATCATGCTGCC
GAGAAGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTGAACCTGGCCAGGAGATC
TACGCCGCATCAAGGTGAAGCAGCTGTGCAAGCTGCGCGCACCAAGGCCCTGACCGAGGTGATC
CCCCCTGACCGAGGAGGGCCGACCTGGAGCTGGCAGAACCGCGAGATCTGAAGGAGGCCGTGCACGAG
GTGTACTACGACCCCAGCAAGGACCTGGTGGCCGAGATCCAGAACGAGCCCCAGTGGACCTAC
CAGATCTACCAAGGAGCCCCCTCAAGAACCTGAAGACCCGCAAGTACGCCGCATGGCCGGCCCCACACC
AACGACGTGAAGCAGCTGACCGAGGGCGTGCAGAACGCTGGTGGCAAGGAGACATCGTATCTGGGCAAG
ATCCCCAAGTTCAAGCTGCCATCCAGAACGGAGACCTGGGAGGGCTGGTGGAGTACTGGCAGGCC
ACCTGGATCCCCGAGTGGGACTTCGTGAACACCCCCCTGGTGAAGCTGTGGTACCAAGCTGGAGAAG
GAGGCCATCGTGGCCGAGACCTTCTACGTGGACGGCGCCCAACCGCGAGACCAAGCTGGGCAAG
GCCGGCTACGTGACCGACCGGGCCGGCAGAACGGTGGTGGAGCATGCCGACACCACCAACCAGAAC
GAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTGCACCGACAGCCAG
TACGCCCTGGGATCATCCAGGCCAGCCGACAAGAGCGAGAGCGAGCTGGTGGAGCCAGATCATCGAG
CAGCTGATCAAGAAGGAGAAGGTGTACCTGGCCTGGTGGCCCAAGGGCATCGCCGGCAACGAG
CAGGTGGACAAGCTGGTGGAGCCGGCATCCGCAAGGTGCTCTAA

Figure 44
(Sheet 1 of 1)

RT.opt.SF2 (native)

GCCACCATGCCCGAGATCACCCGTGGCAGCGCCCCCTGGTACCATCAGGATCGGCGGCCAGCTCAAG
GAGGCGCTGCTCGACACCGGGCGCGACGACACCGTGTGGAGGAGATGAACCTGCCCGCAAGTGGAG
CCCAAGATGATCGCGGGATCGGGGGCTTCATCAAGGTGGCGCACTACGACCAGATCCCGTGGAGATC
TGCAGGCCACAAGGCCATCGGCACCGTGTGGTGGCCCCACCCCGTGAACATCATCGGCCAACCTG
CTGACCCAGATCGGCTGACCCATGAACCTCCCACATCAGCCCCATCGAGACGGTGCCCGTGAAGCTGAAG
CCGGGGATGGACGGGCGCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAAGATCAAGGCCCTGGTGGAG
ATCTGCACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACCC
GTGTTGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGACTTCGCGAGCTGAACAAG
CGCACCCAGGACTCTGGAGGTGCAGCTGGCATCCCCACCCCGCCGCTGAAGAAGAAGAAGAGC
GTGACCGTGCTGGACGTGGCGACGCCCTACTTCAGCGTGCCTGGACAAGGACTTCGCAAGTACACC
GCCTTCACCATCCCCAGCATCAACAACGAGACCCCCGGCATCGCTACCAAGTACAACGTGCTCCCCAG
GGCTGGAAGGGCAGCCCCGCCATCTCCAGAGCAGCATGACCAAGATCCTGGAGCCCTCCGCAAGCAG
AACCCCGACATCGTGTACCATCCAGTACATGGACGACCTGTACGTGGCAGCGACCTGGAGATGGCCAG
CACCGCACCAAGATCGAGGAGCTGCCAGCACCTGCTGCCGCTGGGCTTACCAACCCCGACAAGTGGACCGTGCAGCCC
ATCATGCTGCCAGAGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTGAACCTGG
GCCAGCCAGATCTACGCCGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCCGCGACCAAGGCCCTG
ACCGAGGTGATCCCCCTGACCGAGGAGGCCGAGCTGGAGCTGGCGAGAACCGCGAGATCTGAAGGAG
CCCGTGACGAGGTGACTACGACCCAGCAAGGACCTGGTGGCCGAGATCCAGAACGAGGGCAGGGC
CAGTGGACCTACCAAGATCTACCAAGGAGCCCTCAAGAACCTGAAGAACCGGCAACTACGCCGCATCGC
GGCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAACGGTGAGCACCGAGAGCATCGT
ATCTGGGCAAGATCCCCAAGTTCAAGCTGCCCATCCAGAACGGAGACCTGGGAGGCCTGGTGGAG
TACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCGTGAACACCCCCCTGGTGAAGCTGTGGTAC
CAGCTGGAGAAGGAGCCCATCGTGGCGCGAGACCTCTACGTGGACGGGCCGCAACCGCGAGACC
AAGCTGGCAAGGCCGGCTACGTGACCGACCGGGGCCGAGAACGGTGGTGAGCATGCCGACACC
AACCAAGAGACCAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCTGGAGGTGAACATCGT
ACCGACAGCCAGTACGCCCTGGCATCCAGGCCAGCCGACAAGAGCGAGAGCGAGCTGGTGGAG
CAGATCATCGAGCAGCTGATCAAGAAGGAGAAGGTGTACCTGGCCTGGGTGCCGCCACAAGGGCATC
GGCGGCAACGAGCAGGTGGACAAGCTGGTGGAGCGCCGAGCTGGTGAACATCGTGTAA

Figure 45
(Sheet 1 of 1)

RTmut.SF2 (RT mutated)

GTGAGCCACCATGCCATCAGCCCCATCGAGACGGTCCCCGTGAAGCT
GAAGCCGGGATGGACGGCCCCAAGGTCAAGCAGTGGCCCCGTACCGAG
GAGAAGATCAAGGCCCTGGTGGAGATCTGCACCGAGATGGAGAAGGAGG
GCAAGATCAGCAAGATCGGCCCCGAGAACCCCTACAAACACCCCCGTGTT
GCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGACTTCC
GCGAGCTGAACAAGCGCACCCAGGACTTCTGGGAGGTGCAGCTGGCATC
CCCCACCCCGCCGGCCTGAAGAAGAAGAAGAGCGTGACCGTGCTGGACGT
GGCGACGCCTACTTCAGCGTGGCCCTGGACAAGGACTTCCGCAAGTACA
CCGCCTCACCATCCCCAGCATCAACAACGAGACCCCCGGCATCCGCTAC
CAGTACAACGTGCTGCCAGGGCTGGAAGGGCAGCCCCGCCATCTCCA
GAGCAGCATGACCAAGATCCTGGAGGCCCTCCGCAAGCAGAACCCCGACA
TCGTGATCTACCAGGCCCTGTACGTGGGCAGCGACCTGGAGATCGGC
CAGCACCGCACCAAGATCGAGGAGCTGCGCCAGCACCTGCTGCGCTGGG
CTTCACCACCCCGACAAAGAACGACCAAGAGGCCCTTCCGAG
TCGAGCTGCACCCCGACAAGTGGACCGTGACCCATCATGCTGCCAG
AAGGACAGCTGGACCGTGAAACGACATCCAGAAGCTGGTGGCAAGCTGA
ACTGGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTGTGCAAG
CTGCTCGCGGGCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGA
GGCCGAGCTGGAGCTGGCCAGAACCCCGAGATCCTGAAGGAGGCCGTG
CACGAGGTGTACTACGACCCAGCAAGGACCTGGTGGCCAGATCCAGAA
GCAGGGCCAGGCCAGTGGACCTACCAGATCTACCAAGGAGCCCTCAAGA
ACCTGAAGACCCGGCAAGTACGCCGCATGCGCGGCCACACCAACGAC
GTGAAGCAGCTGACCGAGGCCGTGAGAAGGTGAGCACCGAGAGCATCG
TGATCTGGGCAAGATCCCCAAGTTCAAGCTGCCATCCAGAAGGAGACC
TGGGAGGCCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTG
GGAGTCGTGAACACCCCCCCCCTGGTGAAGCTGTGGTACCAAGCTGGAGA
AGGAGCCATCGTGGCGCCAGACCTTCTACGTGGACGGCGCCGCAAC
CGCGAGACCAAGCTGGCAAGGCCGGTACGTGACCGACCGGGGCCGGC
AGAAGGTGGTAGCATGCCGACACCACCAACCAGAACGACCGAGCTGCA
GGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTGA
CCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGCCGACAAGAGAC
GAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAGCTGATCAAGAAGGAGA
AGGTGTACCTGGCCTGGTGGCCCAAGGGCATCGCGGCAACGAG
CAGGTGGACAAGCTGGTGGAGCGCCGGCATCCGCAAGGTGCTCTAAAGAAT
TC

Figure 46
(Sheet 1 of 1)

tat.exon1_2.opt.C22/37.SF2

```
ATGGAGCCCGTGGACCCCCGCTGGAGCCCTGGAAGCACCCGGCAGCCAGCCAAGACCGCCGGCACC
AACTGCTACTGCAAGAAGTGCTGCTTCCACTGCCAGGTGAGCTTCATCACCAAGGGCTGGGCATCAGC
TACGGCCGCAAGAAGCGCCGCCAGCGCCGCCGCGCCCCCCCCCGACAGCGAGGTGCACCAGGTGAGCCTG
CCCAAGCAGCCGCCAGCCAGCCCCAGGGGAGCCCCACCGGCCCCAAGGAGAGCAAGAAGAAGGTGGAG
CGCGAGACCGAGACCGACCCGTGCAC
```

Figure 47
(Sheet 1 of 1)

tat.exon1_2.opt.C37.SF2

ATGGAGCCCGTGGACCCCCGCTGGAGCCCTGGAAGCACCCGGCAGCCAGCCCAAGACCGCCTGCACC
AACTGCTACTGCAAGAAGTGCTGCTTCCACTGCCAGGTGAGCTTCATCACCAAGGGCCTGGGCATCAGC
TACGGCCGCAAGAAGCGCCGCCAGCGCCGCCGCGCCCCCCCCCGACAGCGAGGTGCACCAGGTGAGCCTG
CCCAAGCAGCCGCCAGCCAGCCCCAGGGCGACCCCACCGGCCCCAAGGAGAGCAAGAAGAAGGTGGAG
CGCGAGACCGAGACCGACCCCGTGCAC

Figure 48
(Sheet 1 of 1)

TatRevNef.opt.native.SF162

```
ATGGAGCCCGTGGACCCCCGCTGGAGCCCTGGAAGCACCCCGCAGCCAGCCCAAGACCGCCTGCACC
AACTGCTACTGCAAGAAGTGTGCTTCCACTGCCAGGTGTGCTTCATCACCAAGGGCTGGGCATCAGC
TACGGCCGCAAGAAGCGCCGCCAGCGCCGCCGCCCGACAGCGAGGTGCACCAGGTGAGCCTG
CCCAAGCAGCCGCCAGCCAGGGCAGCCCCACGGGCCAAGGAGAGCAAGAAGAAGGTTGGAG
CGCGAGACCGAGACCGACCCCGTGCACCCGGGGCCGCCAGCGGGCGACAGCGACGGAGGAGCTGCTG
CAGACCGTGCCTTCATCAAGTTCTGTACACAGAGCAACCCCCCTGCCAGCCCCAAGGGCACCCGCCAG
GCCCGCCGCAACCGCCGCCGCCAGCGCCAGCGCCAGATCCAGAGCATCAGCGCCTGGATC
ATCAGCACCCACCTGGGCCCGCAGCACCGAGCCCCGTGCCCCCTGCAGCTGCCCTGGAGCGCCTGAAC
CTGGACTGCAGCGAGGACTGCGGCACCAGCGGACCCAGGGGTGGGCAGCCCCCAGGTGCTGGCGAG
AGCCCCGCCGTGCTGGACAGCGGCACCAAGGAGCTCGAGGGCGCAAGTGGAGCAAGCGCATGAGCGC
TGGAGCGCCGTGCGCGAGCGCATGAAGCGCGCAGGCCGCCAGCCGCCAGGGGTGGCGCC
GTGAGCCCGACCTGGAGAACGACGGGCCATCACCAAGCAGCACACCCGCCAACAACGCCGACTGC
GCCTGGCTGGAGGCCAGGAGGACGAGGACGTGGCTTCCCCGTGCGCCCCCAGGTGCCCTGCGCCCC
ATGACCTACAAGGCCCTGGACCTGAGCCACTTCTGAAGGAGAACGGGCCCTGGAGGGCCTGATC
TACAGCCAGAACGCCAGGACATCCTGGACCTGTGGATCCACACACCCAGGGCTACTTCCCCGACTGG
CAGAACTACACCCCCGGCCCGCATCCCTAACCCCCCTGACCTCGGCTGGCTTCAAGCTGGTGCC
GTGGACCCCGACTACGTGGAGGAGGCCAACGCCAGAACACAGCCTGCTGCACCCCATGAGCCAG
CACGGCATGGACGACCCCCGAGAAGGAGGTGCTGGTGTGGCGCTTCGACAGCCGCCCTGGCTTCCACCCAC
ATGGCCCGAGCTGCACCCCGAGTACTACAAGGACTGC
```

Figure 49
(Sheet 1 of 1)

TatRevNef.opt.SF162

```
ATGGAGCCGTGGACCCCGCCTGGAGCCCTGGAAGCACCCGGCAGCCAGGCCAAGACCGCCGGCACC
AACTGCTACTGCAAGAAGTGCTGCTTCCACTGCCAGGTGAGCTTCATCACCAAGGGCTGGGCATCAGC
TACGGCCGCAAGAAGCGCCGCCAGGCCGCCGCCGCCACAGCGAGGTGACCAGGTGAGCCTG
CCCAAGCAGCCCAGCCAGCCCCAGGGCGACCCACCGGCCCAAGGAGAGCAAGAAGAAGGTGGAG
CGCGAGACCGAGACCGACCCCGTGCACCCGGGGCCGGCGAGCGGGAGACAGCAGGAGCTGCTG
CAGACCGTGCCTTCATCAAGTTCTGTACCAAGAGCAACCCCTGCCAGCCCCAAGGGCACCCGCCAG
GCCGACCTGAACCGCCGCCGCCCTGGCGAGCGCCAGCGCCAGATCCAGAGCATAGCGCCTGGATC
ATCAGCACCCACCTGGGCCAGCAGCACCGAGCCGTGCCCTGCACTGCCCCCGACCTGCGCCTGAAC
CTGGACTGCAGCGAGGACTGCAGCACCGGGCACCCAGGGCTGGGAGCAGCCCCAGGTGCTGGCGAG
AGCCCCCGCGTGTGGACAGCGCACCAAGGAGCTCGAGGCCAGTGAGCAAGCGCATGAGCGC
TGGAGCGCCGTGCGCGAGCGCATGAAGCGCCGAGGCCGCGAGGCCGCCGACGGCGTGGCGCC
GTGAGCCCGAGCCTGGAGAAGCACGGCGCATCACCAAGCAGCAACACCGCCCAACAACGCCGACTGC
GCCTGGCTGGAGGCCAGGGAGCAGGGACGTGGCTTCCCGTGCGCCCGAGGTGCCCTGCGCCCC
ATGACCTACAAGGCCGCTGGACCTGAGCCACTTCTGTGAAGGAGAAGGGCGGCCCTGGAGGGCTGATC
TACAGCCAGAAGCGCCAGGACATCCTGGACCTGTGGATCCACCAACCCAGGGCTACTCCCCGGCTGG
CAGAACTACACCCCCCGGCCGCTGGACCTGGCTACCCCTGACCTTGGCTGGCTTCAAGCTGGTGC
GTGGACCCGACTACGTGGAGGAGGCCAACGCCGGAGAACAAACAGCCTGCTGCACCCCATGAGCCAG
CACGGCATGGACGACCCCGAGAAGGAGGTGCTGGTGTGGCGCTTCGACAGCCGCTGGCCTTCCACCAC
ATGGCCCGAGCTGCACCCCGAGTACTACAAGGACTGC
```

Figure 50
(Sheet 1 of 1)

TatRevNefGag_B

GGCACCATGGAGCCCGTGGACCCCCGCTGGAGCCCTGGAAGCACCCCGCAGCCAGCCAAAGACCGCC
GGCACCAACTGCTACTGCAAGAAGTGTGCTTCACTGCCAGGTGAGCTTCATCCAAGGGCTGGC
ATCAGCTACGGCCGCAAGAAGGCCAGGCCAGGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCC
AGCCTGCCAAGCAGCCGCCAGCCAGCCCCAGGGCAGCCCCACCGGCCAAGGAGAGCAAGAAGAAG
GTGGAGCGAGACCGAGACCGACCCGGGGCGGGCGGGCGGGCGGGCGGGCGGGCGGGCGGGCGGG
CTGCTGCAGACCGTGCCTCATCAAGTTCCCTGTACCAGAGCAACCCCTGCCAGCCCCAAGGGCACC
CGCCAGGCCAGCTGAACCGCCGCCGCTGGCGAGGCCAGGCCAGATCCAGAGCATCAGCGCC
TGGATCATCAGCACCCACCTGGGCCAGCACCGAGGCCGTGCCCTGCAGCTGCCCGACCTGC
CTGAACCTGGACTGCAAGCAGGACTGCCGACCCAGGCCAGGGCGTGGGCAGCCCCAGGTGCTG
GGCGAGAGCCCCGCCGTGGACAGCCGACCAAGGAGCTGAGGCCAGGCCAGGCCAGGCCAGGCC
AGCGGCTGGAGCGCCGTGGCGAGCCATGAAGCGCCGAGCCGCCGAGGCCGCCGACGGCGTG
GGCGCCGTGAGCCGCGACCTGGAGAAGCACGGGCCATCACCAGCAGCAACACCCGCCAACAGCC
GAETGCCCTGGCTGGAGGCCAGGGAGCAGAGCTGGCTTCCCGTGCGCCCGAGGTGCCCTG
CGCCCCATGACCTACAAGGCCGCCCTGGACCTGAGCCACTTCCCTGAAGGAGAAGGGCGGCC
CTGATCTACAGCCAGAAGGCCAGGACATCCTGGACCTGTGGATCCACCACACCCAGGGCTACT
GGCTGGCAGAACTACACCCCGGCCGATCCGCTACCCCTGACCTTGGCTGGCTTCAGCTG
GTGCCCGTGGACCCGACTACGTGGAGGAGGCCAACGCCGGCAGAACACAAGCCTGCTGCACCC
AGCCAGCACGGCATGGACGACCCGAGAAGGAGGTGCTGGTGTGGCGCTTCGACAGCCGCTGG
CACACATGGGCCGAGCTGCACCCGAGTACTACAAGGACTGCGAATTGGCCGGCGCAGCGTG
CTGAGCGGCCGGAGCTGGACAAGTGGAGAAGATCCGCTGGCCGGCAAGAAGAAGTACAAG
CTGAAGCACATCGTGTGGCCAGCCGAGCTGGAGCCTGCGCTGAACCCGGCCTGCTGGAGACC
AGCGAGGGCTGCCAGATCCTGGCCAGCTGCGACCCAGCCTGCGAGACCCGGCAGCGAGGAGCT
AGCCTGTACAACACCGTGGCCACCTGTACTGCGTGCACCAAGCAGTCAGTCAAGGACACCAAGGAG
GCCCTGGAGAAGATCGAGGAGGAGCAGAACAGTCCAAGAAGAAGGCCAGCAGGCCGCCGCC
GGCACCGGCAACAGCAGCCAGGTGAGCCAGAACACTACCCATCGTGCAGAACCTGCA
GAG
CACCAAGGCCATCAGCCCCCGCACCTGAACGCCGGTGAAGGTGGAGGAGAAGGCC
GAGGTGATCCCCATGTTAGCGCCCTGAGCGAGGGCGCCACCCCGAGGACCTGAACAC
GATGTTGAACACCGTGGCCACCAGGCCCATGCCAGATGCTGAAGGAGGAGGAGGAGGAG
GACCGCGTGCACCCCGTGCACGCCGCCCATGCCGGGCGAGATGCCGAGGCCGCCAGCGAC
ATCGCCGGCACCACCAGCACCCCTGCAAGGAGCAGATCGCTGGATGACCAACAC
GGCGAGATCTACAAGCGGTGGATCATCTGGCTGAACAAAGATCGTGGGATGTACAG
ATCCCTGGACATCCGCCAGGGCCCCAAGGAGGCCCTCCCGCAACTCGTGGACCGCT
CGCGCTGAGCAGGCCAGGACGCTGAAGAAGTGGATGACCGAGACCC
CCCGACTGCAAGACCATCCTGAAGGCTCTGCCGCCGCCACCC
CAGGGCGTGGCGGCCACAAGGCCGCCAGGAGGAGGAGGAGGAGGAGGAGGAG
GCGACCATCATGATGCAGGCCAGGAACCTCCGAACCAGCGGAAGACCG
AAGGAGGGCCACCCGCCAGGAACCTGCCGCCGCCAGGCC
GGCCACCAAGATGAAGGACTGCACCGAGGCCAGGCCACTT
GGCCAGGAGAAGACCACCCAGGCCAGGAAGCAGGCCACCG
GGCGAGGAGAAGACCACCCAGGCCAGGAAGCAGGCCAG
CTGCGCAGCCTGTTGGCAACGACCCAGCAGCCAGTAA

Figure 51
(Sheet 1 of 2)

TatRevNefgagCpolIna_B

GTCGACGCCACCATGGAGCCGTGGACCCCGCCTGGAGCCCTGGAAGCACCCGGCAGCCAGCCAAG
 ACCGCCGGCACCAACTGCTACTGCAAGAAGTGTGCTTCACTGCCAGGTGAGCTTCATCACCAAGGGC
 CTGGGCATCAGCTACGGCCGCAAGAAGCGCCGCCAGCGCCGCCGCCCCCCCCGACAGCAGGGTGCAC
 CAGGTGAGCCTGCCAACAGCAGCCGCCAGCCAGCCCCAGGGCGACCCACCAGGCCCAAGGAGAGCAAG
 AAGAAGGTGGAGGEGEGAGACCGAGACCGACCCCGTGCACCCCGGGCCGGCGACAGCGAC
 GAGGAGCTGCTGCAGACCGTGCCTCATCAAGTTCCTGTACCAAGAGCAACCCCTGCCAGCCCCAAG
 GGCACCCGCCAGGCCGACCTGAACGCCGCCGCTGGCGAGCGCCAGCGCCAGATCCAGAGCATC
 AGCGCCTGGATCATCAGCACCCACCTGGGCCGAGCACCAGGCCAGCCCCGTGCCCTGCAGCTGCCCGAC
 CTGCGCCTGAACCTGGACTGCAGCAGGACTGCGGCACCAGCGCACCCAGGGCGTGGCAGCCCCCAG
 GTGCTGGGCGAGAGCCCCCGCTGCTGGACAGCGCACCAAGGAGCTGAGGGGGCAAGTGGAGCAAG
 CGCATGAGCGGCTGGAGGCCGTGCGCAGCGCATGAAGCGCCGAGCCCAGGAGCCCCGCCGAC
 GGCCTGGGCGCCGTGAGCCCGACCTGGAGAAGCACGGGCCATCACAGCAGCAACACGCCGCCAAC
 AACGCCGACTGCCCTGGCTGGAGGCCAGGAGGACGAGGACGTGGCTTCCCCGTGCGCCCCCAGGTG
 CCCCTGCGCCCCATGACCTACAAGGCCGCCCTGGACCTGAGCCACTTCTGAGGGAGAAGGGCGGCTG
 GAGGGCCTGATCTACAGCCAGAAGGCCAGGACATCCCTGGACCTGTGGATCCACACACCCAGGGCTAC
 TTCCCCGGCTGGCAGAACTACACCCCGGCCCGCATCCGCTACCCCTGACCTCGGCTGGTGTTC
 AAGCTGGTGGCCCGTGGAGCCGACTACGTGGAGGGCCAAACGCCGGAGAACAAACAGCCTGCTGCAC
 CCCATGAGCCAGCACGGCATGGACGACCCCGAGAAGGAGGTGCTGGTGTGGCCTTCGACAGCCGCTG
 GCCTCCACCACATGGCCCGCGAGCTGCACCCCGAGTACTACAAGGACTGCCTCGAGGGGCCGCGCC
 AGCGTGTGAGCGGGCGAGCTGGACAAGTGGAGAAGATCCGCTGCGCCCCGGCGCAAGAAGAAG
 TACAAGCTGAAGCACATCGTGTGGCCAGCCGAGCTGGAGCAGCTGGAGCGCTTCGCGTGAACCCGGCTG
 GAGACCAGCGAGGGCTGCCAGATCCCTGGCCAGCTGCAGCCAGGCTGAGACCGGAGCGAGGAG
 CTGCGCAGCGTGTACAACACCGTGGCCACCCCTGTACTGCGTGCACCAGCGCATCGACGTCAAGGACACC
 AAGGAGGCCCTGGAGAAGATCGAGGAGGAGCAGAACAAAGTCAAGAAGAAGGCCAGCAGGCCGCC
 GCCGCCGGCACCGCAACAGCAGCCAGGTGAGCCAGAACTACCCCATGTCAGAACCTGCAAGGGCCAG
 ATGGTGCACCAGGCCATCAGCCCCCGCACCCCTGAAACGCTGGGTGAAGGTGGAGGAGAAGGCCCTTC
 AGCCCCGAGGTGATCCCCATGTTAGCGCCCTGAGCGAGGGCCACCCCCCAGGACCTGAACACGATG
 TTGACACCCGTGGCGGCCACCAGGCCCATCGAGATGCTGAAGGAGACCATCAACGAGGAGGCC
 GAGTGGGACCGCGTGCACCCCGTGCACGCCGGCCATGCCCGGGCAGATGCGCAGGCCGGCG
 AGCGACATGCCGGCACCCAGCACCCTGCAAGGAGGTGATCATCTGGGCTGAAACAAGATCGTGGATGTACGCC
 CCCGTGGCGAGATCTACAAGCGGTGGATCATCTGGGCTGAAACAAGATCGTGGATGTACGCC
 ACCAGCATCTGGACATCCGCCAGGGCCCAAGGGCCCTCCCGGACTACGTGGACCCCTTACAAG
 ACCCTGCGCCTGAGCAGGCCAGGACGTGAAGAACTGGATGACCGAGACCCCTGCTGGTGCAGAAC
 GCCAACCCCGACTGCAAGAACCATCCTGAAGGCTCTGCCGGCCACCCCTGGAGGAGATGAC
 GCCTGCCAGGGCGTGGCGGCCACAAGGCCCGCTGCTGGCCAGGGGATGAGCCAGGTGAC
 AACCCGGGACCATCATGATGCAAGCGGGCAACTTCCGCAACCAGCGGAAGACCCCTCAAGTGTCTCAAC
 TGCAGCAAGGAGGGCACCCGCCAGGAACCTGCGCGCCGGCAAGAAGGGCTGCTGGCGTGC
 CGCAGGGCCACCGAGATGAAGGACTGCACCGAGCGCCAGGCCACCTCCGCAAGATCTGGCCAGC
 TACAAGGCCGCCGGCAACTTCCCTGCAGAGCGCCCCGAGCCCACCGCCCCCGAGGGAGAGCTTC
 CGCTCGGCGAGGAGAAGACCAACCCAGCCAGAAGCAGGGACCCATCGACAAGGAGCTGTACCCCTG
 ACCAGCCTGCGCAGCCTGTTGGCAACGACCCAGCAGCCAGAAAGAATTCAAGGCCCGTGTGGC
 GAGGCAGGAGCCAGGTGACGAACCGCGACCATCATGATGCAAGCGCCAGCTTCCGCAACCAGCG
 AAGACCGTCAAGTGTCTCAACTGCGCAAGGAGGGCACACCGCCAGGAACCTGCCGCCCGCAAG
 AAGGGCTGCTGGCGCTGCGGCCGCAAGGACACCAATGAAAGATTGACTGAGAGACAGGCTAATTTC
 TTCCCGAGGACCTGGCCTTCCCTGCAGGGCAAGGCCCGAGTTCAGCAGCGAGCAGACCCGCCAAC
 AGCCCCACCCGCCGAGCTGCAGGTGTGGGGCGGAGAACAAACAGCCTGAGCGAGGCCGGCG
 CGCCAGGGCACCGTGAGCTCAACTTCCCGAGATCACCCCTGTCAGGCCGCCCTGGTACCATCAGG
 ATCGCGGCCAGCTCAAGGAGGCCTGCTGCCACCGCGGCCAGCACCCGTGCTGGAGGAGATGAAC
 CTGCCCGCAAGTGGAAAGCCAAGATGATCGGGGGATCGGGGCTTCATCAAGGTGCGGAGTACGAC
 CAGATCCCCGTGGAGATCTGCGGCCACAAGGCCATCGGCACCGTGCCTGGTGGGGCCCCACCCCGTGAAC
 ATCATCGGCCGCAACCTGCTGACCCAGATCGGCTGCACCCCTGAACCTCCCATCAGCCCCATCGAGACG
 GTGCCCGTGAAGCTGAAGGCCGGGATGGACGCCAGGAGTCAAGCAGTGGCCCTGACCGAGGGAGAAG
 ATCAAGGCCCTGGTGGAGATCTGCAACCGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAG
 AACCCCTACAACACCCCGTGTTCGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGGAC

Figure 51
(Sheet 2 of 2)

TTCCCGAGCTGAACAAGCGCACCCAGGACTTCTGGGAGGTGCAGCTGGGCATCCCCAACCCGCCGGCTGAAGAAGAAGAAGAGCGTGACCGTGCTGGACGTGGCGACGCCACTTCAGCGTGCCCCCTGGACAAGGACTTCCGCAAGTACACCGCCTTCACCATCCCCAGCATCAACAACGAGACCCCCGGCATCCGCTACCAAGTCCGCTACCGTGTGATCTACCAGGCCCCCTGTACGTGGGCAGCGACCTGGCCAGCACCTGCTGCGCTGGGCTTCACCACCCCGACAAGAACGACCAAGGAGCCCCCTTCCTGCCCATCGAGCTGCACCCCCGACAAGTGAGCTGGACCGTGCAGCCCCTCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTGAACTGGGCCAGCCAGATCTACGCCGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCGCGGACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGAGGCCGAGCTGGAGCTGGCCGAGAACCGCGAGATCCTGAAGGAGCCGTGCACGAGGTGTACTACGACCCAGCAAGGACCTGGTGGCCGAGATCCAGAACGAGGCCAGGGCCAGTGGACCTACCAGATCTACCAAGGAGCCCTCAAGAACCTGAAGAACCGCAAGTACGCCGCATGCCGGCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAAGAGGTGAGCACCCGAGAGATCGTGATCTGGGCAAGATCCCCAAGTTCAAGCTGCCCATCCAGAACGGAGACCTGGGAGGCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGGAGTTCTGTGAACACCCCCCCCCTGGTGAAGCTGGTACAGCTGGAGACCTTCTACGTGGACGGCGCCGCAACCGCAGAACAGCTGGCAAGGGCCGGCTACGTGACCGACCGGGGGCCGGCAGAACGGTGGTGAACGATCGCCGACACCACCAACCAGAACGACCGAGCTGCCAGGCCATCCACCTGGCCCTGCAGGACAGCGGCCCTGGAGGTGAACATCGTGACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAGGCCACAAGAGCGAGAGCGAGCTGGAGCCAGATCATCGAGCAGCTGATCAAGAACGGAGAACGGTGTACCTGGCCTGGGTGCCCCCCCACAAGGGCATCGCGGCCAACGAGCAGGCCAGTGGTGAACAGCTGGTGAACGGCATCGATGGCGGCATCGTGAATCTACCAAGTACATGGACGACCTGTACGTGGGCAGCGGCCGGCTAGGATCGATTAAAAGCTTCCCGGGCTAGCACCAGGTTCTAGA

Figure 52
(Sheet 1 of 2)

TatRevNefGagProtInaRTmut_B

Figure 52
(Sheet 2 of 2)

CGCTGGGCTTACCAACCCCCGACAAGAAGCACCAGAAGGAGCCCCCTTCCTGCCCATCGAGCTGCAC
CCCGACAAGTGGACCGTGCAGCCCATCATGCTGCCGAGAAGGACAGCTGGACCGTGAACGACATCCAG
AAGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTGTGCAAG
CTGCTCGCGGCCACCAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGGAGGCCAGCTGGAGCTGGCC
GAGAACCGCGAGATCCTGAAGGAGGCCGTGCACCGAGGTGACTACGACCCAGCAAGGACCTGGTGGCC
GAGATCCAGAAGCAGGGCAGGGCCAGTGGACCTACCAGATCTACCAAGGAGCCCTCAAGAACCTGAAG
ACCGCAAGTACGCCGCATGCCGGCCACCCAAGGACGTGAAGCAGCTGACCGAGGCCGTGCAG
AAGGTGAGCACCGAGAGCATCGTGAATCTGGGCAAGATCCCCAAGTTCAAGCTGCCCATCCAGAAGGAG
ACCTGGGAGGCCTGGTGGATGGAGTACTGGCAGGCCACCTGGATCCCCAGTGGGAGTTCTGTAACACC
CCCCCTGGTGAAGCTGGTACCAAGCTGGAGAAGGAGCCATCGTGGCGCCGAGACCTCTACGTG
GACGGCGCCGCCAACCGAGACCAAGCTGGCAAGGCCGGCTACGTGACCGACCGGGGCCAGAAG
GTGGTGAGCATCGCGACACCACCAACCAGAAGACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGAC
AGCGCCTGGAGGTGAACATCGTGAACCGACAGCAGTACGCCCTGGCATCATCCAGGCCAGGCCAC
AAGAGCGAGAGCGAGCTGGTGGAGCCAGATCATCGAGCAGCTGATCAAGAAGGAGAAGGTGACCTGGCC
TGGGTGCCGCCACAAGGGCATCGCGGCAACGAGCAGGTGGACAAGCTGGTGAAGCAGGCCATCCGC
AAGGTGCTCTAA

Figure 53
(Sheet 1 of 1)

TatRevNefp2Pol.opt_B

```

GCCACCATGGAGCCCGTGGACCCCGCCTGGAGCCCTGGAAGCACCCCGGAGCCAGCCCCAAGACGCC
GGCACCAACTGCTACTGCAAGAAGTGTGCTTCACTGCCAGGTGAGCTTCATCACCAAGGGCCTGGC
ATCAGCTACGGCCGCAAGAAGCGCCGCCAGCGCCGCCGCCCCCCCCGACAGCGAGGTGACCCAGGTG
AGCCTGCCAAGCAGCCCGCCAGCCAGCCCAGGGCGACCCCACCGGCCCAAGGAGAGCAAGAAGAAG
GTGGAGCCCGAGACCGAGACCGACCCCGTGCACCCCCGGGCGCCGAGGGCGACAGCGACGGAGGAG
CTGCTGCAGACCGTGCCTTCATCAAGTCTCTGTACAGAGCAACCCCTGCCAGCCCCAAGGGCACC
CGCCAGGGCGACCTGAACCGCCGCCGCTGGCGCAGCGCCAGCGCCAGATCCAGAGCATCAGCGCC
TGGATCATCAGCACCCACCTGGGCCGAGCACCGAGCCCCTGCAGCTGCCCTGCAAGCTGCCCTGACCTGCGC
CTGAACCTGGACTGCAGCAGGGACTGCCGACCAGCGGACCCAGGGCTGGGCAAGCCCCCAGGTGCTG
GGCGAGAGCCCCGCCGTGCTGGACAGCGGCCACCAAGGAGCTCGAGGCCGGCAAGTGGAGCAAGCGCATG
AGCGGCTGGAGCGCCGTGCGCGAGCGCATGAAGCGGCCGAGCCCAGGCCGAGCCCGCCGACGGCGTG
GGCGCCGTGAGCCCGACCTGGAGAAGCACGGCGCATCACAGCAGCAACACCGGCCAACAACGCC
GACTGCGCTGGCTGGAGGCCAGGAGGACGAGGACGTGGCTTCCCCGTGCGCCCCCAGGTGCCCTG
CGCCCCATGACCTACAAGGCCCTGGACCTGAGCCACTTCTGAAGGAGAAGGGCGGCTGGAGGGC
CTGATCTACAGCCAGAAGCGCAGGACATCTGGACCTGTGGATCCACCACACCAGGGCTACTTCCCC
GGCTGGCAGAACTACACCCCCGGCCCGCATCCGCTACCCCCGTGACCTTCGGCTGGTGTCAAGCTG
GTGCCCGTGGACCCGACTACGTGGAGGAGGCAACGCCGGAGAACAAACAGCCTGCTGCACCCATG
AGCCAGCACGGCATGGACGACCCCGAGAAGGAGGTGCTGGTGTGGCGCTTCGACAGCCGCTGGCCTTC
CACCATGGCCCGCGAGCTGACCCCGAGTACTACAAGGACTGCGAATTGCCGAGGGCATGAGCCAG
GTGACGAACCGGGGACCATCATGATGCGAGCGGGCAACTTCCGCAACCAGCGGAAGACCGTCAAGTGC
TTCAACTGCGGCAAGGAGGCCACACCGCCAGGAACCTGCCGCCCCCGCAAGAAGGGCTGCTGGCGC
TGCAGGGCGAAGGACACCAATGAAAGATTGCACTGAGAGACAGGCTAATTCTCCGCGAGGACCTG
GCCTCCTGCAGGGCAAGGCCCGAGTTCAAGCAGGAGACCCCGCGCAACAGCCCCACCCGCCGC
GAGCTGCAGGTGTGGGGCGGAGAACAAACAGCCTGAGCGAGGCCGGCGCCAGGGCACCGTG
AGCTCAACTTCCCCAGATCACCTGTGGCAGCGCCCCCTGGTACCATCAGGATCGCGGGCCAGCTC
AAGGAGGCCTGCTGCCACCGCCGAGCACGACACCGTGTGGAGGAGATGAACCTGCCGGCAAGTGG
AAGCCCAAGATGATCGGGGATCGGGGCTTCATCAAGGTCCGGCAGTACGACCAGATCCCCGTGGAG
ATCTGCGGCCACAAGGCCATCGCACCGTGTGGTGGGCCACCCCCGTGAAACATCATCGGGCGCAAC
CTGCTGACCCAGATCGGCTGCACCCCTGAACCTTCCCCATCAGCCCCATCGAGACGGTGCCGTGAAGCTG
AAGCCGGGATGGACGGCCCCAAGGTCAAGCAGTGGCCCTGACCGAGGAGAACATCAAGGCCCTGGTG
GAGATCTGCAACGAGATGGAGAAGGAGGGCAAGATCAGCAAGATCGGCCCGAGAACCCCTACAACACC
CCCGTGTTCGCCATCAAGAAGAAGGACAGCACCAAGTGGCGCAAGCTGGTGTGGACTTCCGCGAGCTGAAC
AAGCGCACCCAGGACTCTGGAGGTGCAGCTGGCATCCCCCAGCCGGCTGAAGAAGAAGAACAG
AGCGTGACCGTGTGGACGTGGCGACGCTACTTCAGCGTGGCCCTGGACAGGACTTCCGCAAGTAC
ACCGCCTTCACCATCCCCAGCATCAACACGAGACCCCGGATCCGCTACCAAGTACGTGCTGCC
CAGGGCTGGAAGGGCAGCCCCGCATCTTCAGAGCAGCATGACCAAGATCTGGAGGCCCTCCGCAAG
CAGAACCCGACATCGTGTACCTACAGGCCCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCAC
CGCACCAAGATCGAGGAGCTGCCAGCACCTGCTGCCCTGGCTTCAACACCCCGACAAGAACGAC
CAGAAGGAGCCCCCTCTGCCATCGAGCTGCACCCGACAAGTGGAGCGCAGCCCATCATGCTG
CCCGAGAAGGACAGCTGGACCGTGAACGACATCCAGAACGCTGGTGGCAAGCTGAACCTGGCCAGCCAG
ATCTACGCCGCATCAAGGTGAAGCAGCTGTGCAAGCTGCTGCCGGCACAAGGCCCTGACCGAGGTG
ATCCCCCTGACCGAGGAGGCCAGCTGGAGCTGGCCGAGAACCGCGAGATCTGAGGGAGCCCTGAC
GAGGTGTACTACGACCCCAGCAAGGACCTGGTGGCCGAGATCCAGAAGCAGGGCAGGGCCAGTGGAC
TACCAAGATCTACCAAGGAGCCCTCAAGAACCTGAGAACGGCGCAAGTACGCCCGCATGCCGGGCCAC
ACCAACGACGTGAAGCAGCTGACCGAGGCCGTGCAGAACGGTGAAGCAGCGACCGAGAGCATCGTGTAC
AAGATCCCCAAGTTCAAGCTGCCATCCAGAACGGAGACCTGGGAGGCCCTGGTGGAGATGGAGTACTGGCAG
GCCACCTGGATCCCCAGTGGGAGTTCGTGAACACCCCCCTGGTGAAGCTGTGGTACCAAGCTGGAG
AAGGAGCCCATCGTGGCGCCGAGACCTCTACGTGGACGGCGCCGACAACCGCGAGGACCAAGCTGGC
AAGGCCGCTACGTGACCGAGCGGGCCGAGAACGGTGGTGAAGCATGCCGACACCACCAACCGAGAAG
ACCGAGCTGCAGGCCATCCACCTGGCCCTGCAGGACAGCGGGCTGGAGGTGAACATCGTGAACCGACAGC
CACTACGCCCTGGCATCATCCAGGCCAGCCGACAAGAGCAGAGCGAGAGCTGGTGAAGGCCAGATCATC
GAGCAGCTGATCAAGAAGGAGAAGGTGTACCTGGCTGGGTGCCCCACAAGGGCATCGGCCGAAAC
GAGCAGGTGGACAAGCTGGTGAACCGGCCGATCCGCAAGGTGTAA

```

Figure 54
(Sheet 1 of 1)

TatRevNef.ProtRT.opt_B

GCCACCATGGAGCCCGTGGACCCCCCTGGAGCCCTGGAGCCACCCGGCAGCCAGCCAAGACCGCC
 GGCACCAACTGCTACTGCAAGAAGTGTGCTTCACTGCCAGGTGAGCTTCATCACCAAGGGCCTGGC
 ATCAGCTACGGCCGCAAGAAGCGCCGCCAGCGCCGCCGCCCCCCCCGACAGCGAGGTGACCAGGTG
 AGCCTGCCAAGCAGCCCCCAGCCAGCCCCAGGGCGACCCACCGCCCCAAGGAGAGCAAGAAGAAG
 GTGGAGCGCGAGACCGAGAACCGACCCGTGCACTCCCCGGGCEGGCGAGCGGGCACAGCAGGAG
 CTGCTGCAGACCGTGGCTTCATCAAGTTCTGTACCAGAGCAACCCCTGCCAGCCCCAAGGGCACC
 CGCCAGGCCACCTGAACCGCCGCCGCTGGCGAGCGCCAGCGCCAGATCCAGAGCATCAGCGCC
 TGGATCATCAGCACCCACCTGGGCCGAGCACCGAGCCCCGTGCCCCCTGCAGCTGCCCTGACCTGCGC
 CTGAACCTGGACTGCAGCAGGACTGCCGACCCAGCGGACCCAGGGGTGGGCAGCCCCCAGGTGCTG
 GGCAGAGCCCCCGCTGCTGGACAGCGGACCAAGGAGCTGAGGCCAGGGCAAGTGGAGCAAGCGCATG
 AGCGGCTGGAGCGCCGTGCGCGAGCGCATGAAGCGCGCCGAGCCGCCGAGCCGCCGACGGCGTG
 GGCAGCGTGGAGCCGACCTGGAGAACGACGGGCCATCACCAGCAGCAACACCAGCCAAACAACGCC
 GACTGCGCTGGCTGGAGGCCAGGGAGCAGGGACGTGGCTTCCCCGTGCGCCCCCAGGTGCCCTG
 CGCCCCATGACCTACAAGGCCGCCCTGGACCTGAGCCACTTCTGAAGGAGAAGGGCGGCTGGAGGGC
 CTGATCTACAGCCAGAAGCGCAGGACATCCTGGACCTGTTGATCCACCACACCAGGGCTACTTCCCC
 GGCTGGCAGAACTACACCCCCGGCCCCGGCATCCGCTACCCCTGACCTTGGCTGGTCTCAAGCTG
 GTGCCCGTGGACCCGACTACGTGGAGGGAGGCCAACGCCGGCAGAACACAACAGCTGCTGCACCCATG
 AGCCAGCACGGCATGGACGACCCGAGAACGGAGGTGCTGGTGTGGCGCTTCGACAGCGCCCTGGCTTC
 CACCATGGCCCGCAGCTGACCCCGAGTACTACAAGGACTGCGAATTCCCCAGATCACCTGTGG
 CAGGCCCTGGTGGACCATCAGGATGGCGGCCAGCTCAAGGAGGCCGTGCTGCCACGGCGCCGAC
 GACACCGTGTGGAGGGAGATGAACCTGCCGGCAAGTGGAGCCAAAGATGATGGCGGGATGGGGG
 TTCATCAAGGTGGCGGAGTACGACCAAGATCCCCGTGGAGATCTGCGGCCACAAGGCCATGGCACCGTG
 CTGGTGGGCCACCCCGTGAACATCATCGGCCGCAACCTGCTGACCCAGATGGCTGACCCCTGAAC
 TTCCCCATCAGCCCCATCGAGACGGTGGCCGTGAAGCTGAAGCAGGCCGATGGACGCCAGGTCAAG
 CAGTGGCCCTGACCGAGGGAGAACATCAAGGCCCTGGTGGAGATCTGACCGAGATGGAGAAGGAGGGC
 AAGATCAGCAAGATCGGCCCGAGAACCCCTACAAACACCCCGTGGCCATCAAGAAGAAGGACAGC
 ACCAAGTGGCGCAAGCTGGACTTCCCGAGCTGAACAAGCAGCCACCCAGGACTCTGGAGGTGCGAG
 CTGGCATCCCCACCCCGGCCCTGAAGAACGAGCTGGAGATCTCCGCAAGTACACCGCCTTACCATCCCAG
 GAGACCCCGGCATCCGCTACCGATCAACGTGCTGCCAGGGCTGGAAGGGAGCCGCATCTTC
 CAGAGCAGCATGACCAAGATCTGGAGCCCTCCGCAAGCAGAACCCGACATCGTGAATCTACCAGGCC
 CCCCTGTACGTGGCAGCGACCTGGAGATCGGCCAGCACCGACCAAGATCGAGGAGCTGCCAGCAC
 CTGCTGCCTGGGCTTCACCACCCCGACAAGAACGACCCAGAGGGAGCCCCCTTCCCTGCCATCGAG
 CTGCACCCGACAAGTGGACCGTGCAGCCCATCATGCTGCCAGAACGGACAGCTGGACCGTGAACGAC
 ATCCAGAAGCTGGTGGCAAGCTGAACCTGGCCAGCCAGATCTACGCCGGCATCAAGGTGAAGCAGCTG
 TGCAAGCTGCTGGGGGCCACAAGGCCCTGACCGAGGTGATCCCCCTGACCGAGGGAGGCCAGCTGGAG
 CTGGCCGAGAACCGCGAGATCCTGAGGAGCCCTGGCAGCAGGGTGTACTACGACCCAGCAAGGACCTG
 GTGGCCGAGATCCAGAAGCAGGCCAGGGCCAGTGGACCTACCGATCTACAGGAGGCCCTTCAAGAAC
 CTGAAGACCGGCAAGTACGCCGATGCGCGCCACACCAACGACGTGAAGCAGCTGACCGAGGCC
 GTGCAGAAGGTGAGCACCGAGAGCATCGTGAATCTGGGCAAGATCCCCAGTCAAGCTGCCCATCCAG
 AAGGAGACCTGGGAGGCCTGGTGGAGTGGAGTACTGGCAGGCCACCTGGATCCCCGAGTGGAGTTCTG
 AACACCCCCCCCCTGGTGAAGCTGTGGTACCGAGCTGGAGAACGGAGGCCATCGTGGGCCGAGACCTTC
 TACGTGGACGGCGCCGACCAACCGCGAGACCAAGCTGGCAAGGCCGTACGTGACCGACCGGGCCGG
 CAGAAGGTGGTGAAGCATGCCGACACCACCAACAGAACGGAGCTGCCAGGCCATCCACCTGGCCCTG
 CAGGACAGCGGCCCTGGAGGTGAACATCGTGAACCGACAGCCAGTACGCCCTGGCATCATCCAGGCCAG
 CCCGACAAGAGCGAGAGCGAGCTGGTGGAGGCCAGATCATCGAGCAGCTGATCAAGAAGGAGAACGGTGTAC
 CTGGCCTGGGTGCCCCGCCCACAAGGGCATCGGCCGACAGCAGGTGGACAAGCTGGTGAAGCGCCGG
 ATCCGCAAGGTGCTCTAA

Figure 55
(Sheet 1 of 1)

vif.opt.SF2

ATGGAGAACCGCTGGCAGGTGATGATCGTGTGGCAGGTGGACCGCATGCGCATCCGCACCTGGAAGAGC
CTGGTGAAGCACCACATGTACATCAGCAAGAAGGCCAAGGGCTGGTTCTACCGCCACCACTACGAGAGC
ACCCACCCCCCGCGTGAGCAGCGAGGTGCACATCCCCCTGGGCAGCAGCCAAGCTGGTGATCACCACCTAC
TGGGGCCTGCACACCCGGCGAGCGCGAGTGGCACCTGGGCCAGGGCGTGGCATCGAGTGGCGCAAGAAG
AAGTACAGCACCCAGGTGGACCCGGCTGGCGACCGAGCTGATCCACCTGCACTACTTCGACTGCTTC
AGCGAGAGCGCCATCAAGAACGCCATCCTGGCTACCGCGTGAGCCCCCGCTGCGAGTACCGAGGCC
CACAAACAAGGTGGGCAGCCTGCAGTACCTGGCCCTGGCCGCCCTGATCACCCCCAAGAACGACCAAGCCC
CCCCCTGCCAGCGTGAGAACGCTGACCGAGGACCGCTGGAACAAGCCCCAGAACGACCAAGGGCCACCGC
GGCAGCCACACCATGAACGGCCAC

Figure 56
(Sheet 1 of 1)

vpr.opt.SF2

ATGGAGCAGGCCCGAGGACCAGGGCCCCAGCGCGAGCCCTACAACGAGTGGACCTGGAGCTGCTG
GAGGAGCTGAAGCGCGAGGCCGTGCACCTCCCCCGCCCTGGCTGCACAGCCTGGCCAGTACATC
TACGAGACCTACGGCGACACCTGGCCGGCGTGGAGGCCATCATCCGCATCCTGCAGCAGCTGCTGTTTC
ATCCACTTCCGCATCGGCTGCCAGCACAGCCGCATCGGCATCATCCAGCAGCGCCGCCGCAAC
GGCGCCAGCCGCAGC

Figure 57
(Sheet 1 of 1)

vpu.opt.SF162

ATGCAGCCCCTGCAGATCCTGGCCATCGTGGCCCTGGTGGTGGCCGCATCGCCATCGTGGTGTGG
ACCATCGTGTACATCGAGTACCGCAAGATCCTGCGCCAGCGCAAGATCGACCGCCTGATCGACCGCATT
ACCGAGCGCGCCGAGGGACAGCGGCAACGAGAGCGAGGGCGACCAGGAGGAGCTGAGCGCCCTGGTGGAG
CGCGGCCACCTGGCCCCCTGGGACGTGGACGACCTG

FIGURE 58 (SEQ ID NO:61)

gp140modSF162.GM135-154-186-195

1 atggatcaa tgaagagagg gctctgtgt gtgtgtgc tggatggatc agtcttcgtt
61 tcgcccagcg ccgtggagaa gctgtgggtt accgtgtact acggcggtgc cgtgtggaaag
121 gaggccacca ccaccctgtt ctgcggccagc gacgccaagg cctacgacac cgaggtgcac
181 aacgtgtggg ccacccacgc ctgcgtgccc accgacccca acccccagga gatcggtctg
241 gagaacgtga ccgagaactt caacatgtgg aagaacaaca tggatggatc gatgcacgag
301 gacatcatca gcctgtggg ccagagcctg aagccctgc tgaagctgac ccccccgtgc
361 gtgaccctgc actgcaccaa cctgaagcagc gccaccaaca ccaagagcag caactggaag
421 gagatggacc gcggcgagat caagcgtgc agcttcaagg tgaccaccag catccgcaac
481 aagatgcaga aggatgtacgc cctgttctac aagctggatc tggatggccat cgacaacgac
541 cagaccagct acaagctgtat caactgcac accagcgtga tcacccaggc ctgccccaaag
601 gtgagcttcg agcccatccc catccactac tgcgcggcc cggcgttcgc catcctgaag
661 tgcaacgaca agaagttcaa cggcageggc cccgtcacca acgtgagcac cggtgcgtgc
721 acccacggca tccgccccgtt ggtgacccatc cagctgtgc tgaacggcag cctggccgag
781 gagggcggtgg tggatccgcag cgagaacttc accgacaaacg ccaagaccat catcggtcag
841 ctgaaggaga gctgtggagat caactgcacc cggcccaaca acaacacccg caagagcatc
901 accatcgcc cggccgcgc ctctacgccc accggcgaca tcatcgccga catccggcag
961 gcccactgca acatcagcgg cgagaagtgg aacaacaccc tgaagcagat cgtgaccaag
1021 ctgcaggccc agttcgccaa caagaccatc gtgttcaagc agagcagcgg cggcgacccc
1081 gagatgtga tgcacagctt caactcgcc ggcgagtttct tctactgaa cagcacccag
1141 ctgttcaaca gcacctgaa caacaccatc gggcccaaca acaccaacgg caccatcacc
1201 ctgcccgtcc gcatcaagca gatcatcaac cgctggcagg aggtggccaa ggccatgtac
1261 gccccccca tccgcggcca gatccgtgc agcagcaaca tcacccggct gctgtgacc
1321 cgcgacggcg gcaaggagat cagcaacacc accgagatct tccgccccgg cggccggcgc
1381 atgcgcgaca actggcgccag cgagctgtac aagtacaagg tggatggat ctagccctg
1441 ggcgtggccc ccaccaaggc caagcgccgc gtggatggcagc gcgagaagcg cgccgtgacc
1501 ctggcgccca tggatccgtgg ctccctgggc gcccggca gcaccatggg cgcccgccgc
1561 ctgaccctgtt ccgtgcaggc cggccagctg ctgagccgc tgcgtgcagca gcagaacaac
1621 ctgcgtgcgc ccatcgaggc ccagcagcac ctgcgtgcagc tgaccgtgt gggcatcaag
1681 cagctgcagg cccgcgtgtt ggcgcgtggag cgctacatgtt agggaccagca gctgtgggc
1741 atctggggctt gcaaggccaa gctgtatgc accaccggcc tggatggccaa cgccagctgg
1801 agcaacaaga gcctggatc gatctggaaac aacatgtatc ggatggatc ggagcgcgc
1861 atcgacaact acaccaaccc tgcgtatgcagg agagccagaa ccagcaggag
1921 aagaacgagc aggatgtgtt ggatggatc aagtggccaa gcctgtggaa ctggatgtac
1981 atcgacaatg ggatggatc catctaa

FIGURE 59 (SEQ ID NO:62)

gp140modSF162.GM154

1 atggatcaa tgaagagagg gctctgtgt gtgctgctgc tgtgtggagc agtctcggt
61 tcgcccagcg ccgtggagaa gctgtgggtg accgtgtact acggcgtgcc cggtgtggaaag
121 gaggccacca ccaccctgtt ctgcgcacgc gacgccaagg cctacgacac cgaggtgcac
181 aacgtgtggg ccacccacgc ctgcgtgccc accgacccca acccccagga gatcgtgctg
241 gagaacgtga ccgagaactt caacatgtgg aagaacaaca tggtggagca gatgeacag
301 gacatcatca gcctgtggga ccagagctg aagccctgctg tgaagctgac cccctgtgc
361 gtgaccctgc actgcaccaa cctgaagaac gccaccaaca ccaagagcag caactggaag
421 gagatggacc gcggcgagat caagcagtgc agcttcaagg tgaccaccag catccgcaac
481 aagatgcaga aggagtagcgc cctgttctac aagctggacg tggtgccat cgacaacgc
541 aacaccagct acaagctgat caactgcac accagcgtga tcacccaggc ctgccccaaag
601 gtgagcttcg agcccatccc catccactac tgcgcccccg ccggcttcgc catcctgaag
661 tgcaacgaca agaagtcaa cggcagcggc ccctgacca acgtgagc acgtcagtgc
721 acccacggca tccgccccgt ggtgagcacc cagctgctgc tgaacggcag cctggccgag
781 gagggcgtgg tggatccgcag cgagaacttc accgacaacg ccaagaccat catcgtgcag
841 ctgaaggaga gctgtggagat caactgcacc cggcccaaca acaacacccg caagagcatc
901 accatcgccc cggcccgccgc ctctacgccc accggcgaca tcatcgccgaa catccgccc
961 gccccactgca acatcagcgg cgagaagtgg aacaacaccc tgaaggagat cgtgaccaag
1021 ctgcaggccc agttcgccaa caagaccatc gtgttcaagc agagcaggc cggcgacccc
1081 gagatcgta tgcacagtt caactgcggc ggcgagttct tctactgcaa cagcacccag
1141 ctgttcaaca gcacctggaa caacaccatc ggccccaaaca acaccaacgg caccatcacc
1201 ctgcccctgcc gcatcaagca gatcatcaac cgcctggcagg aggtggccaa ggccatgtac
1261 gccccccccca tccgccccca gatccgtgc accgagatct tccgccccgg cggccggcgc
1321 cgcgcacggc gcaaggagat cagcaacacc accgagatct tccgccccgg cggccggcgc
1381 atgcgcgaca actggcgccag cgagctgtac aagtacaagg tggtaagat cgagccctg
1441 ggcgtggccc ccaccaaggc caagcggccgc gtggcgcagc gcgagaagcg cggccgtgacc
1501 ctggccgcca tggccctggg ctgcgtggc gccgccccca gacccatggg cggccggc
1561 ctgaccctga ccgtgcaggc cccgcacgc ctgagccggc tgcgtgcagca gcagaacaac
1621 ctgcgtgcgc ccatcgaggc ccagcagcac ctgcgtgcagc tgaccgtgtg gggcatcaag
1681 cagctgcagg cccgcgtgtc ggccgtggag cgcttacctga aggaccagca gctgctggc
1741 atctggggct gcagcggcaa gctgatctgc accaccggc tgccctggaa cgccagctgg
1801 agcaacaaga gcctggacca gatctggaa aacatgaccc ggttggagtg ggagcgcgag
1861 atcgacaact acaccaaccc gatctacacc ctgatcgagg agagccagaa ccagcaggag
1921 aagaacgagc aggagctgtct ggagctggac aagtggccaa gcctgtggaa ctggttcgac
1981 atcagcaagt ggctgtggta catctaa

FIGURE 60 (SEQ ID NO:63)

gp140modSF162.Gm154-186-195

1 atggatcaa tgaagagagg gctctgtgt gtgctgtgc tttgtggagg agtcttcgtt
61 tcgcccagcg ccgtggagaa gctgtgggtg accgtgtact acggcgtgcc cgtgtggaaag
121 gaggccacca ccaccctgtt ctgcgccagc gacgccaagg cctacgacac cgaggtgcac
181 aacgtgtggg ccaccacgc ctgcgtgccc accgacccca acccccagga gatcgtgctg
241 gagaacgtga ccgagaactt caacatgtgg aagaacaaca tggtggagca gatgcacgag
301 gacatcatca ccgtgtggga ccagagcctg aagccctgc tgaagctgac-ccccctgtgc
361 gtgaccctgc actgcaccaa cctgaagaac gccaccaaca ccaagagcag caactggaaag
421 gagatggacc gggcgagat caagcagtgc agctcaagg tgaccaccat catccgcaac
481 aagatgcaga aggagtagc cctgttctac aagctggacg tggccat cgacaacgac
541 cagaccagct acaagctgat caactgccag accagcgtga tcacccaggc ctgccccaaag
601 gtgagcttcg agcccatccc catccactac tgcgcccccg cggcttcgc catcctgaag
661 tgcaacgaca agaagtcaa cggcagcggc cctgtcacca acgtgaggcac cgtagtgc
721 acccacggca tccgccccgt ggtgaggcacc cagctgtgc tgaacggcag cctggccgag
781 gagggcgtgg tggatcccgag cgagaacttc accgacaacg ccaagaccat catcgtag
841 ctgaaggaga gctgtggagat caactgcacc cgccccaaaca acaacacccg caagagcatc
901 accatcgccc cggccgcgc ctctacgac accggcgaca tcatcgccga catccgcccag
961 gcccactgca acatcagcgg cgagaagtgg aacaacaccc tgaagcagat cgtgaccaag
1021 ctgcaggccc agttcgccaa caagaccatc gtgtcaagc agagcagcgg cggcgacccc
1081 gagatcgta tgcacagctt caactcgccg ggcgaggatct tctactgcaaa cagcacccag
1141 ctgtcaaca gcacctggaa caacaccatc gggcccaaca acaccaacgg caccatcacc
1201 ctgcccctgca gcatcaagca gatcatcaac cgctggcagg aggtggccaa ggcacatgtac
1261 gccccccca tccggccca gatccgctgc agcagcaaca tcacccggct gctgctgacc
1321 cgcgacggcg gcaaggagat cagcaacacc accgagatct tccgccccgg cggcgccgac
1381 atgcgcgaca actggcgccg cgagctgtac aagtacaagg tggtaagat cgagccctg
1441 ggctggccc ccaccaaggc caagcgccgc gtggcggc ggcgagaagcg cgccgtgacc
1501 ctggcgccca tttccctgggg ctccctgggc gcccggca gcaccatggg cgccccgcgc
1561 ctgaccctga ccgtgcaggc cccggcagctg ctgagcggca tcgtgcagca gcagaacaac
1621 ctgctgcggc ccatcgaggc ccagcagcac ctgctgcagg tgaccgtgt gggcatcaag
1681 cagctgcagg cccgcgtgct ggcgtggag cgctacctga aggaccagca gctgctggc
1741 atctgggct gcagcggcaa gctgatctgc accaccgcgg tggccctggaa cgccagctgg
1801 agcaacaaga gcctggacca gatctggaa aacatgaccc ggtatggatg ggagcgcgag
1861 atcgacaact acaccaaccc gatctacacc ctgatcgagg agagccagaa ccagcaggag
1921 aagaacgagc aggagctgct ggagctggac aagtggccca gcctgtggaa ctggttcgac
1981 atcagcaagt ggctgtggta catctaa

FIGURE 61 (SEQ ID NO:64)

gp140mut7.modSF162.GM154

1 atggatgcaa tgaagagagg gctctgtgt gtgtgtgc tggggagc agtcttcgtt
61 tcgcccagcg ccgtggagaa gctgtgggtg accgtgtact acggcgtgcc cgtgtggaaag
121 gaggccacca ccaccctgtt ctgcgccagc gacgccaagg cctacgacac cgaggtgcac
181 aacgtgtggg ccaccacgc ctgcgtgccc accgacccc acccccaagga gatcgtgctg
241 gagaacgtga ccgagaactt caacatgtgg aagaacaaca tggggagca gatcacgag
301 gacatcatca gcctgtggga ccagagcctg aagccctgcg tgaagctgac cccccctgtc
361 gtgaccctgc actgcaccaa cctgaagaac gccaccaaca ccaagagcag caactggaag
421 gagatggacc gcggcgagat caagcagtgc agcttcaagg tgaccaccag catcccaac
481 aagatgcaga aggagtaacgc cctgttctac aagctggacg tggtgcccat cgacaacgac
541 aacaccagct acaagctgat caactgcaac accagcgtga tcacccagc ctgccccaaag
601 gtgagcttcg agcccatccc catccactac tgcgcccccg cggcgtcgc catcctgaag
661 tgcaacgaca agaagttcaa cggcagcggc ccctgcacca acgtgagcac cgtcagtgc
721 acccacggca tccgccccgt ggtgagcacc cagctgctgc tgaacggcag cctggccgag
781 gagggcggtgg tggatcccgag cgagaacttc accgacaacg ccaagaccat catcgtgcag
841 ctgaaggaga gcgtggagat caactgcacc cggcccaaca acaacacccg caagagcatc
901 accatcgccc cggccgcgc ctctacgccc accggcgcaca tcatcgccgacatccgcag
961 gcccactgca acatcagcgg cgagaagtgg aacaacaccc tgaagcagat cgtgaccaag
1021 ctgcaggcccc agttcgccaa caagaccatc gtgtcaagc agagcagcgg cggcggacccc
1081 gagatcgtga tgcacagctt caactgcggc ggccgagttct tctactgcaa cagcacccag
1141 ctgttcaaca gcacctggaa caacaccatc gggcccaaca acaccaacgg caccatcacc
1201 ctgcccctgccc gcatcaagca gatcatcaac cgctggcagg aggtggccaa ggccatgtac
1261 gccccccccca tccgccccca gatccgctgc agcagcaaca tcaccggcct gctgctgacc
1321 cgcgacggcgc gcaaggagat cagcaacacc accgagatct tccgccccgg cggggcgcac
1381 atgcgcgaca actggcgccg cgagctgtac aagtacaagg tggtaagat cgagccctg
1441 ggcgtggccc ccaccaaggc catcagcagc gtggcaga ggcgagaagag cgccgtgacc
1501 ctggggccca tggatccggg cttccctggc gccgccccca gacccatggg cggccgcgc
1561 ctgaccctgca ccgtgcaggc cccgcgcgc ctgagcggca tcgtgcagca gcagaacaac
1621 ctgcgtgcgc ccaatcgaggc ccagcagcac ctgcgtgcagc tgaccgtgt gggcatcaag
1681 cagctgcagg cccgcgtgc ggcgtggag cgctaccctgaa aggaccagca gctgctggc
1741 atctggggct gcagccggaa gctgatctgc accaccggc tgccctggaa cgccagctgg
1801 agcaacaaga gcctggacca gatctggaa acatgaccc tggatggagtg ggagcgcgag
1861 atcgacaact acaccaaccc gatctacacc ctgatcgagg agagccagaa ccagcaggag
1921 aagaacgagc aggagctgct ggagctggac aagtggccca gcctgtggaa ctggatcgac
1981 atcagcaagt ggctgtggta catctaa

Translation of:
 gp140modSF162
 gp140.modSF162.GM154
 gp140.modSF162.GM154-186-195
 gp140.modSF162.GM135-154-186-195
 Consensus


101
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKNC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC

150
 Translation of:
 gp140modSF162
 gp140.modSF162.GM154
 gp140.modSF162.GM154-186-195
 gp140.modSF162.GM135-154-186-195
 Consensus

101
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKNC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC
 (101) DIISLWDQSLKPCVVKLTPLCVTLHCTNLKNAATNTKS SNWKEMDRGEIKQC

FIGURE 62

Figure 63
(Sheet 1 of 1)



Gag-Pol precursor p160




Figure 64




Figure 65




Figure 66

Group	Animal	% Virus Inhibition			
		Post-2 nd DNA (1:20)	Post-2 nd - DNA (1:100)	Post-Prot (1:100)	Post-Prot (1:500)
1	1	0	60	0	17
	2	34	59	50	21
	3	0	0	12	38
	4	95	92	83	57
2	5	100	69	99	99
	6	0	28	27	35
	7	0	0	43	0
	8	95	38	79	74
3	9	40	0	61	26
	10	0	0	0	0
	11	94	41	91	57
	12	0	0	12	19
4	13	100	86	78	18
	14	20	0	68	0
	15	99	70	100	31
	16	0	33	0	24
5	17	100	67	100	75
	18	69	36	100	53
	19	58	33	NA	NA
	20	99	80	92	39
6	21	NA	NA	NA	NA
	22	78	12	100	88
	23	67	63	92	17
	24	70	62	77	0
7	29	100	100	74	68
	30	81	63	55	28
	31	100	79	100	91
	32	100	78	100	45
Sub B positive serum	20480	100	100	100	100

Figure 67

Group	Animal	% Virus Inhibition		ELISA Titer
		TV1	TV2	
1	1	0	38	19716
	2	25	67	37994
	3	0	0	7529
	4	0	79	41963
2	5	30	51 [#]	112768
	6	0	0	57677
	7	23	9	26247
	8	47	78	90376
3	9	0	42	62004
	10	13	0	5741
	11	0	36 [#]	53599
4	12	21	12	37597
	13	0	22 [#]	45543
	14	0	0	24885
5	15	0	17 [#]	87556
	16	28 [#]	59	19838
	17	72	80	124618
6	18	0	77	143905
	19	NA	NA	NA
	20	19	56 [#]	91808
Sub B positive pool	21	NA	NA	NA
	22	34	44	31413
	23	51	50 [#]	62925
	24	22	31 [#]	28620
	29	0	9	62604
	30	0	50 [#]	15932
	31	0	58	22418
Sub C positive pool	32	41	0	21119
		46	56	NA
		36	85	NA

Figure 68

Group	Animal	% Virus Inhibition			ELISA titer
		TV1	Du174	SF162	
1	1	28	20	12	19716
	2	33	19	9	37994
	3	0	0	0	7529
	4	52	61	79	41963
2	5	33	0	95	112768
	6	3	0	14	57677
	7	0	0	0	26247
	8	54	0	86	90376
3	9	0	52	73	62004
	10	0	58	15	5741
	11	0	0	71	53599
4	12	0	0	0	37597
	13	15	0	69	45543
	14	0	0	0	24885
	15	0	13	0	87556
5	16	14	0	0	19838
	17	0	0	0	124618
	18	0	0	30	143905
	19	NA	NA	NA	NA
6	20	63	0	56	91808
	21	NA	NA	NA	NA
	22	24	NV	38	31413
	23	7	65	76	62925
7	24	0	NV	NV	28620
	29	32	0	82	62604
	30	6	NV	0	15932
	31	0	0	98	22418
	32	34	0	0	21119

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21342

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/00
US CL : 435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/5, 69.1, 320.1, 456, 475, 476; 514/44; 536/23.72

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/39302 A2 (CHIRON CORPORATION) 06 July 2000 (06.07.2000), see claims.	1, 11-56
Y	WO 00/39304 A2 (CHIRON CORPORATION) 06 July 2000 (06.07.2000), see claims.	1, 11-56
Y, P	WO 02/04493 A2 (CHIRON CORPORATION) 17 January 2002 (17.01.2002), see claims.	1, 11-56

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"B"	earlier application or patent published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search
16 June 2003 (16.06.2003)

Date of mailing of the international search report
16 OCT 2003

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703)305-3230

Authorized officer
Ulrike Winkler
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21342

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1 and 11-56 as the claims read on SEQ ID NO:9

Remark on Protest The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/21342

Continuation of B. FIELDS SEARCHED Item 3:
WEST, DERWENT, STN-BIOSIS, MEDLINE, EMBASE
Sequence search SEQ ID NO:9, inventor search, HIV expression cassette.